"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B1,US 9511828 B1,168-082-440-289-51X,2016-12-06,2016,US 201414532049 A,2014-11-04,US 201414532049 A,2014-11-04,Personal safety survival device,"The personal safety survival device includes a plurality of elongated inflation members that collectively form a triangular enclosure. The triangular enclosure has an opening at distal ends, which enables an end user to climb into the triangular enclosure. The personal safety survival device includes an auto-inflation system that inflates the triangular enclosure when triggered, and is to be used as a life raft that keeps the end user out of water, and safe from drowning. The auto-inflation system includes a CO2 canister in fluid communication with all the elongated inflation members. Each of the elongated inflation members include a manual inflate nozzle. When deflated, the personal safety survival device is able to be rolled up into a relatively small size, and includes a carrying strap as well as a pull cord.",BRANCH JOHN,BRANCH JOHN,,https://lens.org/168-082-440-289-51X,Granted Patent,yes,15,2,1,1,0,B63C9/21;;B63C9/21;;B63C9/065;;B63C9/065;;B63C2009/042;;B63C2009/042,B63C9/06;;B63B45/00;;B63C9/03;;B63C9/04,,0,0,,,,ACTIVE
2,US,B1,US 6398766 B1,176-418-500-234-315,2002-06-04,2002,US 47224899 A,1999-12-27,US 47224899 A,1999-12-27,Eye wash system,"
    An eye wash system including a first base member slidable on a second base member from a retracted storage position to an extended operative position. One base member has an eye piece on its front end. The other base member pivotally supports a coupling assembly on which a flexible squeeze bottle is attached. A fluid line from the coupling assembly leads to a spray nozzle mounted on the front end of the other base member. A seal structure on the back side of the eye piece is moved rectilinearly into engagement with the spray nozzle to seal it when the one base member is in its retracted storage position. The bottom wall of the other base member has a resilient tongue with a detent ridge at its free end. Detent grooves on the coupling assembly cooperate with the detent ridge to latch it in the vertical or horizontal positions of the coupling assembly. Modifications of the spray nozzle include means for metering the liquid to be sprayed. 
",VISTA INNOVATIONS INC,BRANCH JOHN D,VISTA INNOVATIONS INC (1999-12-23),https://lens.org/176-418-500-234-315,Granted Patent,yes,16,64,1,1,0,A61H35/02;;A61H35/02,A61H35/02,604/302;;604/294;;604/295;;604/298;;604/300,0,0,,,,EXPIRED
3,US,A,US 4332496 A,190-088-212-837-435,1982-06-01,1982,US 26248481 A,1981-05-11,US 26248481 A,1981-05-11,Bow pencil,"A music marking pencil is provided for use in combination with a violin bow or the like. The device attaches to the hand held end portion of a violin bow or the like and can be used by the musician to mark his music or perform similar writing tasks as needed. The device provides a pencil which can be a threaded mechanical mechanism affixed at the end portion of the violin bow which is normally hand held. The pencil aligns itself with the central axis of the bow with the pencil marking tip protruding beyond the hand held end portion of the bow. In the preferred embodiment, the pencil structure replaces the bow screw which normally adjusts tension of the bow hair. Thereafter, the bow pencil additionally provides the hair adjustment function.",BRANCH JOHN K,BRANCH JOHN K,,https://lens.org/190-088-212-837-435,Granted Patent,yes,6,3,1,1,0,B43K29/00;;G10D3/16;;G10D3/16;;B43K29/00,B43K29/00;;G10D3/16,401/52,0,0,,,,EXPIRED
4,US,A,US 3897794 A,021-833-248-554-858,1975-08-05,1975,US 44969774 A,1974-03-11,US 44969774 A,1974-03-11,Grooming implement,"A pocket-sized self-contained battery-powered hair comb having oscillating teeth for separating, unsnarling, and smoothing difficult hair.",BRANCH JOHN W,BRANCH JOHN W,,https://lens.org/021-833-248-554-858,Granted Patent,no,2,29,1,1,0,A45D24/007;;A45D24/007,A45D24/00,132 11A,0,0,,,,EXPIRED
5,GB,A,GB 1144084 A,088-229-976-507-646,1969-03-05,1969,GB 3788766 A,1966-08-24,GB 3788766 A,1966-08-24,Improvements in or relating to lubricant additives,"1,144,084. Basic lubricant additives. ORO. BIS Ltd. 27 July, 1967 [24 Aug., 1966], No. 37887/66. Heading C2C. [Also in Division C5] A basic lubricant additive is prepared by heating an alkyl phenol, e.g. dodecyl phenol, and sulphur in the presence of a catalyst. mixing the product with an oxide, alkoxide or hydroxide of a metal of Group IIA of the Periodic Table and an amine compound of the general formula or where R and R<SP>1</SP> = H or alkyl groups, and removing the amine by distillation and adding CO 2 to the mixture. When a hydroxy-amine is used, it may be removed from the mixture after addition of CO 2 . The alkyl phenol is preferably predominantly para-substituted and the alkyl substituent may have 8-50 C atoms. The amine compound is advantageously ethanol-amine or ethylene diamine and the compound of the Group IIA metal may be Ca(OH) 2 or BaO, which may be added to the mixture as a slurry in a diluent oil. The catalyst used in the first stage of the reaction is preferably an oxide, alkoxide, hydroxide or sulphide of an element of Groups IA or IIA of the Periodic Table, e.g. NaOH or KOH, and the metal is preferably removed before the second stage of the reaction is carried out, e.g. by the addition of phosphoric acid.",OROBIS LTD,BRANCH SIDNEY JOHN,,https://lens.org/088-229-976-507-646,Granted Patent,no,0,3,5,5,0,C10M159/22;;C10M2219/087;;C10M2219/088;;C10M2219/089;;C10N2050/02;;C10M159/22;;C10M2219/088;;C10M2219/087;;C10M2219/089;;C10N2050/02,C10M159/22,C2C CXX;;C2C C22Y;;C2C C220;;C2C C29Y;;C2C C292;;C2C C30Y;;C2C C781;;C2C C782;;C2C C783;;C2C C795;;C4X X13           X13;;C5F FA            A;;C5F F649          A;;C5F F80Y          A;;C5F F801          A,0,0,,,,EXPIRED
6,AU,A,AU 1994/068717 A,187-249-361-106-333,1995-02-09,1995,AU 1994/068717 A,1994-07-26,NZ 24828793 A,1993-07-29,Manufacture of arsenic acid,,BRANCH JOHN AYRTON,BRANCH JOHN AYRTON,,https://lens.org/187-249-361-106-333,Patent Application,no,0,0,3,3,0,,C01G28/00;;C01G28/02,,0,0,,,,EXPIRED
7,CH,A,CH 362700 A,107-768-792-629-93X,1962-06-30,1962,CH 4996757 A,1957-08-30,GB 2808156 A,1956-09-14,Procédé de préparation de l'acide déhydro-acétique,,DISTILLERS CO YEAST LTD,SIDNEY JOHN BRANCH,,https://lens.org/107-768-792-629-93X,Granted Patent,no,0,0,1,1,0,,,"12Q,24",0,0,,,,EXPIRED
8,US,A,US 5607410 A,141-035-886-889-403,1997-03-04,1997,US 39041895 A,1995-02-17,US 39041895 A;;US 19711694 A;;US 1837793 A,1993-02-16,Vision directed eye wash,A vision directed eye wash system includes an eye support for positioning an eye member to be flushed. A reservoir contains a supply of fluid. A tube is coupled at one end to the reservoir and the other end thereof is positioned adjacent the eye support for dispensing fluid from the reservoir into the eye. A mirror is positioned adjacent the reservoir for enabling the user to view the eye member between flushes. The tube may be positioned in a trough interconnecting the reservoir and eye support. The trough is generally of U-shaped cross-sectional configuration and the axis of the trough and the axis of the reservoir are generally perpendicular to each other when the eye member is viewed in the mirror and parallel to each other when the system is closed for storage.,BRANCH; JOHN D.,BRANCH JOHN D,,https://lens.org/141-035-886-889-403,Granted Patent,yes,11,88,1,1,0,A61H35/02;;A61M2205/075;;A61F9/0026;;B05B11/04;;B05B11/0054;;A61H35/02;;A61M2205/075,A61H35/02,604/302;;604/295;;604/300,0,0,,,,EXPIRED
9,GB,A,GB 823803 A,069-850-700-955-292,1959-11-18,1959,GB 3461656 A,1956-11-13,GB 3461656 A,1956-11-13,Improved double-sided cattle manger and hay rack,"823,803. Animal feeding appliances. HARE & SONS Ltd., E. F. Feb. 10, 1958 [Nov. 13, 1956], No. 34616/56. Class 5(2). A combined manger and hay rack comprises a manger C and hay rack A of V-shape in cross-section, supported at their ends by A- shaped end frames B, the manger, rack and end frames being formed as separate units and adapted to be rigidly secured together by readily releasable fastenings. The hay rack A is fastened to the end frames by bolts 7, whilst the manger is supported on the cross members 3 of the frames and is also bolted to the frames at 6. A vertical support 8 bolted to the manger serves to support the lower horizontal bar 9 of the hay rack, additional support for the manger being provided by struts 10 bolted at their upper ends to the base of the manger, and being recessed at their lower ends to engage with the cross members 4 of the end frames B.",E F HARE AND SONS LTD,BRANCH JOHN GEORGE,,https://lens.org/069-850-700-955-292,Granted Patent,no,0,3,1,1,0,A01K1/10,A01K1/10,A1M M12           M12,0,0,,,,EXPIRED
10,FR,A,FR 1182559 A,096-226-639-588-752,1959-06-26,1959,FR 1182559D A,1957-09-10,GB 1182559X A,1956-09-14,Procédé de production de l'acide déhydracétique à partir de dicétène,,DISTILLERS CO YEAST LTD,BRANCH SIDNEY JOHN,,https://lens.org/096-226-639-588-752,Granted Patent,no,0,0,1,1,0,C07D309/38,C07D309/38,,0,0,,,,EXPIRED
11,US,A,US 3509053 A,034-472-863-762-991,1970-04-28,1970,US 3509053D A,1967-08-02,GB 3788766 A,1966-08-24,LUBRICANT ADDITIVES,,OROBIS LTD,BRANCH SIDNEY JOHN,,https://lens.org/034-472-863-762-991,Granted Patent,no,2,4,5,5,0,C10M159/22;;C10M2219/087;;C10M2219/088;;C10M2219/089;;C10N2050/02;;C10M159/22;;C10M2219/088;;C10M2219/087;;C10M2219/089;;C10N2050/02,C10M159/22,252/42.7,0,0,,,,EXPIRED
12,US,A1,US 2003/0032930 A1,059-541-284-695-230,2003-02-13,2003,US 27318102 A,2002-10-18,US 27318102 A;;US 77678201 A,2001-02-06,Eye drop dispensing system,"
   An eye drop dispensing device includes a trough member with a space to receive a cartridge housing enclosing a collapsible bag containing an ophthalmic liquid and comprising a spring finger applying pressure to the bag. The bag includes a wall pierced by a needle coupling the liquid to pump means through a one-way valve. The pump means includes a plunger biased to a resting position establishing a dosage chamber. Actuator means moves the plunger to enlarge the dosage chamber, causing a drop in pressure which draws a predetermined quantity of the liquid through the one-way valve into the dosage chamber. The actuator means then releases the plunger so that it moves to compress the dosage chamber to pump the liquid in the dosage chamber through a second one-way valve to spray the liquid through pinholes formed in a nozzle angled to direct the liquid as eye drops to the user's eye. Another embodiment receives a cartridge housing enclosing three collapsible bags containing three different prescription ophthalmic drug solutions. The embodiment includes three shuttle pumps which are controlled by a common control member to dispense the solutions simultaneously into the patient's eye. 
",VISTA INNOVATIONS INC,BRANCH JOHN D,VISTA INNOVATIONS INC (2002-10-18),https://lens.org/059-541-284-695-230,Patent Application,yes,2,42,1,3,0,B65D35/28;;B65D35/28,B65D35/28,604/298;;604/302,0,0,,,,DISCONTINUED
13,DE,B,DE 1083807 B,081-226-802-568-256,1960-06-23,1960,DE D0026332 A,1957-08-29,GB 1083807X A,1956-09-14,Verfahren zur Herstellung von Dehydracetsaeure durch Dimerisieren von Diketen,,DISTILLERS CO YEAST LTD,BRANCH SIDNEY JOHN,,https://lens.org/081-226-802-568-256,Patent Application,no,2,0,1,1,0,C07C51/00,,,0,0,,,,DISCONTINUED
14,GB,A,GB 813196 A,144-809-569-690-594,1959-05-13,1959,GB 2808156 A,1956-09-14,,,Production of dehydroacetic acid,"Dehydroacetic acid is prepared by a process comprising adding diketene to an inert solvent in the presence of trimethylamine and recovering the resulting dehydro acetic acid, the addition being made and reaction effected at a temperature from -10 DEG to 50 DEG C. under substantially anhydrous conditions, i.e. the reaction mixture should not contain more than 0.1 per cent by weight of water. The solvent may be an aromatic hydrrbon, ocae.g. benzene, toluene or xylene. The diketene is preferably added at a rate no greater than that at which it is consumed. The catalyst may be used dissolved in a non-aqueous solvent such as the reaction medium or methanol. The process may be operated continuously, all or part of the resulting acid being separated and the residue containing inert solvent being recycled, preferably after removal of any acetic acid therein. The crude acid may be purified by washing with a suitable solvent followed by sublimation, or by co-distillation with methyl acetoacetate. Numerous examples are given wherein, typically, diketene is slowly added at 15 DEG C. to toluene containing about 0.3 per cent by volume of trimethylamine (introduced in methanol), the resulting dehydro acetic acid is filtered off and the residue is re-used as inert solvent for a subsequent reaction with or without prior removal of acetic acid therein by distillation. Comparative experiments are described employing temperatures above 50 DEG C. or using triethylamine as catalyst. According to the Provisional Specification, other catalysts may be used instead of trimethylamine, for example, alkali metal salts of aliphatic alcohols and of phenols, alkali metal hydroxides and tertiary amines generally, such as trialkylamines.",DISTILLERS CO YEAST LTD,BRANCH SIDNEY JOHN,,https://lens.org/144-809-569-690-594,Granted Patent,no,0,0,1,1,0,,,C2C CTV;;C2C C1671;;C2C C215;;C2C C247;;C2C C25Y;;C2C C253;;C2C C30Y;;C2C C304;;C2C C305;;C2C C35Y;;C2C C351;;C2C C352;;C2C C355;;C2C C386;;C2C C40Y;;C2C C407;;C2C C645;;C2C C675;;C2C C760;;C2C C761;;C2C C767;;C2C C776,0,0,,,,EXPIRED
15,FR,A,FR 1297062 A,041-417-325-163-010,1962-06-22,1962,FR 870412 A,1961-08-09,FR 870412 A,1961-08-09,Procédé de préparation d'acétoacétyl-arylamides,,DISTILLERS CO YEAST LTD,BRANCH SIDNEY JOHN,,https://lens.org/041-417-325-163-010,Granted Patent,no,0,1,1,1,0,C07C231/00,C07C231/00,,0,0,,,,EXPIRED
16,AU,B2,AU 684078 B2,114-319-453-084-015,1997-12-04,1997,AU 1994/068717 A,1994-07-26,NZ 24828793 A,1993-07-29,Manufacture of arsenic acid,,BRANCH JOHN AYRTON,BRANCH JOHN AYRTON,,https://lens.org/114-319-453-084-015,Granted Patent,no,1,0,3,3,0,,C01G28/00;;C01G28/02,,0,0,,,,EXPIRED
17,NZ,A,NZ 248287 A,153-362-490-896-707,1995-12-21,1995,NZ 24828793 A,1993-07-29,NZ 24828793 A,1993-07-29,PRODUCTION OF ARSENIC ACID BY OXIDATION OF ARSENIC TRIOXIDE WITH HYDROGEN PEROXIDE AND ITS USE IN THE PRODUCTION OF COPPER CHROME ARSENATE,,BRANCH JOHN AYRTON,BRANCH JOHN AYRTON,"CHEMICAL RESOURCES LIMITED, NZ (2004-07-30)",https://lens.org/153-362-490-896-707,Patent Application,no,0,0,3,3,0,,C01G28/00;;C01G28/02,,0,0,,,,PENDING
18,GB,A,GB 962227 A,170-980-317-367-339,1964-07-01,1964,GB 2906160 A,1960-08-23,GB 2906160 A,1960-08-23,Production of aceto-acetarylamides,"Acetoacetarylamides are prepared by mixing an arylamine with diketene as rapidly as possible for example within a period of 30 seconds, and allowing the mixture to attain a maximum temperature in the range 50 to 80 DEG C. The mixture is preferably allowed to attain a temperature from 55 to 70 DEG C. within 10 to 25 minutes from mixing. Arylamines specified are aniline, toluidines, benzidine, diphenylamine, nitroanilines, chloroanilines and alkyl esters of amino benzoic acids. The reaction is preferably carried out in the presence, as catalyst, of a tertiary amine or the salt of a tertiary amine with a weak acid, e.g. trimethylamine, triethylamine and their acetates. In the examples o-chloroaniline is reacted with diketene in the presence of trimethylamine using toluene as a solvent for the reaction mixture.",DISTILLERS CO YEAST LTD,BRANCH SIDNEY JOHN,,https://lens.org/170-980-317-367-339,Granted Patent,no,0,3,1,1,0,C07C231/02,,C2C CKS;;C2C C22Y;;C2C C220;;C2C C227;;C2C C281;;C2C C30Y;;C2C C31Y;;C2C C313;;C2C C32Y;;C2C C321;;C2C C338;;C2C C34Y;;C2C C342;;C2C C351;;C2C C355;;C2C C591;;C2C C62X;;C2C C625,0,0,,,,EXPIRED
19,GB,A,GB 2142057 A,095-196-167-650-173,1985-01-09,1985,GB 8315234 A,1983-06-03,GB 8315234 A,1983-06-03,Garden shed,"A garden or other shed is constructed of a plurality of modules fixed end-to-end. Each module comprises a frame (18 Fig. 5), a front panel, a rear panel, a roof panel (42 Fig. 5), and one or more floor members (46 Fig. 5). The shed also comprises two end panels 22 one of which contains a door and both of which correspond in outline shape to that of the frame. To increase the size of the shed would require merely the removal of an end panel, the addition of the desired number of modules, and the replacement of the end panel on the end of the new end module. <IMAGE>",PETTITT JOINERY COMPANY LIMITE,BRANCH JOHN WILLIAM FREDERICK,,https://lens.org/095-196-167-650-173,Patent Application,no,5,11,2,2,0,E04H1/1205,E04H1/12,E1D DGS           GS2019;;E1D DLFQW2        GS2019;;E1D D2019         GS2019;;E1D D503          GS2019;;U1S S1731,0,0,,,,DISCONTINUED
20,US,B1,US 7461974 B1,105-066-503-398-92X,2008-12-09,2008,US 96918908 A,2008-01-03,US 96918908 A;;US 86560904 A,2004-06-09,Beta variation cancellation in temperature sensors,"An apparatus and method for canceling variations in the beta for a bipolar junction transistor so that the diode equation can be employed to accurately measure the temperature of the transistor based at least in part on a ratio of two target collector currents and two measurements of the base-emitter voltage of the transistor. If the determined collector current of the transistor is relatively equivalent to one of the first and second target collector currents, the transistor's base-emitter voltage is measured and stored. An analog feedback circuit can be employed to change the determined collector current to be relatively equivalent to the first and second target collector currents. The analog feedback circuit can include an optional sample and hold component to further reduce power consumption and reduce noise. A digital circuit can be employed to change the determined collector current to be relatively equivalent to the first and second target collector currents. Additionally, the transistor can be remotely located in another integrated circuit.",NAT SEMICONDUCTOR CORP,ASLAN MEHMET;;BRANCH JOHN W,NATIONAL SEMICONDUCTOR CORPORATION (2004-06-07);;FIREHOSE LLC (2007-12-21),https://lens.org/105-066-503-398-92X,Granted Patent,yes,90,15,4,4,0,G01K7/015;;G01K7/015,G01K7/00,374/178;;327/512,24,6,100-161-868-002-688;;012-846-896-392-566;;086-519-900-681-114;;013-133-060-011-176;;051-606-580-724-474;;006-751-864-938-983,10.1080/002072196136463;;10.1109/jssc.1980.1051368;;10.1109/icsens.2002.1037251;;10.1109/jssc.2005.858476;;10.1109/iscas.2001.921869;;10.1109/jsen.2004.826742,"Office Action Mailed Aug. 4, 2008 in U.S. Appl. No. 11/767,467.;;Allan, Roger, editorial sponsored by Analog Devices Inc., ""Design FAQs, Frequently Asked Questions: Temperature Sensors,"" Oct. 20, 2005, 2 pages, <http://www.elecdesign.com/Files/29/11082/11082-01.pdf>.;;Analog Devices, Inc., ""Intelligent Temperature Monitor and PWM Fan Controller ADM 1030,"" 2003, pp. 1-28.;;Analog Devices, Inc., ""Low-Noise, Precision Operational Amplifier OP27,"" 2003, pp. 1-20.;;Bakker, A., ""High-Accuracy CMOS Smart Temperature Sensors,"" 2000, pp. 106-116.;;Filanovsky, M. et al., ""BiCMOS bandgap voltage reference with base current compensation,"" INT. J. Electronics, 1996, vol. 81, No. 5, pp. 565-570.;;Gray, P.R. et al., ""Analysis and Design of Analog Integrated Circuits,"" Third Edition, 1993, pp. 454-460.;;Hamidi, A. et al., ""Contact termperature measurements on chip surface for reliability investigations of high power IGBT modules in traction applications,"" EuPac'98, 3rd European Conference on Electronic Packaging Technology and 9th International Conference on Interconnection Technology in Electronics, Jun. 1998, pp. 160-162.;;Maxim Integrated Products, ""Dual Remote/Local Temperature Sensors and Four-Channel Voltage Monitors,"" Rev. 1, May 2006, pp. 1-18.;;Maxim Integrated Products, ""Temperature Monitoring Using the MAX1253/54 and MAX1153/54,"" Mar. 21, 2003, 5 pages.;;Meijer, G.C.M. et al., ""Measurement of the temperature dependence of the Ic(Vbe) characteristics of integrated bipolar transistors,"" IEEE Journal of Solid-State Circuits, vol. SC-15, Issue 2, Apr. 1980, pp. 237-240.;;National Semiconductor Corporation, ""LM32 Dual Thermal Diode Temperature Sensor with SensorPath Bus,"" May 2004, pp. 1-24.;;National Semiconductor Corporation, ""LM34/LM35 Precision Monolithic Temperature Sensors,"" Oct. 1986, pp. 1-10.;;National Semiconductor Corporation, ""LM86 ±0.75° C Accurate, Remote Diode and Local Digital Temperature Sensor with Two-Wire Interface,"" Apr. 2003, pp. 1-21.;;National Semiconductor Corporation, ""LM95231 Precision Dual Remote Diode Temperature Sensor with SMBus Interface and TruThermae Technology,"" Aug. 2006, pp. 1-20.;;National Semiconductor Corporation, ""LM95235 Precision Remote Diode Temperature Sensor with SMBus Interface and TruThermae Technology,"" Jun. 2006, pp. 1-25.;;Peppiette, G., ""Temperature measurement on an IC-chip,"" Electronic Equipment News, vol. 15, Issue 11, Apr.-May 1974, p. 107.;;Pertijs, M.A.P. et al., ""37.2: Non-Idealities of Temperature Sensors using Substrate PNP Transistors,"" 2002, IEEE, pp. 1018-1023.;;Pertijs, M.A.P. et al., ""A CMOS Smart Temperature Sensor With a 3o Inaccuracy of ±0.1° C From -55 ° C to 125 ° C,"" IEEE Journal of Solid-State Circuits, vol. 40, No. 12, Dec. 2005, pp. 2805-2815.;;Pertijs, M.A.P. et al., ""A high-accuracy temperature sensor with second-order curvature correction and digital bus interface,"" IEEE, vol. 1, May 2001, pp. I-368-I-371.;;Pertijs, M.A.P. et al., ""Precision Temperature Measurement Using CMOS Substrate PNP Transistors,"" IEEE Sensors Journal, vol. 4, No. 3, Jun. 2004, pp. 294-300.;;University of Delaware, Department of Physics & Astronomy, ""The bipolar transistor,"" 7 pages, <http://www.physics.udel.edu/~nowak/phys645/The-bipolar-transistor.htm>.;;Analog Devices, Inc., Data Sheet for ""ADM1032, +/-1 degree Celsius Remote and Local System Temperature Monitor,"" 2001, 12 pages.;;Office Action Mailed Mar. 11, 2008 in U.S. Appl. No. 11/767,467.",ACTIVE
21,CA,A,CA 77986 A,077-311-304-249-086,1902-10-28,1902,CA 77986D A,1902-04-24,CA 77986T A,1902-04-24,COATING FOR NAILS,,HEMANN BENNARD;;BRANCH JOHN V,HEMANN BENNARD;;BRANCH JOHN V,,https://lens.org/077-311-304-249-086,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
22,US,A1,US 2007/0237207 A1,048-494-412-197-917,2007-10-11,2007,US 76746707 A,2007-06-22,US 76746707 A;;US 86560904 A,2004-06-09,BETA VARIATION CANCELLATION IN TEMPERATURE SENSORS,"An apparatus and method for canceling variations in the beta for a bipolar junction transistor so that the diode equation can be employed to accurately measure the temperature of the transistor based at least in part on a ratio of two target collector currents and two measurements of the base-emitter voltage of the transistor. If the determined collector current of the transistor is relatively equivalent to one of the first and second target collector currents, the transistor's base-emitter voltage is measured and stored. An analog feedback circuit can be employed to change the determined collector current to be relatively equivalent to the first and second target collector currents. The analog feedback circuit can include an optional sample and hold component to further reduce power consumption and reduce noise. A digital circuit can be employed to change the determined collector current to be relatively equivalent to the first and second target collector currents. Additionally, the transistor can be remotely located in another integrated circuit.",NAT SEMICONDUCTOR CORP,ASLAN MEHMET;;BRANCH JOHN W,NATIONAL SEMICONDUCTOR CORPORATION (2004-06-07),https://lens.org/048-494-412-197-917,Patent Application,yes,41,14,4,4,0,G01K7/015;;G01K7/015,G01K7/00,374/178,0,0,,,,DISCONTINUED
23,GB,A,GB 1177835 A,110-384-273-870-639,1970-01-14,1970,GB 433667 A,1967-01-28,GB 433667 A,1967-01-28,Overbased Detergents,"1,177,835. Polyolefin derivatives. OROBIS Ltd. 25 Jan., 1968 [28 Jan., 1967], No. 4336/67. Heading C3P. [Also in Division C5] Overbased detergent additives for lubricating oils are prepared by reacting a sulphurized phenol of formula where R<SP>1</SP>, R<SP>2</SP> and R<SP>3</SP> are hydrogen or alkyl, x is 1 to 4 and n is 0 to 4, with a reaction product of a phosphosulphurized polyolefin and an amine, and excess of an oxide, hydroxide or alcoholate of a Group IIA metal, and reacting the resulting mixture with carbon dioxide. The sulphurized phenol may be prepared in situ from a phenol or alkyl phenol and sulphur or a sulphur halide. The polyolefin may be a polybutene of molecular weight 200 to 5000, and may be reacted with phosphorus pentasulphide. Specified amines are alkanolamines and polyolefin-substituted succinimide derivatives of polyalkylene polyamines. The addition of the metal compound is preferably effected in the presence of a vicinal glycol, and water is preferably removed from the mixture before carbonation. In examples phosphosulphurized polybutenes are reacted with (1) ethanolamine and (2) a polyisobutenyl succinimide derivative of tetraethylene pentamine, the products are treated with dodecyl phenol, sulphur, lime and ethylene glycol and, after the removal of water by distillation, with carbon dioxide.",OROBIS LTD,BRANCH SIDNEY JOHN;;COUPLAND KEITH,,https://lens.org/110-384-273-870-639,Granted Patent,no,0,0,1,1,0,C10M159/22;;C07F9/04;;C10M2223/045;;C10M2225/041;;C10N2010/04,C07F9/04;;C10M159/22,C3J JAL           JZ3H;;C3J JAL           PD9&;;C3J JAX           JZ3H;;C3J JAX           PD9&;;C3J JCE           JZ3H;;C3J JCE           PD9&;;C3J JCF           JZ3H;;C3J JCF           PD9&;;C3J JCQ           JZ3H;;C3J JCQ           PD9&;;C3J JCS           JZ3H;;C3J JCS           PD9&;;C3J JDX           JZ3H;;C3J JDX           PD9&;;C3P PD9D7D1       PD9&;;C3P PD9F1         PD9&;;C3P P7D1B         -;;C3P P7D1X         -;;C3P P7T2X         -;;C4X X13           X13;;C5F FA            A;;C5F F678          A;;C5F F684          A;;C5F F762          A,0,0,,,,EXPIRED
24,US,B1,US 7766546 B1,149-214-707-252-058,2010-08-03,2010,US 28450108 A,2008-09-23,US 28450108 A;;US 86560904 A,2004-06-09,Beta variation cancellation in temperature sensors,"An apparatus and method for canceling variations in the beta for a bipolar junction transistor so that the diode equation can be employed to accurately measure the temperature of the transistor based at least in part on a ratio of two target collector currents and two measurements of the base-emitter voltage of the transistor. If the determined collector current of the transistor is relatively equivalent to one of the first and second target collector currents, the transistor's base-emitter voltage is measured and stored. An analog feedback circuit can be employed to change the determined collector current to be relatively equivalent to the first and second target collector currents. The analog feedback circuit can include an optional sample and hold component to further reduce power consumption and reduce noise. A digital circuit can be employed to change the determined collector current to be relatively equivalent to the first and second target collector currents. Additionally, the transistor can be remotely located in another integrated circuit.",NAT SEMICONDUCTOR CORP,ASLAN MEHMET;;BRANCH JOHN W,,https://lens.org/149-214-707-252-058,Granted Patent,yes,8,4,4,4,0,G01K7/015;;G01K7/015,G01K7/00;;H01L31/00,374/178;;327/512,0,0,,,,ACTIVE
25,US,B1,US 8021042 B1,171-948-947-720-455,2011-09-20,2011,US 80328910 A,2010-06-23,US 80328910 A;;US 28450108 A;;US 86560904 A,2004-06-09,Beta variation cancellation in temperature sensors,"An apparatus and method for canceling variations in the beta for a bipolar junction transistor so that the diode equation can be employed to accurately measure the temperature of the transistor based at least in part on a ratio of two target collector currents and two measurements of the base-emitter voltage of the transistor. If the determined collector current of the transistor is relatively equivalent to one of the first and second target collector currents, the transistor's base-emitter voltage is measured and stored. An analog feedback circuit can be employed to change the determined collector current to be relatively equivalent to the first and second target collector currents. The analog feedback circuit can include an optional sample and hold component to further reduce power consumption and reduce noise. A digital circuit can be employed to change the determined collector current to be relatively equivalent to the first and second target collector currents. Additionally, the transistor can be remotely located in another integrated circuit.",NAT SEMICONDUCTOR CORP,ASLAN MEHMET;;BRANCH JOHN W,,https://lens.org/171-948-947-720-455,Granted Patent,yes,8,7,4,4,0,G01K7/015;;G01K7/015,G01K7/00;;H01L31/00,374/178;;327/512,0,0,,,,INACTIVE
26,GB,A,GB 1172276 A,020-282-804-797-670,1969-11-26,1969,GB 433467 A,1967-01-28,GB 433467 A,1967-01-28,Alkaline-Earth Derivatives of Alkylene Bridged Phenols and their use as Lubricant Additives,"1,172,276. Alkaline-earth phenolates. OROBIS Ltd. 25 Jan., 1968 [28 Jan., 1967], No. 4334/67. Heading C2C. [Also in Division C5] Phenolates are prepared from phenols of the formula in which R denotes an alkyl group, R<SP>1</SP> and K<SP>11</SP> denote hydrogen atoms or alkyl groups and n is 0-4, by treating the phenols with an alkalineearth oxide, hydroxide or alcoholate and reacting the products with carbon dioxide. The initial phenols may be prepared by reacting alkylated phenols with aldehydes, ketones, mixtures of aldehydes or ketones or compounds yielding aldehydes or ketones, e.g. formaldehyde polymer, in the presence of a catalyst, a number of which are specified. The reaction of the phenol with the alkaline-earth compound is preferably effected in a diluent, e.g. mineral oil. A vicinal glycol, e.g. ethylene glycol, may also be present. The reaction with carbon dioxide may be effected at a raised temperature. Examples are given of the treatment of a methylene-bridged phenol derived from pdodecylphenol. The products are useful as lubricant additives (see Division C5).",OROBIS LTD,BRANCH SIDNEY JOHN;;COUPLAND KEITH,,https://lens.org/020-282-804-797-670,Granted Patent,no,0,1,1,1,0,C10M159/22;;C07C37/115;;C07C37/66;;C10M2207/027;;C10M2215/04;;C10M2215/26;;C10M2217/046;;C10M2217/06;;C10M2223/045;;C10N2010/04,C07C37/11;;C07C37/20;;C07C37/66;;C10M159/22,C2C CWQ;;C2C C22Y;;C2C C220;;C2C C227;;C2C C30Y;;C2C C36Y;;C2C C365;;C2C C43X;;C2C C633;;C2C C643;;C2C C662;;C2C C699;;C2C C79Y;;C2C C795;;C4X X13           X13;;C5F FA            A;;C5F F483          A;;C5F F619          A;;C5F F678          A;;C5F F762          A,0,0,,,,EXPIRED
27,GB,A,GB 1145189 A,082-272-428-861-383,1969-03-12,1969,GB 5221566 A,1966-11-22,GB 5221566 A,1966-11-22,Lubricant additives,"1,145,189. Lubricants. BP CHEMICALS (U.K.) Ltd. 9 Nov., 1967 [22 Nov., 1966], No. 52215/66. Heading C5F. A lubricant comprises a base oil, at least one substituted 2-hydroxyphenylamine of formula where X is phenyl; naphthyl ; biphenyl ; phenyl substituted with alkyl, alkoxy or halogen; or a radical of formula where Y is arylene and R<SP>1</SP> and R<SP>2</SP> are alkyl, aralkyl, alkenyl or aralkenyl; and an organic compound containing a sulphide or polysulphide linkage. Sulphides specified are 4,4<SP>1</SP>-thiobis-(2- methyl - 6 - tert - butyl phenol), lauryl dithiopropionate, and compounds prepared by the sulphurization of terpenes and chlorinated oils. The base oil may be mineral or synthetic, e.g. dioctyl sebacate, trimethylol propane tricaprylate pentaerythritol esters and the keto esters described in Specification 1,036,692. The composition may also contain calcium petroleum sulphonate, overbased calcium phenates and a polyisobutylene succinimide.",BP CHEM INT LTD,BRANCH SIDNEY JOHN;;COUPLAND KEITH,,https://lens.org/082-272-428-861-383,Granted Patent,no,0,14,1,1,0,C10M1/08;;C10M2207/028;;C10M2207/281;;C10M2207/282;;C10M2207/283;;C10M2207/286;;C10M2207/34;;C10M2215/062;;C10M2215/086;;C10M2215/28;;C10M2219/022;;C10M2219/044;;C10M2219/085;;C10M2219/087;;C10M2219/088;;C10M2219/089;;C10N2050/02;;C10N2050/10,,C5F FA            P;;C5F FB            P;;C5F F478          P;;C5F F531          P;;C5F F537          P;;C5F F599          P;;C5F F605          P;;C5F F622          P;;C5F F632          P;;C5F F647          P;;C5F F649          P;;C5F F80Y          P;;C5F F801          P;;C5F F802          P,0,0,,,,EXPIRED
28,FR,A,FR 1416163 A,040-413-408-890-083,1965-10-29,1965,FR 996587 A,1964-11-27,FR 996587 A;;GB 1351264 A;;GB 4696863 A,1963-11-28,Composition de base pour lubrifiants synthétiques,,DISTILLERS CO YEAST LTD,COUPLAND KEITH;;PENNINGTON JOHN;;BRANCH SIDNEY JOHN,,https://lens.org/040-413-408-890-083,Granted Patent,no,0,0,1,7,0,C10M3/00;;C10M2207/28;;C10M2207/281;;C10M2207/282;;C10M2207/283;;C10M2207/286;;C10M2207/34;;C10M2209/084;;C10M2211/044;;C10M2211/06;;C10N2030/08;;C10N2040/12;;C10N2040/13,,C5F F531          -;;C5F F537          -;;C5F F548          -;;C5F F577          -;;C5F F733          -,0,0,,,,EXPIRED
29,US,A,US 3313732 A,077-942-822-507-955,1967-04-11,1967,US 41077264 A,1964-11-12,GB 1351264 A;;GB 4696863 A,1963-11-28,Cyclic keto esters and lubricants containing them,,DISTILLERS CO YEAST LTD,KEITH COUPLAND;;JOHN PENNINGTON;;JOHN BRANCH SIDNEY,,https://lens.org/077-942-822-507-955,Granted Patent,no,5,0,6,7,0,C10M3/00;;C10M3/00;;C10M2207/28;;C10M2207/28;;C10M2207/281;;C10M2207/281;;C10M2207/282;;C10M2207/282;;C10M2207/283;;C10M2207/283;;C10M2207/286;;C10M2207/286;;C10M2207/34;;C10M2207/34;;C10M2209/084;;C10M2209/084;;C10M2211/044;;C10M2211/044;;C10M2211/06;;C10M2211/06;;C10N2030/08;;C10N2030/08;;C10N2040/12;;C10N2040/12;;C10N2040/13;;C10N2040/13,C10M169/00,,0,0,,,,EXPIRED
30,GB,A,GB 1036692 A,143-489-280-229-733,1966-07-20,1966,GB 4696863 A,1963-11-28,GB 4696863 A;;GB 1351264 A,1963-11-28,Lubricants,"The invention comprises a synthetic lubricant base containing at least one keto-ester of the formula <FORM:1036692/C4-C5/1> where R1, R2, R3, R4 and R5 ar are alkyl groups. Preferably R1, R2, R3 and R4 have at least 4 carbon atoms and R5 is methyl. The lubricant base may also contain a compound having at least two ester groupings in the molecule, e.g. dioctyl sebacate, dinonyl sebacate, esters of trimethylol propane such as trimethylol propane tricaprylate, esters of pentaerythritol, alkyl esters of organic dicarboxylic acids and monocarboxylic acid esters of polyalcohols. The bases are useful in turbine engine lubricants.ALSO:Ketoesters suitable as lubricants (see Division C5) comprise compounds of the formulae <FORM:1036692/C2/1> the triesters of which are novel, wherein R1-R5 are alkyl groups. Preferably, R1-R4 contain at least four carbon atoms and R5 is methyl. The compounds are prepared by cyanoethylation of the appropriate alkyl cycloalkanone followed by hydrolysis of the resulting nitrile to give the acid which is then esterified with the appropriate alcohol in the presence of an entrainer and an esterification catalyst. The entrainer may be benzene, toluene, cyclohexane or any other hydrocarbon which forms a binary azeotrope with water. The preferred catalyst is sulphuric acid.",DISTILLERS CO YEAST LTD,COUPLAND KEITH;;PENNINGTON JOHN;;BRANCH SIDNEY JOHN,,https://lens.org/143-489-280-229-733,Granted Patent,no,0,1,6,7,0,C10M3/00;;C10M3/00;;C10M2207/28;;C10M2207/28;;C10M2207/281;;C10M2207/281;;C10M2207/282;;C10M2207/282;;C10M2207/283;;C10M2207/283;;C10M2207/286;;C10M2207/286;;C10M2207/34;;C10M2207/34;;C10M2209/084;;C10M2209/084;;C10M2211/044;;C10M2211/044;;C10M2211/06;;C10M2211/06;;C10N2030/08;;C10N2030/08;;C10N2040/12;;C10N2040/12;;C10N2040/13;;C10N2040/13,C10M169/00,C2C CMD;;C2C CUF;;C2C C1175;;C2C C22Y;;C2C C22Y;;C2C C221;;C2C C221;;C2C C225;;C2C C225;;C2C C227;;C2C C227;;C2C C30Y;;C2C C30Y;;C2C C304;;C2C C326;;C2C C351;;C2C C351;;C2C C353;;C2C C353;;C2C C366;;C2C C367;;C2C C368;;C2C C387;;C2C C490;;C2C C491;;C2C C625;;C2C C625;;C2C C64Y;;C2C C648;;C2C C65X;;C2C C656;;C2C C658;;C2C C79Y;;C2C C795;;C5F FB            B;;C5F F531          B;;C5F F537          B;;C5F F538          B;;C5F F574          B;;C5F F733          B,0,0,,,,EXPIRED
31,DE,A1,DE 1693161 A1,034-544-178-144-474,1972-05-04,1972,DE 1693161 A,1964-11-25,GB 1351264 A;;GB 4696863 A,1963-11-28,Ketoester als Schmieroele oder Schmieroelzusaetze,,DISTILLERS CO YEAST LTD,COUPLAND KEITH;;PENNINGTON JOHN;;JOHN BRANCH SIDNEY,,https://lens.org/034-544-178-144-474,Patent Application,no,0,0,6,7,0,C10M3/00;;C10M3/00;;C10M2207/28;;C10M2207/28;;C10M2207/281;;C10M2207/281;;C10M2207/282;;C10M2207/282;;C10M2207/283;;C10M2207/283;;C10M2207/286;;C10M2207/286;;C10M2207/34;;C10M2207/34;;C10M2209/084;;C10M2209/084;;C10M2211/044;;C10M2211/044;;C10M2211/06;;C10M2211/06;;C10N2030/08;;C10N2030/08;;C10N2040/12;;C10N2040/12;;C10N2040/13;;C10N2040/13,C10M169/00,,0,0,,,,DISCONTINUED
32,EP,A2,EP 0034443 A2,073-851-048-342-506,1981-08-26,1981,EP 81300479 A,1981-02-04,GB 8005037 A,1980-02-14,"Beta-lactam antibacterial compounds, their preparation and pharmaceutical compositions containing them.","The present invention provides the compounds of the formula (II):
  and pharmaceutically acceptable salts and cleavable esters thereof wherein RCONH is an organic acylamino group and E is a carboxy group or pharmaceutically acceptable salt or ester thereof or is a cyano group. Their preparation is described as is their use in compositions containing them. Compounds wherein RCONH is replaced by an azido group are described as useful intermediates.",BEECHAM GROUP PLC,PEARSON MICHAEL JOHN;;BRANCH CLIVE LESLIE,BEECHAM GROUP PLC (1982-05-12),https://lens.org/073-851-048-342-506,Patent Application,yes,0,2,7,7,0,C07D205/085;;C07D477/24;;C07F9/568;;C07F7/1804;;A61P31/04;;C07D205/085;;C07D477/24;;C07F7/1804;;C07F9/568,A61K31/397;;A61K31/40;;A61P31/04;;C07D205/08;;C07D205/085;;C07D477/24;;C07D477/00;;C07D487/04;;C07F7/18;;C07F9/568,,0,0,,,,EXPIRED
33,EP,A1,EP 0073100 A1,047-355-338-030-53X,1983-03-02,1983,EP 82303858 A,1982-07-22,GB 8124817 A,1981-08-13,"Beta-lactam compounds, their preparation and their use.","A compound of formula (I):
  or a pharmaceutically acceptable salt or cleavable ester thereof, wherein RCONH- represents an organic acylamino group, and E is a carboxy group or a pharmaceutically acceptable salt or C,., o  alkyl or substituted C 1-10  alkyl ester thereof or is a cyano group.",BEECHAM GROUP PLC,PEARSON MICHAEL JOHN;;BRANCH CLIVE LESLIE,,https://lens.org/047-355-338-030-53X,Patent Application,yes,3,3,4,4,0,A61P31/04;;C07D205/085;;C07C205/50;;C07D477/24;;C07F9/568,C07D477/00;;A61K31/397;;A61K31/40;;A61P31/04;;C07C205/50;;C07D205/085;;C07D477/24;;C07F9/568,,0,0,,,,EXPIRED
34,GB,A,GB 901215 A,082-630-195-484-130,1962-07-18,1962,GB 658960 A,1960-02-25,GB 658960 A,1960-02-25,Improvements in or relating to a fail safe electrical circuit,"901,215. Circuits for bi-stable magnetic cores. STANDARD TELEPHONES & CABLES Ltd. Feb. 24, 1961 [Feb. 25, 1960], No. 6589/60. Class 40 (9). A fail-safe circuit comprises a core A having input windings wal . .. wa3, a shift winding wa4, a bias winding wa6 and an output winding wa5 connected in a common-emitter transistor circuit T1 via a resistance R 1 to the input winding wb1 of a second core B having an output winding wb2 and a shift winding wb3 connected in series with the bias winding wa6. Core A operates as an AND circuit for pulses on wal ... wa3 which are applied simultaneously with an opposing bias pulse (see Fig. 2), all three cores having to be pulsed to overcome the bias and set the core. The immediately following shift pulse A resets the core to cause transistor T1 to conduct, thereby setting core B. The next shift B pulse resets core B to produce an output from wb2 via transistor T2 to the next stage. If two or less of the cores wa1 . wa3 are pulsed then, since the hysteresis loop is not perfectly rectangular a short duration "" sneak "" pulse may be produced when wa4 is energized, thereby partially setting core B. In the succeeding stage this will be fed to core A during the early part of the shift B/bias pulse, but, as seen from Fig. 2, the shift A pulse is still present at this time and prevents the sneak pulse from effecting the core A. The design of the circuit ensures that in the event of any winding being open or short-circuited or any of the supplies failing or any of the cores or the transistor failing no output pulse is provided.",STANDARD TELEPHONES CABLES LTD,BRANCH MAURICE CHARLES;;LANGLOIS PETER JOHN,,https://lens.org/082-630-195-484-130,Granted Patent,no,0,0,2,2,0,B61L1/20;;H03K19/16,B61L1/20;;H03K19/16,H3B B200          AF;;H3B B270          AF;;H3B B271          AF;;H3B B314          AF;;H3B B350          AF;;H3B B390          AF;;H3B B393          AF;;H3B B460          AF;;H3B B488          AF;;H3B B515          AF;;H3B B523          AF,0,0,,,,EXPIRED
35,AU,A,AU 2001/064998 A,182-789-416-625-727,2002-01-21,2002,AU 2001/064998 A,2001-05-25,US 20781200 P;;US 85297801 A;;US 0117061 W,2000-05-30,System and method for converting light hydrocarbons into heavier hydrocarbons and for treating contaminated water,,SYNTROLEUM CORP,O'BECK JOHN TIMOTHY;;RUSSELL BRANCH JAMES,,https://lens.org/182-789-416-625-727,Patent Application,no,0,0,3,3,0,C10G2/32;;C10G2/32;;C02F1/02;;C02F1/02;;C07C1/0485;;C07C1/0485,C02F1/02;;C07C1/04;;C10G2/00,,0,0,,,,PENDING
36,DE,D1,DE 3266694 D1,081-321-509-900-884,1985-11-07,1985,DE 3266694 T,1982-07-22,GB 8124817 A,1981-08-13,"BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND THEIR USE",,BEECHAM GROUP PLC,PEARSON MICHAEL JOHN;;BRANCH CLIVE LESLIE,,https://lens.org/081-321-509-900-884,Granted Patent,no,0,0,4,4,0,A61P31/04;;C07D205/085;;C07C205/50;;C07D477/24;;C07F9/568,C07D477/00;;A61K31/397;;A61K31/40;;A61P31/04;;C07C205/50;;C07D205/085;;C07D477/24;;C07F9/568,,0,0,,,,EXPIRED
37,US,A1,US 2009/0221577 A1,060-605-929-122-487,2009-09-03,2009,US 56804905 A,2005-04-15,GB 0408777 A;;GB 2005001449 W,2004-04-20,COMPOUNDS HAVING MORPHOLINYL AND PIPERIDINYL GROUPS FOR USE AS GLYT1 INHIBITORS,"The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , n and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",GLAXO GROUP LTD,BRANCH CLIVE LESLIE;;NASH DAVID JOHN,GLAXO GROUP LIMITED (2005-05-19),https://lens.org/060-605-929-122-487,Patent Application,yes,0,2,5,5,0,A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D211/26;;C07D211/26,A61K31/5377;;A61K31/5375;;C07D211/26;;C07D413/12,514/235.5;;544/130,0,0,,,,DISCONTINUED
38,EP,A1,EP 0086563 A1,129-475-654-904-656,1983-08-24,1983,EP 83300234 A,1983-01-18,GB 8201777 A,1982-01-22,"Antibacterial agents, their preparation and use.",The present invention provides a β-lactam antibiotic having a sulphonic acid substituent or salt thereof at the 1-position and a hydroxymethylsubstituent at the 3-positions.,BEECHAM GROUP PLC,BRANCH CLIVE LESLIE;;PEARSON MICHEL JOHN,,https://lens.org/129-475-654-904-656,Patent Application,yes,3,1,2,2,0,A61P31/04;;C07D403/04;;C07D205/085;;C07D403/12;;C07F7/10;;C07F7/1804,C07D209/48;;A61K31/395;;A61K31/397;;A61P31/04;;C07D205/08;;C07D205/085;;C07D403/04;;C07D403/12;;C07F7/10;;C07F7/18,,0,0,,,,DISCONTINUED
39,US,A1,US 2002/0006969 A1,029-402-862-109-793,2002-01-17,2002,US 85297801 A,2001-05-10,US 85297801 A;;US 20781200 P,2000-05-30,System and method for converting light hydrocarbons into heavier hydrocarbons and for treating contaminated water,"
   Light hydrocarbons are converted into heavier hydrocarbons by preparing a synthesis gas, converting the synthesis gas to heavier hydrocarbons. Heat generated while preparing and converting synthesis gas is removed by creating steam that is then used in a water treatment unit to treat a water stream to remove contaminants such as salt. A process for preparing heavier hydrocarbons from light hydrocarbons, electricity, and treated water uses the energy of the conversion process is used to power a electrical generator and the thermal energy is used to assist in treating the water. Systems to convert light hydrocarbons to heavier with water treatment and electrical production are also presented. 
",O'BECK JOHN TIMOTHY;;RUSSELL BRANCH JAMES,O'BECK JOHN TIMOTHY;;RUSSELL BRANCH JAMES,SYNTROLEUM CORPORATION (2001-06-08),https://lens.org/029-402-862-109-793,Patent Application,yes,0,20,3,3,0,C10G2/32;;C10G2/32;;C02F1/02;;C02F1/02;;C07C1/0485;;C07C1/0485,C02F1/02;;C07C1/04;;C10G2/00,518/704,0,0,,,,DISCONTINUED
40,US,A,US 647820 A,191-457-570-061-54X,1900-04-17,1900,US 1899/0724783 A,1899-07-22,US 1899/0724783 A,1899-07-22,COMBINED TRUCK AND SACK-HOLDER.,,FINLEY JOHN B;;BRANCH BENJAMIN O,FINLEY JOHN B;;BRANCH BENJAMIN O,,https://lens.org/191-457-570-061-54X,Granted Patent,no,0,0,1,1,0,B65B67/1227;;B65B67/1227,,,0,0,,,,EXPIRED
41,EP,A3,EP 0034443 A3,071-950-139-165-323,1981-10-07,1981,EP 81300479 A,1981-02-04,GB 8005037 A,1980-02-14,"BETA-LACTAM ANTIBACTERIAL COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM","The present invention provides the compounds of the formula (II):
  and pharmaceutically acceptable salts and cleavable esters thereof wherein RCONH is an organic acylamino group and E is a carboxy group or pharmaceutically acceptable salt or ester thereof or is a cyano group. Their preparation is described as is their use in compositions containing them. Compounds wherein RCONH is replaced by an azido group are described as useful intermediates.",BEECHAM GROUP PLC,"PEARSON, MICHAEL JOHN;;BRANCH, CLIVE LESLIE",BEECHAM GROUP PLC (1982-05-12),https://lens.org/071-950-139-165-323,Search Report,yes,0,0,7,7,0,C07D205/085;;C07D477/24;;C07F9/568;;C07F7/1804;;A61P31/04;;C07D205/085;;C07D477/24;;C07F7/1804;;C07F9/568,A61K31/397;;A61K31/40;;A61P31/04;;C07D205/08;;C07D205/085;;C07D477/24;;C07D477/00;;C07D487/04;;C07F7/18;;C07F9/568,,0,0,,,,EXPIRED
42,US,B2,US 9126006 B2,141-327-440-029-956,2015-09-08,2015,US 201313848285 A,2013-03-21,US 201313848285 A;;US 2009/0065282 W;;US 201113130238 A;;US 11652508 P,2008-11-20,Subdural drainage catheter with self contained mechanism for restoration of flow following catheter obstruction,"A subdural drainage system includes (a) a subdural drainage device having an opening formed therethrough, said subdural drainage device having an upper portion, a body portion, and a lower portion; (b) a housing having an upper portion and lower portion, with said housing connected to said subdural drainage device; said housing movable between (i) a first configuration and (ii) a second configuration; and (c) a stylet positioned inside said housing, said stylet having an upper portion and a lower portion and configured such that said stylet is moved between (i) a withdrawn position with said stylet withdrawn from a portion of said subdural evacuation port device, and (ii) an extended position with said stylet extending through said subdural drainage device such that blockages are disrupted in the subdural drainage device when said housing is moved between said first and second housing configurations; and (d) an external drain opening formed on either said subdural drainage device or said housing.",UNIV WAKE FOREST HEALTH SCIENCES,BRANCH CHARLES L;;EICKMAN JOHN P,,https://lens.org/141-327-440-029-956,Granted Patent,yes,19,0,5,5,0,A61M27/00;;A61M27/00;;A61M25/01;;A61M25/01;;A61M25/04;;A61M25/04,A61M27/00;;A61B5/00;;A61M25/01;;A61M25/04,,3,1,046-582-133-950-168,16418360;;pmc7976074,"International Preliminary Report on Patentability Corresponding to International Patent Application No. PCT/US2009/065282; mailed May 24, 2011.;;Lollis et al. ""Imaging Characteristics of the Subdural Evacuating Port System, a New Bedside Therapy for Subacute/Chronic Subdural Hematoma"" American Journal of Neuroradiology 27:74-75 (2006).;;""Subdural Drainage Catheter Kit: Subdural Catheter"" Integra Neurosciences Instructions for Use: 3 pages (2003).",ACTIVE
43,DE,D1,DE 3166235 D1,044-963-189-503-259,1984-10-31,1984,DE 3166235 T,1981-02-04,GB 8005037 A,1980-02-14,"BETA-LACTAM ANTIBACTERIAL COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",The present invention provides the compounds of the formula (II):and pharmaceutically acceptable salts and cleavable esters thereof wherein RCONH is an organic acylamino group and E is a carboxy group or pharmaceutically acceptable salt or ester thereof or is a cyano group. Their preparation is described as is their use in compositions containing them. Compounds wherein RCONH is replaced by an azido group are described as useful intermediates.,BEECHAM GROUP PLC,PEARSON MICHAEL JOHN;;BRANCH CLIVE LESLIE,,https://lens.org/044-963-189-503-259,Granted Patent,no,0,0,7,7,0,C07D205/085;;C07D477/24;;C07F9/568;;C07F7/1804;;A61P31/04;;C07D205/085;;C07D477/24;;C07F7/1804;;C07F9/568,C07D477/00;;A61K31/397;;A61K31/40;;A61P31/04;;C07D205/08;;C07D205/085;;C07D477/24;;C07D487/04;;C07F7/18;;C07F9/568,,0,0,,,,EXPIRED
44,WO,A1,WO 2002/004387 A1,059-635-914-977-61X,2002-01-17,2002,US 0117061 W,2001-05-25,US 20781200 P;;US 85297801 A,2000-05-30,SYSTEM AND METHOD FOR CONVERTING LIGHT HYDROCARBONS INTO HEAVIER HYDROCARBONS AND FOR TREATING CONTAMINATED WATER,"Light hydrocarbons are converted into heavier hydrocarbons by preparing a synthesis gas, converting the synthesis gas to heavier hydrocarbons. Heat generated while preparing and converting synthesis gas is removed by creating steam that is then used in a water treatment unit to treat a water stream to remove contaminants such as salts. A process for preparing heavier hydrocarbons from light hydrocarbons, electricity, and treated water uses the energy of the conversion process is used to power a electrical generator and the thermal energy is used to assist in treating the water. Systems to convert light hydrocarbons to heavier with water treatment and electrical production are also presented.",SYNTROLEUM CORP,O'BECK JOHN TIMOTHY;;RUSSELL BRANCH JAMES,,https://lens.org/059-635-914-977-61X,Patent Application,yes,2,3,3,3,0,C10G2/32;;C10G2/32;;C02F1/02;;C02F1/02;;C07C1/0485;;C07C1/0485,C02F1/02;;C07C1/04;;C10G2/00,,0,0,,,,PENDING
45,FR,A,FR 1375565 A,126-938-146-687-455,1964-10-16,1964,FR 955150 A,1963-11-27,FR 955150 A,1963-11-27,Procédé de préparation d'acide sorbique,,DISTILLERS CO YEAST LTD,BRANCH SIDNEY JOHN;;DAVEY RONALD ERNEST,,https://lens.org/126-938-146-687-455,Granted Patent,no,0,0,1,1,0,C07C51/09,C07C51/09,,0,0,,,,EXPIRED
46,EP,B1,EP 0034443 B1,151-882-625-642-269,1984-09-26,1984,EP 81300479 A,1981-02-04,GB 8005037 A,1980-02-14,"BETA-LACTAM ANTIBACTERIAL COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",The present invention provides the compounds of the formula (II):and pharmaceutically acceptable salts and cleavable esters thereof wherein RCONH is an organic acylamino group and E is a carboxy group or pharmaceutically acceptable salt or ester thereof or is a cyano group. Their preparation is described as is their use in compositions containing them. Compounds wherein RCONH is replaced by an azido group are described as useful intermediates.,BEECHAM GROUP PLC,"PEARSON, MICHAEL JOHN;;BRANCH, CLIVE LESLIE",BEECHAM GROUP PLC (1982-05-12),https://lens.org/151-882-625-642-269,Granted Patent,yes,3,0,7,7,0,C07D205/085;;C07D477/24;;C07F9/568;;C07F7/1804;;A61P31/04;;C07D205/085;;C07D477/24;;C07F7/1804;;C07F9/568,A61K31/397;;A61K31/40;;A61P31/04;;C07D205/08;;C07D205/085;;C07D477/24;;C07D477/00;;C07D487/04;;C07F7/18;;C07F9/568,,0,0,,,,EXPIRED
47,DE,A1,DE 1443716 A1,190-858-163-389-493,1968-11-21,1968,DE 1443716 A,1963-11-29,GB 4685062 A,1962-12-12,Verfahren zur Herstellung von Sorbinsaeure,,DISTILLERS CO YEAST LTD,JOHN BRANCH SIDNEY;;ERNEST DAVEY RONALD,,https://lens.org/190-858-163-389-493,Patent Application,no,0,0,3,3,0,C07C51/00;;C07C51/09,C07C51/00;;C07C51/09,,0,0,,,,DISCONTINUED
48,WO,A1,WO 2019/241441 A1,069-477-738-162-703,2019-12-19,2019,US 2019/0036847 W,2019-06-12,US 201862683692 P,2018-06-12,TMEM-MCD IN THE MINIMALLY INVASIVE ASSESSMENT OF THE ACTIVITY STATUS OF TMEM IN ITS DISSEMINATION OF TUMOR CELLS,"Methods are provided for measuring the activity of TMEM sites in a tumor comprising measuring a transient increase in permeability of blood vessels at TMEM sites that allows tumor cells to enter the blood vessels, wherein permeability is measured using a modality selected from the group consisting of MRI, PET, CT, and SPECT, and wherein a transient increase in permeability indicates that a TMEM site is active. The method can include, for example, obtaining a MenaINV score assessed by fine needle aspiration in the same tissue. The present invention can be used as both a prognostic for dissemination and a predictive end point for identification and validation of dissemination inhibitors/anti-metastasis drugs.",ALBERT EINSTEIN COLLEGE OF MEDICINE;;MONTEFIORE MED CENTER,CONDEELIS JOHN;;BRANCH CRAIG;;OKTAY MAJA,,https://lens.org/069-477-738-162-703,Patent Application,yes,2,0,2,2,0,A61K31/444;;A61K49/105;;A61K31/337;;A61K31/357;;A61K31/675;;A61K31/704;;A61K31/7048;;A61K33/243;;A61K49/105;;G01N2800/52,G01N33/574;;A61K49/06;;C07K16/22;;C07K16/28;;C07K16/30,,1,1,117-941-313-229-648,pmc5592784;;10.1126/scitranslmed.aan0026;;28679654,"KARAGIANNIS ET AL.: ""Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism"", SCI TRANSL MED, vol. 9, no. 397, 5 July 2017 (2017-07-05), pages eaan0026, XP055663783",PENDING
49,EP,A1,EP 1737849 A1,097-125-904-655-738,2007-01-03,2007,EP 05734214 A,2005-04-15,GB 2005001449 W;;GB 0408777 A,2004-04-20,COMPOUNDS HAVING MORPHOLINYL AND PIPERIDINYL GROUPS FOR USE AS GLYT1 INHIBITORS,,GLAXO GROUP LTD,BRANCH CLIVE LESLIE;;NASH DAVID JOHN,,https://lens.org/097-125-904-655-738,Patent Application,yes,0,0,5,5,0,A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D211/26;;C07D211/26,C07D413/04;;A61K31/5375;;A61P25/00;;C07D211/26;;C07D413/12,,1,0,,,See references of WO 2005103042A1,DISCONTINUED
50,CA,A,CA 38899 A,157-464-064-855-227,1892-05-09,1892,CA 38899D A,,CA 38899T A,,GAME,,SIBLEY WHITE JOHN;;COLBY BRANCH HARRIS,SIBLEY WHITE JOHN;;COLBY BRANCH HARRIS,,https://lens.org/157-464-064-855-227,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
51,US,A1,US 2021/0244830 A1,044-958-793-420-656,2021-08-12,2021,US 201916972798 A,2019-06-12,US 201916972798 A;;US 201862683692 P;;US 2019/0036847 W,2018-06-12,TMEM-MCD IN THE MINIMALLY INVASIVE ASSESSMENT OF THE ACTIVITY STATUS OF TMEM IN ITS DISSEMINATION OF TUMOR CELLS,"Methods are provided for measuring the activity of TMEM sites in a tumor comprising measuring a transient increase in permeability of blood vessels at TMEM sites that allows tumor cells to enter the blood vessels, wherein permeability is measured using a modality selected from the group consisting of MRI, PET, CT, and SPECT, and wherein a transient increase in permeability indicates that a TMEM site is active. The method can include, for example, obtaining a MenaINV score assessed by fine needle aspiration in the same tissue. The present invention can be used as both a prognostic for dissemination and a predictive end point for identification and validation of dissemination inhibitors/anti-metastasis drugs.",ALBERT EINSTEIN COLLEGE OF MEDICINE;;MONTEFIORE MED CENTER,CONDEELIS JOHN;;BRANCH CRAIG;;OKTAY MAJA,ALBERT EINSTEIN COLLEGE OF MEDICINE (2021-10-08);;MONTEFIORE MEDICAL CENTER (2023-01-17),https://lens.org/044-958-793-420-656,Patent Application,yes,0,0,2,2,0,A61K49/105;;G01N2800/52;;A61K31/444;;A61K31/337;;A61K31/357;;A61K31/7048;;A61K31/704;;A61K33/243;;A61K31/675;;A61K49/105,A61K49/10,,2,2,002-677-878-837-480;;031-299-912-237-662,10.1259/bjr/31662734;;12595324;;10.1007/s10585-011-9388-6;;21484349;;pmc3459587,"Li, Kaloh L., et al. ""Simultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data."" The British Journal of Radiology 76.901 (2003): 39-51. (Year: 2003);;Roussos ET, Goswami S, Balsamo M, Wang Y, Stobezki R, Adler E, Robinson BD, Jones JG, Gertler FB, Condeelis JS, Oktay MH. Mena invasive (Mena INV) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM. Clinical & experimental metastasis. 2011 Aug;28:515-27. (Year: 2011)",PENDING
52,EP,A1,EP 0048096 A1,063-133-308-550-127,1982-03-24,1982,EP 81303889 A,1981-08-26,GB 8029660 A,1980-09-13,Beta-lactam antibacterial agents.,"A compound of formula (I) or a salt thereof:
  
 wherein R' is an amino group, an azido group, or an acylamino group as found in antibacterially active penicillins or cephalosporins; R 2  is a hydrogen atom or a C 1-4  alkyl group; R 3  is a hydrogen atom, or a C 1-4  alkyl group optionally substituted by a carboxyl, carboxylic ester, hydroxy, C 1-4  alkyloxy, acyloxy or heterocyclylthio group; and R 4  is hydrogen or a readily removable carboxyl protecting group. The compounds wherein R 1  is an acylamino group are found in known antibacterially active penicillins and cephalosporins and wherein R 4  is a hydrogen, a pharmaceutically acceptable salting ion or an in vivo hydrolysable ester forming radical may be formulated in pharmaceutical compositions. Processes for the preparation of the compound (I) are also described.",BEECHAM GROUP PLC,PEARSON MICHAEL JOHN;;BRANCH CLIVE LESLIE,BEECHAM GROUP PLC (1982-05-12),https://lens.org/063-133-308-550-127,Patent Application,yes,1,0,3,3,0,C07D205/085;;C07D487/14;;C07F7/0812;;Y02P20/55;;A61P31/04;;C07D487/14;;C07F7/0812;;C07D205/085;;Y02P20/55,A61K31/495;;A61P31/04;;C07D205/085;;C07D487/14;;C07F7/08,,0,0,,,,DISCONTINUED
53,US,A1,US 2013/0218101 A1,065-991-316-194-322,2013-08-22,2013,US 201313848285 A,2013-03-21,US 201313848285 A;;US 2009/0065282 W;;US 201113130238 A;;US 11652508 P,2008-11-20,Subdural Drainage Catheter with Self Contained Mechanism for Restoration of Flow Following Catheter Obstruction,"A subdural drainage system includes (a) a subdural drainage device having an opening formed therethrough, said subdural drainage device having an upper portion, a body portion, and a lower portion; (b) a housing having an upper portion and lower portion, with said housing connected to said subdural drainage device; said housing movable between (i) a first configuration and (ii) a second configuration; and (c) a stylet positioned inside said housing, said stylet having an upper portion and a lower portion and configured such that said stylet is moved between (i) a withdrawn position with said stylet withdrawn from a portion of said subdural evacuation port device, and (ii) an extended position with said stylet extending through said subdural drainage device such that blockages are disrupted in the subdural drainage device when said housing is moved between said first and second housing configurations; and (d) an external drain opening formed on either said subdural drainage device or said housing.",UNIV WAKE FOREST HEALTH SCIENCES;;UNIV WAKE FOREST HEALTH SCIENCES,BRANCH CHARLES L;;EICKMAN JOHN P,,https://lens.org/065-991-316-194-322,Patent Application,yes,5,0,5,5,0,A61M27/00;;A61M27/00;;A61M25/01;;A61M25/01;;A61M25/04;;A61M25/04,A61M27/00,604/267,0,0,,,,ACTIVE
54,DE,B,DE 1196229 B,166-420-457-947-378,1965-07-08,1965,DE J0019495 A,1961-02-25,GB 658960 A,1960-02-25,Sicherheitsschaltung mit magnetisierbaren Ringkernen fuer Eisenbahnsicherungszwecke,,INT STANDARD ELECTRIC CORP,BRANCH MAURICE CHARLES;;LANGLOIS PETER JOHN,,https://lens.org/166-420-457-947-378,Patent Application,no,1,3,2,2,0,B61L1/20;;H03K19/16,B61L1/20;;H03K19/16,,0,0,,,,DISCONTINUED
55,GB,A,GB 989798 A,195-922-887-093-327,1965-04-22,1965,GB 4685062 A,1962-12-12,GB 4685062 A,1962-12-12,Production of sorbic acid,"Sorbic acid is prepared by reacting ketene with crotonaldehyde in presence of a catalyst and heating the resulting polyester with a mineral acid in an aromatic hydrocarbon medium to form sorbic acid which is recovered from the product. Catalysts may be barium, calcium, mercury, nickel, cobalt and copper salts of aliphatic carboxylic acids such as acetic, propionic and sorbic acids, and zinc resinate is preferred. The intermediate polyester may be used as the crude reaction product or separated from the catalyst and excess reactant. The aromatic hydrocarbon medium may be, benzene, toluene, a xylene, ethyl benzene, higher methyl benzene, a polyethyl benzene or mixtures thereof, and the preferred mineral acids are sulphuric or orthophosphoric acids. The heating stage may be from 50 DEG to 200 DEG C., batchwise or continuous, and the sorbic acid is crystallized from the aromatic hydrocarbon medium.",DISTILLERS CO YEAST LTD,BRANCH SIDNEY JOHN;;DAVEY RONALD ERNEST,,https://lens.org/195-922-887-093-327,Granted Patent,no,0,1,3,3,0,C07C51/00;;C07C51/09,C07C51/00;;C07C51/09,C2C CCQ;;C2C CCY;;C2C C20Y;;C2C C20Y;;C2C C200;;C2C C21X;;C2C C21X;;C2C C237;;C2C C30Y;;C2C C30Y;;C2C C304;;C2C C36Y;;C2C C360;;C2C C362;;C2C C366;;C2C C366;;C2C C367;;C2C C367;;C2C C368;;C2C C37X;;C2C C47X;;C2C C490;;C2C C490;;C2C C491;;C2C C50Y;;C2C C507;;C2C C509;;C2C C623;;C2C C628;;C2C C648;;C2C C66Y,0,0,,,,EXPIRED
56,AT,T1,AT E9584 T1,049-935-199-982-402,1984-10-15,1984,AT 81300479 T,1981-02-04,EP 81300479 A;;GB 8005037 A,1980-02-14,"ANTIBAKTERIELLE BETA-LACTAM-VERBINDUNGEN, IHRE HERSTELLUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN.",The present invention provides the compounds of the formula (II):and pharmaceutically acceptable salts and cleavable esters thereof wherein RCONH is an organic acylamino group and E is a carboxy group or pharmaceutically acceptable salt or ester thereof or is a cyano group. Their preparation is described as is their use in compositions containing them. Compounds wherein RCONH is replaced by an azido group are described as useful intermediates.,BEECHAM GROUP PLC,"PEARSON, MICHAEL JOHN;;BRANCH, CLIVE LESLIE",,https://lens.org/049-935-199-982-402,Granted Patent,no,0,0,7,7,0,C07D205/085;;C07D477/24;;C07F9/568;;C07F7/1804;;A61P31/04;;C07D205/085;;C07D477/24;;C07F7/1804;;C07F9/568,C07D477/00;;A61K31/397;;A61K31/40;;A61P31/04;;C07D205/08;;C07D205/085;;C07D477/24;;C07D487/04;;C07F7/18;;C07F9/568,,0,0,,,,DISCONTINUED
57,CA,A,CA 163013 A,140-172-678-089-449,1915-06-08,1915,CA 163013D A,1915-02-08,CA 163013T A,1915-02-08,"INDEX FOR LAND TITLES, ETC.",,BRANCH JOHN LAWRENCE;;BUCHANAN CLINTON C,BRANCH JOHN LAWRENCE;;BUCHANAN CLINTON C,,https://lens.org/140-172-678-089-449,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
58,WO,A1,WO 2005/103042 A1,155-273-355-794-415,2005-11-03,2005,GB 2005001449 W,2005-04-15,GB 0408777 A,2004-04-20,COMPOUNDS HAVING MORPHOLINYL AND PIPERIDINYL GROUPS FOR USE AS GLYT1 INHIBITORS,"The invention provides a compound of formula (I) or a salt or solvate thereof: (I); wherein R, R1, R2, R3, R4, R5, R6, R7, R8, n and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",GLAXO GROUP LTD;;BRANCH CLIVE LESLIE;;NASH DAVID JOHN,BRANCH CLIVE LESLIE;;NASH DAVID JOHN,,https://lens.org/155-273-355-794-415,Patent Application,yes,3,5,5,5,0,A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D211/26;;C07D211/26,A61K31/5375;;C07D211/26;;C07D413/12,,0,0,,,,PENDING
59,US,A,US 4108992 A,045-685-228-800-790,1978-08-22,1978,US 76621377 A,1977-02-07,GB 1974475 A;;US 68407876 A,1975-05-10,CEPHALOSPORIN ANALOGUES AND COMPOSITIONS,"Novel cephalosporin analogues, salts and esters thereof, their preparation, intermediates and antibacterial compositions containing them. The compositions are formulated for human use into unit dosage form containing 100-4,000 mg of antibacterial compound. The cephem analogues are characterized by having a ring O-heteroatom instead of a ring N-heteroatom and are designated as oxacephems.",BEECHAM GROUP LTD,PEARSON MICHAEL JOHN;;BRANCH CLIVE LESLIE,,https://lens.org/045-685-228-800-790,Granted Patent,yes,6,9,1,3,0,C07D505/00;;C07D505/00;;C07D205/085;;C07D205/085;;C07F9/568;;C07F9/568,C07D205/085;;C07D505/00;;C07F9/568,424/248.53,1,1,062-588-083-853-040,10.1002/jhet.5570050607,"J. Heterocyclic Chem. 5, 779-783, 1968-Sheehan et al., ""The Synthesis of Oxygen Analogs of Cepham"".",EXPIRED
60,EP,B1,EP 0073100 B1,006-027-122-257-022,1985-10-02,1985,EP 82303858 A,1982-07-22,GB 8124817 A,1981-08-13,"BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND THEIR USE",,BEECHAM GROUP PLC,"PEARSON, MICHAEL JOHN;;BRANCH, CLIVE LESLIE",,https://lens.org/006-027-122-257-022,Granted Patent,yes,0,0,4,4,0,A61P31/04;;C07D205/085;;C07C205/50;;C07D477/24;;C07F9/568,C07D477/00;;A61K31/397;;A61K31/40;;A61P31/04;;C07C205/50;;C07D205/085;;C07D477/24;;C07F9/568,,0,0,,,,EXPIRED
61,WO,A1,WO 2014/153508 A1,072-753-723-936-717,2014-09-25,2014,US 2014/0031441 W,2014-03-21,US 201361803952 P,2013-03-21,SUBDURAL DRAINAGE CATHETER WITH SELF CONTAINED MECHANISM FOR RESTORATION OF FLOW FOLLOWING CATHETER OBSTRUCTION,"A subdural drainage system includes: (a) a subdural drainage device having an opening formed therethrough, said subdural drainage device having an upper portion, a body portion, and a lower portion; (b) a housing having an upper portion and lower portion, with said housing connected to said subdural drainage device; said housing movable between (i) a first configuration and (ii) a second configuration; and (c) an elongated element positioned inside said housing, said elongated element having an upper portion, a lower portion and a deformable member connected to the lower portion; said elongated element being configured such that said elongated element is moved between (i) a retracted position with said elongated element inside a portion of said subdural drainage device and said deformable member inside said housing, and (ii) an extended position with said elongated element extending through said subdural drainage device such that said deformable member automatically extends to an extended, deformed position in which blockages are disrupted in the subdural drainage device when said housing is moved between said first and second housing configurations; and (d) an external drain opening formed on either said subdural drainage device or said housing.",UNIV WAKE FOREST HEALTH SCIENCES,BRANCH CHARLES L JR;;EICKMAN JOHN P,,https://lens.org/072-753-723-936-717,Patent Application,yes,6,2,3,3,0,A61M27/00;;A61M27/00;;A61M25/02;;A61M25/02;;A61M39/02;;A61M39/08;;A61M39/08;;A61M2025/0019;;A61M2025/0233;;A61M2025/0233;;A61M2039/025;;A61M2039/0276;;A61M2210/0687;;A61M2210/0687,A61M1/00;;A61B19/02;;A61M25/01;;A61M27/00;;A61M39/08,,0,0,,,,PENDING
62,US,A1,US 2011/0282263 A1,192-037-479-037-632,2011-11-17,2011,US 200913130238 A,2009-11-20,US 200913130238 A;;US 11652508 P;;US 2009/0065282 W,2008-11-20,Subdural Drainage Catheter with Flow Restoration Mechanism,"A subdural drainage system includes (a) a subdural drainage device having an opening formed therethrough, said subdural drainage device having an upper portion, a body portion, and a lower portion; (b) a housing having an upper portion and lower portion, with said housing connected to said subdural drainage device; said housing movable between (i) a first configuration and (ii) a second configuration; and (c) a stylet positioned inside said housing, said stylet having an upper portion and a lower portion and configured such that said stylet is moved between (i) a withdrawn position with said stylet withdrawn from a portion of said subdural evacuation port device, and (ii) an extended position with said stylet extending through said subdural drainage device such that blockages are disrupted in the subdural drainage device when said housing is moved between said first and second housing configurations; and (e) an external drain opening formed on either said subdural drainage device or said housing.",BRANCH JR CHARLES L;;EICKMAN JOHN P,BRANCH JR CHARLES L;;EICKMAN JOHN P,WAKE FOREST UNIVERSITY HEALTH SCIENCES (2011-07-07),https://lens.org/192-037-479-037-632,Patent Application,yes,5,9,5,5,0,A61M27/00;;A61M27/00;;A61M25/01;;A61M25/01;;A61M25/04;;A61M25/04,A61M5/00;;B65D71/00,604/8;;206/223,0,0,,,,INACTIVE
63,US,B2,US 9993630 B2,113-916-205-469-767,2018-06-12,2018,US 201414778340 A,2014-03-21,US 201414778340 A;;US 201361803952 P;;US 2014/0031441 W,2013-03-21,Subdural drainage catheters with self contained mechanism for restoration of flow following catheter obstruction,"A subdural drainage system includes: (a) a subdural drainage device having an opening formed therethrough, said subdural drainage device having an upper portion, a body portion, and a lower portion; (b) a housing having an upper portion and lower portion, with said housing connected to said subdural drainage device; said housing movable between (i) a first configuration and (ii) a second configuration; and (c) an elongated element positioned inside said housing, said elongated element having an upper portion, a lower portion and a deformable member connected to the lower portion; said elongated element being configured such that said elongated element is moved between (i) a retracted position with said elongated element inside a portion of said subdural drainage device and said deformable member inside said housing, and (ii) an extended position with said elongated element extending through said subdural drainage device such that said deformable member automatically extends to an extended, deformed position in which blockages are disrupted in the subdural drainage device when said housing is moved between said first and second housing configurations; and (d) an external drain opening formed on either said subdural drainage device or said housing.",UNIV WAKE FOREST HEALTH SCIENCES,BRANCH JR CHARLES L;;EIKMAN JOHN P,WAKE FOREST UNIVERSITY HEALTH SCIENCES (2018-05-14),https://lens.org/113-916-205-469-767,Granted Patent,yes,6,0,3,3,0,A61M27/00;;A61M27/00;;A61M25/02;;A61M25/02;;A61M39/02;;A61M39/08;;A61M39/08;;A61M2025/0019;;A61M2025/0233;;A61M2025/0233;;A61M2039/025;;A61M2039/0276;;A61M2210/0687;;A61M2210/0687,A61M27/00;;A61M25/00;;A61M25/02;;A61M39/02;;A61M39/08,,0,0,,,,INACTIVE
64,US,A,US 3152431 A,196-346-683-342-831,1964-10-13,1964,US 19192562 A,1962-05-02,US 19192562 A,1962-05-02,Lawn mower,,OTT VIVIAN L;;BEAMAN JR JOHN BRANCH,OTT VIVIAN L;;BEAMAN JR JOHN BRANCH,,https://lens.org/196-346-683-342-831,Granted Patent,no,10,39,1,1,0,A01D34/412;;A01D34/66;;A01D34/412;;A01D34/66,A01D34/412;;A01D34/66,,0,0,,,,EXPIRED
65,US,A1,US 2017/0291017 A1,085-459-065-867-530,2017-10-12,2017,US 201515511475 A,2015-09-23,US 201515511475 A;;US 201462053964 P;;US 2015/0051679 W,2014-09-23,SUBDURAL DRAINAGE CATHETER WITH SELF CONTAINED MECHANISM FOR RESTORATION OF FLOW FOLLOWING CATHETER OBSTRUCTION,"A subdural drainage device includes a subdural drainage housing defining a drainage passageway. The drainage passageway has a A subdural drainage device includes a subdural drainage housing defining a drainage passageway. The drainage passageway has a lower opening configured to connect to a subdural space of a patient and an upper opening. A blockage removal unit is in the housing, and the blockage removal unit has an end portion that is configured to reduce or remove blockages adjacent the lower opening of the drainage passageway that is movable between a retracted position in which the end portion is in the subdural drainage housing and an extended position in which the end portion of the blockage removal unit extends away from the subdural drainage housing via the lower opening of the drainage passageway. At least one side delivery port is in the housing and in fluid communication with the drainage passageway.",UNIV WAKE FOREST HEALTH SCIENCES,BRANCH JR CHARLES L;;EICKMAN JOHN P,,https://lens.org/085-459-065-867-530,Patent Application,yes,25,1,2,2,0,A61M27/00;;A61M27/00;;A61M25/0017;;A61M25/0017;;A61M25/002;;A61M39/0247;;A61M39/0247;;A61M39/04;;A61M2025/0019;;A61M2025/0019;;A61M2039/025;;A61M2039/0264;;A61M2039/0264;;A61M2039/0273;;A61M2039/0273;;A61M2039/0276;;A61M2205/0266,A61M27/00;;A61M25/00;;A61M39/02;;A61M39/04,,0,0,,,,DISCONTINUED
66,US,A,US 3190479 A,149-164-528-992-808,1965-06-22,1965,US 24765162 A,1962-12-27,US 24765162 A,1962-12-27,Hand trucks,,OTT VIVIAN L;;BEAMAN JR JOHN BRANCH,OTT VIVIAN L;;BEAMAN JR JOHN BRANCH,,https://lens.org/149-164-528-992-808,Granted Patent,no,5,1,1,1,0,B62B1/264;;B62B1/264;;B62B1/206;;B62B1/206;;B62B2202/20;;B62B2202/20,B62B1/20;;B62B1/26,,0,0,,,,EXPIRED
67,US,A,US 3218789 A,040-408-522-408-987,1965-11-23,1965,US 23014462 A,1962-10-12,US 23014462 A,1962-10-12,Lawn edge and hedge trimmer,,OTT VIVIAN L;;BEAMAN JR JOHN BRANCH,OTT VIVIAN L;;BEAMAN JR JOHN BRANCH,,https://lens.org/040-408-522-408-987,Granted Patent,no,11,6,1,1,0,A01G3/062;;A01G3/062,A01G3/06,,0,0,,,,EXPIRED
68,US,A,US 3116073 A,171-067-642-067-731,1963-12-31,1963,US 18813262 A,1962-04-17,US 18813262 A,1962-04-17,Tricycle structure,,OTT VIVIAN L;;BEAMAN JR JOHN BRANCH,OTT VIVIAN L;;BEAMAN JR JOHN BRANCH,,https://lens.org/171-067-642-067-731,Granted Patent,no,9,7,1,1,0,B62K9/02;;B62K9/02,B62K9/02,,0,0,,,,EXPIRED
69,GB,A,GB 2126298 A,196-101-455-350-922,1984-03-21,1984,GB 8223537 A,1982-08-16,GB 8223537 A,1982-08-16,Soldered joint for copper pipes,"A method of making a joint between a fitting and a pipe includes providing the fitting with an inwardly- chamfered open end (46), encircling the pipe with a ring of solder (54), and entering the pipe into the fitting. The ring of solder is moved along the pipe towards the fitting until it at least partly occupies the space bounded by the chamfer, the pipe is heated at a region spaced from the fitting so that the solder spreads into the space between the confronting surfaces of the pipe and the fitting and bonds them together. The chamfer on the open end of the fitting may for example be such as to provide a surface at from about 20 to 40 degrees to the axis of the fitting. <IMAGE>",BRANCH JOHN WILLIAM FREDERICK;;MEGENBIER KARL HEINZ,BRANCH JOHN WILLIAM FREDERICK;;MEGENBIER KARL HEINZ,,https://lens.org/196-101-455-350-922,Patent Application,no,1,6,1,1,0,F16L13/08,F16L13/08,B3R RBJ           RBJ;;B3R R115          RBJ;;B3R R22G          R22G;;B3R R309          RBJ;;F2G G18           G18Z;;F2G G18A          G18Z,0,0,,,,DISCONTINUED
70,DE,C3,DE 2003525 C3,143-877-854-153-462,1985-10-03,1985,DE 2003525 A,1970-01-27,US 79692369 A;;US 86422769 A,1969-02-05,DE 2003525 C3,,"INTERNATIONAL FLAVORS & FRAGRANCES INC., NEW YORK, N.Y., US","EVERS, WILLIAM JOHN, LONG BRANCH, N.J., US",,https://lens.org/143-877-854-153-462,Granted Patent,no,0,0,23,38,0,C07D307/30;;C07D307/64;;C07D307/68;;A23L27/2052,A23L13/00;;A23L27/20;;A23L27/60;;C07D307/30;;C07D307/64;;C07D307/68;;C07D307/82;;C07D495/14,,0,0,,,,EXPIRED
71,US,A,US 3140575 A,182-649-898-886-000,1964-07-14,1964,US 24757862 A,1962-12-27,US 24757862 A,1962-12-27,Cutter unit for rotary mowers,,OTT VIVIAN L;;BEAMAN JR JOHN BRANCH,OTT VIVIAN L;;BEAMAN JR JOHN BRANCH,,https://lens.org/182-649-898-886-000,Granted Patent,no,3,11,1,1,0,A01D34/73;;A01D34/73;;A01D2101/00;;A01D2101/00,A01D34/63,,0,0,,,,EXPIRED
72,WO,A1,WO 2016/049155 A1,194-785-061-351-41X,2016-03-31,2016,US 2015/0051679 W,2015-09-23,US 201462053964 P,2014-09-23,SUBDURAL DRAINAGE CATHETER WITH SELF CONTAINED MECHANISM FOR RESTORATION OF FLOW FOLLOWING CATHETER OBSTRUCTION,"A subdural drainage device includes a subdural drainage housing defining a drainage passageway. The drainage passageway has a A subdural drainage device includes a subdural drainage housing defining a drainage passageway. The drainage passageway has a lower opening configured to connect to a subdural space of a patient and an upper opening. A blockage removal unit is in the housing, and the blockage removal unit has an end portion that is configured to reduce or remove blockages adjacent the lower opening of the drainage passageway that is movable between a retracted position in which the end portion is in the subdural drainage housing and an extended position in which the end portion of the blockage removal unit extends away from the subdural drainage housing via the lower opening of the drainage passageway. At least one side delivery port is in the housing and in fluid communication with the drainage passageway.",UNIV WAKE FOREST HEALTH SCIENCES,BRANCH JR CHARLES L;;EICKMAN JOHN P,,https://lens.org/194-785-061-351-41X,Patent Application,yes,5,0,2,2,0,A61M27/00;;A61M27/00;;A61M25/0017;;A61M25/0017;;A61M25/002;;A61M39/0247;;A61M39/0247;;A61M39/04;;A61M2025/0019;;A61M2025/0019;;A61M2039/025;;A61M2039/0264;;A61M2039/0264;;A61M2039/0273;;A61M2039/0273;;A61M2039/0276;;A61M2205/0266,A61M27/00;;A61M25/00;;A61M25/04,,0,0,,,,PENDING
73,CA,A,CA 861500 A,000-447-552-362-888,1971-01-19,1971,CA 861500D A,,CA 861500T A,,LUBRICANTS,,DISTILLERS CO YEAST LTD,COUPLAND KEITH;;PENNINGTON JOHN;;BRANCH SIDNEY J,,https://lens.org/000-447-552-362-888,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
74,US,B2,US 8403878 B2,002-155-571-652-483,2013-03-26,2013,US 200913130238 A,2009-11-20,US 200913130238 A;;US 11652508 P;;US 2009/0065282 W,2008-11-20,Subdural drainage catheter with flow restoration mechanism,"A subdural drainage system includes (a) a subdural drainage device having an opening formed therethrough, said subdural drainage device having an upper portion, a body portion, and a lower portion; (b) a housing having an upper portion and lower portion, with said housing connected to said subdural drainage device; said housing movable between (i) a first configuration and (ii) a second configuration; and (c) a stylet positioned inside said housing, said stylet having an upper portion and a lower portion and configured such that said stylet is moved between (i) a withdrawn position with said stylet withdrawn from a portion of said subdural evacuation port device, and (ii) an extended position with said stylet extending through said subdural drainage device such that blockages are disrupted in the subdural drainage device when said housing is moved between said first and second housing configurations; and (e) an external drain opening formed on either said subdural drainage device or said housing.",BRANCH JR CHARLES L;;EICKMAN JOHN P;;UNIV WAKE FOREST HEALTH SCIENCES,BRANCH JR CHARLES L;;EICKMAN JOHN P,WAKE FOREST UNIVERSITY HEALTH SCIENCES (2011-07-07),https://lens.org/002-155-571-652-483,Granted Patent,yes,18,6,5,5,0,A61M27/00;;A61M27/00;;A61M25/01;;A61M25/01;;A61M25/04;;A61M25/04,A61M5/00,604/8;;604/541,5,2,046-582-133-950-168;;046-582-133-950-168,16418360;;pmc7976074;;16418360;;pmc7976074,"""Subdural Drainage Catheter Kit Subdural Catheter"" 2003 by Intega NeuroSciences pp. 1-8).;;S.S. Lollis et al; ""Imaging Characteristics of the Subdural Evacuating Port System, a New Bedside Therapy for Subacute/Chronic Subdura Hematoma"", Jan. 2006, Lollis/AJNR 27, www.ajnr.org.;;International Preliminary Report of Patentability for PCT/US2009/065282 mailed Jun. 3, 2011.;;""Subdural Drainage Catheter Kit"" Integra NeuroSciences, 2003 BL91506-10.;;S.S. Lolis; ""Imaging Characteristics of the Subdural Evacuating Port System, a New Bedside Therapy for Subacute/Chronic Subdural Hematoma""; 74 Lollis/AJNR 27/ Jan. 2006; www.ajnr.org.",INACTIVE
75,GB,A,GB 189818044 A,044-202-663-828-91X,1899-08-19,1899,GB 189818044D A,1898-08-22,GB 189818044T A,1898-08-22,Improvements in the Manufacture of Boots and Shoes.,"18,044. Law, S. F., Smith, R., and Branch, J. Aug.22. Lasting.-The tacks b used to temporarily connect the insole, uppers, and outer sole are withdrawn, after stitching, preferably by a tape or strip c through which the tacks are pressed before they are driven into the insole a.",LAW SAMUEL FRANK;;SMITH RICHARD;;BRANCH JOHN,LAW SAMUEL FRANK;;SMITH RICHARD;;BRANCH JOHN,,https://lens.org/044-202-663-828-91X,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
76,WO,A1,WO 2010/059915 A1,112-122-686-818-663,2010-05-27,2010,US 2009/0065282 W,2009-11-20,US 11652508 P,2008-11-20,SUBDURAL DRAINAGE CATHETER WITH FLOW RESTORATION MECHANISM,"A subdural drainage system includes (a) a subdural drainage device having an opening formed therethrough, said subdural drainage device having an upper portion, a body portion, and a lower portion; (b) a housing having an upper portion and lower portion, with said housing connected to said subdural drainage device; said housing movable between (i) a first configuration and (ii) a second configuration; and (c) a stylet positioned inside said housing, said stylet having an upper portion and a lower portion and configured such that said stylet is moved between (i) a withdrawn position with said stylet withdrawn from a portion of said subdural evacuation port device, and (ii) an extended position with said stylet extending through said subdural drainage device such that blockages are disrupted in the subdural drainage device when said housing is moved between said first and second housing configurations; and (e) an external drain opening formed on either said subdural drainage device or said housing.",UNIV WAKE FOREST HEALTH SCIENCES;;BRANCH CHARLES L JR;;EICKMAN JOHN P,BRANCH CHARLES L JR;;EICKMAN JOHN P,,https://lens.org/112-122-686-818-663,Patent Application,yes,3,0,5,5,0,A61M27/00;;A61M27/00;;A61M25/01;;A61M25/01;;A61M25/04;;A61M25/04,A61M27/00,,0,0,,,,PENDING
77,GB,A,GB 1148282 A,044-740-033-831-952,1969-04-10,1969,GB 1692666 A,1966-04-18,GB 1692666 A,1966-04-18,Magnetic position responsive switches,"1,148,282. Movable magnet switches. V. L. OTT and J. B. BEAMAN. 18 April, 1966, No. 16926/66. Heading H1N. A manually operable movable magnet switch has a contact movable between a pair of fixed contacts and mounted on a carrier which also carries a permanent magnet arranged so that the carrier is moved to change-over the contacts in response to actuation of a manually operable member movable normal to the carrier and having an operating permanent magnet which influences the permanent magnet on the carrier. In Fig. 3, a brass contact carrier arm 148 pivoted on a screw 150 carries a permanent magnet 154 and co-operates with resiliently mounted fixed contacts 142. The arm 148 moves in response to movement of permanent magnets 122, 124 on arms 114, 116 on a shaft 104 controlled by an operating lever 106, which is adjustably mounted on the shaft 104 and may be moved against the bias of a compression spring (Figs. 2 and 4, not shown). In Fig. 9, the operating magnets 62, 64 are mounted on a block 56 on a projecting slidable rod 30. A compression spring 66 urges the block 56 to the full line position shown and the paths of movement of the operating and contact magnets are substantially normal to each other as in Fig. 3. A plurality of operating magnets for a plurality of switches may be mounted on a common movable bar (Fig. 7, not shown) and the magnets can be located so as to reduce or prevent arcing at the contacts (Fig. 6, not shown). The housings may be transparent.",VIVIAN LAMONT OTT;;JOHN BRANCH BEAMAN,OTT VIVIAN LAMONT;;BEAMAN JOHN BRANCH JR,,https://lens.org/044-740-033-831-952,Granted Patent,no,0,1,1,2,0,H01H36/0073;;H01H19/186;;H01H21/28,H01H19/18;;H01H21/28;;H01H36/00,H1N NET           NET;;H1N N330          QD;;H1N N343          QD;;H1N N353          NET;;H1N N353          QD;;H1N N360          NET;;H1N N360          QD;;H1N N367          NET;;H1N N367          QD;;H1N N391          QD;;H1N N616          NET;;H1N N616          QD;;H1N N625          NET;;H1N N625          QD;;H1N N631          NET;;H1N N631          QD;;H1N N639          NET;;H1N N688          NET;;H1N N688          QD;;H1N N701          NET;;H1N N701          QD;;H1N N703          NET;;H1N N703          QD;;H1N N704          NET;;H1N N704          QD;;H1N N706          NET;;H1N N706          QD;;H1N N744          NET;;H1N N744          QD,0,0,,,,EXPIRED
78,US,A,US 3180507 A,055-583-711-353-586,1965-04-27,1965,US 24759162 A,1962-12-27,US 24759162 A,1962-12-27,Wheeled can carrier of reinforced tubular material,,OTT VIVIAN L;;BEAMAN JR JOHN BRANCH,OTT VIVIAN L;;BEAMAN JR JOHN BRANCH,,https://lens.org/055-583-711-353-586,Granted Patent,no,10,7,1,1,0,B62B1/264;;B62B2202/028;;B62B2203/40;;B62B1/264;;B62B2203/40;;B62B2202/028,B62B1/26,,0,0,,,,EXPIRED
79,US,A1,US 2016/0166812 A1,153-218-386-692-10X,2016-06-16,2016,US 201414778340 A,2014-03-21,US 201414778340 A;;US 201361803952 P;;US 2014/0031441 W,2013-03-21,Subdural Drainage Catheters with Self Contained Mechanism for Restoration of Flow Following Catheter Obstruction,"A subdural drainage system includes: (a) a subdural drainage device having an opening formed therethrough, said subdural drainage device having an upper portion, a body portion, and a lower portion; (b) a housing having an upper portion and lower portion, with said housing connected to said subdural drainage device; said housing movable between (i) a first configuration and (ii) a second configuration; and (c) an elongated element positioned inside said housing, said elongated element having an upper portion, a lower portion and a deformable member connected to the lower portion; said elongated element being configured such that said elongated element is moved between (i) a retracted position with said elongated element inside a portion of said subdural drainage device and said deformable member inside said housing, and (ii) an extended position with said elongated element extending through said subdural drainage device such that said deformable member automatically extends to an extended, deformed position in which blockages are disrupted in the subdural drainage device when said housing is moved between said first and second housing configurations; and (d) an external drain opening formed on either said subdural drainage device or said housing.",UNIV WAKE FOREST HEALTH SCIENCES,BRANCH JR CHARLES L;;ELKMAN JOHN P,WAKE FOREST UNIVERSITY HEALTH SCIENCES (2018-05-14),https://lens.org/153-218-386-692-10X,Patent Application,yes,0,1,3,3,0,A61M27/00;;A61M27/00;;A61M25/02;;A61M25/02;;A61M39/02;;A61M39/08;;A61M39/08;;A61M2025/0019;;A61M2025/0233;;A61M2025/0233;;A61M2039/025;;A61M2039/0276;;A61M2210/0687;;A61M2210/0687,A61M27/00;;A61M39/02,,0,0,,,,INACTIVE
80,GB,A,GB 1162436 A,066-811-334-842-034,1969-08-27,1969,GB 1281567 A,1967-03-18,GB 1281567 A,1967-03-18,Ashless Dispersants,"1,162,436. Lubricants; fuels. OROBIS Ltd. 8 March, 1968 [18 March, 1967], No. 12815/67. Headings C5F and C5G. [Also in Division C3] Lubricant and fuel compositions comprise as detergent additive the reaction product of a compound having one of the formulµ with a compound having one of the formulµ where n and m are 0 or integers, R is hydrogen or alkyl, and R<SP>1</SP> and R<SP>2</SP> are substantially aliphatic hydrocarbon radicals in which either R<SP>1</SP> or R<SP>2</SP> has a chain length of less than 50 carbon atoms and the arithmetic mean of the chain lengths of R<SP>1</SP> and R<SP>2</SP> is greater than 50. The hydrocarbon chains may be derived from polyethylene, polypropylene or polybutylene, and the additives may be prepared by reacting a polyalkenyl succinic acid or anhydride with an alkylene polyamine, e,g. ethylene diamine, propylene diamines, diethylene triamine, triethylene tetramine, tetraethylene pentamine, tripropylene tetramines and octaethylene non- amine, and further reacting the product with a polyalkenyl succinic acid or anhydride. Convention additives may be present and an example describes a composition of a mineral lubricating oil, calcium phenate, zinc dialkyl dithiophosphate and the product obtained by reacting a 47 C polyisobutenyl succinic anhydride with tetraethylene pentamine and reacting the product with 78 C polyisobutenyl succinic anhydride.",OROBIS LTD,BRANCH SIDNEY JOHN;;COUPLAND KEITH;;RICHARDSON DAVID ANDREW,,https://lens.org/066-811-334-842-034,Granted Patent,no,0,19,1,1,0,C07D207/412;;C10L1/2222;;C10L1/224;;C10L1/2383;;C10L10/04;;C10M133/16;;C10M133/56;;C10M141/10;;C10M2203/10;;C10M2207/027;;C10M2215/02;;C10M2215/04;;C10M2215/08;;C10M2215/082;;C10M2215/086;;C10M2215/26;;C10M2215/28;;C10M2217/046;;C10M2217/06;;C10M2223/045;;C10N2010/04;;C10N2050/02,C07D207/40;;C07D207/412;;C10L1/22;;C10L1/224;;C10L1/2383;;C10L10/04;;C10M133/16;;C10M133/56;;C10M141/10,C3J JCE           JZ3A;;C3J JCE           PD9&;;C3J JCF           JZ3A;;C3J JCF           PD9&;;C3J JCS           JZ3A;;C3J JCS           PD9&;;C3P PD9D7D1       PD9&;;C3P PD9F1         PD9&;;C3P P7D1B         -;;C3P P7T2X         -;;C5F FA            A;;C5F F477          A;;C5F F600          A;;C5F F605          A;;C5F F619          A;;C5F F678          A;;C5F F762          A;;C5F F80Y          A;;C5F F801          A;;C5F F808          A;;C5G GAA           AA;;C5G G1A1          -;;C5G G1A1E3        G1A1;;C5G G1A1F1        G1A1;;C5G G121          AA;;C5G G124          AA;;C5G G137          AA;;C5G G301          AA;;C5G G302          AA;;C5G G309          AA;;C5G G312          AA;;C5G G401          AA,0,0,,,,EXPIRED
81,WO,A1,WO 2003/051368 A1,171-906-171-653-914,2003-06-26,2003,GB 0205773 W,2002-12-18,GB 0130335 A,2001-12-19,N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,"According to the invention there is provided compounds of formula ࿈1&rpar;ᛢ Whereinᛢ X represents a bond, oxygen, NR3 or a group ࿈CH2&rpar;n wherein n represents 1 of 2&semi; Y represents =࿈CH2&rpar;qNHC࿈O&rpar;, ᇁ࿈CH2&rpar;qO࿈CH2&rpar;p, ᇁ࿈CH2&rpar;qS࿈CH2&rpar;p, ᇁ࿈CH2&rpar;qC࿈O&rpar;࿈CH2&rpar;p, ࿈CH2&rpar;qSO2࿈CH2&rpar;p, ᇁ࿈CH2&rpar;qCH=CH࿈CH2&rpar;p, ᇁ࿈CH2&rpar;pCH࿈OH&rpar;࿈CH2&rpar;p, ᇁC࿈O&rpar;, ᇁ࿈CH2&rpar;3,ᇁ࿈CH2&rpar;qNH, ᇁ ࿈CH2&rpar;qNHCONK or ᇁ࿈CH2&rpar;qCONH&semi; wherein q represents 1 or 2 and p represents 0 or 1&semi; Ar1 represents a phenyl, naphthyl or 5 or 6 membered heteroaryl group containing up to 3 heteroatorns selected from N, O, and S, or a bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S any ofwhich can be optionally substituted&semi; Ar2 represents an optionally substituted phenyl or a 5ᇁ or 6ᇁmembered&apos;heteroaryl group containing up to 3 heteroatoms selected from N, O and S&semi; Ar3 represents an optionally substituted R5&period;isᇁO ࿈CH2&rpar;mNR1R2 Or ࿈CH2&rpar;mNR1 R2 each of R1 and R2 independently represents a hydrogen atom or an optionally substituted ࿈C1ᇁ6&rpar;alkyl group or R1 and R2 together with the nitrogen to which they are attached form part of a ࿈C3ᇁ6&rpar;azacycloalkane or ࿈C3ᇁ6&rpar;࿈2ᇁoxo&rpar;azacycloalkane ring, or R1 with at least one CH2 of &period; the ࿈CH2&rpar; m portion of the group form a ࿈C3ᇁ6&rpar; azacycloalkane and R2 represents hydrogen, an optionally substituted ࿈C1ᇁ6&rpar;alkyl group, piperidine, pyrrolidine, morpholine or with the nitrogen to which they are attached forms a second ࿈C3ᇁ6&rpar;azacycloalkane fused to the first ࿈C3ᇁ6&rpar;azacycloalkane&semi; R3 represents hydrogen or optionally substituted ࿈C1ᇁ6&rpar; alkyl&semi; m represents an integer from &apos;2 to 6&semi; and Ar3 is attached to Ar2 ortho to the amide carbonyl group&semi; The compounds of formula ࿈I&rpar; and their pharmaceutically acceptable derivatives are useful for the treatment of diseases or disorders where an antagonist of a human orexin receptor is required",SMITHKLINE BEECHAM PLC;;BRANCH CLIVE LESLIE;;NASH DAVID JOHN;;STEMP GEOFFREY,BRANCH CLIVE LESLIE;;NASH DAVID JOHN;;STEMP GEOFFREY,,https://lens.org/171-906-171-653-914,Patent Application,yes,5,0,3,3,0,C07D409/06;;C07D409/14;;C07D417/06,C07D409/06;;C07D409/14;;C07D417/06,,0,0,,,,PENDING
82,AU,A1,AU 2002/352447 A1,161-086-392-215-48X,2003-06-30,2003,AU 2002/352447 A,2002-12-18,GB 0130335 A;;GB 0205773 W,2001-12-19,N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,,SMITHKLINE BEECHAM PLC,STEMP GEOFFREY;;BRANCH CLIVE LESLIE;;NASH DAVID JOHN,,https://lens.org/161-086-392-215-48X,Patent Application,no,0,0,3,3,0,C07D409/06;;C07D409/14;;C07D417/06,C07D409/06;;C07D409/14;;C07D417/06,,0,0,,,,DISCONTINUED
83,MX,A,MX 2015013023 A,014-162-361-786-29X,2016-07-05,2016,MX 2015013023 A,2014-03-13,US 201361787308 P;;US 2014/0025650 W,2013-03-15,"SYSTEM, METHOD AND INTERFACE FOR COMPILED LITERARY WORK.","A system, method and interface for compiling literary works from specialized databases and/or from unique interfaces is provided, including a custom database compiled from plural existing literary indexes, wherein a master index is harmonized from said existing indexes according to common terms (e.g., book, chapter and verse for biblical indexes) with deleted duplicates. In exemplary embodiments, the master index is also augmented by ingestion of additional literary works in digital form that are chopped up based on said common terms (e.g., book, chapter, verse) extracted from the literary work.",HARPERCOLLINS CHRISTIAN PUBLISHING,CRAWFORD JOHN;;EDINGTON ROBERT L;;CAIN JOHN;;HENDRICKS JEFFREY;;BRANCH ROBERT,,https://lens.org/014-162-361-786-29X,Patent Application,no,0,0,9,9,0,G06F16/93;;G06F16/93,G06F17/30,,0,0,,,,PENDING
84,US,B2,US 11580171 B2,133-478-142-767-596,2023-02-14,2023,US 201414210955 A,2014-03-14,US 201414210955 A;;US 201361787308 P,2013-03-15,"System, method and interface for compiled literary work","A system, method and interface for compiling literary works from specialized databases and/or from unique interfaces is provided, including a custom database compiled from plural existing literary indexes, wherein a master index is harmonized from said existing indexes according to common terms (e.g., book, chapter and verse for biblical indexes) with deleted duplicates. In exemplary embodiments, the master index is also augmented by ingestion of additional literary works in digital form that are chopped up based on said common terms (e.g., book, chapter, verse) extracted from the literary work.",HARPERCOLLINS CHRISTIAN PUBLISHING INC,EDINGTON ROBERT L;;CAIN JOHN;;HENDRICKS JEFFREY;;CRAWFORD JOHN;;BRANCH ROBERT,HARPERCOLLINS CHRISTIAN PUBLISHING INC (2014-03-12),https://lens.org/133-478-142-767-596,Granted Patent,yes,7,0,9,9,0,G06F16/93;;G06F16/93,G06F7/00;;G06F16/93,,5,0,,,"International Application No. PCT/US2014/025650 International Search Report and Written Opinion dated Sep. 18, 2014, 8 pages.;;EP Application No. 14769401.2 Extended Search Report dated Aug. 22, 2016, 7 pages.;;CA Application No. 2,905,933 Office Action dated Feb. 5, 2020, 6 pages.;;Canada Office Action for Canada Application No. 2905933; filed Sep. 11, 2015; dated Feb. 23, 2022; 4 pages.;;European Office Action for European Application No. 14769401.2; dated Sep. 18, 2019; 6 pages.",ACTIVE
85,WO,A9,WO 2014/151399 A9,067-768-020-981-205,2014-12-31,2014,US 2014/0025650 W,2014-03-13,US 201361787308 P,2013-03-15,"SYSTEM, METHOD AND INTERFACE FOR COMPILED LITERARY WORK","A system, method and interface for compiling literary works from specialized databases and/or from unique interfaces is provided, including a custom database compiled from plural existing literary indexes, wherein a master index is harmonized from said existing indexes according to common terms (e.g., book, chapter and verse for biblical indexes) with deleted duplicates. In exemplary embodiments, the master index is also augmented by ingestion of additional literary works in digital form that are chopped up based on said common terms (e.g., book, chapter, verse) extracted from the literary work.",HARPERCOLLINS CHRISTIAN PUBLISHING,EDINGTON ROBERT L;;CAIN JOHN;;HENDRICKS JEFFREY;;CRAWFORD JOHN;;BRANCH ROBERT,,https://lens.org/067-768-020-981-205,Search Report,yes,0,0,9,9,0,G06F16/93;;G06F16/93,G06F17/30,,0,0,,,,PENDING
86,WO,A2,WO 2014/151399 A2,137-419-169-504-45X,2014-09-25,2014,US 2014/0025650 W,2014-03-13,US 201361787308 P,2013-03-15,"SYSTEM, METHOD AND INTERFACE FOR COMPILED LITERARY WORK","A system, method and interface for compiling literary works from specialized databases and/or from unique interfaces is provided, including a custom database compiled from plural existing literary indexes, wherein a master index is harmonized from said existing indexes according to common terms (e.g., book, chapter and verse for biblical indexes) with deleted duplicates. In exemplary embodiments, the master index is also augmented by ingestion of additional literary works in digital form that are chopped up based on said common terms (e.g., book, chapter, verse) extracted from the literary work.",HARPERCOLLINS CHRISTIAN PUBLISHING,EDINGTON ROBERT L;;CAIN JOHN;;HENDRICKS JEFFREY;;CRAWFORD JOHN;;BRANCH ROBERT,,https://lens.org/137-419-169-504-45X,Patent Application,yes,1,0,9,9,0,G06F16/93;;G06F16/93,,,0,0,,,,PENDING
87,WO,A3,WO 2014/151399 A3,144-467-758-786-096,2014-11-13,2014,US 2014/0025650 W,2014-03-13,US 201361787308 P,2013-03-15,"SYSTEM, METHOD AND INTERFACE FOR COMPILED LITERARY WORK","A system, method and interface for compiling literary works from specialized databases and/or from unique interfaces is provided, including a custom database compiled from plural existing literary indexes, wherein a master index is harmonized from said existing indexes according to common terms (e.g., book, chapter and verse for biblical indexes) with deleted duplicates. In exemplary embodiments, the master index is also augmented by ingestion of additional literary works in digital form that are chopped up based on said common terms (e.g., book, chapter, verse) extracted from the literary work.",HARPERCOLLINS CHRISTIAN PUBLISHING,EDINGTON ROBERT L;;CAIN JOHN;;HENDRICKS JEFFREY;;CRAWFORD JOHN;;BRANCH ROBERT,,https://lens.org/144-467-758-786-096,Search Report,yes,5,0,9,9,0,G06F16/93;;G06F16/93,G06F17/30,,0,0,,,,PENDING
88,CA,A1,CA 2905933 A1,107-792-619-838-279,2014-09-25,2014,CA 2905933 A,2014-03-13,US 201361787308 P;;US 2014/0025650 W,2013-03-15,"SYSTEM, METHOD AND INTERFACE FOR COMPILED LITERARY WORK","A system, method and interface for compiling literary works from specialized databases and/or from unique interfaces is provided, including a custom database compiled from plural existing literary indexes, wherein a master index is harmonized from said existing indexes according to common terms (e.g., book, chapter and verse for biblical indexes) with deleted duplicates. In exemplary embodiments, the master index is also augmented by ingestion of additional literary works in digital form that are chopped up based on said common terms (e.g., book, chapter, verse) extracted from the literary work.",HARPERCOLLINS CHRISTIAN PUBLISHING,EDINGTON ROBERT L;;CAIN JOHN;;HENDRICKS JEFFREY;;CRAWFORD JOHN;;BRANCH ROBERT,,https://lens.org/107-792-619-838-279,Patent Application,no,0,0,9,9,0,G06F16/93;;G06F16/93,G06F17/30,,0,0,,,,DISCONTINUED
89,US,A1,US 2014/0279710 A1,190-536-417-218-036,2014-09-18,2014,US 201414210955 A,2014-03-14,US 201414210955 A;;US 201361787308 P,2013-03-15,"SYSTEM, METHOD AND INTERFACE FOR COMPILED LITERARY WORK","A system, method and interface for compiling literary works from specialized databases and/or from unique interfaces is provided, including a custom database compiled from plural existing literary indexes, wherein a master index is harmonized from said existing indexes according to common terms (e.g., book, chapter and verse for biblical indexes) with deleted duplicates. In exemplary embodiments, the master index is also augmented by ingestion of additional literary works in digital form that are chopped up based on said common terms (e.g., book, chapter, verse) extracted from the literary work.",HARPERCOLLINS CHRISTIAN PUBLISHING INC,EDINGTON ROBERT L;;CAIN JOHN;;HENDRICKS JEFFREY;;CRAWFORD JOHN;;BRANCH ROBERT,HARPERCOLLINS CHRISTIAN PUBLISHING INC (2014-03-12),https://lens.org/190-536-417-218-036,Patent Application,yes,2,1,9,9,0,G06F16/93;;G06F16/93,G06F17/30;;G06Q30/02,705/400;;707/728;;707/722,0,0,,,,ACTIVE
90,EP,A4,EP 2973058 A4,104-111-865-047-75X,2016-09-21,2016,EP 14769401 A,2014-03-13,US 201361787308 P;;US 2014/0025650 W,2013-03-15,"SYSTEM, METHOD AND INTERFACE FOR COMPILED LITERARY WORK",,HARPERCOLLINS CHRISTIAN PUBLISHING,EDINGTON ROBERT L;;CAIN JOHN;;HENDRICKS JEFFREY;;CRAWFORD JOHN;;BRANCH ROBERT,,https://lens.org/104-111-865-047-75X,Search Report,no,0,0,9,9,0,G06F16/93;;G06F16/93,G06F17/30,,1,0,,,No further relevant documents disclosed,DISCONTINUED
91,EP,A2,EP 2973058 A2,024-453-250-383-124,2016-01-20,2016,EP 14769401 A,2014-03-13,US 201361787308 P;;US 2014/0025650 W,2013-03-15,"SYSTEM, METHOD AND INTERFACE FOR COMPILED LITERARY WORK",,HARPERCOLLINS CHRISTIAN PUBLISHING,EDINGTON ROBERT L;;CAIN JOHN;;HENDRICKS JEFFREY;;CRAWFORD JOHN;;BRANCH ROBERT,,https://lens.org/024-453-250-383-124,Patent Application,yes,0,0,9,9,0,G06F16/93;;G06F16/93,G06F17/30,,0,0,,,,DISCONTINUED
92,US,B2,US 6610036 B2,113-931-063-693-039,2003-08-26,2003,US 77678201 A,2001-02-06,US 77678201 A,2001-02-06,Eye drop dispensing system,"
    An eye drop dispensing device includes a trough member with a space to receive a cartridge housing enclosing a collapsible bag containing an ophthalmic liquid and comprising a spring finger applying pressure to the bag. The bag includes a wall pierced by a needle coupling the liquid to pump means through a one-way valve. The pump means includes a plunger biased to a resting position establishing a dosage chamber. Actuator means moves the plunger to enlarge the dosage chamber, causing a drop in pressure which draws a predetermined quantity of the liquid through the one-way valve into the dosage chamber. The actuator means then releases the plunger so that it moves to compress the dosage chamber to pump the liquid in the dosage chamber through a second one-way valve to spray the liquid through pinholes formed in a nozzle angled to direct the liquid as eye drops to the user's eye. 
",VISTA INNOVATIONS INC,BRANCH JOHN D;;DUHAMEL STEVEN R;;GANAJA SCOTT O,,https://lens.org/113-931-063-693-039,Granted Patent,yes,12,69,2,3,0,B65D35/28;;B65D35/28,B65D35/28,604/295;;604/297;;604/302,0,0,,,,EXPIRED
93,US,A,US 3105869 A,188-945-028-959-231,1963-10-01,1963,US 18190862 A,1962-03-23,US 18190862 A,1962-03-23,Electrical connection of microminiature circuit wafers,,HUGHES AIRCRAFT CO,BRANCH GERALD L;;RICHARDSON JOHN E;;SCAPPLE ROBERT Y,,https://lens.org/188-945-028-959-231,Granted Patent,no,2,47,1,1,0,H05K3/363;;H05K3/363;;H05K1/0284;;H05K1/0284;;H05K1/117;;H05K1/117;;H05K1/148;;H05K1/148;;H05K3/284;;H05K3/284;;H05K3/36;;H05K3/36;;H05K3/4092;;H05K3/4092;;H05K2201/0397;;H05K2201/0397;;H05K2201/09472;;H05K2201/09472;;H05K2201/10977;;H05K2201/10977;;H05K2201/2009;;H05K2201/2009,H05K1/00;;H05K1/11;;H05K1/14;;H05K3/28;;H05K3/36;;H05K3/40,,0,0,,,,EXPIRED
94,DE,A1,DE 1642102 A1,173-363-736-708-56X,1972-05-18,1972,DE 1642102 A,1967-12-08,GB 5507066 A;;GB 5507266 A;;GB 5507366 A;;GB 5507466 A,1966-12-08,Maschine zum Sterilisieren und Fuellen von Behaeltern,,NAT RES DEV,FRANK BRANCH SYDNEY;;FREDERICK HANSEN WILLIAM;;ANTHONY PAVEY JOHN,,https://lens.org/173-363-736-708-56X,Patent Application,no,0,4,6,8,0,B67C7/0073;;B65B55/04;;B65B55/10;;B67C2003/2691,B67B3/24;;B65B55/04;;B65B55/10;;B67C3/26;;B67C7/00,,0,0,,,,EXPIRED
95,WO,A1,WO 2004/113280 A1,080-619-979-048-644,2004-12-29,2004,EP 2004006595 W,2004-06-17,GB 0314476 A,2003-06-20,GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS,"Use of a compound of formula (I): or a salt, solvate or a physiologically functional derivative thereof, for the manufacture of a medicament for treating a disorder mediated by GlyT1, such as foe example schizophrenia, is disclosed, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification.",GLAXO GROUP LTD;;BRANCH CLIVE LESLIE;;NASH DAVID JOHN;;PORTER RODERICK ALAN,BRANCH CLIVE LESLIE;;NASH DAVID JOHN;;PORTER RODERICK ALAN,,https://lens.org/080-619-979-048-644,Patent Application,yes,4,13,2,2,0,A61P25/18;;C07D211/46;;C07C311/18;;C07D207/04,A61P25/18;;C07C311/18;;C07D207/04;;C07D211/46,,7,6,003-684-551-168-707;;024-846-952-194-587;;016-264-724-444-679;;003-495-553-754-512;;002-804-059-118-49X;;062-268-405-376-783,10.1016/0960-894x(96)00035-2;;11347961;;10.1016/s0014-827x(01)01025-4;;10.1016/0040-4039(95)01203-t;;10.1021/ja963462e;;34182655;;10.1002/(sici)1521-3773(19990712)38:13/14<1931::aid-anie1931>3.0.co;2-4;;10.1021/jm0208323;;12109915,"J.N. FRESKOS, ET AL.: ""(Hydroxyethyl) sulphonamide HIV-1 protease inhibitors: identification of the 2-methylbenzoyl moiety at P-2"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 4, 20 February 1996 (1996-02-20), ELSEVIER SCIENCE, OXFORD, GB, pages 445 - 450, XP004135054, ISSN: 0960-894X;;A.K. GHOSH, ET AL.: ""Structure-based design of non-peptide HIV protease inhibitors"", IL FARMACO, vol. 56, no. 1-2, 1 March 2001 (2001-03-01), SOCIETA CHIMICA ITALIANA, PAVIA, IT, pages 29 - 32, XP002298273;;K. NAKAI, ET AL.: ""A one-pot aza-Payne rearrangement-epoxide ring opening reaction of 2-aziridinemethanols: a regio- and stereoselective synthetic route to diastereomerically pure 1,2-amino alcohols"", TETRAHEDRON LETTERS, vol. 36, no. 35, 28 August 1995 (1995-08-28), ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, pages 6247 - 6250, XP004027360, ISSN: 0040-4039;;D.L. FLYNN, ET AL.: ""Chemical library purification strategies based on principles of complementary molecular reactivity and molecular recognition"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 119, no. 20, 21 May 1997 (1997-05-21), AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, pages 4874 - 4881, XP002109475, ISSN: 0002-7863;;E.J. COREY, ET AL.: ""re- and si-Face-selective nitroaldol reactions catalysed by a rigid chiral quaternary ammonium salt: a highly stereoselective synthesis of the HIV protease inhibitor amprenavir (Vertex 478)"", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 38, no. 13/14, 12 July 1999 (1999-07-12), WILEY-VCH VERLAG, WEINHEIM, DE, pages 1931 - 1934, XP002298274;;R.J. BERGERON, ET AL.: ""Synthesis of hydroxylated polyamine as antiproliferatives"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 2, 28 December 1999 (1999-12-28), AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, pages 224 - 235, XP002298275;;L. ROCHEBLAVE, ET AL.: ""Synthesis and antiviral activity of new anti-HIV amprenavir biosteres"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 15, 18 July 2002 (2002-07-18), AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, pages 3321 - 3324, XP002298279",PENDING
96,GB,A,GB 1024322 A,077-592-441-860-256,1966-03-30,1966,GB 4431361 A,1962-12-11,GB 4431361 A,1962-12-11,Shot-blast head,"1,024,322. Shot blasting. RHEEM LYSAGHT Ltd. Dec. 11, 1962 [Dec. 11, 1961], No. 44313/61. Heading B3D. A shot-blast head comprises two chambers one of which is adapted for communication with a source of air under pressure and the other is adapted to communicate with a reservoir of shot, a plurality of nozzles being mounted in the head each comprising an elongated body having a mixing chamber, an axial air inlet in communication with one of the chambers, an axial outlet for the mixed air and shot and an inlet for the shot in communication with the other of the chambers, said shot inlet being inclined to the axis of the nozzle. A head suitable for shot-blasting a cylindrical surface comprises concentric chambers 1, 2, the chamber 1 being in direct communication with a source of high pressure air and the chamber 2 forming the lower end of a reservoir of shot. Two sets of nozzles are arranged radially of the axis of the chambers, each set having fifteen nozzles with their axes lying in a horizontal plane. The nozzles of one set are staggered relatively to the nozzles of the other set. The front portion 3 of each nozzle is mounted in the outer wall 4 of chamber 2 and the rear is mounted in the wall 5 common to both chambers. An inlet portion 6 has axial bore 7 providing air inlet passage, and an internal annular groove 8 forms an air jet 9 projecting into a mixing chamber 10. A shot inlet passage 11 extends through the wall of the nozzle from chamber 2 to the groove 8. The inlet 11 is at an angle of 15 degrees to the inlet 7. The front portion of the nozzle is bored at 12, 13 providing an outlet for the mixed air and shot.",RHEEM LYSAGHT LTD,NAISH WILLIAM JENKINS;;COGGINS JOHN RICHMOND;;BRANCH ALBERT GEORGE,,https://lens.org/077-592-441-860-256,Granted Patent,no,0,0,1,1,0,B24C5/02,B24C5/02,B3D DBG           DBG;;B3D D8A1          D8,0,0,,,,EXPIRED
97,GB,A,GB 1023941 A,100-852-842-493-346,1966-03-30,1966,GB 187162 A,1962-01-18,GB 187162 A,1962-01-18,Method and apparatus for shot-blasting,"1,023,941. Delivering measured quantities of granular material. RHEEM LYSAGHT Ltd. Jan. 18, 1963 [Jan. 18, 1962], No. 1871/62. Heading B8N. [Also in Division B3] Shot-blasting apparatus comprises a hopper 9, the discharge opening 10 of which is provided with a valve 11 normally closed by a spring 12. A metering device comprises an inclined shoot 14. Its lower end is above the hopper 9 and has in its lower portion a circular port normally closed by a hinged shutter 16 loaded by a spring 17. An arcuate deflector shoot 19 opens and closes the upper end of the shoot 14. The shutter 16 and shoot 19 are connected so that one is open and the other closed; the valve 11 is opened when the shutter 16 is opened. Actuation is by an air cylinder 32. A bucket elevator continuously lifts shot and deposits it into a shoot 36 whence it drops into an agitated vessel 40 having a sieve to reject large objects. The shoot 36 is moved about its pivot 37 to distribute shot evenly over the surface of the sieve 41. Sieved shot falls into the shoot 14. The amount of shot dispensed can be predetermined by adjustment of a weir 18 so as to vary the effective area of the floor of the shoot 14. Operation.-Shot continuously falls down the shoot 14 against the shutter 16 which is closed and piles up against it, lying on the floor of the shoot until the edge of the pile moving back up the shoot reaches the free edge of the weir 18. After this, little extra shot is held in the shoot 14, most of the incoming flow falling from the free edge of the weir or to the surface 42 and thence to a collection area at the base of the elevator so that it feeds back into the elevator for recirculation. A shot-blasting cycle is initiated by an operator when a workpiece has been placed in position; the cycle is electrically controlled, the circuitry providing suitable delays. Admission of air to the cylinder 32 first moves shoot 19 to closed position, so that falling shot is diverted to the bottom of the elevator via surface 42, and subsequently opens the valve 11 and then moves the shutter 16 to open position allowing the contents of the metering device to escape. When sufficient time has elapsed for the charge of shot to have emptied out of the hopper the return stroke of the air cylinder causes the parts to return to their original positions.",RHEEM LYSAGHT LTD,NAISH WILLIAM JENKINS;;COGGINS JOHN RICHMOND;;BRANCH ALBERT GEORGE,,https://lens.org/100-852-842-493-346,Granted Patent,no,0,0,1,1,0,B24C7/0053,B24C7/00,B3D D8A1          D8;;B8N NN            N;;B8N N6A1C         N;;B8N N6A2          N,0,0,,,,EXPIRED
98,US,B2,US 8311577 B2,044-612-150-860-983,2012-11-13,2012,US 48446709 A,2009-06-15,US 48446709 A,2009-06-15,Proactive control of mobile communications devices,"At least one embodiment of the invention addresses the problem of accidental user operation (e.g., dialing) of a mobile communication device such as a mobile telephone. In this regard, embodiments of the invention provide a proactive solution for preventing unintended operation of a mobile device based on various types of input data of the device, most notably sensory data.",BIVENS JOHN ALLAN;;BRANCH JOEL W;;SOW DABY MOUSSE;;IBM,BIVENS JOHN ALLAN;;BRANCH JOEL W;;SOW DABY MOUSSE,INTERNATIONAL BUSINESS MACHINES CORPORATION (2009-06-12),https://lens.org/044-612-150-860-983,Granted Patent,yes,10,5,2,2,0,H04M1/724;;H04M1/724;;H04M2250/12;;H04M2250/12,H04M1/00,455/556.1;;455/565,1,1,019-096-353-005-245,10.1145/1065907.1066036,"Dragovic, B., et al, Information Exposure Control Through Data Manipulation for Ubiquitous Computing, Proceedings of the 2004 Workshop on New Security Paradigms, 2004.",INACTIVE
99,GB,A,GB 1212503 A,049-614-281-989-454,1970-11-18,1970,GB 5507466 A,1966-12-08,GB 5507066 A,1966-12-08,CONTAINER STERILISING AND FILLING APPARATUS,"1,212,503. Pipe couplings. NATIONAL RESEARCH DEVELOPMENT CORP. 5 Dec., 1967 [8 Dec., 1966 (4)], Nos. 55070/66, 55072/66, 55073/66 and 55074/66. Heading F2G. [Also in Division B8] A coupling between a rotatable reservoir 34 and a non-rotating supply conduit 74 comprises an annular collar 72 mounted on a neck 71 of the reservoir, the collar having an annular groove 73 on its outer surface, the conduit having a flange 75 with a dependent skirt 76 which is a sliding fit around the periphery of the collar 72 above the groove 73 Spaced equally around and on top of the flange are four sealing rams arranged so that piston-rods 81 extend through apertures 77 in the skirt and attach to a split ring 82 which is located in the groove 73. An anti-friction disc is bonded to one of the mating surfaces 86 and 87 of the flange and collar. Movement apart of the surfaces for cleaning and sterilizing is also incorporated.",NAT RES DEV,BRANCH SYDNEY FRANK;;PAVEY JOHN ANTHONY;;HANSEN WILLIAM FREDERICK,,https://lens.org/049-614-281-989-454,Granted Patent,no,0,7,1,8,0,B65B55/10;;B65B55/04;;B67C7/0073;;B67C2003/2691,B65B55/04;;B65B55/10;;B67C3/26;;B67C7/00,B8T TFDH          TFDH;;B8T T401          TFDH;;B8T T65           -;;B8T T71           -;;B8T T72           -;;F2G G6C2          G6C2,0,0,,,,EXPIRED
100,US,A1,US 2010/0317400 A1,153-243-861-592-373,2010-12-16,2010,US 48446709 A,2009-06-15,US 48446709 A,2009-06-15,PROACTIVE CONTROL OF MOBILE COMMUNICATIONS DEVICES,"At least one embodiment of the invention addresses the problem of accidental user operation (e.g., dialing) of a mobile communication device such as a mobile telephone. In this regard, embodiments of the invention provide a proactive solution for preventing unintended operation of a mobile device based on various types of input data of the device, most notably sensory data.",IBM,BIVENS JOHN A;;BRANCH JOEL W;;SOW DABY M,INTERNATIONAL BUSINESS MACHINES CORPORATION (2009-06-12),https://lens.org/153-243-861-592-373,Patent Application,yes,9,11,2,2,0,H04M1/724;;H04M1/724;;H04M2250/12;;H04M2250/12,H04M1/00;;G06F15/18;;G06N7/02,455/556.1;;706/12;;706/52;;706/16;;706/26,0,0,,,,INACTIVE
101,DE,A1,DE 2823875 A1,113-890-579-916-434,1979-09-13,1979,DE 2823875 A,1978-05-31,US 88507978 A;;US 88611878 A;;US 89393778 A,1978-03-09,"VERFAHREN UND EINRICHTUNG ZUR KOMPENSATION VON UMGEBUNGSEFFEKTEN AUF MESSEINRICHTUNGEN, INSBESONDERE DIFFERENZDRUCKFUEHLER",,AMERICAN CHAIN & CABLE CO,RAVEN JOHN NEVIN;;BRANCH III HOWARD RAY;;BIRGER BLADE GABREILSON,,https://lens.org/113-890-579-916-434,Patent Application,no,3,3,5,8,0,G01L9/0052;;G01B7/18;;G01D3/0365;;G01L9/065;;G01L13/025,G01B7/16;;G01D3/036;;G01L9/00;;G01L9/06;;G01L13/02,,0,0,,,,DISCONTINUED
102,WO,A3,WO 2009/014721 A3,024-102-608-859-04X,2009-04-16,2009,US 2008/0008960 W,2008-07-24,US 95156907 P,2007-07-24,SURGICAL HEAD SUPPORT SYSTEM,"A planar support assembly for use with a patient body support, an extension support assembly, and a plurality of interchangeable head supports is provided. The extension support assembly is releasably mounted on a portion of the patient body support such that the extension support assembly extends outwardly from the patient body support. The planar support assembly includes a generally planar support configured to releasably attach to an end of the extension support assembly opposite the patient body support. The planar support is configured to receive and support one of a plurality of interchangeable head supports, and the planar support is adjustable with respect to the patient body support in two or more dimensions.",UNIV WAKE FOREST HEALTH SCIENCES;;BERRY JOEL L;;REYNOLDS JOHN E;;BRANCH JR CHARLES L,BERRY JOEL L;;REYNOLDS JOHN E;;BRANCH JR CHARLES L,,https://lens.org/024-102-608-859-04X,Search Report,yes,5,0,4,4,0,A61G13/12;;A61G13/12;;A61B90/14;;A61B90/14;;A61G7/07;;A61G13/0054;;A61G13/0054;;A61G13/1205;;A61G13/121;;A61G13/121;;A61G13/128;;A61G13/129;;A61G2200/325;;A61G2200/325,A61B19/00,,0,0,,,,PENDING
103,US,A1,US 2010/0319706 A1,031-518-342-362-273,2010-12-23,2010,US 67023708 A,2008-07-24,US 67023708 A;;US 95156907 P;;US 2008/0008960 W,2007-07-24,Surgical Head Support Adapter,"A planar support assembly for use with a patient body support, an extension support assembly, and a plurality of interchangeable head supports is provided. The extension support assembly is releasably mounted on a portion of the patient body support such that the extension support assembly extends outwardly from the patient body support. The planar support assembly includes a generally planar support configured to releasably attach to an end of the extension support assembly opposite the patient body support. The planar support is configured to receive and support one of a plurality of interchangeable head supports, and the planar support is adjustable with respect to the patient body support in two or more dimensions.",BERRY JOEL L;;REYNOLDS JOHN E;;BRANCH JR CHARLES L,BERRY JOEL L;;REYNOLDS JOHN E;;BRANCH JR CHARLES L,WAKE FOREST UNIVERSITY HEALTH SCIENCES (2010-01-29),https://lens.org/031-518-342-362-273,Patent Application,yes,14,8,4,4,0,A61G13/12;;A61G13/12;;A61B90/14;;A61B90/14;;A61G7/07;;A61G13/0054;;A61G13/0054;;A61G13/1205;;A61G13/121;;A61G13/121;;A61G13/128;;A61G13/129;;A61G2200/325;;A61G2200/325,A61G15/00,128/845,0,0,,,,INACTIVE
104,US,B2,US 9095489 B2,041-430-483-015-319,2015-08-04,2015,US 67023708 A,2008-07-24,US 67023708 A;;US 95156907 P;;US 2008/0008960 W,2007-07-24,Surgical head support adapter,"A planar support assembly for use with a patient body support, an extension support assembly, and a plurality of interchangeable head supports is provided. The extension support assembly is releasably mounted on a portion of the patient body support such that the extension support assembly extends outwardly from the patient body support. The planar support assembly includes a generally planar support configured to releasably attach to an end of the extension support assembly opposite the patient body support. The planar support is configured to receive and support one of a plurality of interchangeable head supports, and the planar support is adjustable with respect to the patient body support in two or more dimensions.",BERRY JOEL L;;REYNOLDS JOHN E;;BRANCH JR CHARLES L;;UNIV WAKE FOREST HEALTH SCIENCES,BERRY JOEL L;;REYNOLDS JOHN E;;BRANCH JR CHARLES L,WAKE FOREST UNIVERSITY HEALTH SCIENCES (2010-01-29),https://lens.org/041-430-483-015-319,Granted Patent,yes,17,1,4,4,0,A61G13/12;;A61G13/12;;A61B90/14;;A61B90/14;;A61G7/07;;A61G13/0054;;A61G13/0054;;A61G13/1205;;A61G13/121;;A61G13/121;;A61G13/128;;A61G13/129;;A61G2200/325;;A61G2200/325,A61G13/12;;A61B19/00;;A61G7/07;;A61G13/00,,1,0,,,"International Search Report and the Written Opinion of the ISA for PCT/US2008/008960, mailed Feb. 11, 2009.",INACTIVE
105,WO,A2,WO 2009/014721 A2,040-516-128-235-06X,2009-01-29,2009,US 2008/0008960 W,2008-07-24,US 95156907 P,2007-07-24,SURGICAL HEAD SUPPORT SYSTEM,"A planar support assembly for use with a patient body support, an extension support assembly, and a plurality of interchangeable head supports is provided. The extension support assembly is releasably mounted on a portion of the patient body support such that the extension support assembly extends outwardly from the patient body support. The planar support assembly includes a generally planar support configured to releasably attach to an end of the extension support assembly opposite the patient body support. The planar support is configured to receive and support one of a plurality of interchangeable head supports, and the planar support is adjustable with respect to the patient body support in two or more dimensions.",UNIV WAKE FOREST HEALTH SCIENCES;;BERRY JOEL L;;REYNOLDS JOHN E;;BRANCH JR CHARLES L,BERRY JOEL L;;REYNOLDS JOHN E;;BRANCH CHARLES L JR,,https://lens.org/040-516-128-235-06X,Patent Application,yes,0,2,4,4,0,A61G13/12;;A61G13/12;;A61B90/14;;A61B90/14;;A61G7/07;;A61G13/0054;;A61G13/0054;;A61G13/1205;;A61G13/121;;A61G13/121;;A61G13/128;;A61G13/129;;A61G2200/325;;A61G2200/325,A61B19/00,,0,0,,,,PENDING
106,WO,A1,WO 2006/002956 A1,190-441-987-811-622,2006-01-12,2006,EP 2005007136 W,2005-06-29,GB 0414797 A,2004-07-01,PIPERIDINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS,"The invention provides a compound of formula (1), or a salt or solvate thereof: wherein R, R5, R6, R7, R8, R9, X, n and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",GLAXO GROUP LTD;;BOZZOLI ANDREA;;BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN,BOZZOLI ANDREA;;BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN,,https://lens.org/190-441-987-811-622,Patent Application,yes,1,0,2,2,0,A61P25/00;;C07D211/62;;C07D401/06;;C07D405/12,A61K31/445;;C07D211/62;;C07D401/06;;C07D405/12,,1,1,127-991-754-125-658,10.1517/eotp.14.2.201.26400,"A. SLASSI, I. EGLE: ""Recent progress in the use of glycine transporter-1 inhibitors for the treatment of central and peripheral nervous system diseases"", EXPERT OPIN. THER. PATENTS, vol. 14, no. 2, February 2004 (2004-02-01), pages 201-214, XP002345324",PENDING
107,US,A1,US 2009/0253700 A1,094-795-811-507-633,2009-10-08,2009,US 56804405 A,2005-04-15,GB 0408772 A;;GB 2005001437 W,2004-04-20,N-'4-4(4-MORPHOLINYL) PHENYL!- '(4-PIPERIDINYL) METHYL! CARBOXAMIDE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS,"The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , n and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",BRANCH CLIVE LESLIE;;NASH DAVID JOHN;;MARSHALL HOWARD;;PORTER RODERICK,BRANCH CLIVE LESLIE;;NASH DAVID JOHN;;MARSHALL HOWARD;;PORTER RODERICK,GLAXO GROUP LIMITED (2005-05-19),https://lens.org/094-795-811-507-633,Patent Application,yes,0,0,5,5,0,C07D211/26;;C07D405/12;;A61P25/00;;A61P25/18;;A61P25/28;;C07D211/26;;C07D405/12,A61K31/5377;;A61P25/00;;A61P25/18;;C07D211/26;;C07D405/12;;C07D413/12;;C07D413/14,514/237.2;;544/130,0,0,,,,DISCONTINUED
108,US,S,US D0603967 S,101-427-403-162-165,2009-11-10,2009,US 29930707 F,2007-12-21,US 29930707 F,2007-12-21,Surgical head support adapter,,UNIV WAKE FOREST HEALTH SCIENCES,BERRY JOEL L;;REYNOLDS JOHN E;;BRANCH JR CHARLES L,WAKER FOREST UNIVERSITY HEALTH SCIENCE (2010-01-06);;WAKE FOREST UNIVERSITY HEALTH SCIENCES (2009-08-18),https://lens.org/101-427-403-162-165,Design Right,no,0,12,1,1,0,,,2401;;D24/184,0,0,,,,EXPIRED
109,US,B1,US 10038715 B1,005-135-720-173-533,2018-07-31,2018,US 201715793569 A,2017-10-25,US 201715793569 A;;US 201762539961 P,2017-08-01,Identifying and mitigating denial of service (DoS) attacks,"A server receives a SYN packet and generates a SYN packet signature from the SYN packet. The server generates multiple aggregate signatures for the SYN packet signature that each include a generalized value for at least one element, where each aggregate signature has a different level of specificity and corresponds with a different fingerprint table. The server sequentially iterates through the fingerprint tables starting with the most specific aggregate signature and the most specific fingerprint table until a match exceeding a counter threshold is found, if any. If an aggregate signature does not match a fingerprint in a fingerprint table, the aggregate signature is added to that fingerprint table and an initial value for the counter is set. A bytecode using an attack fingerprint as input is generated in a form understandable by a network filter, and installed in a network filter.",CLOUDFLARE INC,MAJKOWSKI MAREK PRZEMYSLAW;;BERTIN GILBERTO;;BRANCH CHRISTOPHER PHILIP;;GRAHAM-CUMMING JOHN,CLOUDFLARE INC (2017-10-23),https://lens.org/005-135-720-173-533,Granted Patent,yes,11,22,1,1,0,H04L63/0263;;H04L63/1458;;H04L63/0227;;H04L63/1416;;H04L63/1425;;H04L63/1425;;H04L63/1458;;H04L63/1466,H04L29/06,,5,0,,,"Transmission Control Protocol, DARPA Internet Program Protocol Specification, RFC: 793, by Information Sciences Institute, University of Southern California, Sep. 1981, 91 pages.;;Marek Majkowski, BPF—the forgotten bytecode, Cloudflare Blog, Cloudflare, Inc., May 21, 2014, 8 pages.;;Marek Majkowski, Introducing the BPF Tools, Cloudflare Blog, Cloudflare, Inc., Jul. 3, 2014, 8 pages.;;Steven McCanne et al., The BSD Packet Filter: A New Architecture for User-level Packet Capture, Dec. 19, 1992, Winter USENIX—Jan. 1993—San Diego, CA, 11 pages.;;William Stearns, IPTables U32 Match Tutorial, Dec. 18, 2003, 9 pages.",ACTIVE
110,US,B2,US 9784376 B2,028-715-420-415-188,2017-10-10,2017,US 201414333460 A,2014-07-16,US 201414333460 A;;US 201361846794 P,2013-07-16,Check valve assembly,"A valve assembly for a compressor includes a flow passage defining an inlet, an outlet, and a valve seat located proximate the inlet. The valve assembly also has a valve member that includes a head portion engageable with the valve seat. The head portion has a front face, a rear face located closer to the outlet than the front face, and a side face extending between the front and rear faces. The head portion further has a first convex curvature formed between the front face and the side face. The valve member also includes a collar portion extending toward the outlet from the rear face of the head portion.",TRANE INT INC,ABDELHAMID YAHIA;;SMERUD SCOTT JOSEPH;;BRANCH SCOTT MICHAEL;;SAULS JOHN ROBERT,TRANE INTERNATIONAL INC (2014-07-17),https://lens.org/028-715-420-415-188,Granted Patent,yes,24,0,2,2,0,F16K15/023;;F16K15/023;;Y10T137/0318;;Y10T137/0318;;Y10T137/7837;;Y10T137/7837,F16K15/02,,0,0,,,,ACTIVE
111,WO,A1,WO 2005/103000 A1,171-316-541-385-962,2005-11-03,2005,GB 2005001437 W,2005-04-15,GB 0408772 A,2004-04-20,N-`4-4(4-MORPHOLINYL) PHENYL!-`(4-PIPERIDINYL) METHYL! CARBOXAMIDE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS,"The invention provides a compound of formula (I) or a salt or solvate thereof wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, n and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",GLAXO GROUP LTD;;BRANCH CLIVE LESLIE;;NASH DAVID JOHN;;MARSHALL HOWARD;;PORTER RODERICK ALAN,BRANCH CLIVE LESLIE;;NASH DAVID JOHN;;MARSHALL HOWARD;;PORTER RODERICK ALAN,,https://lens.org/171-316-541-385-962,Patent Application,yes,4,6,5,5,0,C07D211/26;;C07D405/12;;A61P25/00;;A61P25/18;;A61P25/28;;C07D211/26;;C07D405/12,C07D211/26;;C07D405/12;;C07D413/14,,0,0,,,,PENDING
112,US,B2,US 7166608 B2,003-452-593-125-833,2007-01-23,2007,US 49225004 A,2004-07-02,EP 0211316 W;;GB 0124463 A,2001-10-11,N-aroyl piperazine derivatives as orexin receptor antagonists,"This invention relates to N-aroyl piperazine derivatives of formula (I), wherein: Y represents NR 2 ; m represents 1, 2 or 3; p represents 0 or 1; X is O, S, C═O, SO 2 , or CH═CH—; Ar 1 is aryl, or a mono or bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; any of which may be optionally substituted; Ar 2 represents phenyl or a 5- or 6-membered heterocyclyl group containing 1 to 3 heteroatoms selected from N, O and S, wherein the phenyl heterocyclyl group is substituted by R 1 and further optional substituents; or Ar 2 represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing 1 to 4 heteroatoms selected from N, O and S; R 1 represents optionally substituted (C 1-4 )alkoxy, halo, optionally substituted (C 1-6 )alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S; R 2 represents hydrogen, optionally substituted (C 1-4 )alkyl, optionally substituted (C 1-6 )alkanoyl, optionally subtituted (C 1-6 )alkanoxycarbonyl or optionally substituted aryl(C 1-6 )alkyloxycarbonyl; and their use as orexin receptor-antagonists.",SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;STEMP GEOFFREY,SMITHKLINE BEECHAM P.L.C (2004-03-10),https://lens.org/003-452-593-125-833,Granted Patent,yes,7,10,8,8,1,C07D241/04;;C07D413/10;;C07D417/06;;A61P11/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P19/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/10;;A61P3/04;;A61P5/02;;A61P9/00;;C07D413/10;;C07D241/04;;C07D417/06,A61K31/496;;A61K31/495;;A61P3/04;;A61P3/10;;A61P5/02;;A61P9/00;;A61P11/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P19/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;C07D241/04;;C07D413/06;;C07D413/10;;C07D417/06,514/254.02;;514/254.03;;544/367;;544/369,17,15,051-058-212-425-724;;012-351-604-758-470;;015-451-806-293-402;;029-836-899-292-569;;045-228-127-987-257;;034-882-327-596-637;;057-803-665-807-229;;083-018-851-541-531;;046-641-365-452-325;;082-858-121-007-885;;088-688-006-859-838;;008-837-569-840-780;;036-128-714-171-303;;029-287-258-575-906;;012-469-368-317-65X,12450737;;10.1016/s0143-4179(02)00085-9;;pmc1574197;;14691055;;10.1038/sj.bjp.0705610;;11459658;;10.1016/s0960-894x(01)00343-2;;11205420;;10.1007/s002130000550;;15893404;;10.1016/j.peptides.2005.03.042;;10.1016/j.bbr.2004.11.011;;15836896;;15639184;;10.1016/j.bbr.2004.07.012;;15059692;;10.1016/j.physbeh.2004.01.009;;10.1016/s0304-3940(03)00066-1;;12697296;;10.1016/s0167-0115(01)00358-5;;11830290;;10.1016/s0304-3959(00)00470-x;;11323129;;11298806;;10.1046/j.0953-816x.2001.01518.x;;10.1038/sj.bjp.0703953;;11250867;;pmc1572677;;10.1007/s002130000551;;11205421;;11102651;;10.1016/s0167-0115(00)00199-3,"Fujii et al. Chemical Abstracts, vol. 124, No. 34333, Abstract for JP 08040999 (1996).;;Rodgers et al. Neuropeptides, vol. 36(5), p. 303-325 (2002).;;Cai et al. Expert Opin. Ther. Patents, vol. 16, p. 631-646 (2006).;;Langmead et al. Br. J. Pharmacol., 141: 340-346 (2004).;;Porter et al. Bioorg. & Med. Chem. Lett., 11: 1907-1910 (2001).;;Duxon et al. Psychopharmacology, 153: 203-209 (2001).;;White et al. Peptides, 26: 2331-2338 (2005).;;Ishii et al. Behav. Brain Res., 160: 11-24 (2005).;;Ishii et al. Behav. Brain Res., 157: 331-341 (2005).;;Ishii et al. Physiol. & Behav., 81: 129-140 (2004).;;Smith et al. Neurosci. Lett., 341: 256-258 (2003).;;Haynes et al. Regulatory Peptides, 104: 153-159 (2002).;;Bingham et al. Pain, 92: 81-90 (2001).;;Rodgers et al. Eur. J. Neurosci., 13: 1444-1452 (2001).;;Smart et al. Br. J. Pharmacol., 132: 1179-1182 (2001).;;Jones et al. Psychopharmacology, 153: 210-218 (2001).;;Haynes et al. Regulatory Peptides, 96: 45-51 (2000).",EXPIRED
113,TW,B,TW 482818 B,184-765-559-277-623,2002-04-11,2002,TW 87101247 A,1998-02-02,GB 9700904 A;;GB 9700905 A,1997-01-17,Method of manufacture of a laminate having gas barrier properties,"The invention relates to a method of laminating two substrates by coating at least one side of a substrate with a laminating adhesive, bringing a coated side of said substrate into contact with a second substrate to form a three layer film, and treating said three layer film with a free radical initiator, wherein said laminating adhesive is formed by mixing an ethylenically unsaturated acid and a polyamine.",EG TECHNOLOGY LP;;DOW CORNING;;UCB FILMS PLC,FUTTER DAN;;MERLIN PATRICK;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;BRANCH KAREN,,https://lens.org/184-765-559-277-623,Granted Patent,no,0,0,1,36,0,,C09J179/00,,0,0,,,,EXPIRED
114,TW,B,TW 397854 B,091-246-604-879-185,2000-07-11,2000,TW 87101245 A,1998-02-02,GB 9700988 A,1997-01-17,Alkylenimine/organic barrier coatings method of manufacture and applications thereof,"Organic barrier coating composition comprising: an ethylenically unsaturated acid and a polyethylenimine, characterized in that the composition has a crosslinker reacted therein; said polyethylenimine has four or more A, B, or C units, where: A is an -R2-N(R1)2 unit, B is an -R1-N(R2-)2 unit, and C is an (-R2)3N- unit, where: R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, and alkylaryl, and R2 is independently selected from the group consisting of: linear or branched alkylene groups or substituted alkylene groups having from 1 to 18 carbon atoms, and arylene groups or substituted arylene groups having from 6 to 18 carbon atoms; the molar ratio of nitrogen atoms on the polyethylenimine to the acid groups on the ethylenically unsaturated acid is from 10:1 to 1:100; the ethylenically unsaturated acid is selected from the group consisting of itaconic, fumaric, maleic, citraconic, acrylic, methacrylic, and cinnamic, itaconic acid monomethylester, vinylphosphonic acid, mesaconic acid, sorbic acid, and vinyl sulphonic acid, and mixtures thereof; the composition includes an additive selected from the group consisting of antiblock and slip aides, polar additives, a silane, an acrylate or methacrylate, polyethylenimine, glycidyl methacrylate, glycidol, ethyleneglycol diglycidylether, bisphenol A diglycidylether and wetting agents; the crosslinker is a reactive silane having the general formula QSiRm(OR)3-m,where Q contains a group selected from the group consisting of acrylates, aldehydes, methacrylates, acrylamides, methacrylamides, isocyanates, isothiocyanate, anhydrides, epoxides, acid chlorides, linear or branched halogenated alkyl, and halogenated aryl. And m is 1, 2 or 3 and R is a group having 1 to 4 carbon atoms; and, said composition has optionally been neutralized.",DOW CORNING;;EG TECHNOLOGY LP;;UCB FILMS PLC,FUTTER DAN;;MERLIN PATRICK;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;BRANCH KAREN,,https://lens.org/091-246-604-879-185,Granted Patent,no,0,0,2,36,0,,C08L33/00,,0,0,,,,EXPIRED
115,US,A1,US 2015/0020885 A1,029-543-079-621-356,2015-01-22,2015,US 201414333460 A,2014-07-16,US 201414333460 A;;US 201361846794 P,2013-07-16,CHECK VALVE ASSEMBLY,"A valve assembly for a compressor includes a flow passage defining an inlet, an outlet, and a valve seat located proximate the inlet. The valve assembly also has a valve member that includes a head portion engageable with the valve seat. The head portion has a front face, a rear face located closer to the outlet than the front face, and a side face extending between the front and rear faces. The head portion further has a first convex curvature formed between the front face and the side face. The valve member also includes a collar portion extending toward the outlet from the rear face of the head portion.",TRANE INT INC,ABDELHAMID YAHIA;;SMERUD SCOTT JOSEPH;;BRANCH SCOTT MICHAEL;;SAULS JOHN ROBERT,TRANE INTERNATIONAL INC (2014-07-17),https://lens.org/029-543-079-621-356,Patent Application,yes,13,2,2,2,0,F16K15/023;;F16K15/023;;Y10T137/0318;;Y10T137/0318;;Y10T137/7837;;Y10T137/7837,F16K27/02;;F16K15/02,137/1;;137/511,0,0,,,,ACTIVE
116,WO,A1,WO 2003/032991 A1,130-632-302-375-393,2003-04-24,2003,EP 0211316 W,2002-10-09,GB 0124463 A,2001-10-11,N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,"This invention relates to N-aroyl piperazine derivatives of formula (I), wherein: Y represents NR2; m represents 1, 2 or 3; p represents 0 or 1; X is O, S, C=O, SO¿2?, or CH=CH-; Ar?1¿ is aryl, or a mono or bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; any of which may be optionally substituted; Ar2 represents phenyl or a 5- or 6-membered heterocyclyl group containing 1 to 3 heteroatoms selected from N, O and S, wherein the phenyl heterocyclyl group is substituted by R1 and further optional substituents; or Ar2 represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing 1 to 4 heteroatoms selected from N, O and S; R1 represents optionally substituted (C¿1-4?)alkoxy, halo, optionally substituted (C1-6)alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S; R?2 ¿represents hydrogen, optionally substituted (C¿1-4?)alkyl, optionally substituted (C1-6)alkanoyl, optionally subtituted (C1-6)alkanoxycarbonyl or optionally substituted aryl(C1-6)alkyloxycarbonyl; and their use as orexin receptor-antagonists.",SMITHKLINE BEECHAM PLC;;BRANCH CLIVE LESLIE;;JOHSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;STEMP GEOFFREY,BRANCH CLIVE LESLIE;;JOHSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;STEMP GEOFFREY,,https://lens.org/130-632-302-375-393,Patent Application,yes,6,0,8,8,0,C07D241/04;;C07D413/10;;C07D417/06;;A61P11/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P19/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/10;;A61P3/04;;A61P5/02;;A61P9/00;;C07D413/10;;C07D241/04;;C07D417/06,A61K31/495;;A61K31/496;;A61P3/04;;A61P3/10;;A61P5/02;;A61P9/00;;A61P11/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P19/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;C07D241/04;;C07D413/10;;C07D417/06,,0,0,,,,PENDING
117,US,B2,US 7405217 B2,147-593-360-998-204,2008-07-29,2008,US 55799806 A,2006-11-09,US 55799806 A;;GB 0124463 A;;US 49225004 A;;EP 0211316 W,2001-10-11,N-aroyl piperazine derivatives as orexin receptor antagonists,This invention relates to N-aroyl cyclic amino derivatives and their use as pharmaceuticals.,SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;STEMP GEOFFREY,,https://lens.org/147-593-360-998-204,Granted Patent,yes,11,0,8,8,1,C07D241/04;;C07D413/10;;C07D417/06;;A61P11/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P19/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/10;;A61P3/04;;A61P5/02;;A61P9/00;;C07D413/10;;C07D241/04;;C07D417/06,A61K31/495;;A61K31/496;;A61P3/04;;A61P3/10;;A61P5/02;;A61P9/00;;A61P11/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P19/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;C07D241/04;;C07D413/10;;C07D417/06;;C07D417/12,514/254.02;;514/254.03;;544/180;;544/182;;544/238;;544/295;;544/350;;544/353;;544/355;;544/357;;544/360;;544/362;;544/363;;544/364;;544/367;;544/368;;544/391,18,15,012-351-604-758-470;;015-451-806-293-402;;029-836-899-292-569;;045-228-127-987-257;;034-882-327-596-637;;057-803-665-807-229;;083-018-851-541-531;;046-641-365-452-325;;082-858-121-007-885;;088-688-006-859-838;;008-837-569-840-780;;036-128-714-171-303;;029-287-258-575-906;;012-469-368-317-65X;;051-058-212-425-724,pmc1574197;;14691055;;10.1038/sj.bjp.0705610;;11459658;;10.1016/s0960-894x(01)00343-2;;11205420;;10.1007/s002130000550;;15893404;;10.1016/j.peptides.2005.03.042;;10.1016/j.bbr.2004.11.011;;15836896;;15639184;;10.1016/j.bbr.2004.07.012;;15059692;;10.1016/j.physbeh.2004.01.009;;10.1016/s0304-3940(03)00066-1;;12697296;;10.1016/s0167-0115(01)00358-5;;11830290;;10.1016/s0304-3959(00)00470-x;;11323129;;11298806;;10.1046/j.0953-816x.2001.01518.x;;10.1038/sj.bjp.0703953;;11250867;;pmc1572677;;10.1007/s002130000551;;11205421;;11102651;;10.1016/s0167-0115(00)00199-3;;12450737;;10.1016/s0143-4179(02)00085-9,"Langmead et al. Br. J. Pharmacol . . , 141: 340-346 (2004).;;Porter et al. Bioorg. & Med. Chem. Lett., 11: 1907-1910 (2001).;;Duxon et al. Psychopharmacology, 153: 203-209 (2001).;;White et al. Peptides, 26: 2331-2338 (2005).;;Ishii et al. Behav. Brain Res., 160: 11-24 (2005).;;Ishii et al. Behav. Brain Res., 157: 331-341 (2005).;;Ishii et al. Physiol. & Behav.; 81: 129-140 (2004).;;Smith et al. Neurosci., 341: 256-258 (2003).;;Haynes et al. Regulatory Peptides, 104: 153-159 (2002).;;Bingham et al. Pain, 92: 81-90 (2001).;;Rodgers et al. Eur. J. Neurosci., 13: 1444-1452 (2001).;;Smart et al. Br. J. Pharmacol., 132: 1179-1182 (2001).;;Jones et al. Psychopharmacology, 153: 210-218 (2001).;;Haynes et al. Regulatory Peptides, 96: 45-51 (2000).;;Rodgers et al. Neuropeptides, 36(5): 303-325 (2002).;;Cai et al. Expert Opin. Ther. Patents, 16: 631-646 (2006).;;Fujii et al. Chemical Abstracts, 124(No. 34333): Abstract for JP 08040999 (1996).;;USPTO office action dated Oct. 10, 2007, U.S. Appl. No. 10/481,133.",EXPIRED
118,WO,A1,WO 2007/116061 A1,111-767-639-764-561,2007-10-18,2007,EP 2007053468 W,2007-04-10,GB 0607398 A,2006-04-12,"1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO [4.5]DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS","Novel acetophenone compounds of formula (I), compositions containing (I), processes for the preparation of (I), and use of (I) as inhibitors of the glycine transporter, are provided. Definitions of Ar, R 5 , R 6 , R 7 , R 8 and n are provided in the specification.",GLAXO GROUP LTD;;BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,,https://lens.org/111-767-639-764-561,Patent Application,yes,1,9,5,5,0,C07D235/02;;C07D401/10;;C07D405/06;;A61P25/18;;A61P25/28;;C07D235/02;;C07D405/06;;C07D401/10,C07D235/02;;A61K31/4184;;C07D401/10;;C07D405/06,,0,0,,,,PENDING
119,WO,A1,WO 2005/058882 A1,145-050-669-012-390,2005-06-30,2005,EP 2004014469 W,2004-12-16,GB 0329362 A,2003-12-18,COMPOUNDS HAVING MORPHOLINYL AND PIPERIDINYL GROUPS FOR USE AS GLYT1 AND GLYT2 INHIBITORS,"The invention provides a compound of formula (I) or a salt or solvate thereof, wherein R1, R3 and R4, Het, X and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",GLAXO GROUP LTD;;BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,,https://lens.org/145-050-669-012-390,Patent Application,yes,1,16,2,2,0,A61P25/00;;C07D401/12;;C07D405/14,C07D401/12;;C07D405/14,,0,0,,,,PENDING
120,US,A1,US 2004/0242575 A1,169-757-681-506-844,2004-12-02,2004,US 49225004 A,2004-07-02,EP 0211316 W;;GB 0124463 A,2001-10-11,N-aroyl piperazine derivatives as orexin receptor antagonists,"
    This invention relates to N-aroyl piperazine derivatives of formula (I), wherein: Y represents NR ² ; m represents 1, 2 or 3; p represents 0 or 1; X is O, S, CO, SO ₂ , or CHCH; Ar ¹ is aryl, or a mono or bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; any of which may be optionally substituted; Ar ² represents phenyl or a 5- or 6-membered heterocyclyl group containing 1 to 3 heteroatoms selected from N, O and S, wherein the phenyl heterocyclyl group is substituted by R ¹ and further optional substituents; or Ar ² represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing 1 to 4 heteroatoms selected from N, O and S; R ¹ represents optionally substituted (C ₁₋₄ )alkoxy, halo, optionally substituted (C ₁₋₆ )alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S; R2 represents hydrogen, optionally substituted (C ₁₋₄ )alkyl, optionally substituted (C ₁₋₆ )alkanoyl, optionally subtituted (C ₁₋₆ )alkanoxycarbonyl or optionally substituted aryl(C ₁₋₆ )alkyloxycarbonyl; and their use as orexin receptor-antagonists. 
",BRANCH CLIVE LESLIE;;JOHNSON CHIRSTOPHER NORBERT;;NASH DAVID JOHN;;STEMP GEOFFREY,BRANCH CLIVE LESLIE;;JOHNSON CHIRSTOPHER NORBERT;;NASH DAVID JOHN;;STEMP GEOFFREY,SMITHKLINE BEECHAM P.L.C (2004-03-10),https://lens.org/169-757-681-506-844,Patent Application,yes,0,5,8,8,1,C07D241/04;;C07D413/10;;C07D417/06;;A61P11/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P19/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/10;;A61P3/04;;A61P5/02;;A61P9/00;;C07D413/10;;C07D241/04;;C07D417/06,A61K31/495;;A61K31/496;;A61P3/04;;A61P3/10;;A61P5/02;;A61P9/00;;A61P11/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P19/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;C07D241/04;;C07D413/10;;C07D417/06,514/227.8;;514/235.5;;514/253.11;;514/255.01;;X544 6;;544/114;;X54436;;544/386,0,0,,,,EXPIRED
121,EP,A1,EP 2027098 A1,003-116-870-451-256,2009-02-25,2009,EP 07727936 A,2007-04-10,EP 2007053468 W;;GB 0607398 A,2006-04-12,"1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO (4.5)DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS",,GLAXO GROUP LTD,BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,,https://lens.org/003-116-870-451-256,Patent Application,yes,0,0,5,5,0,C07D235/02;;C07D401/10;;C07D405/06;;A61P25/18;;A61P25/28;;C07D235/02;;C07D405/06;;C07D401/10,C07D235/02;;A61K31/4184;;C07D401/10;;C07D405/06,,0,0,,,,DISCONTINUED
122,WO,A1,WO 2003/051873 A1,195-106-052-291-581,2003-06-26,2003,GB 0205676 W,2002-12-13,GB 0130393 A,2001-12-19,PIPERAZINE COMPOUNDS AND THEIR PHAMACEUTICAL USE,This invention relates to piperazine derivatives and their use as pharmaceuticals.,SMITHKLINE BEECHAM PLC;;BRANCH CLIVE LESLIE;;COULTON STEVEN;;NASH DAVID JOHN;;PORTER RODERICK ALAN,BRANCH CLIVE LESLIE;;COULTON STEVEN;;NASH DAVID JOHN;;PORTER RODERICK ALAN,,https://lens.org/195-106-052-291-581,Patent Application,yes,1,0,3,3,0,A61P25/00;;C07D401/14;;C07D403/14;;C07D417/14,A61P25/00;;C07D401/14;;C07D403/14;;C07D417/14,,0,0,,,,PENDING
123,EP,A1,EP 1441729 A1,017-105-023-063-951,2004-08-04,2004,EP 02790347 A,2002-11-06,EP 0212476 W;;GB 0127145 A,2001-11-10,PIPERAZINE BIS-AMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE OREXIN RECEPTOR,,SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;STEMP GEOFFREY,SMITHKLINE BEECHAM LIMITED (2010-04-21),https://lens.org/017-105-023-063-951,Patent Application,yes,0,0,6,6,0,A61P1/08;;A61P9/10;;A61P43/00;;C07D417/14;;C07D417/14,C07D405/14;;A61K31/496;;A61P1/08;;A61P9/10;;A61P43/00;;C07D417/14,,1,0,,,See references of WO 03041711A1,DISCONTINUED
124,US,A1,US 2010/0029700 A1,122-865-609-835-435,2010-02-04,2010,US 29671207 A,2007-04-10,GB 0607398 A;;EP 2007053468 W,2006-04-12,"1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO [4.5]DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS","Novel acetophenone compounds of formula (I), compositions containing (I), processes for the preparation of (I), and use of (I) as inhibitors of the glycine transporter, are provided. Definitions of Ar, R 5 , R 6 , R 7 , R 8 and n are provided in the specification.",BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,GLAXO GROUP LIMITED (2009-01-23),https://lens.org/122-865-609-835-435,Patent Application,yes,1,0,5,5,0,C07D235/02;;C07D401/10;;C07D405/06;;A61P25/18;;A61P25/28;;C07D235/02;;C07D405/06;;C07D401/10,A61K31/438;;A61K31/415;;C07D209/54;;C07D401/02,514/278;;548/408;;514/385;;546/15,0,0,,,,DISCONTINUED
125,TW,B,TW 565595 B,044-903-216-869-519,2003-12-11,2003,TW 87101239 A,1998-02-02,GB 9700910 A;;GB 9700964 A,1997-01-17,Silicone/multifunctional acrylate barrier coatings,"The invention is a composition made by mixing a multifunctional acrylate with an aminofunctional silane and an ethylenically unsaturated acid to form a reaction product, optionally dissolved in a solvent, characterized in that multifunctional acrylate has a molecular weight of from about 100 to about 3000. The composition can be coated on a substrate, then optionally exposed to moisture and treated to initiate a free radical reaction. The invention can be applied to a variety of substrates used in packaging applications. The reaction mixture can further be cured by heating in the presence of moisture. The free radical reaction can be initiated by electron beam irradiation, ultraviolet radiation, gamma radiation, and/or heat and chemical free radical initiators.",EG TECHNOLOGY LP;;DOW CORNING;;UCB FILMS PLC,FUTTER DAN;;MERLIN PATRICK;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;BRANCH KAREN,,https://lens.org/044-903-216-869-519,Granted Patent,no,0,2,10,12,0,B65D65/38;;B65D65/38;;C08F290/14;;C08F290/14;;Y10T428/1352;;Y10T428/1352;;Y10T428/1393;;Y10T428/1393,B65D65/02;;B65D65/38;;C08F290/14;;C08L79/00;;C09D4/00,,0,0,,,,EXPIRED
126,WO,A1,WO 2003/041711 A1,053-781-298-162-333,2003-05-22,2003,EP 0212476 W,2002-11-06,GB 0127145 A,2001-11-10,PIPERAZINE BIS-AMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE OREXIN RECEPTOR,This invention relates to piperazine bisᇁamide derivatives and their use as pharmaceuticals&period;,SMITHKLINE BEECHAM PLC;;BRANCH CLIVE LESLIE;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;STEMP GEOFFREY,BRANCH CLIVE LESLIE;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;STEMP GEOFFREY,,https://lens.org/053-781-298-162-333,Patent Application,yes,2,0,6,6,0,A61P1/08;;A61P9/10;;A61P43/00;;C07D417/14;;C07D417/14,C07D405/14;;A61K31/496;;A61P1/08;;A61P9/10;;A61P43/00;;C07D417/14,,1,0,,,"DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; OMODEI-SALE, A. ET AL: ""Hexahydroimidazo[1,5-a]pyrazines. I. Synthesis of 7-methyl-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-3(2H)-one and derivatives"", XP002229197, retrieved from STN Database accession no. 83:131550",PENDING
127,AU,A1,AU 2002/352389 A1,142-485-633-931-460,2003-06-30,2003,AU 2002/352389 A,2002-12-13,GB 0130393 A;;GB 0205676 W,2001-12-19,PIPERAZINE COMPOUNDS AND THEIR PHAMACEUTICAL USE,,SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;COULTON STEVEN;;NASH DAVID JOHN;;PORTER RODERICK ALAN,,https://lens.org/142-485-633-931-460,Patent Application,no,0,0,3,3,0,A61P25/00;;C07D401/14;;C07D403/14;;C07D417/14,A61P25/00;;C07D401/14;;C07D403/14;;C07D417/14,,0,0,,,,DISCONTINUED
128,EP,A1,EP 1737822 A1,068-035-177-496-687,2007-01-03,2007,EP 05734492 A,2005-04-15,GB 2005001437 W;;GB 0408772 A,2004-04-20,N-'4-4(4-MORPHOLINYL) PHENYL!-'(4-PIPERIDINYL) METHYL! CARBOXAMIDE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS,,GLAXO GROUP LTD,BRANCH CLIVE LESLIE;;NASH DAVID JOHN;;MARSHALL HOWARD;;PORTER RODERICK ALAN,,https://lens.org/068-035-177-496-687,Patent Application,yes,0,0,5,5,0,C07D211/26;;C07D405/12;;A61P25/00;;A61P25/18;;A61P25/28;;C07D211/26;;C07D405/12,C07D211/26;;A61K31/5377;;A61P25/18;;A61P25/28;;C07D405/12;;C07D413/14,,0,0,,,,DISCONTINUED
129,US,B2,US 7365077 B2,040-110-894-843-291,2008-04-29,2008,US 49502104 A,2004-10-15,GB 0127145 A;;EP 0212476 W,2001-11-10,Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor,Disclosed are piperazine bis-amide derivatives useful as antagonists of the orexin receptor and pharmaceutical compositions containing the same.,SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;STEMP GEOFFREY,SMTIHKLINE BEECHAM P.L.C (2004-06-30),https://lens.org/040-110-894-843-291,Granted Patent,yes,13,8,6,6,1,A61P1/08;;A61P9/10;;A61P43/00;;C07D417/14;;C07D417/14,A61K31/496;;C07D405/14;;A61P1/08;;A61P9/10;;A61P43/00;;C07D401/12;;C07D405/12;;C07D417/14,514/253.06;;514/254.02;;514/254.09;;544/363;;544/369;;544/371;;544/373,5,3,051-058-212-425-724;;012-351-604-758-470;;035-230-547-171-641,12450737;;10.1016/s0143-4179(02)00085-9;;pmc1574197;;14691055;;10.1038/sj.bjp.0705610;;10.1021/cr950066q;;11848856,"Rodgers et al. Neuropeptides, vol.36(5), p. 303-325 (2002).;;Langmead et al. Br. J. Pharmacol., 141, p. 340-346 (2004).;;Cai et al. Expert Opin. Ther. Patents, vol. 16, p. 631-646 (2006).;;Database CA 'Online!Chemical Abstracts Service. ""Hexahydroimidazo '1,5-a!pyrazines. I. Synthesis of 7-methyl-1,5,6,7,8,8a-hexahydroimidazo '1,5-a!pyrazin-3(2H)-one and derivatives"". Database Accession No. 83:131550. XP002229197.;;Patani et al. Chem. Rev., 96: 3147-3176 (1996).",EXPIRED
130,US,B1,US 7537616 B1,157-884-831-739-78X,2009-05-26,2009,US 31217400 A,2000-10-20,US 31217400 A;;US 16050699 P;;US 0041392 W,1999-10-20,Impacted orthopedic bone support implant,"This invention relates to a porous bone implant ( 10, 110 , and 210 ), a method of manufacturing the implant and a method of orthopedic treatment. The mesh implant can be manufactured using extrusion techniques and a variety of cutting and machining processes to provide the implant with the desired structural features and in the required dimensions to be matingly received within the bone defect or cavity. The implant can be used to strengthen bone structures and support bone tissue adjacent to a defect of cavity. Thus, the implant can be used to provide improved treatment of patients having bone defects or diseases with decreased postoperative pain and a shorter recovery time.",WARSAW ORTHOPEDIC INC,BRANCH CHARLES L;;WHITE JOHN L;;ESTES BRADLEY T;;RAY III EDDIE,SDGI HOLDINGS INC (2003-04-01),https://lens.org/157-884-831-739-78X,Granted Patent,yes,21,126,15,15,0,A61B17/14;;A61B17/1604;;A61F2/28;;A61F2/2846;;A61F2/30965;;A61F2/442;;A61F2/4455;;A61F2/446;;A61F2/4603;;A61F2/4611;;A61F2002/2835;;A61F2002/2839;;A61F2002/30112;;A61F2002/30138;;A61F2002/30153;;A61F2002/30154;;A61F2002/30156;;A61F2002/30235;;A61F2002/30324;;A61F2002/30593;;A61F2002/30616;;A61F2002/30774;;A61F2002/30777;;A61F2002/30785;;A61F2002/30787;;A61F2002/30789;;A61F2002/3082;;A61F2002/30836;;A61F2002/30879;;A61F2002/30912;;A61F2002/3097;;A61F2002/4649;;A61F2002/4681;;A61F2230/0004;;A61F2230/0017;;A61F2230/0019;;A61F2230/0021;;A61F2230/0023;;A61F2230/0069;;A61F2230/0082;;A61F2250/0036;;A61F2310/00017;;A61F2310/00023;;A61F2310/00179;;A61F2002/30261;;A61F2/446;;A61F2002/30324;;A61F2230/0023;;A61F2230/0082;;A61F2310/00023;;A61F2002/3097;;A61F2230/0021;;A61F2002/30774;;A61F2002/30789;;A61F2230/0017;;A61F2/28;;A61F2/2846;;A61F2/4611;;A61F2002/30138;;A61F2002/30154;;A61F2/442;;A61B17/1604;;A61F2/4603;;A61F2230/0019;;A61F2/30965;;A61F2002/3082;;A61F2/4455;;A61F2230/0004;;A61F2250/0036;;A61F2002/30785;;A61F2002/2839;;A61F2310/00017;;A61F2002/30112;;A61F2002/30153;;A61F2310/00179;;A61F2002/30912;;A61B17/14;;A61F2002/2835;;A61F2002/30593;;A61F2002/30879;;A61F2002/4649;;A61F2002/30777;;A61F2002/30235;;A61F2002/30616;;A61F2002/30156;;A61F2002/4681;;A61F2002/30787;;A61F2002/30836;;A61F2230/0069;;A61F2002/30261,A61F2/44;;A61B17/14;;A61B17/16;;A61F2/00;;A61F2/28;;A61F2/30;;A61F2/46,623/17.16;;623/17.11,0,0,,,,EXPIRED
131,DE,C3,DE 1642102 C3,191-176-017-749-639,1975-04-03,1975,DE 1642102 A,1967-12-08,GB 5507066 A;;GB 5507266 A;;GB 5507366 A;;GB 5507466 A,1966-12-08,DE 1642102 C3,,"NATIONAL RESEARCH DEVELOPMENT CORP., LONDON","BRANCH, SYDNEY FRANK, LONDON;;HANSEN, WILLIAM FREDERICK, WOKINGHAM;;PAVEY, JOHN ANTHONY, READING",,https://lens.org/191-176-017-749-639,Granted Patent,no,0,0,6,8,0,B67C7/0073;;B65B55/04;;B65B55/10;;B67C2003/2691,B67B3/24;;B65B55/04;;B65B55/10;;B67C3/26;;B67C7/00,,0,0,,,,EXPIRED
132,DE,B2,DE 1642102 B2,051-752-540-237-925,1974-08-15,1974,DE 1642102 A,1967-12-08,GB 5507066 A;;GB 5507266 A;;GB 5507366 A;;GB 5507466 A,1966-12-08,DE 1642102 B2,,"NATIONAL RESEARCH DEVELOPMENT CORP., LONDON","BRANCH, SYDNEY FRANK, LONDON;;HANSEN, WILLIAM FREDERICK, WOKINGHAM;;PAVEY, JOHN ANTHONY, READING",,https://lens.org/051-752-540-237-925,Patent Application,no,0,2,6,8,0,B67C7/0073;;B65B55/04;;B65B55/10;;B67C2003/2691,B67B3/24;;B65B55/04;;B65B55/10;;B67C3/26;;B67C7/00,,0,0,,,,EXPIRED
133,US,A1,US 2009/0299474 A1,082-822-718-731-206,2009-12-03,2009,US 45449809 A,2009-05-19,US 45449809 A;;US 31217403 A;;US 0041392 W;;US 16050699 P,1999-10-20,Impacted orthopedic support implant,"This invention relates to a porous bone implant ( 10, 110 , and 210 ), a method of manufacturing the implant and a method of orthopedic treatment. The mesh implant can be manufactured using extrusion techniques and a variety of cutting and machining processes to provide the implant with the desired structural features and in the required dimensions to be matingly received within the bone defect or cavity. The implant can be used to strengthen bone structures and support bone tissue adjacent to a defect of cavity. Thus, the implant can be used to provide improved treatment of patients having bone defects or diseases with decreased postoperative pain and a shorter recovery time.",BRANCH CHARLES L;;WHITE JOHN L;;ESTES BRADLEY T;;RAY III EDDIE,BRANCH CHARLES L;;WHITE JOHN L;;ESTES BRADLEY T;;RAY III EDDIE,,https://lens.org/082-822-718-731-206,Patent Application,yes,36,2,15,15,0,A61B17/14;;A61B17/1604;;A61F2/28;;A61F2/2846;;A61F2/30965;;A61F2/442;;A61F2/4455;;A61F2/446;;A61F2/4603;;A61F2/4611;;A61F2002/2835;;A61F2002/2839;;A61F2002/30112;;A61F2002/30138;;A61F2002/30153;;A61F2002/30154;;A61F2002/30156;;A61F2002/30235;;A61F2002/30324;;A61F2002/30593;;A61F2002/30616;;A61F2002/30774;;A61F2002/30777;;A61F2002/30785;;A61F2002/30787;;A61F2002/30789;;A61F2002/3082;;A61F2002/30836;;A61F2002/30879;;A61F2002/30912;;A61F2002/3097;;A61F2002/4649;;A61F2002/4681;;A61F2230/0004;;A61F2230/0017;;A61F2230/0019;;A61F2230/0021;;A61F2230/0023;;A61F2230/0069;;A61F2230/0082;;A61F2250/0036;;A61F2310/00017;;A61F2310/00023;;A61F2310/00179;;A61F2002/30261;;A61F2/446;;A61F2002/30324;;A61F2230/0023;;A61F2230/0082;;A61F2310/00023;;A61F2002/3097;;A61F2230/0021;;A61F2002/30774;;A61F2002/30789;;A61F2230/0017;;A61F2/28;;A61F2/2846;;A61F2/4611;;A61F2002/30138;;A61F2002/30154;;A61F2/442;;A61B17/1604;;A61F2/4603;;A61F2230/0019;;A61F2/30965;;A61F2002/3082;;A61F2/4455;;A61F2230/0004;;A61F2250/0036;;A61F2002/30785;;A61F2002/2839;;A61F2310/00017;;A61F2002/30112;;A61F2002/30153;;A61F2310/00179;;A61F2002/30912;;A61B17/14;;A61F2002/2835;;A61F2002/30593;;A61F2002/30879;;A61F2002/4649;;A61F2002/30777;;A61F2002/30235;;A61F2002/30616;;A61F2002/30156;;A61F2002/4681;;A61F2002/30787;;A61F2002/30836;;A61F2230/0069;;A61F2002/30261,A61B17/14;;A61F2/28;;A61B17/16;;A61F2/00;;A61F2/30;;A61F2/44;;A61F2/46,623/16.11,0,0,,,,DISCONTINUED
134,AT,T1,AT E305276 T1,192-941-894-335-86X,2005-10-15,2005,AT 00988472 T,2000-10-20,US 16050699 P;;US 0041392 W,1999-10-20,EINGESCHLAGENES ORTHOPÄDISCHES KNOCHENSTÜTZIMPLANTAT,"This invention relates to a porous bone implant (10, 110, and 210), a method of manufacturing the implant and a method of orthopedic treatment. The mesh implant can be manufactured using extrusion techniques and a variety of cutting and machining processes to provide the implant with the desired structural features and in the required dimensions to be matingly received within the bone defect or cavity. The implant can be used to strengthen bone structures and support bone tissue adjacent to a defect of cavity. Thus, the implant can be used to provide improved treatment of patients having bone defects or diseases with decreased postoperative pain and a shorter recovery time.",SDGI HOLDINGS INC,BRANCH CHARLES L;;WHITE JOHN L;;ESTES BRADLEY T;;RAY EDDIE F III,,https://lens.org/192-941-894-335-86X,Granted Patent,no,0,0,15,15,0,A61B17/14;;A61B17/1604;;A61F2/28;;A61F2/2846;;A61F2/30965;;A61F2/442;;A61F2/4455;;A61F2/446;;A61F2/4603;;A61F2/4611;;A61F2002/2835;;A61F2002/2839;;A61F2002/30112;;A61F2002/30138;;A61F2002/30153;;A61F2002/30154;;A61F2002/30156;;A61F2002/30235;;A61F2002/30324;;A61F2002/30593;;A61F2002/30616;;A61F2002/30774;;A61F2002/30777;;A61F2002/30785;;A61F2002/30787;;A61F2002/30789;;A61F2002/3082;;A61F2002/30836;;A61F2002/30879;;A61F2002/30912;;A61F2002/3097;;A61F2002/4649;;A61F2002/4681;;A61F2230/0004;;A61F2230/0017;;A61F2230/0019;;A61F2230/0021;;A61F2230/0023;;A61F2230/0069;;A61F2230/0082;;A61F2250/0036;;A61F2310/00017;;A61F2310/00023;;A61F2310/00179;;A61F2002/30261;;A61F2/446;;A61F2002/30324;;A61F2230/0023;;A61F2230/0082;;A61F2310/00023;;A61F2002/3097;;A61F2230/0021;;A61F2002/30774;;A61F2002/30789;;A61F2230/0017;;A61F2/28;;A61F2/2846;;A61F2/4611;;A61F2002/30138;;A61F2002/30154;;A61F2/442;;A61B17/1604;;A61F2/4603;;A61F2230/0019;;A61F2/30965;;A61F2002/3082;;A61F2/4455;;A61F2230/0004;;A61F2250/0036;;A61F2002/30785;;A61F2002/2839;;A61F2310/00017;;A61F2002/30112;;A61F2002/30153;;A61F2310/00179;;A61F2002/30912;;A61B17/14;;A61F2002/2835;;A61F2002/30593;;A61F2002/30879;;A61F2002/4649;;A61F2002/30777;;A61F2002/30235;;A61F2002/30616;;A61F2002/30156;;A61F2002/4681;;A61F2002/30787;;A61F2002/30836;;A61F2230/0069;;A61F2002/30261,A61B17/14;;A61B17/16;;A61F2/00;;A61F2/28;;A61F2/30;;A61F2/44;;A61F2/46,,0,0,,,,EXPIRED
135,US,A1,US 2016/0366268 A1,050-641-266-803-374,2016-12-15,2016,US 201514736573 A,2015-06-11,US 201514736573 A,2015-06-11,RAPID SERIAL VISUAL PRESENTATION TO DELIVER MESSAGES IN SOCIAL SPACES,"A private message can be delivered by a computer system to a user in an environment, using a display in the environment, a user device, and sensors in the space. The device is detected and connected to a system once it enters a space. A private message is directed to the device and it is received by the system, which notifies the device that the message has been received. The user can then look up at a device to display the message and the system can determine where the user is looking, in order to deliver the message using rapid serial visual presentation to the user on the display device.",IBM,AARON ANDREW S;;BRANCH JOEL W;;GIL DARIO;;LENCHNER JONATHAN;;NELSON JOHN C,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-06-04),https://lens.org/050-641-266-803-374,Patent Application,yes,5,0,2,2,0,H04M1/72436;;H04M1/72412;;H04L51/222;;H04L51/52;;H04L51/063;;H04M1/72436;;H04M1/72412;;H04L51/52;;H04L51/222,H04M1/72436;;H04L12/58;;H04M1/72412,,0,0,,,,ACTIVE
136,AU,B2,AU 775465 B2,059-775-722-082-082,2004-08-05,2004,AU 2001/024678 A,2000-10-20,US 16050699 P;;US 0041392 W,1999-10-20,Impacted orthopedic bone support implant,"This invention relates to a porous bone implant (10, 110, and 210), a method of manufacturing the implant and a method of orthopedic treatment. The mesh implant can be manufactured using extrusion techniques and a variety of cutting and machining processes to provide the implant with the desired structural features and in the required dimensions to be matingly received within the bone defect or cavity. The implant can be used to strengthen bone structures and support bone tissue adjacent to a defect of cavity. Thus, the implant can be used to provide improved treatment of patients having bone defects or diseases with decreased postoperative pain and a shorter recovery time.",SDGI HOLDINGS INC,BRANCH CHARLES L;;WHITE JOHN L;;ESTES BRADLEY T;;RAY EDDIE F III,,https://lens.org/059-775-722-082-082,Granted Patent,no,1,0,15,15,0,A61B17/14;;A61B17/1604;;A61F2/28;;A61F2/2846;;A61F2/30965;;A61F2/442;;A61F2/4455;;A61F2/446;;A61F2/4603;;A61F2/4611;;A61F2002/2835;;A61F2002/2839;;A61F2002/30112;;A61F2002/30138;;A61F2002/30153;;A61F2002/30154;;A61F2002/30156;;A61F2002/30235;;A61F2002/30324;;A61F2002/30593;;A61F2002/30616;;A61F2002/30774;;A61F2002/30777;;A61F2002/30785;;A61F2002/30787;;A61F2002/30789;;A61F2002/3082;;A61F2002/30836;;A61F2002/30879;;A61F2002/30912;;A61F2002/3097;;A61F2002/4649;;A61F2002/4681;;A61F2230/0004;;A61F2230/0017;;A61F2230/0019;;A61F2230/0021;;A61F2230/0023;;A61F2230/0069;;A61F2230/0082;;A61F2250/0036;;A61F2310/00017;;A61F2310/00023;;A61F2310/00179;;A61F2002/30261;;A61F2/446;;A61F2002/30324;;A61F2230/0023;;A61F2230/0082;;A61F2310/00023;;A61F2002/3097;;A61F2230/0021;;A61F2002/30774;;A61F2002/30789;;A61F2230/0017;;A61F2/28;;A61F2/2846;;A61F2/4611;;A61F2002/30138;;A61F2002/30154;;A61F2/442;;A61B17/1604;;A61F2/4603;;A61F2230/0019;;A61F2/30965;;A61F2002/3082;;A61F2/4455;;A61F2230/0004;;A61F2250/0036;;A61F2002/30785;;A61F2002/2839;;A61F2310/00017;;A61F2002/30112;;A61F2002/30153;;A61F2310/00179;;A61F2002/30912;;A61B17/14;;A61F2002/2835;;A61F2002/30593;;A61F2002/30879;;A61F2002/4649;;A61F2002/30777;;A61F2002/30235;;A61F2002/30616;;A61F2002/30156;;A61F2002/4681;;A61F2002/30787;;A61F2002/30836;;A61F2230/0069;;A61F2002/30261,A61B17/14;;A61B17/16;;A61F2/00;;A61F2/28;;A61F2/30;;A61F2/44;;A61F2/46,,0,0,,,,EXPIRED
137,US,B2,US 10666613 B2,027-804-659-874-499,2020-05-26,2020,US 201816160294 A,2018-10-15,US 201816160294 A;;US 201715719537 A,2017-09-28,Establishing and using a tunnel from an origin server in a distributed edge compute and routing service,"An edge server of a distributed edge compute and routing service receives a tunnel connection request from a tunnel client residing on an origin server, that requests a tunnel be established between the edge server and the tunnel client. The request identifies the hostname that is to be tunneled. An IP address is assigned for the tunnel. DNS record(s) are added or changed that associate the hostname with the assigned IP address. Routing rules are installed in the edge servers of the distributed edge compute and routing service to reach the edge server for the tunneled hostname. The edge server receives a request for a resource of the tunneled hostname from another edge server that received the request from a client, where the other edge server is not connected to the origin server. The request is transmitted from the edge server to the origin server over the tunnel.",CLOUDFLARE INC,KNECHT DANE ORION;;GRAHAM-CUMMING JOHN;;GRANT DANI;;BRANCH CHRISTOPHER PHILIP;;PASEKA TOM,CLOUDFLARE INC (2018-04-19),https://lens.org/027-804-659-874-499,Granted Patent,yes,9,0,6,6,0,H04L67/1031;;H04L67/10;;H04L67/1017;;H04L67/02;;H04L12/4633;;H04L12/4641;;H04L61/5007;;H04L61/4511;;H04L61/2592;;H04L67/02;;H04L12/4633;;H04L12/4641;;H04L67/1031;;H04L67/10;;H04L67/1017;;H04L61/4511;;H04L67/01;;H04L61/5007,H04L29/12;;H04L12/46;;H04L29/06;;H04L29/08,,6,0,,,"GitHub, “Localtunnel-Server, README.md,” Feb. 8, 2017, downloaded from https://github.com/localtunnel/server/blob/48475a404b632739fc1a16efb1d74e48178ab75f/README.md., 2 pages.;;Mizerany B, “Simplicity and Security through Reverse Tunnels,” Backplane, Feb. 8, 2017, downloaded from https://blog.backplane.io/simplicity-and-security-through-reverse-tunnels-6824d0af3196 , 7 pages.;;GitHub, “Localtunnel-Client, README.md,” Mar. 11, 2016, downloaded from https://github.com/localtunnel/localtunnel/blob/371db2870a52318245c3e48a8f1fbc1417de096d/README.md, 2 pages.;;Notice of Allowance from U.S. Appl. No. 15/719,537, dated Jan. 24, 2018, 12 pages.;;Notice of Allowance from U.S. Appl. No. 15/719,537, dated Jun. 20, 2018, 16 pages.;;“Secure Introspectable Tunnels to Localhost,” ngrok, inconshreveable 2017, downloaded from https://web.archive.org/web/20170129155734/hllps://ngrok.com/docs., 14 pages.",ACTIVE
138,AU,A,AU 2001/024678 A,033-791-687-345-284,2001-04-30,2001,AU 2001/024678 A,2000-10-20,US 16050699 P;;US 0041392 W,1999-10-20,Impacted orthopedic bone support implant,"This invention relates to a porous bone implant (10, 110, and 210), a method of manufacturing the implant and a method of orthopedic treatment. The mesh implant can be manufactured using extrusion techniques and a variety of cutting and machining processes to provide the implant with the desired structural features and in the required dimensions to be matingly received within the bone defect or cavity. The implant can be used to strengthen bone structures and support bone tissue adjacent to a defect of cavity. Thus, the implant can be used to provide improved treatment of patients having bone defects or diseases with decreased postoperative pain and a shorter recovery time.",WARSAW ORTHOPEDIC INC,BRANCH CHARLES L;;WHITE JOHN L;;ESTES BRADLEY T;;RAY EDDIE F III,,https://lens.org/033-791-687-345-284,Patent Application,no,0,0,15,15,0,A61B17/14;;A61B17/1604;;A61F2/28;;A61F2/2846;;A61F2/30965;;A61F2/442;;A61F2/4455;;A61F2/446;;A61F2/4603;;A61F2/4611;;A61F2002/2835;;A61F2002/2839;;A61F2002/30112;;A61F2002/30138;;A61F2002/30153;;A61F2002/30154;;A61F2002/30156;;A61F2002/30235;;A61F2002/30324;;A61F2002/30593;;A61F2002/30616;;A61F2002/30774;;A61F2002/30777;;A61F2002/30785;;A61F2002/30787;;A61F2002/30789;;A61F2002/3082;;A61F2002/30836;;A61F2002/30879;;A61F2002/30912;;A61F2002/3097;;A61F2002/4649;;A61F2002/4681;;A61F2230/0004;;A61F2230/0017;;A61F2230/0019;;A61F2230/0021;;A61F2230/0023;;A61F2230/0069;;A61F2230/0082;;A61F2250/0036;;A61F2310/00017;;A61F2310/00023;;A61F2310/00179;;A61F2002/30261;;A61F2/446;;A61F2002/30324;;A61F2230/0023;;A61F2230/0082;;A61F2310/00023;;A61F2002/3097;;A61F2230/0021;;A61F2002/30774;;A61F2002/30789;;A61F2230/0017;;A61F2/28;;A61F2/2846;;A61F2/4611;;A61F2002/30138;;A61F2002/30154;;A61F2/442;;A61B17/1604;;A61F2/4603;;A61F2230/0019;;A61F2/30965;;A61F2002/3082;;A61F2/4455;;A61F2230/0004;;A61F2250/0036;;A61F2002/30785;;A61F2002/2839;;A61F2310/00017;;A61F2002/30112;;A61F2002/30153;;A61F2310/00179;;A61F2002/30912;;A61B17/14;;A61F2002/2835;;A61F2002/30593;;A61F2002/30879;;A61F2002/4649;;A61F2002/30777;;A61F2002/30235;;A61F2002/30616;;A61F2002/30156;;A61F2002/4681;;A61F2002/30787;;A61F2002/30836;;A61F2230/0069;;A61F2002/30261,A61B17/14;;A61B17/16;;A61F2/00;;A61F2/28;;A61F2/30;;A61F2/44;;A61F2/46,,0,0,,,,EXPIRED
139,US,B2,US 10110726 B2,071-392-444-994-714,2018-10-23,2018,US 201514736573 A,2015-06-11,US 201514736573 A,2015-06-11,Rapid serial visual presentation to deliver messages in social spaces,"A private message can be delivered by a computer system to a user in an environment, using a display in the environment, a user device, and sensors in the space. The device is detected and connected to a system once it enters a space. A private message is directed to the device and it is received by the system, which notifies the device that the message has been received. The user can then look up at a device to display the message and the system can determine where the user is looking, in order to deliver the message using rapid serial visual presentation to the user on the display device.",IBM,AARON ANDREW S;;BRANCH JOEL W;;GIL DARIO;;LENCHNER JONATHAN;;NELSON JOHN C,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-06-04),https://lens.org/071-392-444-994-714,Granted Patent,yes,9,1,2,2,0,H04M1/72436;;H04M1/72412;;H04L51/222;;H04L51/52;;H04L51/063;;H04M1/72436;;H04M1/72412;;H04L51/52;;H04L51/222,G06F15/173;;H04M1/72436;;H04L12/58;;H04M1/72412,,3,0,,,"Mell et al., “The NIST Definition of Cloud Computing”, National Institute of Standards and Technology, U.S. Department of Commerce, Special Publication 800-145, Sep. 2011. 7 pages.;;Unknown, “Splitview”, Mercedes-Benz, © 2015 Daimler AG. All rights reserved. 5 pages. http://techcenter.mercedes-benz.com/en/splitview/detail.html.;;Wikipedia, “Rapid serial visual presentation”, Wikipedia the Free Encyclopedia, last modified Dec. 24, 2014. 6 pages. http://en.wikipedia.org/wiki/Rapid_serial_visual_presentation.",ACTIVE
140,WO,A3,WO 2001/028461 A3,196-811-135-988-827,2002-01-03,2002,US 0041392 W,2000-10-20,US 16050699 P,1999-10-20,IMPACTED ORTHOPEDIC BONE SUPPORT IMPLANT,"This invention relates to a porous bone implant (10, 110, and 210), a method of manufacturing the implant and a method of orthopedic treatment. The mesh implant can be manufactured using extrusion techniques and a variety of cutting and machining processes to provide the implant with the desired structural features and in the required dimensions to be matingly received within the bone defect or cavity. The implant can be used to strengthen bone structures and support bone tissue adjacent to a defect of cavity. Thus, the implant can be used to provide improved treatment of patients having bone defects or diseases with decreased postoperative pain and a shorter recovery time.",SDGI HOLDINGS INC;;BRANCH CHARLES L;;WHITE JOHN L;;ESTES BRADLEY T;;RAY EDDIE F III,BRANCH CHARLES L;;WHITE JOHN L;;ESTES BRADLEY T;;RAY EDDIE F III,,https://lens.org/196-811-135-988-827,Search Report,yes,13,0,15,15,0,A61B17/14;;A61B17/1604;;A61F2/28;;A61F2/2846;;A61F2/30965;;A61F2/442;;A61F2/4455;;A61F2/446;;A61F2/4603;;A61F2/4611;;A61F2002/2835;;A61F2002/2839;;A61F2002/30112;;A61F2002/30138;;A61F2002/30153;;A61F2002/30154;;A61F2002/30156;;A61F2002/30235;;A61F2002/30324;;A61F2002/30593;;A61F2002/30616;;A61F2002/30774;;A61F2002/30777;;A61F2002/30785;;A61F2002/30787;;A61F2002/30789;;A61F2002/3082;;A61F2002/30836;;A61F2002/30879;;A61F2002/30912;;A61F2002/3097;;A61F2002/4649;;A61F2002/4681;;A61F2230/0004;;A61F2230/0017;;A61F2230/0019;;A61F2230/0021;;A61F2230/0023;;A61F2230/0069;;A61F2230/0082;;A61F2250/0036;;A61F2310/00017;;A61F2310/00023;;A61F2310/00179;;A61F2002/30261;;A61F2/446;;A61F2002/30324;;A61F2230/0023;;A61F2230/0082;;A61F2310/00023;;A61F2002/3097;;A61F2230/0021;;A61F2002/30774;;A61F2002/30789;;A61F2230/0017;;A61F2/28;;A61F2/2846;;A61F2/4611;;A61F2002/30138;;A61F2002/30154;;A61F2/442;;A61B17/1604;;A61F2/4603;;A61F2230/0019;;A61F2/30965;;A61F2002/3082;;A61F2/4455;;A61F2230/0004;;A61F2250/0036;;A61F2002/30785;;A61F2002/2839;;A61F2310/00017;;A61F2002/30112;;A61F2002/30153;;A61F2310/00179;;A61F2002/30912;;A61B17/14;;A61F2002/2835;;A61F2002/30593;;A61F2002/30879;;A61F2002/4649;;A61F2002/30777;;A61F2002/30235;;A61F2002/30616;;A61F2002/30156;;A61F2002/4681;;A61F2002/30787;;A61F2002/30836;;A61F2230/0069;;A61F2002/30261,A61B17/14;;A61B17/16;;A61F2/00;;A61F2/28;;A61F2/30;;A61F2/44;;A61F2/46,,0,0,,,,PATENTED
141,US,A1,US 2019/0319919 A1,045-107-292-236-747,2019-10-17,2019,US 201816160294 A,2018-10-15,US 201816160294 A;;US 201715719537 A,2017-09-28,ESTABLISHING AND USING A TUNNEL FROM AN ORIGIN SERVER IN A DISTRIBUTED EDGE COMPUTE AND ROUTING SERVICE,"An edge server of a distributed edge compute and routing service receives a tunnel connection request from a tunnel client residing on an origin server, that requests a tunnel be established between the edge server and the tunnel client. The request identifies the hostname that is to be tunneled. An IP address is assigned for the tunnel. DNS record(s) are added or changed that associate the hostname with the assigned IP address. Routing rules are installed in the edge servers of the distributed edge compute and routing service to reach the edge server for the tunneled hostname. The edge server receives a request for a resource of the tunneled hostname from another edge server that received the request from a client, where the other edge server is not connected to the origin server. The request is transmitted from the edge server to the origin server over the tunnel.",CLOUDFLARE INC,KNECHT DANE ORION;;GRAHAM-CUMMING JOHN;;GRANT DANI;;BRANCH CHRISTOPHER PHILIP;;PASEKA TOM,CLOUDFLARE INC (2018-04-19),https://lens.org/045-107-292-236-747,Patent Application,yes,4,13,6,6,0,H04L67/1031;;H04L67/10;;H04L67/1017;;H04L67/02;;H04L12/4633;;H04L12/4641;;H04L61/5007;;H04L61/4511;;H04L61/2592;;H04L67/02;;H04L12/4633;;H04L12/4641;;H04L67/1031;;H04L67/10;;H04L67/1017;;H04L61/4511;;H04L67/01;;H04L61/5007,H04L29/12;;H04L12/46;;H04L29/06;;H04L29/08,,0,0,,,,ACTIVE
142,WO,A2,WO 2001/028461 A2,065-356-122-643-043,2001-04-26,2001,US 0041392 W,2000-10-20,US 16050699 P,1999-10-20,IMPACTED ORTHOPEDIC BONE SUPPORT IMPLANT,"This invention relates to a porous bone implant (10, 110, and 210), a method of manufacturing the implant and a method of orthopedic treatment. The mesh implant can be manufactured using extrusion techniques and a variety of cutting and machining processes to provide the implant with the desired structural features and in the required dimensions to be matingly received within the bone defect or cavity. The implant can be used to strengthen bone structures and support bone tissue adjacent to a defect of cavity. Thus, the implant can be used to provide improved treatment of patients having bone defects or diseases with decreased postoperative pain and a shorter recovery time.",SDGI HOLDINGS INC;;BRANCH CHARLES L;;WHITE JOHN L;;ESTES BRADLEY T;;RAY EDDIE F III,BRANCH CHARLES L;;WHITE JOHN L;;ESTES BRADLEY T;;RAY EDDIE F III,,https://lens.org/065-356-122-643-043,Patent Application,yes,0,11,15,15,0,A61B17/14;;A61B17/1604;;A61F2/28;;A61F2/2846;;A61F2/30965;;A61F2/442;;A61F2/4455;;A61F2/446;;A61F2/4603;;A61F2/4611;;A61F2002/2835;;A61F2002/2839;;A61F2002/30112;;A61F2002/30138;;A61F2002/30153;;A61F2002/30154;;A61F2002/30156;;A61F2002/30235;;A61F2002/30324;;A61F2002/30593;;A61F2002/30616;;A61F2002/30774;;A61F2002/30777;;A61F2002/30785;;A61F2002/30787;;A61F2002/30789;;A61F2002/3082;;A61F2002/30836;;A61F2002/30879;;A61F2002/30912;;A61F2002/3097;;A61F2002/4649;;A61F2002/4681;;A61F2230/0004;;A61F2230/0017;;A61F2230/0019;;A61F2230/0021;;A61F2230/0023;;A61F2230/0069;;A61F2230/0082;;A61F2250/0036;;A61F2310/00017;;A61F2310/00023;;A61F2310/00179;;A61F2002/30261;;A61F2/446;;A61F2002/30324;;A61F2230/0023;;A61F2230/0082;;A61F2310/00023;;A61F2002/3097;;A61F2230/0021;;A61F2002/30774;;A61F2002/30789;;A61F2230/0017;;A61F2/28;;A61F2/2846;;A61F2/4611;;A61F2002/30138;;A61F2002/30154;;A61F2/442;;A61B17/1604;;A61F2/4603;;A61F2230/0019;;A61F2/30965;;A61F2002/3082;;A61F2/4455;;A61F2230/0004;;A61F2250/0036;;A61F2002/30785;;A61F2002/2839;;A61F2310/00017;;A61F2002/30112;;A61F2002/30153;;A61F2310/00179;;A61F2002/30912;;A61B17/14;;A61F2002/2835;;A61F2002/30593;;A61F2002/30879;;A61F2002/4649;;A61F2002/30777;;A61F2002/30235;;A61F2002/30616;;A61F2002/30156;;A61F2002/4681;;A61F2002/30787;;A61F2002/30836;;A61F2230/0069;;A61F2002/30261,A61B17/14;;A61B17/16;;A61F2/00;;A61F2/28;;A61F2/30;;A61F2/44;;A61F2/46,,0,0,,,,PATENTED
143,US,B2,US 11316825 B2,166-053-517-429-889,2022-04-26,2022,US 202016883116 A,2020-05-26,US 202016883116 A;;US 201816160294 A;;US 201715719537 A,2017-09-28,Establishing and using a tunnel from an origin server in a distributed edge compute and routing service,"An edge server of a distributed edge compute and routing service receives a tunnel connection request from a tunnel client residing on an origin server, that requests a tunnel be established between the edge server and the tunnel client. The request identifies the hostname that is to be tunneled. An IP address is assigned for the tunnel. DNS record(s) are added or changed that associate the hostname with the assigned IP address. Routing rules are installed in the edge servers of the distributed edge compute and routing service to reach the edge server for the tunneled hostname. The edge server receives a request for a resource of the tunneled hostname from another edge server that received the request from a client, where the other edge server is not connected to the origin server. The request is transmitted from the edge server to the origin server over the tunnel.",CLOUDFLARE INC,KNECHT DANE ORION;;GRAHAM-CUMMING JOHN;;GRANT DANI;;BRANCH CHRISTOPHER PHILIP;;PASEKA TOM,CLOUDFLARE INC (2018-04-19),https://lens.org/166-053-517-429-889,Granted Patent,yes,13,0,6,6,0,H04L67/1031;;H04L67/10;;H04L67/1017;;H04L67/02;;H04L12/4633;;H04L12/4641;;H04L61/5007;;H04L61/4511;;H04L61/2592;;H04L67/02;;H04L12/4633;;H04L12/4641;;H04L67/1031;;H04L67/10;;H04L67/1017;;H04L61/4511;;H04L67/01;;H04L61/5007,H04L61/2592;;H04L12/46;;H04L61/4511;;H04L61/5007;;H04L67/01;;H04L67/02;;H04L67/10;;H04L67/1017;;H04L67/1031,,7,0,,,"GitHub, “Localtunnel-Client,” available online at <https://github.com/localtunnel/localtunnel/blob/371db2870a52318245c3e48a8f1fbc1417de096d/README.md>, Mar. 11, 2016, 2 pages.;;GitHub, Localtunnel-Server, available online at <https://github.com/localtunnel/server/blob/48475a404b632739fc1a16efb1d74e48f78ab75f/README.md>, Feb. 8, 2017, 2 pages.;;Mizerany, B., “Backplane: Simplicity and Security through Reverse Tunnels”, available online at <https://blog.backplane.io/simplicity-and-security-through-reverse-tunnels-6824d0af3196>, Feb. 8, 2017, 7 pages.;;Ngrok, “Secure Introspectable Tunnels to Localhos”, available online at <https://web.archive.org/web/20170129155734/https://ngrok.com/docs>, Jan. 29, 2017, 14 pages.;;Notice of Allowance, U.S. Appl. No. 15/719,537, dated Jan. 24, 2018, 12 pages.;;Notice of Allowance, U.S. Appl. No. 15/719,537, dated Jun. 20, 2018, 12 pages.;;Notice of Allowance, U.S. Appl. No. 16/160,294, dated Jan. 21, 2020, 11 pages.",ACTIVE
144,EP,A2,EP 1221910 A2,090-897-891-669-000,2002-07-17,2002,EP 00988472 A,2000-10-20,US 0041392 W;;US 16050699 P,1999-10-20,IMPACTED ORTHOPEDIC BONE SUPPORT IMPLANT,"This invention relates to a porous bone implant (10, 110, and 210), a method of manufacturing the implant and a method of orthopedic treatment. The mesh implant can be manufactured using extrusion techniques and a variety of cutting and machining processes to provide the implant with the desired structural features and in the required dimensions to be matingly received within the bone defect or cavity. The implant can be used to strengthen bone structures and support bone tissue adjacent to a defect of cavity. Thus, the implant can be used to provide improved treatment of patients having bone defects or diseases with decreased postoperative pain and a shorter recovery time.",SDGI HOLDINGS INC,BRANCH CHARLES L;;WHITE JOHN L;;ESTES BRADLEY T;;RAY EDDIE F III,,https://lens.org/090-897-891-669-000,Patent Application,yes,0,0,15,15,0,A61B17/14;;A61B17/1604;;A61F2/28;;A61F2/2846;;A61F2/30965;;A61F2/442;;A61F2/4455;;A61F2/446;;A61F2/4603;;A61F2/4611;;A61F2002/2835;;A61F2002/2839;;A61F2002/30112;;A61F2002/30138;;A61F2002/30153;;A61F2002/30154;;A61F2002/30156;;A61F2002/30235;;A61F2002/30324;;A61F2002/30593;;A61F2002/30616;;A61F2002/30774;;A61F2002/30777;;A61F2002/30785;;A61F2002/30787;;A61F2002/30789;;A61F2002/3082;;A61F2002/30836;;A61F2002/30879;;A61F2002/30912;;A61F2002/3097;;A61F2002/4649;;A61F2002/4681;;A61F2230/0004;;A61F2230/0017;;A61F2230/0019;;A61F2230/0021;;A61F2230/0023;;A61F2230/0069;;A61F2230/0082;;A61F2250/0036;;A61F2310/00017;;A61F2310/00023;;A61F2310/00179;;A61F2002/30261;;A61F2/446;;A61F2002/30324;;A61F2230/0023;;A61F2230/0082;;A61F2310/00023;;A61F2002/3097;;A61F2230/0021;;A61F2002/30774;;A61F2002/30789;;A61F2230/0017;;A61F2/28;;A61F2/2846;;A61F2/4611;;A61F2002/30138;;A61F2002/30154;;A61F2/442;;A61B17/1604;;A61F2/4603;;A61F2230/0019;;A61F2/30965;;A61F2002/3082;;A61F2/4455;;A61F2230/0004;;A61F2250/0036;;A61F2002/30785;;A61F2002/2839;;A61F2310/00017;;A61F2002/30112;;A61F2002/30153;;A61F2310/00179;;A61F2002/30912;;A61B17/14;;A61F2002/2835;;A61F2002/30593;;A61F2002/30879;;A61F2002/4649;;A61F2002/30777;;A61F2002/30235;;A61F2002/30616;;A61F2002/30156;;A61F2002/4681;;A61F2002/30787;;A61F2002/30836;;A61F2230/0069;;A61F2002/30261,A61B17/14;;A61B17/16;;A61F2/00;;A61F2/28;;A61F2/30;;A61F2/44;;A61F2/46,,0,0,,,,EXPIRED
145,US,A1,US 2020/0287867 A1,132-381-451-509-753,2020-09-10,2020,US 202016883116 A,2020-05-26,US 202016883116 A;;US 201816160294 A;;US 201715719537 A,2017-09-28,ESTABLISHING AND USING A TUNNEL FROM AN ORIGIN SERVER IN A DISTRIBUTED EDGE COMPUTE AND ROUTING SERVICE,"An edge server of a distributed edge compute and routing service receives a tunnel connection request from a tunnel client residing on an origin server, that requests a tunnel be established between the edge server and the tunnel client. The request identifies the hostname that is to be tunneled. An IP address is assigned for the tunnel. DNS record(s) are added or changed that associate the hostname with the assigned IP address. Routing rules are installed in the edge servers of the distributed edge compute and routing service to reach the edge server for the tunneled hostname. The edge server receives a request for a resource of the tunneled hostname from another edge server that received the request from a client, where the other edge server is not connected to the origin server. The request is transmitted from the edge server to the origin server over the tunnel.",CLOUDFLARE INC,KNECHT DANE ORION;;GRAHAM-CUMMING JOHN;;GRANT DANI;;BRANCH CHRISTOPHER PHILIP;;PASEKA TOM,CLOUDFLARE INC (2018-04-19),https://lens.org/132-381-451-509-753,Patent Application,yes,0,105,6,6,0,H04L67/1031;;H04L67/10;;H04L67/1017;;H04L67/02;;H04L12/4633;;H04L12/4641;;H04L61/5007;;H04L61/4511;;H04L61/2592;;H04L67/02;;H04L12/4633;;H04L12/4641;;H04L67/1031;;H04L67/10;;H04L67/1017;;H04L61/4511;;H04L67/01;;H04L61/5007,H04L12/46;;H04L29/12;;H04L29/06;;H04L29/08,,0,0,,,,ACTIVE
146,US,A1,US 2023/0045757 A1,199-108-258-442-183,2023-02-09,2023,US 202217728407 A,2022-04-25,US 202217728407 A;;US 202016883116 A;;US 201816160294 A;;US 201715719537 A,2017-09-28,ESTABLISHING AND USING A TUNNEL FROM AN ORIGIN SERVER IN A DISTRIBUTED EDGE COMPUTE AND ROUTING SERVICE,"An edge server of a distributed edge compute and routing service receives a tunnel connection request from a tunnel client residing on an origin server, that requests a tunnel be established between the edge server and the tunnel client. The request identifies the hostname that is to be tunneled. An IP address is assigned for the tunnel. DNS record(s) are added or changed that associate the hostname with the assigned IP address. Routing rules are installed in the edge servers of the distributed edge compute and routing service to reach the edge server for the tunneled hostname. The edge server receives a request for a resource of the tunneled hostname from another edge server that received the request from a client, where the other edge server is not connected to the origin server. The request is transmitted from the edge server to the origin server over the tunnel.",CLOUDFLARE INC,KNECHT DANE ORION;;GRAHAM-CUMMING JOHN;;GRANT DANI;;BRANCH CHRISTOPHER PHILIP;;PASEKA TOM,CLOUDFLARE INC (2018-04-19),https://lens.org/199-108-258-442-183,Patent Application,yes,17,2,6,6,0,H04L67/1031;;H04L67/10;;H04L67/1017;;H04L67/02;;H04L12/4633;;H04L12/4641;;H04L61/5007;;H04L61/4511;;H04L61/2592;;H04L67/02;;H04L12/4633;;H04L12/4641;;H04L67/1031;;H04L67/10;;H04L67/1017;;H04L61/4511;;H04L67/01;;H04L61/5007,H04L61/2592;;H04L12/46;;H04L61/4511;;H04L67/01;;H04L67/02;;H04L67/10;;H04L67/1017;;H04L67/1031,,0,0,,,,PENDING
147,TW,B,TW 375578 B,028-311-260-780-045,1999-12-01,1999,TW 87101246 A,1998-02-02,GB 9700903 A,1997-01-17,Method of manufacturing a laminate having barrier properties,"The invention is a laminate structure made by coating at least one side of a substrate with a laminating adhesive, bringing a coated side of said substrate into contact with a second substrate to form a multi-layer film, and treating said multi-layer film with a free radical initiator, wherein said laminating adhesive is the reaction product of a multifunctional acrylate, an aminofunctional silane, and an ethylenically unsaturated acid, optionally dissolved in a solvent, wherein the multifunctional acrylate has a molecular weight of from 100 to 3000.",EG TECHNOLOGY LP;;DOW CORNING;;UCB FILMS PLC,FUTTER DAN;;MERLIN PATRICK;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;BRANCH KAREN;;POWER GARY,,https://lens.org/028-311-260-780-045,Granted Patent,no,0,0,15,15,0,B32B7/12;;B32B7/12;;B32B25/042;;B32B25/06;;B32B25/08;;B32B27/08;;B32B27/10;;B32B29/005;;B32B2310/0887;;B32B2439/00;;C09J4/00,B32B37/00;;B32B7/12;;C09J4/00;;C09J4/02;;C09J183/08,,0,0,,,,EXPIRED
148,CA,A1,CA 2387042 A1,042-279-207-822-648,2001-04-26,2001,CA 2387042 A,2000-10-20,US 16050699 P;;US 0041392 W,1999-10-20,IMPACTED ORTHOPEDIC BONE SUPPORT IMPLANT,"This invention relates to a porous bone implant (10, 110, and 210), a method of manufacturing the implant and a method of orthopedic treatment. The mesh implant can be manufactured using extrusion techniques and a variety of cutting and machining processes to provide the implant with the desired structural features and in the required dimensions to be matingly received within the bone defect or cavity. The implant can be used to strengthen bone structures and support bone tissue adjacent to a defect of cavity. Thus, the implant can be used to provide improved treatment of patients having bone defects or diseases with decreased postoperative pain and a shorter recovery time.",SDGI HOLDINGS INC,ESTES BRADLEY T;;WHITE JOHN L;;BRANCH CHARLES L;;RAY EDDIE F III,,https://lens.org/042-279-207-822-648,Patent Application,no,0,0,15,15,0,A61B17/14;;A61B17/1604;;A61F2/28;;A61F2/2846;;A61F2/30965;;A61F2/442;;A61F2/4455;;A61F2/446;;A61F2/4603;;A61F2/4611;;A61F2002/2835;;A61F2002/2839;;A61F2002/30112;;A61F2002/30138;;A61F2002/30153;;A61F2002/30154;;A61F2002/30156;;A61F2002/30235;;A61F2002/30324;;A61F2002/30593;;A61F2002/30616;;A61F2002/30774;;A61F2002/30777;;A61F2002/30785;;A61F2002/30787;;A61F2002/30789;;A61F2002/3082;;A61F2002/30836;;A61F2002/30879;;A61F2002/30912;;A61F2002/3097;;A61F2002/4649;;A61F2002/4681;;A61F2230/0004;;A61F2230/0017;;A61F2230/0019;;A61F2230/0021;;A61F2230/0023;;A61F2230/0069;;A61F2230/0082;;A61F2250/0036;;A61F2310/00017;;A61F2310/00023;;A61F2310/00179;;A61F2002/30261;;A61F2/446;;A61F2002/30324;;A61F2230/0023;;A61F2230/0082;;A61F2310/00023;;A61F2002/3097;;A61F2230/0021;;A61F2002/30774;;A61F2002/30789;;A61F2230/0017;;A61F2/28;;A61F2/2846;;A61F2/4611;;A61F2002/30138;;A61F2002/30154;;A61F2/442;;A61B17/1604;;A61F2/4603;;A61F2230/0019;;A61F2/30965;;A61F2002/3082;;A61F2/4455;;A61F2230/0004;;A61F2250/0036;;A61F2002/30785;;A61F2002/2839;;A61F2310/00017;;A61F2002/30112;;A61F2002/30153;;A61F2310/00179;;A61F2002/30912;;A61B17/14;;A61F2002/2835;;A61F2002/30593;;A61F2002/30879;;A61F2002/4649;;A61F2002/30777;;A61F2002/30235;;A61F2002/30616;;A61F2002/30156;;A61F2002/4681;;A61F2002/30787;;A61F2002/30836;;A61F2230/0069;;A61F2002/30261,A61B17/14;;A61B17/16;;A61F2/00;;A61F2/28;;A61F2/30;;A61F2/44;;A61F2/46,,0,0,,,,DISCONTINUED
149,US,A,US 5699255 A,158-171-436-022-523,1997-12-16,1997,US 54455495 A,1995-10-18,US 54455495 A,1995-10-18,Map transmission for in-vehicle navigation system with dynamic scale/detail adjustment,"An apparatus and method for providing map information of varying resolution to a navigation device. In one embodiment, a position determining system is attached to a navigation device. The position determining system generates position information, such as location, of the navigation device. The position information is transmitted to a base station containing map information. Map information related to, for example, the location of the navigation device is then transmitted from the base station to the navigation device. The map information is displayed on a display of the navigation device. Therefore, the base station only transmits map information related to the position information of the navigation device.",TRIMBLE NAVIGATION LTD,ELLIS THOMAS W;;MURA-SMITH KIYOKO M;;BRANCH CHARLES N;;SCHIPPER JOHN F,TRIMBLE NAVIGATION LTD (1995-10-13),https://lens.org/158-171-436-022-523,Granted Patent,yes,10,276,1,1,0,G01C21/367;;G01C21/367;;G01C21/3673;;G01C21/3673;;G08G1/0969;;G08G1/0969;;G09B29/106;;G09B29/106,G01C21/36;;G08G1/0969;;G09B29/10,364/449.6;;340/995;;342/450,0,0,,,,EXPIRED
150,EP,B1,EP 1221910 B1,042-805-896-952-882,2005-09-28,2005,EP 00988472 A,2000-10-20,US 0041392 W;;US 16050699 P,1999-10-20,IMPACTED ORTHOPEDIC BONE SUPPORT IMPLANT,"This invention relates to a porous bone implant (10, 110, and 210), a method of manufacturing the implant and a method of orthopedic treatment. The mesh implant can be manufactured using extrusion techniques and a variety of cutting and machining processes to provide the implant with the desired structural features and in the required dimensions to be matingly received within the bone defect or cavity. The implant can be used to strengthen bone structures and support bone tissue adjacent to a defect of cavity. Thus, the implant can be used to provide improved treatment of patients having bone defects or diseases with decreased postoperative pain and a shorter recovery time.",SDGI HOLDINGS INC,BRANCH CHARLES L;;WHITE JOHN L;;ESTES BRADLEY T;;RAY EDDIE F III,,https://lens.org/042-805-896-952-882,Granted Patent,yes,13,0,15,15,0,A61B17/14;;A61B17/1604;;A61F2/28;;A61F2/2846;;A61F2/30965;;A61F2/442;;A61F2/4455;;A61F2/446;;A61F2/4603;;A61F2/4611;;A61F2002/2835;;A61F2002/2839;;A61F2002/30112;;A61F2002/30138;;A61F2002/30153;;A61F2002/30154;;A61F2002/30156;;A61F2002/30235;;A61F2002/30324;;A61F2002/30593;;A61F2002/30616;;A61F2002/30774;;A61F2002/30777;;A61F2002/30785;;A61F2002/30787;;A61F2002/30789;;A61F2002/3082;;A61F2002/30836;;A61F2002/30879;;A61F2002/30912;;A61F2002/3097;;A61F2002/4649;;A61F2002/4681;;A61F2230/0004;;A61F2230/0017;;A61F2230/0019;;A61F2230/0021;;A61F2230/0023;;A61F2230/0069;;A61F2230/0082;;A61F2250/0036;;A61F2310/00017;;A61F2310/00023;;A61F2310/00179;;A61F2002/30261;;A61F2/446;;A61F2002/30324;;A61F2230/0023;;A61F2230/0082;;A61F2310/00023;;A61F2002/3097;;A61F2230/0021;;A61F2002/30774;;A61F2002/30789;;A61F2230/0017;;A61F2/28;;A61F2/2846;;A61F2/4611;;A61F2002/30138;;A61F2002/30154;;A61F2/442;;A61B17/1604;;A61F2/4603;;A61F2230/0019;;A61F2/30965;;A61F2002/3082;;A61F2/4455;;A61F2230/0004;;A61F2250/0036;;A61F2002/30785;;A61F2002/2839;;A61F2310/00017;;A61F2002/30112;;A61F2002/30153;;A61F2310/00179;;A61F2002/30912;;A61B17/14;;A61F2002/2835;;A61F2002/30593;;A61F2002/30879;;A61F2002/4649;;A61F2002/30777;;A61F2002/30235;;A61F2002/30616;;A61F2002/30156;;A61F2002/4681;;A61F2002/30787;;A61F2002/30836;;A61F2230/0069;;A61F2002/30261,A61B17/14;;A61B17/16;;A61F2/00;;A61F2/28;;A61F2/30;;A61F2/44;;A61F2/46,,0,0,,,,EXPIRED
151,WO,A1,WO 2005/058317 A1,116-486-386-711-445,2005-06-30,2005,EP 2004014472 W,2004-12-16,GB 0329360 A;;GB 0413107 A,2003-12-18,GLYCINE TRANSPORTER-1 INHIBIRORS,"The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, and R3 and R10, X and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",GLAXO GROUP LTD;;BOZZOLI ANDREA;;BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,BOZZOLI ANDREA;;BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,,https://lens.org/116-486-386-711-445,Patent Application,yes,2,15,1,3,0,A61P25/00;;C07D451/02,C07D451/02;;C07D471/08,,0,0,,,,PENDING
152,US,B1,US 10104039 B1,127-934-543-379-083,2018-10-16,2018,US 201715719537 A,2017-09-28,US 201715719537 A,2017-09-28,Establishing and using a tunnel from an origin server in a distributed edge compute and routing service,"An edge server of a distributed edge compute and routing service receives a tunnel connection request from a tunnel client residing on an origin server, that requests a tunnel be established between the edge server and the tunnel client. The request identifies the hostname that is to be tunneled. An IP address is assigned for the tunnel. DNS record(s) are added or changed that associate the hostname with the assigned IP address. Routing rules are installed in the edge servers of the distributed edge compute and routing service to reach the edge server for the tunneled hostname. The edge server receives a request for a resource of the tunneled hostname from another edge server that received the request from a client, where the other edge server is not connected to the origin server. The request is transmitted from the edge server to the origin server over the tunnel.",CLOUDFLARE INC,KNECHT DANE ORION;;GRAHAM-CUMMING JOHN;;GRANT DANI;;BRANCH CHRISTOPHER PHILIP;;PASEKA TOM,CLOUDFLARE INC (2018-04-19),https://lens.org/127-934-543-379-083,Granted Patent,yes,7,35,6,6,0,H04L67/1031;;H04L67/10;;H04L67/1017;;H04L67/02;;H04L12/4633;;H04L12/4641;;H04L61/5007;;H04L61/4511;;H04L61/2592;;H04L67/02;;H04L12/4633;;H04L12/4641;;H04L67/1031;;H04L67/10;;H04L67/1017;;H04L61/4511;;H04L67/01;;H04L61/5007,H04L29/12;;H04L12/46;;H04L29/06;;H04L29/08;;H04W28/02,,4,0,,,"Localtunnel-client, README.md, GitHub, Inc., Mar. 11, 2016, 2 pages, downloaded at: https://github.com/localtunnel/localtunnel/blob/371db2870a52318245c3e48a8f1fbc1417de096d/README.md.;;Localtunnel-server, README.md, GitHub, Inc., Feb. 8, 2017, 2 pages, downloaded at: https://github.com/localtunnel/server/blob/48475a404b632739fc1a16efb1d74e48f78ab75f/README.md.;;Secure introspectable tunnels to localhost, ngrok, inconshreveable 2017, 14 pages, downloaded at: https://web.archive.org/web/20170129155734/https://ngrok.com/docs.;;Blake Mizerany, Simplicity and security through reverse tunnels, Backplane, Feb. 8, 2017, 7 pages, downloaded at https://blog.backplane.io/simplicity-and-security-through-reverse-tunnels-6824d0af3196.",ACTIVE
153,WO,A2,WO 2005/058885 A2,101-478-826-874-092,2005-06-30,2005,EP 2004013222 W,2004-11-18,GB 0329363 A;;GB 0413108 A,2003-12-18,COMPOUNDS,"The invention provides a compound of formula (I) or a salt or solvate thereof: (I) wherein R1 to R8, X and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",GLAXO GROUP LTD;;BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,,https://lens.org/101-478-826-874-092,Patent Application,yes,0,13,2,4,0,C07D405/12;;C07D211/26;;C07D401/06;;C07D417/06,C07D211/26;;C07D401/06;;C07D405/12;;C07D417/06,,0,0,,,,PENDING
154,US,B1,US 6686008 B1,126-213-917-709-31X,2004-02-03,2004,US 34125399 A,1999-12-17,BE 9800006 W;;GB 9700910 A;;GB 9700964 A,1997-01-17,Silicone/multifunctional acrylate barrier coatings,"
    The invention is a composition made by mixing a multifunctional acrylate with an aminofunctional silane and an ethylenically unsaturated acid to form a reaction product, optionally dissolved in a solvent, characterized in that the multifunctional acrylate has a molecular weight of from about 100 to about 3000. The composition can be coated on a substrate, then optionally exposed to moisture and treated to initiate a free radical reaction. The invention can be applied to a variety of substrates used in packaging applications. The reaction mixture can further be cured by heating in the presence of moisture. The free radical reaction can be initiated by electron beam irradiation, ultraviolet radiation, gamma radiation, and/or heat and chemical free radical initiators. 
",EG TECHNOLOGY LP;;DOW CORNING;;UBC FILMS PLC STAR HOUSE,MERLIN PATRICK J;;FUTTER DANIEL;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;POWER GARY;;BRANCH KAREN,DOW CORNING CORPORATION (2000-08-03);;UCB FILMS PLC STAR HOUSE (2000-08-24);;EG TECHNOLOGY PARTNERS L.P (2000-08-02);;DOW CORNING S.A (2000-08-02),https://lens.org/126-213-917-709-31X,Granted Patent,yes,19,22,10,12,0,B65D65/38;;B65D65/38;;C08F290/14;;C08F290/14;;Y10T428/1352;;Y10T428/1352;;Y10T428/1393;;Y10T428/1393,B65D65/02;;B65D65/38;;C08F290/14;;C08L79/00;;C09D4/00,428/35.7;;428/36.91;;522/46;;522/106;;524/81;;524/220;;524/221;;524/591;;525/420;;525/423;;525/424;;525/425;;525/426;;525/427;;525/431;;528/271;;528/310;;528/320;;528/322;;528/422,1,0,,,"Grant (ed.), Hack's Chemical Dictionary, 4th edition, pp. 249 and 364 (1969).",EXPIRED
155,CA,C,CA 2278032 C,068-453-121-696-294,2006-08-29,2006,CA 2278032 A,1998-01-16,BE 9800008 W;;GB 9700903 A,1997-01-17,SILICONE CONTAINING LAMINATE ADHESIVE,"The invention is a laminate structure made by coating at least one side of a substrate with a laminating adhesive, bringing a coated side of said substrate into contact with a second substrate to form a multi- layer film, and treating said multi-layer film with a free radical initiator, wherein said laminating adhesive is the reaction product of a multifunctional acrylate, an aminofunctional silane, and an ethylenically unsaturated acid, optionally dissolved in a solvent, wherein t he multifunctional acrylate has a molecular weight of from 100 to 300.",DOW CORNING;;EG TECHNOLOGY PARTNERS LP;;UCB FILMS PLC,WYMAN JOHN E;;MERLIN PATRICK J;;RANGWALLA IMTIAZ;;BRANCH KAREN;;FUTTER DAN;;POWER GARY,,https://lens.org/068-453-121-696-294,Granted Patent,no,0,0,15,15,0,B32B7/12;;B32B7/12;;B32B25/042;;B32B25/06;;B32B25/08;;B32B27/08;;B32B27/10;;B32B29/005;;B32B2310/0887;;B32B2439/00;;C09J4/00,B32B7/12;;B32B37/00;;B32B27/08;;B65B55/00;;C08F230/08;;C09J4/00;;C09J4/02;;C09J183/08,,0,0,,,,EXPIRED
156,US,B2,US 6890206 B2,086-793-980-129-259,2005-05-10,2005,US 37873703 A,2003-03-04,US 37873703 A;;US 36165402 P;;US 38125602 P;;US 38261202 P;;US 42693702 P,2002-03-05,Optical transceiver latch,"The present invention relates to a latching system for an optical transceiver module that eliminates the use of compound latching mechanisms by providing a single latching lever for unplugging the module from its mounting cage. The latching lever includes a pair of arms with a bail handle on one end to facilitate actuation of the latching lever and manipulation of the module. The other end of the latching lever applies a force to the cage to separate first and second mating latching members on the module and the cage, respectively. The fulcrum of the lever is provided by a bend in each arm, which acts like a journal, mounted in a bearing depression formed in the module housing.",JDS UNIPHASE CORP,DISTAD EUGENE E;;GAIO DAVID PETER;;MOTSCHMAN DAVID;;BRANCH SCOTT MICHAEL;;SENDELBACH PAUL JOHN,LUMENTUM OPERATIONS LLC (2015-07-31);;JDS UNIPHASE CORPORATION (2003-02-25),https://lens.org/086-793-980-129-259,Granted Patent,yes,4,50,2,6,0,G02B6/4261;;G02B6/4261;;G02B6/4246;;G02B6/4246;;G02B6/4269;;G02B6/4269;;G02B6/4292;;G02B6/4292,H01R13/62;;H01R13/64,439/372;;439/638;;439/76.1;;439/157;;361/728,0,0,,,,EXPIRED
157,CA,C,CA 2278503 C,023-325-172-587-371,2008-04-15,2008,CA 2278503 A,1998-01-16,BE 9800009 W;;GB 9700904 A,1997-01-17,REACTIVE POLYAMINE CONTAINING BARRIER LAMINATING ADHESIVES AND APPLICATIONS,"The invention relates to a method of laminating two substrates by coating at least one side of a substrate with a laminating adhesive, bringing a coated side of said substrate into contact with a second substrat e to form a three layer film, and treating said three layer film with a free radical initiator, wherein said laminating adhesive is formed by mixing an ethylenically unsaturated acid and a polyamine.",UCB FILMS PLC;;EG TECHNOLOGY PARTNERS LP;;DOW CORNING,POWER GARY;;FUTTER DAN;;BRANCH KAREN;;RANGWALLA IMTIAZ;;WYMAN JOHN E;;MERLIN PATRICK J,,https://lens.org/023-325-172-587-371,Granted Patent,no,0,0,16,36,0,B32B7/12;;C09J4/00;;C09J4/06;;Y10T428/1383;;Y10T428/1383;;B32B2305/72;;B32B27/08;;B32B2439/00;;B32B2310/0887;;B32B7/12;;C09J4/06;;C09J4/00,B32B7/12;;B32B37/00;;B65B55/00;;B65D65/42;;C08F220/00;;C09J4/00;;C09J4/02;;C09J4/06,,0,0,,,,EXPIRED
158,EP,A1,EP 0952999 A1,136-781-958-445-363,1999-11-03,1999,EP 98900485 A,1998-01-16,BE 9800007 W;;GB 9700988 A;;GB 9700905 A,1997-01-17,POLYAMINE/UNSATURATED ORGANIC ACID COMPOSITION FOR BARRIER COATING,,EG TECHNOLOGY PARTNERS LP;;DOW CORNING;;UCB FILMS PLC,WYMAN JOHN E;;RANGWALLA IMTIAZ;;MERLIN PATRICK J;;FUTTER DAN;;POWER GARY;;BRANCH KAREN,,https://lens.org/136-781-958-445-363,Patent Application,yes,0,0,15,36,0,C08F290/14;;C08L51/003;;C09D4/00;;C09D4/06;;Y10T428/31663;;Y10T428/31551;;Y10T428/31663;;Y10T428/31551;;C09D4/00;;C09D4/06;;C08F290/14;;C08L51/003,B65D65/40;;C08F2/48;;C08F20/00;;C08F22/00;;C08F290/14;;C08L51/00;;C09D4/00;;C09D4/02;;C09D4/06,,0,0,,,,EXPIRED
159,AT,T1,AT E373443 T1,180-111-763-518-916,2007-10-15,2007,AT 01909055 T,2001-02-09,US 50220400 A;;US 50244400 A;;US 77928201 A,2000-02-10,ANALYTENSENSOR,"A sensor (400) and method of making the same for implantation in a body that includes a substrate (402) with notches (406) cut in the substrate to form a necked down region (412) in the substrate; and at least one sensor electrode (404) formed from one or more conductive layers. Preferably, the thickness of the substrate (402) ranges from approximately 25 mu to 350 mu , but the thickness of the substrate can range from 5 mu to 750 mu . The sensor may be incorporated into a sensor assembly including a slotted needle (408) having a slot (410). The notches (406) creating the necked down region (412) allow the substrate (402) to slide into the slotted needle, which has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region (414) of the substrate is prevented from pulling out of the slotted needle (408) through the slot (410). The slot (410) of the slotted needle (408) may also permit the necked down region (412) of the substrate (402) to slide down the slot.",MEDTRONIC MINIMED INC,HOLKER JAMES;;CALLE GUILLERMO;;BRANCH KEVIN;;MASTROTORARO JOHN;;VAN ANTWERP WILLIAM;;VAN ANTWERP NANNETTE,,https://lens.org/180-111-763-518-916,Granted Patent,no,0,0,14,18,0,A61B5/14532;;A61B5/14865;;A61B5/6849,A61B5/145;;A61B5/00;;A61B5/1473;;A61B5/1486;;A61B5/15;;A61B5/157;;G01N27/28;;G01N27/327,,0,0,,,,EXPIRED
160,WO,A1,WO 2022/026177 A1,189-307-486-209-681,2022-02-03,2022,US 2021/0041506 W,2021-07-14,US 202063058776 P;;US 202063072571 P,2020-07-30,STRETCHABLE FABRIC SLEEVE FOR FUNCTIONAL ELECTRICAL STIMULATION AND/OR ELECTROMYOGRAPHY,"A device for functional electrical stimulation (FES), neuromuscular electrical stimulation (NMES), and/or in receiving electromyography (EMG) signals includes a sleeve and electrodes. The sleeve is sized and shaped to be worn on a human arm, and comprises a stretchable fabric The sleeve has a distal end disposed on or adjacent a wrist of the human arm when the sleeve is worn on the human arm and a proximal end opposite from the distal end. The electrodes are secured with the sleeve and positioned to contact skin of the human arm when the sleeve is worn on the human arm. The sleeve may include an inner sleeve contact with the skin and an outer sleeve disposed over the inner sleeve. The inner sleeve has openings in which the electrodes are disposed.",BATTELLE MEMORIAL INSTITUTE,BLUM TIMOTHY;;BRANCH JOSHUA;;COLACHIS SAMUEL;;NOONAN AMANDA;;BARTHOLOMEW JOHN;;ANNETTA NICHOLAS;;DAVIS YELENA,,https://lens.org/189-307-486-209-681,Patent Application,yes,7,0,8,8,0,A61B5/4836;;A61B5/389;;A61B5/296;;A61B5/256;;A61B5/304;;A61B5/313;;A61N1/36003;;A61N1/36031;;A61N1/0452;;A61N1/0484;;A61B5/4836;;A61B5/296;;A61B5/389;;A61B5/304;;A61N1/36003;;A61B5/313;;A61N1/36031;;A61B5/256;;A61N1/0452;;A61N1/0484;;A61N1/0452;;A61N1/0456;;A61N1/0476;;A61N1/0484;;A61N1/36031;;A61B5/296;;A61B5/397;;A61B5/301;;A61B5/256;;A61B5/313;;A61B5/4836;;A61B5/6824;;A61B5/725;;A61B2562/0209;;A61B2562/046;;A61B2562/182;;A61N1/36003,A61N1/36;;A61B5/00;;A61B5/256;;A61B5/296;;A61B5/304;;A61B5/389,,0,0,,,,PENDING
161,WO,A1,WO 1998/031719 A1,060-503-698-456-473,1998-07-23,1998,BE 9800007 W,1998-01-16,GB 9700988 A;;GB 9700905 A,1997-01-17,POLYAMINE/UNSATURATED ORGANIC ACID COMPOSITION FOR BARRIER COATING,"The present invention teaches a composition which provides gas, flavor, and aroma barrier to substrates, where the composition is formed by mixing an ethylenically unsaturated acid and a polyamine, wherein said polyamine has a crosslinker reacted therein, and wherein said polyamine has four or more A, B or C units, where A is an -R2-N(R1)2 unit, B is an -R?1-N(R2-)¿2 unit, and C is an (-R2)3N- unit, where R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, and alkylaryl, and R2 is independently selected from the group consisting of: linear or branched alkylene groups or substituted alkylene groups having from 1 to 18 carbon atoms, and arylene groups or substituted arylene groups having from 6 to 18 carbon atoms. The composition is coated on a substrate then optionally treated to initiate a free radical reaction. The invention can be applied as a coating to a variety of substrates used in packaging applications.",EG TECHNOLOGY PARTNERS LP;;DOW CORNING;;UCB FILMS PLC;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;MERLIN PATRICK J;;FUTTER DAN;;POWER GARY;;BRANCH KAREN,WYMAN JOHN E;;RANGWALLA IMTIAZ;;MERLIN PATRICK J;;FUTTER DAN;;POWER GARY;;BRANCH KAREN,,https://lens.org/060-503-698-456-473,Patent Application,yes,1,23,15,36,0,C08F290/14;;C08L51/003;;C09D4/00;;C09D4/06;;Y10T428/31663;;Y10T428/31551;;Y10T428/31663;;Y10T428/31551;;C09D4/00;;C09D4/06;;C08F290/14;;C08L51/003,C08F2/48;;C08F20/00;;C08F22/00;;C08F290/14;;C08L51/00;;B65D65/40;;C09D4/00;;C09D4/02;;C09D4/06,,0,0,,,,PATENTED
162,BR,A,BR 9806760 A,078-005-830-695-175,2000-03-14,2000,BR 9806760 A,1998-01-16,BE 9800006 W;;GB 9700910 A;;GB 9700964 A,1997-01-17,"Composição, processo, e, recipiente de embalagem","""COMPOSIçãO, PROCESSO, E, RECIPIENTE DE EMBALAGEM"". A invenção é uma composição produzida pela misturação de um acrilato multifuncional com um silano aminofuncional e um ácido etilenicamente insaturado para formar um produto de reação, opcionalmente dissolvido em um solvente, caracterizado pelo fato de que o acrilato multifuncional possui um peso molecular de cerca de 100 a cerca de 3000. A composição pode ser revestida sobre um substrato, então opcionalmente exposta à unidade e tratada para iniciar uma reação de radial livre. A invenção pode ser aplicada a uma variedade de substratos usados em aplicações de embalagem. A mistura da reação pode ser adicionalmente curada por aquecimento na presença de umidade. A reação de radical livre pode ser iniciada por irradicação de feixe de elétrons, radiação ultravioleta, radiação gama, e/ou aquecimento e iniciadores de radical livre químicos.",DOW CORNING;;EG TECHNOLOGY PARTNEERS LP;;UCB FILMS PLC,MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;POWER GARY;;BRANCH KAREN,,https://lens.org/078-005-830-695-175,Patent Application,no,0,0,10,12,0,B65D65/38;;B65D65/38;;C08F290/14;;C08F290/14;;Y10T428/1352;;Y10T428/1352;;Y10T428/1393;;Y10T428/1393,B65D65/02;;B65D65/38;;C08F290/14;;C08L79/00;;C09D4/00,,0,0,,,,DISCONTINUED
163,AU,B2,AU 736399 B2,022-520-171-125-340,2001-07-26,2001,AU 1998/055444 A,1998-01-16,BE 9800007 W;;GB 9700988 A;;GB 9700905 A,1997-01-17,Polyamine/unsaturated organic acid composition for barrier coating,,EG TECHNOLOGY PARTNERS LP;;DOW CORNING;;UCB FILMS PLC,WYMAN JOHN E;;RANGWALLA IMTIAZ;;MERLIN PATRICK J;;FUTTER DAN;;POWER GARY;;BRANCH KAREN,,https://lens.org/022-520-171-125-340,Granted Patent,no,3,0,15,36,0,C08F290/14;;C08L51/003;;C09D4/00;;C09D4/06;;Y10T428/31663;;Y10T428/31551;;Y10T428/31663;;Y10T428/31551;;C09D4/00;;C09D4/06;;C08F290/14;;C08L51/003,B65D65/40;;C08F2/48;;C08F20/00;;C08F22/00;;C08F290/14;;C08L51/00;;C09D4/00;;C09D4/02;;C09D4/06,,0,0,,,,EXPIRED
164,WO,A1,WO 1998/031539 A1,053-772-785-214-992,1998-07-23,1998,BE 9800009 W,1998-01-16,GB 9700904 A,1997-01-17,REACTIVE POLYAMINE CONTAINING BARRIER LAMINATING ADHESIVES AND APPLICATIONS,"The invention relates to a method of laminating two substrates by coating at least one side of a substrate with a laminating adhesive, bringing a coated side of said substrate into contact with a second substrate to form a three layer film, and treating said three layer film with a free radical initiator, wherein said laminating adhesive is formed by mixing an ethylenically unsaturated acid and a polyamine.",UCB FILMS PLC;;EG TECHNOLOGY PARTNERS LP;;DOW CORNING;;BRANCH KAREN;;POWER GARY;;RANGWALLA IMTIAZ;;WYMAN JOHN E;;FUTTER DAN;;MERLIN PATRICK J,BRANCH KAREN;;POWER GARY;;RANGWALLA IMTIAZ;;WYMAN JOHN E;;FUTTER DAN;;MERLIN PATRICK J,,https://lens.org/053-772-785-214-992,Patent Application,yes,1,12,16,36,0,B32B7/12;;C09J4/00;;C09J4/06;;Y10T428/1383;;Y10T428/1383;;B32B2305/72;;B32B27/08;;B32B2439/00;;B32B2310/0887;;B32B7/12;;C09J4/06;;C09J4/00,B32B37/00;;B32B7/12;;C08F220/00;;C09J4/00;;C09J4/02;;C09J4/06,B5N N182;;B5N N182;;B5N N186;;B5N N186;;B5N N195;;B5N N195;;B5N N196;;B5N N196;;B5N N197;;B5N N197;;B5N N198;;B5N N198;;B5N N207;;B5N N207;;B5N N21X;;B5N N21X;;B5N N21Y;;B5N N21Y;;B5N N211;;B5N N211;;B5N N215;;B5N N215;;B5N N216;;B5N N216;;B5N N223;;B5N N223;;B5N N224;;B5N N224;;B5N N225;;B5N N225;;B5N N226;;B5N N226;;B5N N237;;B5N N237;;B5N N24Y;;B5N N24Y;;B5N N244;;B5N N244;;B5N N245;;B5N N245;;B5N N246;;B5N N246;;B5N N25Y;;B5N N25Y;;B5N N251;;B5N N251;;B5N N252;;B5N N252;;B5N N254;;B5N N254;;B5N N255;;B5N N255;;B5N N256;;B5N N256;;B5N N257;;B5N N257;;B5N N258;;B5N N258;;B5N N259;;B5N N259;;B5N N26X;;B5N N26X;;B5N N260;;B5N N260;;B5N N261;;B5N N261;;B5N N263;;B5N N263;;B5N N273;;B5N N273;;B5N N276;;B5N N276;;B5N N277;;B5N N277;;B5N N28Y;;B5N N28Y;;B5N N281;;B5N N281;;B5N N282;;B5N N282;;B5N N283;;B5N N283;;B5N N284;;B5N N284;;B5N N286;;B5N N286;;B5N N287;;B5N N287;;B5N N288;;B5N N288,0,0,,,,PATENTED
165,AU,B2,AU 731163 B2,075-035-779-658-392,2001-03-22,2001,AU 1998/055446 A,1998-01-16,BE 9800009 W;;GB 9700904 A,1997-01-17,Reactive polyamine containing barrier laminating adhesives and applications,,UCB FILMS PLC;;DOW CORNING;;EG TECHNOLOGY LP,BRANCH KAREN;;POWER GARY;;RANGWALLA IMTIAZ;;WYMAN JOHN E;;FUTTER DAN;;MERLIN PATRICK J,,https://lens.org/075-035-779-658-392,Granted Patent,no,2,0,16,36,0,B32B7/12;;C09J4/00;;C09J4/06;;Y10T428/1383;;Y10T428/1383;;B32B2305/72;;B32B27/08;;B32B2439/00;;B32B2310/0887;;B32B7/12;;C09J4/06;;C09J4/00,B32B37/00;;B32B7/12;;C08F220/00;;C09J4/00;;C09J4/02;;C09J4/06,,0,0,,,,EXPIRED
166,US,B1,US 6399171 B1,142-670-918-678-408,2002-06-04,2002,US 34125299 A,1999-07-15,BE 9800009 W;;GB 9700904 A,1997-01-17,Reactive silicone/alkylenimine barrier laminating adhesives and applications thereof,"
    The invention relates to a method of laminating two substrates by coating at least one side of a substrate with a laminating adhesive, bringing a coated side of said substrate into contact with a second substrate to form a three layer film, and treating said three layer film with a free radical initiator, wherein said laminating adhesive is formed by mixing an ethylenically unsaturated acid and a polyamine. 
",DOW CORNING;;EG TECHNOLOGY LP;;UCB FILMS PLC STAR HOUSE,MERLIN PATRICK J;;FUTTER DANIEL;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;POWER GARY;;BRANCH KAREN,DOW CORNING CORPORATION (2000-08-03);;UCB FILMS PLC STAR HOUSE (2000-08-24);;EG TECHNOLOGY PARTNERS L.P (2000-08-02);;DOW CORNING S.A (2000-08-02),https://lens.org/142-670-918-678-408,Granted Patent,yes,15,5,16,36,0,B32B7/12;;C09J4/00;;C09J4/06;;Y10T428/1383;;Y10T428/1383;;B32B2305/72;;B32B27/08;;B32B2439/00;;B32B2310/0887;;B32B7/12;;C09J4/06;;C09J4/00,B32B37/00;;B32B7/12;;C08F220/00;;C09J4/00;;C09J4/02;;C09J4/06,428/36.7;;156/273.7;;156/331.1;;156/331.8;;528/392,0,0,,,,EXPIRED
167,AU,A,AU 1998/055444 A,152-755-342-047-771,1998-08-07,1998,AU 1998/055444 A,1998-01-16,BE 9800007 W;;GB 9700988 A;;GB 9700905 A,1997-01-17,Polyamine/unsaturated organic acid composition for barrier coating,,DOW CORNING;;EG TECHNOLOGY LP;;UCB FILMS PLC,WYMAN JOHN E;;RANGWALLA IMTIAZ;;MERLIN PATRICK J;;FUTTER DAN;;POWER GARY;;BRANCH KAREN,,https://lens.org/152-755-342-047-771,Patent Application,no,0,1,15,36,0,C08F290/14;;C08L51/003;;C09D4/00;;C09D4/06;;Y10T428/31663;;Y10T428/31551;;Y10T428/31663;;Y10T428/31551;;C09D4/00;;C09D4/06;;C08F290/14;;C08L51/003,B65D65/40;;C08F2/48;;C08F20/00;;C08F22/00;;C08F290/14;;C08L51/00;;C09D4/00;;C09D4/02;;C09D4/06,,0,0,,,,EXPIRED
168,AU,B2,AU 735818 B2,196-197-716-209-417,2001-07-19,2001,AU 1998/055443 A,1998-01-16,BE 9800006 W;;GB 9700910 A;;GB 9700964 A,1997-01-17,Silicone/multifunctional acrylate barrier coatings,,DOW CORNING;;EG TECHNOLOGY PARTNERS LP;;UCB FILMS PLC,MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;POWER GARY;;BRANCH KAREN,,https://lens.org/196-197-716-209-417,Granted Patent,no,3,0,10,12,0,B65D65/38;;B65D65/38;;C08F290/14;;C08F290/14;;Y10T428/1352;;Y10T428/1352;;Y10T428/1393;;Y10T428/1393,B65D65/02;;B65D65/38;;C08F290/14;;C08L79/00;;C09D4/00,,0,0,,,,EXPIRED
169,CA,A1,CA 2278150 A1,166-045-106-810-490,1998-07-23,1998,CA 2278150 A,1998-01-16,BE 9800006 W;;GB 9700910 A;;GB 9700964 A,1997-01-17,SILICONE/MULTIFUNCTIONAL ACRYLATE BARRIER COATINGS,"The invention is a composition made by mixing a multifunctional acrylate with an aminofunctional silane and an ethylenically unsatturated acid to form a reaction product, optionally dissolved in a solvent, characterized in that multifunctional acrylate has a molecular weight of from about 100 to about 3000. The compositon can be coated on a substrate, then optionally exposed to moisture and treated to initiate a free radical reaction. The invention can be applied to a variety of substrates used in packaging applications. The reaction mixture can further be cured by heating in the presence of moisture. The free radical reaction can be initiated by electron beam irriadiation, ultraviolet radiation, gamma radiation, and/or heat and chemical free radical initiators.",UCB FILMS PLC;;EG TECHNOLOGY PARTNERS LP;;DOW CORNING,RANGWALLA IMTIAZ;;WYMAN JOHN E;;FUTTER DAN;;BRANCH KAREN;;POWER GARY;;MERLIN PATRICK J,,https://lens.org/166-045-106-810-490,Patent Application,no,0,0,10,12,0,B65D65/38;;B65D65/38;;C08F290/14;;C08F290/14;;Y10T428/1352;;Y10T428/1352;;Y10T428/1393;;Y10T428/1393,B65D65/02;;B65D65/38;;C08F290/14;;C08L79/00;;C09D4/00,,0,0,,,,EXPIRED
170,AU,A,AU 1998/055443 A,144-309-196-012-211,1998-08-07,1998,AU 1998/055443 A,1998-01-16,BE 9800006 W;;GB 9700910 A;;GB 9700964 A,1997-01-17,Silicone/multifunctional acrylate barrier coatings,,DOW CORNING;;EG TECHNOLOGY LP;;UCB FILMS PLC,MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;POWER GARY;;BRANCH KAREN,,https://lens.org/144-309-196-012-211,Patent Application,no,0,1,10,12,0,B65D65/38;;C08F290/14;;Y10T428/1352;;Y10T428/1393;;Y10T428/1352;;Y10T428/1393;;C08F290/14;;B65D65/38,B65D65/02;;B65D65/38;;C08F290/14;;C08L79/00;;C09D4/00,,0,0,,,,EXPIRED
171,EP,A1,EP 0952919 A1,165-997-667-440-372,1999-11-03,1999,EP 98900487 A,1998-01-16,BE 9800009 W;;GB 9700904 A,1997-01-17,REACTIVE POLYAMINE CONTAINING BARRIER LAMINATING ADHESIVES AND APPLICATIONS,,UCB FILMS PLC;;EG TECHNOLOGY PARTNERS LP;;DOW CORNING,BRANCH KAREN;;POWER GARY;;RANGWALLA IMTIAZ;;WYMAN JOHN E;;FUTTER DAN;;MERLIN PATRICK J,,https://lens.org/165-997-667-440-372,Patent Application,yes,0,1,16,36,0,B32B7/12;;C09J4/00;;C09J4/06;;Y10T428/1383;;Y10T428/1383;;B32B2305/72;;B32B27/08;;B32B2439/00;;B32B2310/0887;;B32B7/12;;C09J4/06;;C09J4/00,B32B37/00;;B32B7/12;;C08F220/00;;C09J4/00;;C09J4/02;;C09J4/06,,0,0,,,,EXPIRED
172,AU,B2,AU 728150 B2,004-883-288-933-413,2001-01-04,2001,AU 1998/055445 A,1998-01-16,BE 9800008 W;;GB 9700903 A,1997-01-17,Silicone containing laminate adhesive,,UCB FILMS PLC;;DOW CORNING;;EG TECHNOLOGY PARTNERS LP,POWER GARY;;BRANCH KAREN;;MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ,,https://lens.org/004-883-288-933-413,Granted Patent,no,2,0,15,15,0,B32B7/12;;B32B7/12;;B32B25/042;;B32B25/06;;B32B25/08;;B32B27/08;;B32B27/10;;B32B29/005;;B32B2310/0887;;B32B2439/00;;C09J4/00,B32B37/00;;B32B7/12;;C09J4/00;;C09J4/02;;C09J183/08,,0,0,,,,EXPIRED
173,CA,A1,CA 2278503 A1,027-521-398-082-943,1998-07-23,1998,CA 2278503 A,1998-01-16,BE 9800009 W;;GB 9700904 A,1997-01-17,REACTIVE POLYAMINE CONTAINING BARRIER LAMINATING ADHESIVES AND APPLICATIONS,"The invention relates to a method of laminating two substrates by coating at least one side of a substrate with a laminating adhesive, bringing a coated side of said substrate into contact with a second substrate to form a three layer film, and treating said three layer film with a free radical initiator, wherein said laminating adhesive is formed by mixing an ethylenically unsaturated acid and a polyamine.",UCB FILMS PLC;;DOW CORNING;;EG TECHNOLOGY PARTNERS LP,MERLIN PATRICK J;;FUTTER DAN;;BRANCH KAREN;;POWER GARY;;RANGWALLA IMTIAZ;;WYMAN JOHN E,,https://lens.org/027-521-398-082-943,Patent Application,no,0,0,16,36,0,B32B7/12;;C09J4/00;;C09J4/06;;Y10T428/1383;;Y10T428/1383;;B32B2305/72;;B32B27/08;;B32B2439/00;;B32B2310/0887;;B32B7/12;;C09J4/06;;C09J4/00,B32B37/00;;B32B7/12;;C08F220/00;;C09J4/00;;C09J4/02;;C09J4/06,,0,0,,,,EXPIRED
174,US,B1,US 6514584 B1,079-166-238-109-927,2003-02-04,2003,US 34125599 A,1999-07-15,BE 9800008 W;;GB 9700905 A,1997-01-17,Silicone containing laminate adhesive,"
    The invention is a laminate structure made by coating at least one side of a substrate with a laminating adhesive, bringing a coated side of said substrate into contact with a second substrate to form a multi-layer film, and treating said multi-layer film with a free radical initiator, wherein said laminating adhesive is the reaction product of a multifunctional acrylate, an aminofunctional silane, and an ethylenically unsaturated acid, optionally dissolved in a solvent, wherein the multifunctional acrylate has a molecular weight of from 100 to 3000. 
",UCB FILMS PLC STAR HOUSE;;EG TECHNOLOGY LP;;DOW CORNING,MERLIN PATRICK J;;FUTTER DANIEL;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;POWER GARY;;BRANCH KAREN,DOW CORNING CORPORATION (2000-08-03);;UCB FILMS PLC STAR HOUSE (2000-08-24);;EG TECHNOLOGY PARTNERS L.P (2000-08-02);;DOW CORNING S.A (2000-08-02),https://lens.org/079-166-238-109-927,Granted Patent,yes,13,30,2,36,0,C09D4/00;;C09D4/00;;C08F290/14;;C08F290/14;;C08L51/003;;C08L51/003;;C09D4/06;;C09D4/06;;Y10T428/1383;;Y10T428/1383,C08F290/14;;C08L51/00;;C09D4/00;;C09D4/06,428/36.7;;156/273.7;;156/329;;528/26;;528/392,0,0,,,,EXPIRED
175,MY,A,MY 132816 A,108-524-823-532-344,2007-10-31,2007,MY PI9800193 A,1998-01-16,GB 9700904 A,1997-01-17,REACTIVE SILICONE/ ALKYLENIMINE BARRIER LAMINATING ADHESIVES AND APPLICATIONS THEREOF,"THE INVENTION RELATES TO A METHOD OF LAMINATING TWO SUBSTRATES BY COATING AT LEAST ONE SIDE OF A SUBSTRATE WITH A LAMINATING ADHESIVE, BRINGING A COATED SIDE OF SAID SUBSTRATE INTO CONTACT WITH A SECOND SUBSTRATE TO FORM A THREE LAYER FILM, AND TREATING SAID THREE WITH A FREE RADICAL INITIATOR, WHEREIN SAID LAMINATING ADHESIVE IS FORMED BY MIXING AN ETHYLENICALLY UNSATURATED ACID AND A POLYAMINE.",UCB FILMS PLC,KAREN BRANCH;;GARY POWER;;DAN FUTTER;;MERLIN PATRICK J;;IMTIAZ RANGWALLA;;WYMAN JOHN E,,https://lens.org/108-524-823-532-344,Granted Patent,no,0,0,16,36,0,B32B7/12;;C09J4/00;;C09J4/06;;Y10T428/1383;;Y10T428/1383;;B32B2305/72;;B32B27/08;;B32B2439/00;;B32B2310/0887;;B32B7/12;;C09J4/06;;C09J4/00,B32B7/08;;B32B37/00;;B32B7/12;;C08F220/00;;C09J4/00;;C09J4/02;;C09J4/06,,0,0,,,,EXPIRED
176,EP,B1,EP 0952999 B1,159-242-216-835-620,2002-10-02,2002,EP 98900485 A,1998-01-16,BE 9800007 W;;GB 9700988 A;;GB 9700905 A,1997-01-17,POLYAMINE/UNSATURATED ORGANIC ACID COMPOSITION FOR BARRIER COATING,,EG TECHNOLOGY PARTNERS LP;;DOW CORNING;;UCB FILMS PLC,WYMAN JOHN E;;RANGWALLA IMTIAZ;;MERLIN PATRICK J;;FUTTER DAN;;POWER GARY;;BRANCH KAREN,,https://lens.org/159-242-216-835-620,Granted Patent,yes,1,0,15,36,0,C08F290/14;;C08L51/003;;C09D4/00;;C09D4/06;;Y10T428/31663;;Y10T428/31551;;Y10T428/31663;;Y10T428/31551;;C09D4/00;;C09D4/06;;C08F290/14;;C08L51/003,B65D65/40;;C08F2/48;;C08F20/00;;C08F22/00;;C08F290/14;;C08L51/00;;C09D4/00;;C09D4/02;;C09D4/06,,0,0,,,,EXPIRED
177,CA,C,CA 2278027 C,187-923-011-532-510,2007-04-10,2007,CA 2278027 A,1998-01-16,BE 9800007 W;;GB 9700988 A;;GB 9700905 A,1997-01-17,POLYAMINE/UNSATURATED ORGANIC ACID COMPOSITION FOR BARRIER COATING,"The present invention teaches a composition which provides gas, flavor, and aroma barrier to substrates, where the composition is formed by mixing an ethylenically unsaturated acid and a polyamine, wherein said polyamine has a crosslinker reacted therein, and wherein said polyamine has four or more A, B or C units, where A is an -R2-N(R1)2 unit, B is an -R1-N(R2-)2 unit, and C is an (-R2)3N- unit, where R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, and alkylaryl, and R2 is independently selected from the group consisting of: linear or branched alkylene groups or substituted alkylene groups having from 1 to 18 carbon atoms, and arylene groups or substituted arylene groups having fro m 6 to 18 carbon atoms. The composition is coated on a substrate then optionally treated to initiate a free radical reaction. The invention can be applied as a coating to a variety of substrates used in packaging applications.",EG TECHNOLOGY PARTNERS LP;;DOW CORNING;;UCB FILMS PLC,BRANCH KAREN;;POWER GARY;;FUTTER DAN;;WYMAN JOHN E;;MERLIN PATRICK J;;RANGWALLA IMTIAZ,,https://lens.org/187-923-011-532-510,Granted Patent,no,0,0,15,36,0,C08F290/14;;C08L51/003;;C09D4/00;;C09D4/06;;Y10T428/31663;;Y10T428/31551;;Y10T428/31663;;Y10T428/31551;;C09D4/00;;C09D4/06;;C08F290/14;;C08L51/003,B65D65/40;;C08F220/00;;B65D65/00;;C08F2/48;;C08F20/00;;C08F22/00;;C08F290/14;;C08L51/00;;C09D4/00;;C09D4/02;;C09D4/06,,0,0,,,,EXPIRED
178,WO,A1,WO 1998/031720 A1,121-157-829-601-901,1998-07-23,1998,BE 9800006 W,1998-01-16,GB 9700910 A;;GB 9700964 A,1997-01-17,SILICONE/MULTIFUNCTIONAL ACRYLATE BARRIER COATINGS,"The invention is a composition made by mixing a multifunctional acrylate with an aminofunctional silane and an ethylenically unsatturated acid to form a reaction product, optionally dissolved in a solvent, characterized in that multifunctional acrylate has a molecular weight of from about 100 to about 3000. The compositon can be coated on a substrate, then optionally exposed to moisture and treated to initiate a free radical reaction. The invention can be applied to a variety of substrates used in packaging applications. The reaction mixture can further be cured by heating in the presence of moisture. The free radical reaction can be initiated by electron beam irriadiation, ultraviolet radiation, gamma radiation, and/or heat and chemical free radical initiators.",DOW CORNING;;EG TECHNOLOGY PARTNERS LP;;UCB FILMS PLC;;MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;POWER GARY;;BRANCH KAREN,MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;POWER GARY;;BRANCH KAREN,,https://lens.org/121-157-829-601-901,Patent Application,yes,2,14,10,12,0,B65D65/38;;C08F290/14;;Y10T428/1352;;Y10T428/1393;;Y10T428/1352;;Y10T428/1393;;C08F290/14;;B65D65/38,B65D65/02;;B65D65/38;;C08F290/14;;C08L79/00;;C09D4/00,,0,0,,,,PATENTED
179,US,B1,US 6794042 B1,001-032-411-250-286,2004-09-21,2004,US 34125499 A,1999-12-17,BE 9800007 W;;GB 9700905 A;;GB 9700988 A,1997-01-17,Barrier coatings,"
    The present invention teaches a composition which provides gas, flavor, and aroma barrier to substrates, where the composition is formed by mixing an ethylenically unsaturated acid and a polyamine, wherein said polyamine optionally has a crosslinker reacted therein, and wherein said polyamine has four or more A, B, or C units, where: 

    A is an R ^{ 2 } N(R ^{ 1 } ) _{ 2 } unit, B is an R ^{ 1 } N(R ^{ 2 } ) _{ 2 } unit, and C is an (R ^{ 2 } ) _{ 3 } N unit, where: 

    R ^{ 1 } is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, and alkylaryl, and 

    R ^{ 2 } is independently selected from the group consisting of: linear or branched alkylene groups or substituted alkylene groups having from 1 to 18 carbon atoms, and arylene groups or substituted arylene groups having from 6 to 18 carbon atoms. 

    The composition is coated on a substrate then optionally treated to initiate a free radical reaction. The invention can be applied as a coating to a variety of substrates used in packaging applications. 
",EG TECHNOLOGY LP;;UCB FILMS PLC STAR HOUSE;;DOW CORNING,MERLIN PATRICK J;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;FUTTER DANIEL;;POWER GARY;;BRANCH KAREN,DOW CORNING CORPORATION (2000-08-03);;UCB FILMS PLC STAR HOUSE (2000-08-24);;EG TECHNOLOGY PARTNERS L.P (2000-08-02);;DOW CORNING S.A (2000-08-02),https://lens.org/001-032-411-250-286,Granted Patent,yes,21,12,15,36,0,C08F290/14;;C08L51/003;;C09D4/00;;C09D4/06;;Y10T428/31663;;Y10T428/31551;;Y10T428/31663;;Y10T428/31551;;C09D4/00;;C09D4/06;;C08F290/14;;C08L51/003,C08F2/48;;C08F20/00;;B65D65/40;;C08F22/00;;C08F290/14;;C08L51/00;;C09D4/00;;C09D4/02;;C09D4/06,428/423.1;;428/447;;524/81;;524/220;;524/221;;524/591,0,0,,,,EXPIRED
180,ES,T3,ES 2173564 T3,055-544-031-787-354,2002-10-16,2002,ES 98900487 T,1998-01-16,GB 9700904 A,1997-01-17,ADHESIVOS DE ESTRATIFICACION DE BARRERA CON CONTENIDO EN POLIAMINA REACTIVA Y APLICACIONES.,"ESTA INVENCION SE REFIERE A UN PROCEDIMIENTO DE LAMINACION DE DOS SUBSTRATOS MEDIANTE REVESTIMIENTO DE, POR LO MENOS, UN LADO DE UN SUBSTRATO, CON UN ADHESIVO DE LAMINACION, PONIENDO EN CONTACTO UN LADO REVESTIDO DE DICHO SUBSTRATO CON UN SEGUNDO SUBSTRATO PARA FORMAR UNA PELICULA DE TRES CAPAS Y TRATANDO DICHA PELICULA DE TRES CAPAS CON UN INICIADOR RADICAL LIBRE, DONDE DICHO ADHESIVO DE LAMINACION SE FORMA MEZCLANDO UN ACIDO ETILENICAMENTE INSATURADO Y UNA POLIAMINA.",UCB FILMS PLC;;EG TECHNOLOGY PARTNERS LP;;DOW CORNING,BRANCH KAREN;;POWER GARY;;RANGWALLA IMTIAZ;;WYMAN JOHN E;;FUTTER DAN;;MERLIN PATRICK J,,https://lens.org/055-544-031-787-354,Granted Patent,no,0,0,16,36,0,B32B7/12;;C09J4/00;;C09J4/06;;Y10T428/1383;;Y10T428/1383;;B32B2305/72;;B32B27/08;;B32B2439/00;;B32B2310/0887;;B32B7/12;;C09J4/06;;C09J4/00,B32B37/00;;B32B7/12;;C08F220/00;;C09J4/00;;C09J4/02;;C09J4/06,,0,0,,,,EXPIRED
181,ES,T3,ES 2180138 T3,114-462-993-609-195,2003-02-01,2003,ES 98900485 T,1998-01-16,GB 9700988 A;;GB 9700905 A,1997-01-17,COMPOSICION DE POLIAMINA/ACIDO ORGANICO INSATURADO PARA REVESTIMIENTOS DE BARRERA.,"LA PRESENTE INVENCION DESCRIBE UNA COMPOSICION QUE PROPORCIONA A DETERMINADOS SUSTRATOS UNA BARRERA FRENTE A GASES, SABORES Y AROMAS. DICHA COMPOSICION SE FORMA MEZCLANDO UN ACIDO ETILENICAMENTE INSATURADO Y UNA POLIAMINA, EN LA CUAL SE HACE REACCIONAR UN AGENTE RETICULANTE, ESTANDO FORMADA DICHA POLIAMINA POR CUATRO O MAS UNIDADES A, B O C, DONDE A REPRESENTA UNA UNIDAD - R 2 - N(R 1 ) 2 , B REPRESENTA UNA UNIDAD - R 1 - N(R 2- ) 2 , Y C ES UNA UNIDAD (- R 2 ) 3 N -, DONDE R 1 SE SELECCIONA INDEPENDIENTEMENTE A PARTIR DE HIDROGENO, ALQUILO, ALQUILO SUSTITUIDO, ARILO, ARILO SUSTITUIDO, ARILALQUILO Y ALQUILARILO, Y R 2 SE SELECC IONA INDEPENDIENTEMENTE A PARTIR DEL GRUPO FORMADO POR: GRUPOS ALQUILENO LINEALES O RAMIFICADOS, O GRUPOS ALQUILENO SUSTITUIDOS DE 1 A 18 ATOMOS DE CARBONO, Y GRUPOS ARILENO O GRUPOS ARILENO SUSTITUIDOS DE 6 A 18 ATOMOS DE CARBONO. DICHA COMPOSICION SE ENCUENTRA REVISTIENDO UN SUSTRATO Y, A CONTINUACION SE TRATA OPCIONALMENTE PARA INICIAR UNA REACCION DE RADICALES LIBRES. LA INVENCION SE PUEDE APLICAR COMO REVESTIMIENTO A DIVERSOS SUSTRATOS UTILIZADOS EN APLICACIONES DE EMBALAJE.",EG TECHNOLOGY PARTNERS LP;;DOW CORNING;;UCB FILMS PLC,WYMAN JOHN E;;RANGWALLA IMTIAZ;;MERLIN PATRICK J;;FUTTER DAN;;POWER GARY;;BRANCH KAREN,,https://lens.org/114-462-993-609-195,Granted Patent,no,0,0,15,36,0,C08F290/14;;C08L51/003;;C09D4/00;;C09D4/06;;Y10T428/31663;;Y10T428/31551;;Y10T428/31663;;Y10T428/31551;;C09D4/00;;C09D4/06;;C08F290/14;;C08L51/003,B65D65/40;;C08F2/48;;C08F20/00;;C08F22/00;;C08F290/14;;C08L51/00;;C09D4/00;;C09D4/02;;C09D4/06,,0,0,,,,EXPIRED
182,WO,A1,WO 1998/031541 A1,110-599-435-397-863,1998-07-23,1998,BE 9800008 W,1998-01-16,GB 9700903 A,1997-01-17,SILICONE CONTAINING LAMINATE ADHESIVE,"The invention is a laminate structure made by coating at least one side of a substrate with a laminating adhesive, bringing a coated side of said substrate into contact with a second substrate to form a multi-layer film, and treating said multi-layer film with a free radical initiator, wherein said laminating adhesive is the reaction product of a multifunctional acrylate, an aminofunctional silane, and an ethylenically unsaturated acid, optionally dissolved in a solvent, wherein the multifunctional acrylate has a molecular weight of from 100 to 300.",UCB FILMS PLC;;DOW CORNING;;EG TECHNOLOGY PARTNERS LP;;POWER GARY;;BRANCH KAREN;;MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ,POWER GARY;;BRANCH KAREN;;MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ,,https://lens.org/110-599-435-397-863,Patent Application,yes,1,13,15,15,0,B32B7/12;;B32B7/12;;B32B25/042;;B32B25/06;;B32B25/08;;B32B27/08;;B32B27/10;;B32B29/005;;B32B2310/0887;;B32B2439/00;;C09J4/00,B32B37/00;;B32B7/12;;C09J4/00;;C09J4/02;;C09J183/08,B5N N182;;B5N N182;;B5N N186;;B5N N186;;B5N N195;;B5N N195;;B5N N196;;B5N N196;;B5N N197;;B5N N197;;B5N N198;;B5N N198;;B5N N207;;B5N N207;;B5N N21X;;B5N N21X;;B5N N21Y;;B5N N21Y;;B5N N211;;B5N N211;;B5N N216;;B5N N216;;B5N N223;;B5N N223;;B5N N224;;B5N N224;;B5N N225;;B5N N225;;B5N N226;;B5N N226;;B5N N237;;B5N N237;;B5N N24Y;;B5N N24Y;;B5N N244;;B5N N244;;B5N N245;;B5N N245;;B5N N246;;B5N N246;;B5N N25Y;;B5N N25Y;;B5N N251;;B5N N251;;B5N N252;;B5N N252;;B5N N255;;B5N N255;;B5N N256;;B5N N256;;B5N N257;;B5N N257;;B5N N258;;B5N N258;;B5N N259;;B5N N259;;B5N N26X;;B5N N26X;;B5N N260;;B5N N260;;B5N N261;;B5N N261;;B5N N263;;B5N N263;;B5N N273;;B5N N273;;B5N N276;;B5N N276;;B5N N277;;B5N N277;;B5N N28Y;;B5N N28Y;;B5N N281;;B5N N281;;B5N N282;;B5N N282;;B5N N283;;B5N N283;;B5N N284;;B5N N284;;B5N N286;;B5N N286;;B5N N287;;B5N N287;;B5N N288;;B5N N288;;B5N N289;;B5N N289;;B5N N294;;B5N N294,0,0,,,,PATENTED
183,CA,C,CA 2278150 C,163-578-406-084-753,2008-11-18,2008,CA 2278150 A,1998-01-16,BE 9800006 W;;GB 9700910 A;;GB 9700964 A,1997-01-17,SILICONE/MULTIFUNCTIONAL ACRYLATE BARRIER COATINGS,"The invention is a composition made by mixing a multifunctional acrylate wit h an aminofunctional silane and an ethylenically unsatturated acid to form a reaction product, optionally dissolved in a solvent, characterized in that multifunctional acrylate has a molecular weight of from about 100 to about 3000. The compositon can be coated on a substrate, then optionally exposed to moisture and treated to initiate a free radical reaction. The invention can be applied to a varie ty of substrates used in packaging applications. The reaction mixture can further be cured by heating in the presence of moisture. The fre e radical reaction can be initiated by electron beam irriadiation, ultraviolet radiation, gamma radiation, and/or heat and chemical free radica l initiators.",DOW CORNING;;EG TECHNOLOGY PARTNERS LP;;UCB FILMS PLC,POWER GARY;;BRANCH KAREN;;MERLIN PATRICK J;;FUTTER DAN;;RANGWALLA IMTIAZ;;WYMAN JOHN E,,https://lens.org/163-578-406-084-753,Granted Patent,no,0,0,10,12,0,B65D65/38;;B65D65/38;;C08F290/14;;C08F290/14;;Y10T428/1352;;Y10T428/1352;;Y10T428/1393;;Y10T428/1393,B65D65/02;;C08F230/08;;B65D65/00;;B65D65/38;;C08F222/02;;C08F290/14;;C08L43/04;;C08L79/00;;C09D4/00;;C09D4/02;;C09D143/04,,0,0,,,,EXPIRED
184,ES,T3,ES 2224352 T3,096-002-187-273-166,2005-03-01,2005,ES 98900486 T,1998-01-16,GB 9700903 A,1997-01-17,"PROCEDIMIENTO DE ESTRATIFICACION USANDO UN ADHESIVO QUE CONTIENE SILICONA, Y ESTRATIFICADO FABRICADO POR EL MISMO.","ESTA INVENCION SE REFIERE A UNA ESTRUCTURA LAMINADA REALIZADA MEDIANTE UN REVESTIMIENTO DE, POR LO MENOS, UN LADO DE UN SUBSTRATO CON UN ADHESIVO DE LAMINACION, PONIENDO EN CONTACTO UN LADO REVESTIDO DE DICHO SUBSTRATO CON UN SEGUNDO SUBSTRATO, PARA FORMAR UNA PELICULA MULTICAPAS Y TRATANDO DICHA PELICULA MULTICAPAS CON UN INICIADOR RADICAL LIBRE, DONDE DICHO ADHESIVO DE LAMINACION ES EL PRODUCTO DE REACCION DE UN ACRILATO MULTIFUNCIONAL, UN SILANO AMINO FUNCIONAL Y UN ACIDO ETILENICAMENTE NO SATURADO, OCASIONALMENTE DISUELTO EN UN DISOLVENTE, DONDE EL ACRILATO MULTIFUNCIONAL TIENE UN PESO MOLECULAR DE 100 A 300.",UCB FILMS PLC;;DOW CORNING;;EG TECHNOLOGY PARTNERS LP,POWER GARY;;BRANCH KAREN;;MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ,,https://lens.org/096-002-187-273-166,Granted Patent,no,0,0,15,15,0,B32B7/12;;B32B7/12;;B32B25/042;;B32B25/06;;B32B25/08;;B32B27/08;;B32B27/10;;B32B29/005;;B32B2310/0887;;B32B2439/00;;C09J4/00,B32B37/00;;B32B7/12;;C09J4/00;;C09J4/02;;C09J183/08,,0,0,,,,EXPIRED
185,EP,A1,EP 0952922 A1,001-357-048-831-910,1999-11-03,1999,EP 98900486 A,1998-01-16,BE 9800008 W;;GB 9700903 A,1997-01-17,"LAMINATING PROCESS USING A SILICONE CONTAINING ADHESIVE, AND LAMINATE MADE THEREBY",,UCB FILMS PLC;;DOW CORNING;;EG TECHNOLOGY PARTNERS LP,POWER GARY;;BRANCH KAREN;;MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ,,https://lens.org/001-357-048-831-910,Patent Application,yes,0,0,15,15,0,B32B7/12;;B32B7/12;;B32B25/042;;B32B25/06;;B32B25/08;;B32B27/08;;B32B27/10;;B32B29/005;;B32B2310/0887;;B32B2439/00;;C09J4/00,B32B37/00;;B32B7/12;;C09J4/00;;C09J4/02;;C09J183/08,,1,0,,,See references of WO 9831541A1,EXPIRED
186,EP,B1,EP 0952919 B1,012-460-617-176-026,2002-04-10,2002,EP 98900487 A,1998-01-16,BE 9800009 W;;GB 9700904 A,1997-01-17,REACTIVE POLYAMINE CONTAINING BARRIER LAMINATING ADHESIVES AND APPLICATIONS,,UCB FILMS PLC;;EG TECHNOLOGY PARTNERS LP;;DOW CORNING,BRANCH KAREN;;POWER GARY;;RANGWALLA IMTIAZ;;WYMAN JOHN E;;FUTTER DAN;;MERLIN PATRICK J,,https://lens.org/012-460-617-176-026,Granted Patent,yes,1,1,16,36,0,B32B7/12;;C09J4/00;;C09J4/06;;Y10T428/1383;;Y10T428/1383;;B32B2305/72;;B32B27/08;;B32B2439/00;;B32B2310/0887;;B32B7/12;;C09J4/06;;C09J4/00,B32B37/00;;B32B7/12;;C08F220/00;;C09J4/00;;C09J4/02;;C09J4/06,,1,0,,,"DATABASE WPI Week 9513, Derwent World Patents Index; Class A26, AN 95-094032, NIPPON SHOKUBAI CO LTD",EXPIRED
187,EP,A1,EP 0953000 A1,058-046-158-053-750,1999-11-03,1999,EP 98900484 A,1998-01-16,BE 9800006 W;;GB 9700910 A;;GB 9700964 A,1997-01-17,SILICONE/MULTIFUNCTIONAL ACRYLATE BARRIER COATINGS,,DOW CORNING;;EG TECHNOLOGY PARTNERS LP;;UCB FILMS PLC,MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ;;POWER GARY;;BRANCH KAREN,"DOW CORNING CORPORATION (2006-04-19);;INNOVIA FILMS LIMITED (2006-04-19);;EG TECHNOLOGY PARTNERS, LP (2006-04-19)",https://lens.org/058-046-158-053-750,Patent Application,yes,0,0,10,12,0,B65D65/38;;C08F290/14;;Y10T428/1352;;Y10T428/1393;;Y10T428/1352;;Y10T428/1393;;C08F290/14;;B65D65/38,B65D65/02;;B65D65/38;;C08F290/14;;C08L79/00;;C09D4/00,,0,0,,,,DISCONTINUED
188,WO,A3,WO 2005/058885 A3,169-426-532-770-274,2005-09-09,2005,EP 2004013222 W,2004-11-18,GB 0329363 A;;GB 0413108 A,2003-12-18,PIPERIDINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS,"The invention provides a compound of formula (I) or a salt or solvate thereof: (I) wherein R1 to R8, X and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",GLAXO GROUP LTD;;BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;MARSHALL HOWARD;;NASH DAVID JOHN;;PORTER RODERICK ALAN,,https://lens.org/169-426-532-770-274,Search Report,yes,4,0,2,4,0,C07D405/12;;C07D211/26;;C07D401/06;;C07D417/06,C07D211/26;;C07D401/06;;C07D405/12;;C07D417/06,,0,0,,,,PENDING
189,US,A1,US 2003/0171022 A1,023-183-825-356-220,2003-09-11,2003,US 37873703 A,2003-03-04,US 37873703 A;;US 36165402 P;;US 38125602 P;;US 38261202 P;;US 42693702 P,2002-03-05,Optical transceiver latch,"
   The present invention relates to a latching system for an optical transceiver module that eliminates the use of compound latching mechanisms by providing a single latching lever for unplugging the module from its mounting cage. The latching lever includes a pair of arms with a bail handle on one end to facilitate actuation of the latching lever and manipulation of the module. The other end of the latching lever applies a force to the cage to separate first and second mating latching members on the module and the cage, respectively. The fulcrum of the lever is provided by a bend in each arm, which acts like a journal, mounted in a bearing depression formed in the module housing. 
",JDS UNIPHASE CORP,DISTAD EUGENE E;;GAIO DAVID PETER;;MOTSCHMAN DAVID;;BRANCH SCOTT MICHAEL;;SENDELBACH PAUL JOHN,LUMENTUM OPERATIONS LLC (2015-07-31);;JDS UNIPHASE CORPORATION (2003-02-25),https://lens.org/023-183-825-356-220,Patent Application,yes,4,80,2,6,0,G02B6/4261;;G02B6/4261;;G02B6/4246;;G02B6/4246;;G02B6/4269;;G02B6/4269;;G02B6/4292;;G02B6/4292,H01R13/62;;H01R13/64,439/372,0,0,,,,EXPIRED
190,MY,A,MY 124157 A,101-686-039-698-997,2006-06-30,2006,MY PI9800190 A,1998-01-16,GB 9700988 A;;GB 9700905 A,1997-01-17,ALKYLENIMINE/ ORGANIC BARRIER COATINGS METHOD OF MANUFACTURE AND APPLICATIONS THEREOF,"THE PRESENT INVENTION TEACHES A COMPOSITION WHICH PROVIDES GAS, FLAVOR, AND AROMA BARRIER TO SUBSTRATES, WHERE THE COMPOSITION IS FORMED BY MIXING AN ETHYLENICALLY UNSATURATED ACID AND A POLYAMINE, WHERE SAID POLYAMINE OPTIONALLY HAS A CROSSLINKER REACTED THEREIN, AND WHEREIN SAID POLYAMINE HAS FOUR OR MORE A, B, OR C UNITS, WHERE: A IS AN -R²-N(R¹)2 UNIT, B IS AN -R¹- N(R²-)2 UNIT, AND C IS AN(-R²)3N-UNIT,WHERE: R¹ IS INDEPENDENTLY SELECTED FROM HYDROGEN, ALKYL, SUBSTITUTED ALKYL,ARYL,SUBSTITUTED ARYL, ARYLALKYL, AND ALKYLARYL, AND R² IS INDEPENDENTLY SELECTED FROM THE GROUP CONSISTINGLINEAR OR BRANCHED ALKYLENE GROUPS OR SUBSTITUTED ALKYLENE GROUPS HAVING FROM 1 TO 18 CARBON ATOMS, AND ARYLENE GROUPS OR SUBSTITUTED ARYLENE GROUPS HAVING FROM 6 TO 18 CARBON ATOMS.THE COMPOSITION IS COATED ON A SUBSTRATE THEN OPTIONALLY TREATED TO INITIATE A FREE RADICAL REACTION.THE INVENTION CAN BE APPLIED AS A COATING TO A VARIETY OF SUBSTRATES USED IN PACKAGING APPLICATIONS.",INNOVIA FILMS LTD,WYMANN JOHN E;;IMTIAZ RANGWALLA;;MERLIN PATRICK J;;DAN FUTTER;;GARY POWER;;KAREN BRANCH,,https://lens.org/101-686-039-698-997,Granted Patent,no,0,0,15,36,0,C08F290/14;;C08L51/003;;C09D4/00;;C09D4/06;;Y10T428/31663;;Y10T428/31551;;Y10T428/31663;;Y10T428/31551;;C09D4/00;;C09D4/06;;C08F290/14;;C08L51/003,B65D65/00;;C08F2/48;;B65D65/40;;C08F20/00;;C08F22/00;;C08F290/14;;C08L51/00;;C09D4/00;;C09D4/02;;C09D4/06,,0,0,,,,EXPIRED
191,CA,A1,CA 2278032 A1,171-080-909-168-651,1998-07-23,1998,CA 2278032 A,1998-01-16,BE 9800008 W;;GB 9700903 A,1997-01-17,SILICONE CONTAINING LAMINATE ADHESIVE,"The invention is a laminate structure made by coating at least one side of a substrate with a laminating adhesive, bringing a coated side of said substrate into contact with a second substrate to form a multi-layer film, and treating said multi-layer film with a free radical initiator, wherein said laminating adhesive is the reaction product of a multifunctional acrylate, an aminofunctional silane, and an ethylenically unsaturated acid, optionally dissolved in a solvent, wherein the multifunctional acrylate has a molecular weight of from 100 to 300.",DOW CORNING;;EG TECHNOLOGY PARTNERS LP;;UCB FILMS PLC,WYMAN JOHN E;;BRANCH KAREN;;POWER GARY;;FUTTER DAN;;MERLIN PATRICK J;;RANGWALLA IMTIAZ,,https://lens.org/171-080-909-168-651,Patent Application,no,0,0,15,15,0,B32B7/12;;B32B7/12;;B32B25/042;;B32B25/06;;B32B25/08;;B32B27/08;;B32B27/10;;B32B29/005;;B32B2310/0887;;B32B2439/00;;C09J4/00,B32B37/00;;B32B7/12;;C09J4/00;;C09J4/02;;C09J183/08,,0,0,,,,EXPIRED
192,AU,A,AU 1998/055445 A,049-979-268-369-551,1998-08-07,1998,AU 1998/055445 A,1998-01-16,BE 9800008 W;;GB 9700903 A,1997-01-17,Silicone containing laminate adhesive,,DOW CORNING;;EG TECHNOLOGY LP;;UCB FILMS PLC,POWER GARY;;BRANCH KAREN;;MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ,,https://lens.org/049-979-268-369-551,Patent Application,no,0,0,15,15,0,B32B7/12;;C09J4/00;;B32B25/042;;B32B2439/00;;B32B25/08;;B32B25/06;;B32B27/08;;B32B2310/0887;;B32B27/10;;B32B29/005;;B32B7/12,B32B37/00;;B32B7/12;;C09J4/00;;C09J4/02;;C09J183/08,,0,0,,,,EXPIRED
193,CA,A1,CA 2278027 A1,066-216-826-016-656,1998-07-23,1998,CA 2278027 A,1998-01-16,BE 9800007 W;;GB 9700988 A;;GB 9700905 A,1997-01-17,POLYAMINE/UNSATURATED ORGANIC ACID COMPOSITION FOR BARRIER COATING,"The present invention teaches a composition which provides gas, flavor, and aroma barrier to substrates, where the composition is formed by mixing an ethylenically unsaturated acid and a polyamine, wherein said polyamine has a crosslinker reacted therein, and wherein said polyamine has four or more A, B or C units, where A is an -R2-N(R1)2 unit, B is an -R1-N(R2-)2 unit, and C is an (-R2)3N- unit, where R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, and alkylaryl, and R2 is independently selected from the group consisting of: linear or branched alkylene groups or substituted alkylene groups having from 1 to 18 carbon atoms, and arylene groups or substituted arylene groups having from 6 to 18 carbon atoms. The composition is coated on a substrate then optionally treated to initiate a free radical reaction. The invention can be applied as a coating to a variety of substrates used in packaging applications.",EG TECHNOLOGY PARTNERS LP;;DOW CORNING;;UCB FILMS PLC,RANGWALLA IMTIAZ;;WYMAN JOHN E;;POWER GARY;;MERLIN PATRICK J;;FUTTER DAN;;BRANCH KAREN,,https://lens.org/066-216-826-016-656,Patent Application,no,0,0,15,36,0,C08F290/14;;C08L51/003;;C09D4/00;;C09D4/06;;Y10T428/31663;;Y10T428/31551;;Y10T428/31663;;Y10T428/31551;;C09D4/00;;C09D4/06;;C08F290/14;;C08L51/003,B65D65/40;;C08F2/48;;C08F20/00;;C08F22/00;;C08F290/14;;C08L51/00;;C09D4/00;;C09D4/02;;C09D4/06,,0,0,,,,EXPIRED
194,BR,A,BR 9806757 A,079-246-337-340-358,2000-03-14,2000,BR 9806757 A,1998-01-16,BE 9800009 W;;GB 9700904 A,1997-01-17,"Processo para fabricação de um laminado tendo propriedades de barreira, e, recipiente de embalagem.","''PROCESSO PARA FABRICAçãO DE UM LAMINADO TENDO PROPRIEDADES DE BARREIRA, E, RECIPIENTE DE EMBALAGEM"". A invenção diz respeito a um processo de laminação de dois substratos mediante o revestimento de pelo menos um lado de um substrato com um adesivo de laminagem, trazendo um lado revestido de dito substrato em contato com um segundo substrato para formar uma película de três camadas, e tratando dita película de três camadas com um iniciador livre, em que dito adesivo de laminagem é formado por misturar um ácido etilenicamente insaturado e uma poliamina.",UCB FILMS P L C;;EG TECHNOLOGY PARTNERS;;LP E DOW CORNING CORP,BRANCH KAREN;;POWER GARY;;RANGWALLA IMTIAZ;;WYMAN JOHN E;;FUTTER DAN;;MERLIN PATRICK J,,https://lens.org/079-246-337-340-358,Patent Application,no,0,0,16,36,0,B32B7/12;;C09J4/00;;C09J4/06;;Y10T428/1383;;Y10T428/1383;;B32B2305/72;;B32B27/08;;B32B2439/00;;B32B2310/0887;;B32B7/12;;C09J4/06;;C09J4/00,B32B37/00;;B32B7/12;;C08F220/00;;C09J4/00;;C09J4/02;;C09J4/06,,0,0,,,,DISCONTINUED
195,EP,B1,EP 0952922 B1,174-389-092-661-971,2004-09-08,2004,EP 98900486 A,1998-01-16,BE 9800008 W;;GB 9700903 A,1997-01-17,"LAMINATING PROCESS USING A SILICONE CONTAINING ADHESIVE, AND LAMINATE MADE THEREBY",,UCB FILMS PLC;;DOW CORNING;;EG TECHNOLOGY PARTNERS LP,POWER GARY;;BRANCH KAREN;;MERLIN PATRICK J;;FUTTER DAN;;WYMAN JOHN E;;RANGWALLA IMTIAZ,,https://lens.org/174-389-092-661-971,Granted Patent,yes,1,0,15,15,0,B32B7/12;;B32B7/12;;B32B25/042;;B32B25/06;;B32B25/08;;B32B27/08;;B32B27/10;;B32B29/005;;B32B2310/0887;;B32B2439/00;;C09J4/00,B32B37/00;;B32B7/12;;C09J4/00;;C09J4/02;;C09J183/08,,1,0,,,"H. Bennet et al.: 'Concise Chemical and Technical Dictionary', 3rd ed. (1974); Chemical Publishing Co., Inc., New York (US); p. 941",EXPIRED
196,AU,A,AU 1998/055446 A,069-655-221-796-112,1998-08-07,1998,AU 1998/055446 A,1998-01-16,BE 9800009 W;;GB 9700904 A,1997-01-17,Reactive polyamine containing barrier laminating adhesives and applications,,DOW CORNING;;EG TECHNOLOGY LP;;UCB FILMS PLC,BRANCH KAREN;;POWER GARY;;RANGWALLA IMTIAZ;;WYMAN JOHN E;;FUTTER DAN;;MERLIN PATRICK J,,https://lens.org/069-655-221-796-112,Patent Application,no,0,0,16,36,0,B32B7/12;;C09J4/00;;C09J4/06;;Y10T428/1383;;Y10T428/1383;;B32B2305/72;;B32B27/08;;B32B2439/00;;B32B2310/0887;;B32B7/12;;C09J4/06;;C09J4/00,B32B37/00;;B32B7/12;;C08F220/00;;C09J4/00;;C09J4/02;;C09J4/06,,0,0,,,,EXPIRED
197,ES,T3,ES 2273083 T3,075-182-487-057-448,2007-05-01,2007,ES 03797310 T,2003-09-17,GB 0221691 A;;GB 0221690 A,2002-09-18,N-AROILAMINAS CICLICAS COMO ANTAGONISTAS DE LOS RECEPTORES DE OREXINA.,This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals.,GLAXO GROUP LTD,BRANCH CLIVE LESLIE;;COULTON STEVEN;;JOHNS AMANDA;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STEMP GEOFFREY,,https://lens.org/075-182-487-057-448,Granted Patent,no,0,0,10,12,0,C07D231/12;;C07D233/56;;C07D249/08;;C07D401/06;;C07D401/14;;C07D417/14;;A61P1/08;;A61P15/00;;A61P25/02;;A61P25/06;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/36;;A61P3/10;;A61P35/00;;A61P3/04;;A61P43/00;;A61P5/12;;A61P7/04;;A61P9/10;;C07D231/12;;C07D401/14;;C07D233/56;;C07D249/08;;C07D417/14;;C07D401/06,C07D417/12;;A61K31/454;;A61K31/4545;;A61K31/501;;C07D213/73;;C07D239/42;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/12;;C07D417/14;;C07D521/00,,0,0,,,,EXPIRED
198,DE,D1,DE 60309481 D1,129-324-166-067-336,2006-12-14,2006,DE 60309481 T,2003-09-17,GB 0221691 A;;GB 0221690 A;;EP 0310412 W,2002-09-18,CYCLISCHE N-AROYLAMINE ALS OREXINREZEPTORANTAGONISTEN,This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals.,GLAXO GROUP LTD,BRANCH CLIVE LESLIE;;COULTON STEVEN;;JOHNS AMANDA;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STEMP GEOFFREY,,https://lens.org/129-324-166-067-336,Granted Patent,no,0,0,10,12,0,C07D231/12;;C07D233/56;;C07D249/08;;C07D401/06;;C07D401/14;;C07D417/14;;A61P1/08;;A61P15/00;;A61P25/02;;A61P25/06;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/36;;A61P3/10;;A61P35/00;;A61P3/04;;A61P43/00;;A61P5/12;;A61P7/04;;A61P9/10;;C07D231/12;;C07D401/14;;C07D233/56;;C07D249/08;;C07D417/14;;C07D401/06,C07D417/12;;A61K31/454;;A61K31/4545;;A61K31/501;;C07D213/73;;C07D239/42;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/12;;C07D417/14;;C07D521/00,,0,0,,,,EXPIRED
199,US,B1,US 6304436 B1,081-101-594-096-258,2001-10-16,2001,US 45491999 A,1999-12-03,US 45491999 A,1999-12-03,Connector system with outwardly opening door for a removable transceiver module,"A connector system for a removable transceiver module that interfaces with an electronic device, such as a computer, switch, subsystem, peripheral device, disk drive, tape drive and other input/output devices. The electronic device includes an enclosure having a bezel that has an opening for receiving the module. A circuit board is mounted within the enclosure. A guide member is mounted on the circuit board and is elongated between first and second ends along a first axis. A connector block is located at the first end of the guide member, while a door is pivotally mounted at the second end of the guide member. The module is slidably engageable with the guide member in a direction along the first axis. The module also includes electrical contacts electrically connectable with corresponding electrical contacts in the connector block. The door is pivotable between an open position exposing the opening in the bezel and a closed position where a portion of the door outside the enclosure covers the opening. The door effectively minimizes the likelihood of dust entering the electronic device. Preferably, to provide effective EMI shielding, the door and the bezel each comprise an electrically conductive material and are configured to make electrical contact with each other when said door is closed. The door may be positively latched in the closed position and spring biased toward the open position. The door preferably includes features for guiding and latching the module.",IBM,BRANCH SCOTT MICHAEL;;GAIO DAVID PETER;;HANLEY MICHAEL FRANCIS;;HOGAN WILLIAM K;;SENDELBACH PAUL JOHN,JDS UNIPHASE CORPORATION (2001-12-27);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2000-02-01),https://lens.org/081-101-594-096-258,Granted Patent,yes,3,88,1,1,0,G02B6/4277;;G02B6/4277;;G02B6/4246;;G02B6/4246;;G02B6/4261;;G02B6/4261;;G02B6/428;;G02B6/428;;G02B6/4284;;G02B6/4284;;G02B6/4292;;G02B6/4292;;G02B2006/4297;;G02B2006/4297;;H01R13/24;;H01R13/24;;H01R13/5213;;H01R13/5213;;H01R13/6275;;H01R13/6275;;H01R13/6582;;H01R13/6582;;H01R13/6598;;H01R13/6598;;H01R2201/06;;H01R2201/06,G02B6/42;;H01R13/24;;H01R13/52;;H01R13/627;;H01R13/6582;;H01R13/6598,361/683;;361/753;;439/135,4,0,,,"Co-pending patent application ""Removable Latch and Bezel EMI Grounding Feature for Fiber-Optic Transceivers"", Application Serial No. 09/410,786, Filed Oct. 1, 1999.;;Co-pending patent application ""Guide Rail and CAM System with Integrated Lock-Down and Kick-Out Spring for SMT Connector for Pluggable Modules"", Application Serial No. 09/391,974, Filed Sep. 8, 1999.;;Co-pending patent application ""Guide Rail and CAM System with Integrated Connector for Removable Transceiver"", Application Serial No. 09/216,104, Filed Dec. 18, 1998.;;Co-pending patent application ""Guide Rail System with Integrated Wedge Connector for Removable Transceiver"", Application Serial No. 09/215,977, Filed Dec. 18, 1998.",EXPIRED
200,BR,A,BR 9806759 A,051-861-653-114-414,2000-03-14,2000,BR 9806759 A,1998-01-16,BE 9800007 W;;GB 9700988 A;;GB 9700905 A,1997-01-17,"Composição, processo para a manufatura de um substrato tendo propriedades de barreira, e, recipiente de embalagem","""COMPOSIçãO, PROCESSO PARA A MANUFATURA DE UM SUBSTRATO TENDO PROPRIEDADES DE BARREIRA, E, RECIPIENTE DE EMBALAGEM"". A presente invenção ensina uma composição que fornece barreira contra gás, sabor e aroma a substratos, em que a composição é formada pela misturada de um ácido etilenicamente insaturado e uma poliamina, em que a referida poliamina possui um reticulador reagido na mesma, e em que a poliamina possui quatro ou mais unidades A,B ou C, em que A é uma unidade -R^ 2^-N(R^ 1^-)~ 2~, e C é uma unidade (-R^ 2^)~ 3~N-, em que R^ 1^é independentemente selecionado a partir de hidrogênio, alquila, alquila substituída, arila, arila substituída, alquilarila, e arialquila, e R^ 2^ é independentemente selecionado a partir do grupo que consiste de : grupos lineares ou ramificados, grupos alquileno substituídos tendo de 1 a 18 átomos de carbono, e grupos arileno ou grupos arileno substituídos tendo de 6 a 18 átomos de carbono. A composição é revestida sobre um substrato, então opcionalmente tratada para iniciar uma reação de radical livre. A invenção pode ser aplicada como um revestimento a uma variedade de substratos usados em aplicações de embalagem.",EG TECHNOLOGY PARTNERS;;DOW CORNING;;UCB FILMS PLC,WYMAN JOHN E;;RANGWALLA IMTIAZ;;MERLIN PATRICK J;;MERLIN DAN JUBERMONT;;POWER GARY;;BRANCH KAREN,,https://lens.org/051-861-653-114-414,Patent Application,no,0,0,15,36,0,C08F290/14;;C08L51/003;;C09D4/00;;C09D4/06;;Y10T428/31663;;Y10T428/31551;;Y10T428/31663;;Y10T428/31551;;C09D4/00;;C09D4/06;;C08F290/14;;C08L51/003,B65D65/40;;C08F2/48;;C08F20/00;;C08F22/00;;C08F290/14;;C08L51/00;;C09D4/00;;C09D4/02;;C09D4/06,,0,0,,,,DISCONTINUED
201,DE,C3,DE 1922279 C3,104-230-393-008-657,1974-10-24,1974,DE 1922279 A,1969-04-30,US 72541868 A;;US 78963268 A,1968-04-30,DE 1922279 C3,,"ELECTRONIC ASSOCIATES INC., WEST LONG BRANCH, N.J. (V.ST.A.)","CLIFFORD, WILLIAM J., MIDDLETOWN;;DEMKO, JOHN G., NEW SHREWSBURG;;KINDLE, WILLIAM K., WEST LONG BRANCH",,https://lens.org/104-230-393-008-657,Granted Patent,no,0,0,6,8,0,G06F7/66;;G06K15/22,G06F7/66;;G06K15/22,,0,0,,,,EXPIRED
202,EP,A1,EP 4188223 A1,033-219-081-619-052,2023-06-07,2023,EP 21758900 A,2021-07-30,US 202063058776 P;;US 202063072571 P;;US 2021/0043892 W,2020-07-30,"ELECTRONIC DRIVING CIRCUIT FOR SLEEVE FOR FES, NMES, AND/OR EMG READOUT, AND SLEEVE INCLUDING SAME",,BATTELLE MEMORIAL INSTITUTE,BLUM TIMOTHY M;;BRANCH JOSHUA;;COLACHIS SAMUEL;;NOONAN AMANDA;;BARTHOLOMEW JOHN;;ANNETTA NICHOLAS;;DAVIS YELENA,,https://lens.org/033-219-081-619-052,Patent Application,yes,0,0,8,8,0,A61B5/4836;;A61B5/389;;A61B5/296;;A61B5/256;;A61B5/304;;A61B5/313;;A61N1/36003;;A61N1/36031;;A61N1/0452;;A61N1/0484;;A61B5/4836;;A61B5/296;;A61B5/389;;A61B5/304;;A61N1/36003;;A61B5/313;;A61N1/36031;;A61B5/256;;A61N1/0452;;A61N1/0484;;A61N1/0452;;A61N1/0456;;A61N1/0476;;A61N1/0484;;A61N1/36031;;A61B5/296;;A61B5/397;;A61B5/301;;A61B5/256;;A61B5/313;;A61B5/4836;;A61B5/6824;;A61B5/725;;A61B2562/0209;;A61B2562/046;;A61B2562/182;;A61N1/36003,A61B5/256;;A61N1/36,,0,0,,,,PENDING
203,AU,A1,AU 2003/262516 A1,189-746-711-044-727,2004-04-08,2004,AU 2003/262516 A,2003-09-17,EP 0310412 W;;GB 0221691 A;;GB 0221690 A,2002-09-18,N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS,This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals.,GLAXO GROUP LTD,JOHNS AMANDA;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STEMP GEOFFREY;;BRANCH CLIVE LESLIE;;COULTON STEVEN,,https://lens.org/189-746-711-044-727,Patent Application,no,0,0,10,12,0,C07D231/12;;C07D233/56;;C07D249/08;;C07D401/06;;C07D401/14;;C07D417/14;;A61P1/08;;A61P15/00;;A61P25/02;;A61P25/06;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/36;;A61P3/10;;A61P35/00;;A61P3/04;;A61P43/00;;A61P5/12;;A61P7/04;;A61P9/10;;C07D231/12;;C07D401/14;;C07D233/56;;C07D249/08;;C07D417/14;;C07D401/06,C07D401/06;;C07D401/14;;C07D417/14;;C07D521/00,,0,0,,,,DISCONTINUED
204,US,B2,US 9840252 B2,115-440-140-558-110,2017-12-12,2017,US 201615137447 A,2016-04-25,KE 238415 A,2015-12-03,System and method for vehicle assisted response to road conditions,"The invention pertains to methods and systems for assisting drivers, automated driver systems, and other vehicle operators with detection, avoidance, and mitigation of the hazards posed by aberrations in roadways. The invention provides complete or partial relief to vehicles traveling on roadways in a variety of conditions.",IBM,BILLS TIERRA;;BRANCH JOEL;;BRYANT REGINALD;;KAGUMA DAVID;;TATSUBORI MICHIAKI;;WALCOTT AISHA;;WAMBURU JOHN MBARI,INTERNATIONAL BUSINESS MACHINES CORPORATION (2016-02-04),https://lens.org/115-440-140-558-110,Granted Patent,yes,9,4,2,2,0,B60W30/025;;B60W50/14;;B60W2552/35;;B60W2556/50;;B60W30/025;;B60W50/14;;B60W2552/00;;B60W2552/35;;B60W2556/50;;B60W10/06;;B60W10/22;;B60W2050/146;;B60W2710/22,B60W10/06;;B60W10/22;;B60W30/02;;B60W50/14;;G05D1/02,,0,0,,,,ACTIVE
205,EP,B1,EP 1539747 B1,174-846-324-312-166,2006-11-02,2006,EP 03797310 A,2003-09-17,EP 0310412 W;;GB 0221691 A;;GB 0221690 A,2002-09-18,N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS,This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals.,GLAXO GROUP LTD,BRANCH CLIVE LESLIE;;COULTON STEVEN;;JOHNS AMANDA;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STEMP GEOFFREY,,https://lens.org/174-846-324-312-166,Granted Patent,yes,4,0,10,12,0,C07D231/12;;C07D233/56;;C07D249/08;;C07D401/06;;C07D401/14;;C07D417/14;;A61P1/08;;A61P15/00;;A61P25/02;;A61P25/06;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/36;;A61P3/10;;A61P35/00;;A61P3/04;;A61P43/00;;A61P5/12;;A61P7/04;;A61P9/10;;C07D231/12;;C07D401/14;;C07D233/56;;C07D249/08;;C07D417/14;;C07D401/06,C07D417/12;;A61K31/454;;A61K31/4545;;A61K31/501;;C07D213/73;;C07D239/42;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/12;;C07D417/14;;C07D521/00,,0,0,,,,EXPIRED
206,DE,T2,DE 60309481 T2,186-419-501-859-314,2007-06-21,2007,DE 60309481 T,2003-09-17,GB 0221691 A;;GB 0221690 A;;EP 0310412 W,2002-09-18,CYCLISCHE N-AROYLAMINE ALS OREXINREZEPTORANTAGONISTEN,This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals.,GLAXO GROUP LTD,BRANCH CLIVE LESLIE;;COULTON STEVEN;;JOHNS AMANDA;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STEMP GEOFFREY,,https://lens.org/186-419-501-859-314,Granted Patent,no,0,0,10,12,0,C07D231/12;;C07D233/56;;C07D249/08;;C07D401/06;;C07D401/14;;C07D417/14;;A61P1/08;;A61P15/00;;A61P25/02;;A61P25/06;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/36;;A61P3/10;;A61P35/00;;A61P3/04;;A61P43/00;;A61P5/12;;A61P7/04;;A61P9/10;;C07D231/12;;C07D401/14;;C07D233/56;;C07D249/08;;C07D417/14;;C07D401/06,C07D417/12;;A61K31/454;;A61K31/4545;;A61K31/501;;C07D213/73;;C07D239/42;;C07D401/06;;C07D401/12;;C07D401/14;;C07D403/12;;C07D417/14;;C07D521/00,,0,0,,,,EXPIRED
207,EP,A1,EP 1539747 A1,077-665-411-606-032,2005-06-15,2005,EP 03797310 A,2003-09-17,EP 0310412 W;;GB 0221691 A;;GB 0221690 A,2002-09-18,N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS,This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals.,GLAXO GROUP LTD,BRANCH CLIVE LESLIE;;COULTON STEVEN;;JOHNS AMANDA;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STEMP GEOFFREY,,https://lens.org/077-665-411-606-032,Patent Application,yes,0,0,10,12,0,C07D231/12;;C07D233/56;;C07D249/08;;C07D401/06;;C07D401/14;;C07D417/14;;A61P1/08;;A61P15/00;;A61P25/02;;A61P25/06;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/36;;A61P3/10;;A61P35/00;;A61P3/04;;A61P43/00;;A61P5/12;;A61P7/04;;A61P9/10;;C07D231/12;;C07D401/14;;C07D233/56;;C07D249/08;;C07D417/14;;C07D401/06,C07D401/06;;C07D401/14;;C07D417/14;;C07D521/00,,0,0,,,,EXPIRED
208,AT,T1,AT E344261 T1,193-913-742-336-271,2006-11-15,2006,AT 03797310 T,2003-09-17,GB 0221691 A;;GB 0221690 A,2002-09-18,CYCLISCHE N-AROYLAMINE ALS OREXINREZEPTORANTAGONISTEN,This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals.,GLAXO GROUP LTD,BRANCH CLIVE LESLIE;;COULTON STEVEN;;JOHNS AMANDA;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STEMP GEOFFREY,,https://lens.org/193-913-742-336-271,Granted Patent,no,0,0,10,12,0,C07D231/12;;C07D233/56;;C07D249/08;;C07D401/06;;C07D401/14;;C07D417/14;;A61P1/08;;A61P15/00;;A61P25/02;;A61P25/06;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/36;;A61P3/10;;A61P35/00;;A61P3/04;;A61P43/00;;A61P5/12;;A61P7/04;;A61P9/10;;C07D231/12;;C07D401/14;;C07D233/56;;C07D249/08;;C07D417/14;;C07D401/06,C07D401/06;;C07D401/14;;C07D417/14;;C07D521/00,,0,0,,,,EXPIRED
209,WO,A1,WO 2022/026821 A1,022-179-892-250-479,2022-02-03,2022,US 2021/0043892 W,2021-07-30,US 202063058776 P;;US 202063072571 P,2020-07-30,"ELECTRONIC DRIVING CIRCUIT FOR SLEEVE FOR FES, NMES, AND/OR EMG READOUT, AND SLEEVE INCLUDING SAME","A device for functional electrical stimulation (FES), neuromuscular electrical stimulation (NMES), and/or in receiving electromyography (EMG) signals includes a sleeve and electrodes. The sleeve is sized and shaped to be worn on a human arm, and comprises a stretchable fabric The electrodes are secured with the sleeve and positioned to contact skin of the human arm when the sleeve is worn on the human arm. An electronic circuit is configured to operate the electrodes. The electronic circuit includes relays connecting the electrodes with a stimulator for performing FES or NMES, and EMG readout circuitry connecting the electrodes with an EMG amplifier. The relays are closed during FES or NMES to connect the stimulator with the electrodes. The relays are open during EMG readout to isolate the stimulator from the EMG amplifier.",BATTELLE MEMORIAL INSTITUTE,BLUM TIMOTHY M;;BRANCH JOSHUA;;COLACHIS SAMUEL;;NOONAN AMANDA;;BARTHOLOMEW JOHN;;ANNETTA NICHOLAS;;DAVIS YELENA,,https://lens.org/022-179-892-250-479,Patent Application,yes,7,0,8,8,0,A61B5/4836;;A61B5/389;;A61B5/296;;A61B5/256;;A61B5/304;;A61B5/313;;A61N1/36003;;A61N1/36031;;A61N1/0452;;A61N1/0484;;A61B5/4836;;A61B5/296;;A61B5/389;;A61B5/304;;A61N1/36003;;A61B5/313;;A61N1/36031;;A61B5/256;;A61N1/0452;;A61N1/0484;;A61N1/0452;;A61N1/0456;;A61N1/0476;;A61N1/0484;;A61N1/36031;;A61B5/296;;A61B5/397;;A61B5/301;;A61B5/256;;A61B5/313;;A61B5/4836;;A61B5/6824;;A61B5/725;;A61B2562/0209;;A61B2562/046;;A61B2562/182;;A61N1/36003,A61B5/256;;A61N1/36,,0,0,,,,PENDING
210,WO,A1,WO 2004/026866 A1,040-939-206-369-712,2004-04-01,2004,EP 0310412 W,2003-09-17,GB 0221691 A;;GB 0221690 A,2002-09-18,N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS,This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals.,GLAXO GROUP LTD;;BRANCH CLIVE LESLIE;;COULTON STEVEN;;JOHNS AMANDA;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STEMP GEOFFREY,BRANCH CLIVE LESLIE;;COULTON STEVEN;;JOHNS AMANDA;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STEMP GEOFFREY,,https://lens.org/040-939-206-369-712,Patent Application,yes,4,75,10,12,0,C07D231/12;;C07D233/56;;C07D249/08;;C07D401/06;;C07D401/14;;C07D417/14;;A61P1/08;;A61P15/00;;A61P25/02;;A61P25/06;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/36;;A61P3/10;;A61P35/00;;A61P3/04;;A61P43/00;;A61P5/12;;A61P7/04;;A61P9/10;;C07D231/12;;C07D401/14;;C07D233/56;;C07D249/08;;C07D417/14;;C07D401/06,C07D401/06;;C07D401/14;;C07D417/14;;C07D521/00,,0,0,,,,PATENTED
211,IL,A,IL 300162 A,010-953-452-499-398,2023-03-01,2023,IL 30016223 A,2023-01-24,US 202063058776 P;;US 202063072571 P;;US 2021/0043892 W,2020-07-30,"Electronic driving circuit for sleeve for fes, nmes, and/or emg readout, and sleeve including same",,BATTELLE MEMORIAL INSTITUTE;;TIMOTHY M BLUM;;JOSHUA BRANCH;;SAMUEL COLACHIS;;AMANDA NOONAN;;JOHN BARTHOLOMEW;;NICHOLAS ANNETTA;;YELENA DAVIS,TIMOTHY M BLUM;;JOSHUA BRANCH;;SAMUEL COLACHIS;;AMANDA NOONAN;;JOHN BARTHOLOMEW;;NICHOLAS ANNETTA;;YELENA DAVIS,,https://lens.org/010-953-452-499-398,Patent Application,no,0,0,8,8,0,A61B5/4836;;A61B5/389;;A61B5/296;;A61B5/256;;A61B5/304;;A61B5/313;;A61N1/36003;;A61N1/36031;;A61N1/0452;;A61N1/0484;;A61B5/4836;;A61B5/296;;A61B5/389;;A61B5/304;;A61N1/36003;;A61B5/313;;A61N1/36031;;A61B5/256;;A61N1/0452;;A61N1/0484;;A61N1/0452;;A61N1/0456;;A61N1/0476;;A61N1/0484;;A61N1/36031;;A61B5/296;;A61B5/397;;A61B5/301;;A61B5/256;;A61B5/313;;A61B5/4836;;A61B5/6824;;A61B5/725;;A61B2562/0209;;A61B2562/046;;A61B2562/182;;A61N1/36003,,,0,0,,,,PENDING
212,AU,A1,AU 2021/318157 A1,022-296-641-357-549,2023-02-23,2023,AU 2021/318157 A,2021-07-30,US 202063058776 P;;US 202063072571 P;;US 2021/0043892 W,2020-07-30,"Electronic driving circuit for sleeve for fes, nmes, and/or emg readout, and sleeve including same","A device for functional electrical stimulation (FES), neuromuscular electrical stimulation (NMES), and/or in receiving electromyography (EMG) signals includes a sleeve and electrodes. The sleeve is sized and shaped to be worn on a human arm, and comprises a stretchable fabric The electrodes are secured with the sleeve and positioned to contact skin of the human arm when the sleeve is worn on the human arm. An electronic circuit is configured to operate the electrodes. The electronic circuit includes relays connecting the electrodes with a stimulator for performing FES or NMES, and EMG readout circuitry connecting the electrodes with an EMG amplifier. The relays are closed during FES or NMES to connect the stimulator with the electrodes. The relays are open during EMG readout to isolate the stimulator from the EMG amplifier.",BATTELLE MEMORIAL INSTITUTE,BLUM TIMOTHY M;;BRANCH JOSHUA;;COLACHIS SAMUEL;;NOONAN AMANDA;;BARTHOLOMEW JOHN;;ANNETTA NICHOLAS;;DAVIS YELENA,,https://lens.org/022-296-641-357-549,Patent Application,no,0,0,8,8,0,A61B5/4836;;A61B5/389;;A61B5/296;;A61B5/256;;A61B5/304;;A61B5/313;;A61N1/36003;;A61N1/36031;;A61N1/0452;;A61N1/0484;;A61B5/4836;;A61B5/296;;A61B5/389;;A61B5/304;;A61N1/36003;;A61B5/313;;A61N1/36031;;A61B5/256;;A61N1/0452;;A61N1/0484;;A61N1/0452;;A61N1/0456;;A61N1/0476;;A61N1/0484;;A61N1/36031;;A61B5/296;;A61B5/397;;A61B5/301;;A61B5/256;;A61B5/313;;A61B5/4836;;A61B5/6824;;A61B5/725;;A61B2562/0209;;A61B2562/046;;A61B2562/182;;A61N1/36003,A61B5/256;;A61N1/36,,0,0,,,,PENDING
213,DE,B2,DE 1922279 B2,040-263-744-935-403,1974-03-28,1974,DE 1922279 A,1969-04-30,US 72541868 A;;US 78963268 A,1968-04-30,DE 1922279 B2,,"ELECTRONIC ASSOCIATES INC., WEST LONG BRANCH, N.J. (V.ST.A.)","CLIFFORD, WILLIAM J., MIDDLETOWN;;DEMKO, JOHN G., NEW SHREWSBURG;;KINDLE, WILLIAM K., WEST LONG BRANCH",,https://lens.org/040-263-744-935-403,Patent Application,no,0,0,6,8,0,G06F7/66;;G06K15/22,G06F7/66;;G06K15/22,,0,0,,,,EXPIRED
214,DE,T1,DE 154918 T1,169-265-223-198-257,1986-07-24,1986,DE 85102423 T,1985-03-04,US 58966284 A,1984-03-14,DERIVATE DES TERTIAEREN PENTAMETHYLINDANOLS UND IHRE ORGANOLEPTISCHEN ANWENDUNGEN.,,"INTERNATIONAL FLAVORS & FRAGRANCES INC., NEW YORK, N.Y., US","HALL, JOHN B., RUMSON NEW JERSEY, US;;YOSHIDA, TAKAO, WEST LONG BRANCH NEW JERSEY, US",,https://lens.org/169-265-223-198-257,Patent Application,no,0,0,8,12,0,A24B15/345;;A24B15/345;;C11B9/0049;;C11B9/0049;;C07C35/23;;C07C35/23;;C07C35/32;;C07C35/32;;C11D3/50;;C11D3/50,A23L27/20;;A24B3/12;;A24B15/34;;A61K8/34;;A61Q13/00;;B01J31/00;;C07C27/00;;C07C29/56;;C07C35/23;;C07C35/32;;C07C67/00;;C11B9/00;;C11D3/50;;C11D9/44,,0,0,,,,DISCONTINUED
215,US,B1,US 6484045 B1,029-516-331-520-36X,2002-11-19,2002,US 50220400 A,2000-02-10,US 50220400 A,2000-02-10,Analyte sensor and method of making the same,"
    A method of making a sensor includes the steps of providing a preformed self-supporting flexible substrate; sputter-depositing a metal layer on the substrate; etching the sputter-deposited metal layers to form a sensor electrode having a proximal segment and a distal segment; plating a metal layer on the sensor electrode; and separating the sensor electrode and at least a portion of the substrate underlying the sensor electrode from the remainder of the substrate. Sensors prepared according to the inventive methods, and sensor sets including the sensors, are also provided. 
",MEDTRONIC MINIMED INC,HOLKER JAMES D;;CALLE GUILLERMO A;;BRANCH KEVIN D;;MASTROTOTARO JOHN J;;VAN ANTWERP WILLIAM P,MEDTRONIC MINIMED INC (2000-02-03),https://lens.org/029-516-331-520-36X,Granted Patent,yes,21,487,1,18,0,A61B5/14865;;A61B5/14865,A61B5/00,600/345;;600/347;;204/403.01,11,3,006-551-352-957-447;;124-660-118-050-67X;;068-386-284-377-434,10.1016/0956-5663(92)85056-g;;10.1016/0250-6874(89)87015-5;;10.1016/0956-5663(91)85005-h;;2049169,"Spalvins, Talivaldis, ""Ion Plated Gold Films: Properties, Tribological Behavior and Performance"" NASA Technical Memorandum 88977, p. 1-13.*;;Urban, G. et al., ""Miniaturized multi-enzyme biosensors integrated with pH sensor on flexible polymer carriers for in vivo applications"", Biosensors, & Bioelectronics 7 (Elsevier Science Publishers Ltd.-1992), pp. 733-739.;;""3M Specifications and Design Guidelines, Microflex circuits for IC Interconnect Solutions,"" pp. 1-32 (the entire document), 1997 (3M Electronic Products Division, Austin TX).;;""3M Offers More Solutions for the Semiconductor Industry"" the entire document, 1997 ( 3M Electronic Products Division, Austin TX).;;""Microflex Solutions from 3M"", the entire document, 1996 (3M Electronic Products Divisions, Austin TX).;;""Micron Wide Conductors and Spaces on . . . PZT, Alumina, Glass and Flexible Materials"" 1 page, no date (Metrigraphics, Wilmington, MA).;;""Flexible circuits at Extreme Density"", 8 unnumbered pages of various dates (Metrigraphics, Wilmington, MA).;;""Metrigraphics Ion Beam Etching Capability"", 1 page, no date (Metrigraphics, Wilmington, MA).;;Koudelka, M. et al., ""Planar Amperometric Enzyme-Based Glucose Microelectrode"", Sensor and Actuators, 18 (Elsevier Sequoia, The Netherlands-1989), pp. 157-165.;;Koudelka, M. et al., ""In-vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors"", Biosensors & Bioelectronics 6 (Elsevier Science Publishers Ltd., England-1991), pp. 31-36.;;Mastrototaro, John M. et al., ""An Electroenzymatic glucose sensor fabricated on a flexible substrate"", Sensors and Actuators B5 (Elsevier Sequoia-1991), pp. 139-144.",EXPIRED
216,ES,T3,ES 2266549 T3,140-632-471-696-836,2007-03-01,2007,ES 02754750 T,2002-06-25,GB 0115863 A;;GB 0130342 A,2001-06-28,DERIVADOS DE N-AROIL-AMINA CICLICOS COMO ANTAGONISTAS DEL RECEPTOR DE OREXINA.,"Un compuesto de la **fórmula** en donde X representa (CH2); Y representa CH2, CO, CH(OH) o CH2CH(OH); Het es un grupo heteroarilo bicíclico opcionalmente sustituido seleccionado del grupo que consiste en quinoxalinilo, quinazolinilo, piridopirazinilo, benzoxazolilo, benzotienilo, benzofuranilo, bencimidazolilo, naftiridinilo, benzotiazolilo, indolilo, triazolopiridinilo, furopiridinilo, piridopirimidinilo, isoquinolinilo, quinolinilo, oxazolilpiridinilo, tetrahidrobencimidazolilo, tetrahidrobenzofuranilo o tetrahidrotriazolopiridinilo; Ar2 representa un fenilo opcionalmente sustituido o un grupo heterociclilo de 5 ó 6 miembros seleccionado del grupo que consiste en furanilo, tienilo, pirrolilo, oxazolilo, tiazolilo, imidazolilo, oxadiazolilo, tiadiazolilo, triazolilo, triazinilo, piridazinilo, piridinilo, pirimidinilo, isotiazolilo, isoxazolilo, pirazinilo o pirazolilo, en donde el fenilo o grupo heterociclilo está sustituido con R1; o Ar2 representa un grupo aromático bicíclico o un grupo heteroaromático bicíclico opcionalmente sustituido, que contiene hasta 3 heteroátomos seleccionados de N, O y S; o una de sus sales farmacéuticamente aceptables.",SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO,,https://lens.org/140-632-471-696-836,Granted Patent,no,0,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,C07D417/14;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/445;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D407/06;;C07D407/14;;C07D409/14;;C07D411/14;;C07D413/14;;C07D417/04;;C07D471/04;;C07D491/04,,0,0,,,,EXPIRED
217,WO,A2,WO 2023/118901 A2,066-418-125-875-496,2023-06-29,2023,GB 2022053392 W,2022-12-23,GB 202119023 A,2021-12-24,IMMOBILISED ENZYME,"This invention relates to an immobilised protein, typically an immobilised enzyme. The immobilised enzyme retains catalytic activity and finds particular use in carrying out an enzyme-catalysed chemical reaction, for example in an industrial-scale chemical reactor. In particular, the invention relates to an enzyme covalently linked to a bead-immobilised polypeptide, wherein the covalent linkage is an isopeptide bond between an amino acid side chain on the enzyme and an amino acid side chain on the bead-immobilised polypeptide. The invention also provides a chemical reactor comprising the enzyme covalently linked to a bead-immobilised polypeptide, and a method of carrying out an enzyme-catalysed reaction using the immobilised enzyme.",FABRICNANO LTD,BRANCH JESS M;;TORRES LETICIA L;;OPPENHEIMER ROBERT;;UGBEYAN REGINALD;;JAWED KAMRAN;;MEISSNER MURRAY;;DAVIDSON JOHN,,https://lens.org/066-418-125-875-496,Patent Application,yes,0,0,3,3,32,C12N9/00;;C12N11/00;;C07K14/315;;C07K2319/70;;C07K2319/735;;C12N9/96,C12N9/00;;C07K14/315;;C12N9/96;;C12N11/00,,0,0,,,,PENDING
218,WO,A3,WO 2023/118901 A3,095-142-879-502-490,2023-07-27,2023,GB 2022053392 W,2022-12-23,GB 202119023 A,2021-12-24,IMMOBILISED ENZYME,"This invention relates to an immobilised protein, typically an immobilised enzyme. The immobilised enzyme retains catalytic activity and finds particular use in carrying out an enzyme-catalysed chemical reaction, for example in an industrial-scale chemical reactor. In particular, the invention relates to an enzyme covalently linked to a bead-immobilised polypeptide, wherein the covalent linkage is an isopeptide bond between an amino acid side chain on the enzyme and an amino acid side chain on the bead-immobilised polypeptide. The invention also provides a chemical reactor comprising the enzyme covalently linked to a bead-immobilised polypeptide, and a method of carrying out an enzyme-catalysed reaction using the immobilised enzyme.",FABRICNANO LTD,BRANCH JESS M;;TORRES LETICIA L;;OPPENHEIMER ROBERT;;UGBEYAN REGINALD;;JAWED KAMRAN;;MEISSNER MURRAY;;DAVIDSON JOHN,,https://lens.org/095-142-879-502-490,Search Report,yes,1,0,3,3,0,C12N9/00;;C12N11/00;;C07K14/315;;C07K2319/70;;C07K2319/735;;C12N9/96,C12N9/00;;C07K14/315;;C12N9/96;;C12N11/00,,3,3,070-541-868-496-372;;047-787-005-021-730;;045-573-636-056-386,pmc7866670;;10.1186/s12934-021-01530-5;;33549102;;10.1021/acsnano.9b03631;;31356751;;10.1002/cjoc.202000083,"CAI LIXI ET AL: ""A novel all-in-one strategy for purification and immobilization of [beta]-1,3-xylanase directly from cell lysate as active and recyclable nanobiocatalyst"", vol. 20, no. 1, 6 February 2021 (2021-02-06), XP055948669, Retrieved from the Internet <URL:https://microbialcellfactories.biomedcentral.com/track/pdf/10.1186/s12934-021-01530-5.pdf> DOI: 10.1186/s12934-021-01530-5;;QU JIALE ET AL: ""Synthetic Multienzyme Complexes, Catalytic Nanomachineries for Cascade Biosynthesis In Vivo"", ACS NANO, vol. 13, no. 9, 24 September 2019 (2019-09-24), US, pages 9895 - 9906, XP055949389, ISSN: 1936-0851, DOI: 10.1021/acsnano.9b03631;;ZHANG FAN ET AL: ""Encrypting Chemical Reactivity in Protein Sequences toward Information-Coded Reactions"", vol. 38, no. 8, 25 May 2020 (2020-05-25), CN, pages 864 - 878, XP055938884, ISSN: 1001-604X, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/cjoc.202000083> DOI: 10.1002/cjoc.202000083",PENDING
219,US,A1,US 2017/0158191 A1,124-224-110-174-757,2017-06-08,2017,US 201615137447 A,2016-04-25,KE 238415 A,2015-12-03,System and Method for Vehicle Assisted Response to Road Conditions,"The invention pertains to methods and systems for assisting drivers, automated driver systems, and other vehicle operators with detection, avoidance, and mitigation of the hazards posed by aberrations in roadways. The invention provides complete or partial relief to vehicles traveling on roadways in a variety of conditions.",IBM,BILLS TIERRA;;BRANCH JOEL W;;BRYANT REGINALD;;KAGUMA DAVID;;TATSUBORI MICHIAKI;;WALCOTT AISHA;;WAMBURU JOHN MBARI,INTERNATIONAL BUSINESS MACHINES CORPORATION (2016-02-04),https://lens.org/124-224-110-174-757,Patent Application,yes,6,26,2,2,0,B60W30/025;;B60W50/14;;B60W2552/35;;B60W2556/50;;B60W30/025;;B60W50/14;;B60W2552/00;;B60W2552/35;;B60W2556/50;;B60W10/06;;B60W10/22;;B60W2050/146;;B60W2710/22,B60W30/02;;B60W10/06;;B60W10/22;;B60W50/14;;G05D1/02,,0,0,,,,ACTIVE
220,US,A1,US 2012/0218102 A1,009-776-357-891-99X,2012-08-30,2012,US 201113036612 A,2011-02-28,US 201113036612 A,2011-02-28,MANAGING EMERGENCY RESPONSE SERVICES USING MOBILE COMMUNICATION DEVICES,One or more embodiments manage emergency response services. An emergency event is determined to have occurred. A set of civilian responders currently available to respond to the emergency event is selected from a plurality of civilian responders in response to determining that the emergency event has occurred. Each civilian responder in the set of civilian responders is associated with at least one wireless communication device. The set of civilian responders is notified that the emergency event has occurred. A set of emergency event information associated with the emergency event is transmitted to at least one wireless communication device associated with each civilian responder in the set of civilian responders.,BIVENS JOHN ALAN;;BRANCH JOEL W;;DAS RAJARSHI;;FARRELL ROBERT GEORGE;;HOBSON STACY F;;SOW DABY M;;IBM,BIVENS JOHN ALAN;;BRANCH JOEL W;;DAS RAJARSHI;;FARRELL ROBERT GEORGE;;HOBSON STACY F;;SOW DABY M,GENERAC HOLDINGS INC (2022-01-01);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2011-03-01);;GENERAC POWER SYSTEMS INC (2022-01-01);;ECOBEE TECHNOLOGIES ULC (2021-12-31);;ECOBEE TECHNOLOGIES INC (2021-12-22),https://lens.org/009-776-357-891-99X,Patent Application,yes,3,127,2,2,0,G08B25/003;;G08B25/003;;G08B25/005;;G08B25/005;;G08B25/009;;G08B25/009,G08B1/08,340/539.13;;340/539.11,0,0,,,,ACTIVE
221,WO,A8,WO 2004/036183 A8,141-472-430-992-360,2004-07-01,2004,US 0333065 W,2003-10-17,US 27376702 A,2002-10-18,ANALYTE SENSORS AND METHODS FOR MAKING THEM,"Embodiments of the invention provide analyte sensors having stabilized coating compositions and methods for making such sensors. Illustrative embodiments include electrochemical glucose sensors having stabilized glucose oxidase coatings that are generated for example, via spin coating processes.",MEDTRONIC MINIMED INC,HOLKER JAMES D;;MASTROTOTARO JOHN J;;NORONHA GLENN;;SHAH RAJIV;;ZHANG YANAN;;HOSS UDO;;BRANCH KEVIN D,,https://lens.org/141-472-430-992-360,Patent Application,no,0,0,10,10,0,A61B5/1486;;A61B5/1486;;C12Q1/006;;C12Q1/006;;G01N27/307;;G01N27/307,A61B5/00;;C12Q1/00;;G01N27/30,,0,0,,,,PENDING
222,EP,A4,EP 1554567 A4,172-547-655-596-623,2009-04-15,2009,EP 03777673 A,2003-10-17,US 0333065 W;;US 27376702 A,2002-10-18,ANALYTE SENSORS AND METHODS FOR MAKING THEM,,MEDTRONIC MINIMED INC,HOLKER JAMES D;;MASTROTOTARO JOHN J;;NORONHA GLENN;;SHAH RAJIV;;ZHANG YANAN;;HOSS UDO;;BRANCH KEVIN D,,https://lens.org/172-547-655-596-623,Search Report,no,2,0,10,10,0,A61B5/1486;;C12Q1/006;;G01N27/307;;A61B5/1486;;C12Q1/006;;G01N27/307,A61B5/00;;G06F19/00;;B05D1/40;;C12Q1/00;;G01N27/30;;G01N27/403,,0,0,,,,DISCONTINUED
223,WO,A3,WO 2004/036183 A3,063-356-462-224-168,2005-03-24,2005,US 0333065 W,2003-10-17,US 27376702 A,2002-10-18,ANALYTE SENSORS AND METHODS FOR MAKING THEM,"Embodiments of the invention provide analyte sensors (100) having stabilized coating compositions and methods for making such sensors. Illustrative embodiments include electrochemical glucose sensors (100) having stabilized glucose oxidase coatings (110) that are generated for example, via spin coating processes.",MEDTRONIC MINIMED INC,HOLKER JAMES D;;MASTROTOTARO JOHN J;;NORONHA GLENN;;SHAH RAJIV;;ZHANG YANAN;;HOSS UDO;;BRANCH KEVIN D,,https://lens.org/063-356-462-224-168,Search Report,yes,3,0,10,10,0,A61B5/1486;;A61B5/1486;;C12Q1/006;;C12Q1/006;;G01N27/307;;G01N27/307,A61B5/00;;C12Q1/00;;G01N27/30,,2,1,008-325-799-821-658,10.1016/s0376-7388(00)85104-2,"KIMURA ET AL.: ""Evaluation of an albumin-based, spin-coated, enzyme-immobilized membrane for an isfet glucose sensor by computer simulation"", J. MEMBRANE SCI., vol. 43, 1989, pages 291 - 305, XP008042392;;See also references of EP 1554567A4",PENDING
224,EP,A1,EP 4188525 A1,129-250-289-505-229,2023-06-07,2023,EP 21751922 A,2021-07-14,US 202063058776 P;;US 202063072571 P;;US 2021/0041506 W,2020-07-30,STRETCHABLE FABRIC SLEEVE FOR FUNCTIONAL ELECTRICAL STIMULATION AND/OR ELECTROMYOGRAPHY,,BATTELLE MEMORIAL INSTITUTE,BLUM TIMOTHY M;;BRANCH JOSHUA;;COLACHIS SAMUEL;;NOONAN AMANDA I;;BARTHOLOMEW JOHN E;;ANNETTA NICHOLAS;;DAVIS YELENA,,https://lens.org/129-250-289-505-229,Patent Application,yes,0,0,8,8,0,A61B5/4836;;A61B5/389;;A61B5/296;;A61B5/256;;A61B5/304;;A61B5/313;;A61N1/36003;;A61N1/36031;;A61N1/0452;;A61N1/0484;;A61B5/4836;;A61B5/296;;A61B5/389;;A61B5/304;;A61N1/36003;;A61B5/313;;A61N1/36031;;A61B5/256;;A61N1/0452;;A61N1/0484;;A61N1/0452;;A61N1/0456;;A61N1/0476;;A61N1/0484;;A61N1/36031;;A61B5/296;;A61B5/397;;A61B5/301;;A61B5/256;;A61B5/313;;A61B5/4836;;A61B5/6824;;A61B5/725;;A61B2562/0209;;A61B2562/046;;A61B2562/182;;A61N1/36003,A61N1/36;;A61B5/00;;A61B5/256;;A61B5/296;;A61B5/304;;A61B5/389,,0,0,,,,PENDING
225,AU,A1,AU 2003/286473 A1,155-768-586-670-14X,2004-05-04,2004,AU 2003/286473 A,2003-10-17,US 27376702 A;;US 0333065 W,2002-10-18,ANALYTE SENSORS AND METHODS FOR MAKING THEM,,MEDTRONIC MINIMED INC,HOLKER JAMES D;;MASTROTOTARO JOHN J;;NORONHA GLENN;;SHAH RAJIV;;ZHANG YANAN;;HOSS UDO;;BRANCH KEVIN D,,https://lens.org/155-768-586-670-14X,Patent Application,no,0,0,10,10,0,A61B5/1486;;A61B5/1486;;C12Q1/006;;C12Q1/006;;G01N27/307;;G01N27/307,A61B5/00;;C12Q1/00;;G01N27/30,,0,0,,,,DISCONTINUED
226,EP,A1,EP 2121624 A1,168-603-727-604-485,2009-11-25,2009,EP 08708401 A,2008-01-30,EP 2008051084 W;;GB 0701986 A;;GB 0701977 A,2007-02-01,GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS,,GLAXO GROUP LTD;;UNIV NOTTINGHAM,AHMAD NADIA MAMOONA;;JAXA-CHAMIEC ALBERT ANDRZEJ;;LAI JUSTINE YEUN QUAI;;NASH DAVID JOHN;;BRANCH CLIVE LESLIE,,https://lens.org/168-603-727-604-485,Patent Application,yes,0,0,4,6,0,C07D235/02;;A61P15/10;;A61P21/02;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P29/00;;A61P43/00;;C07D235/02,C07D235/02;;A61K31/4166;;A61P25/00;;A61P25/18;;A61P25/28,,0,0,,,,DISCONTINUED
227,CA,A1,CA 2502277 A1,017-459-617-660-137,2004-04-29,2004,CA 2502277 A,2003-10-17,US 27376702 A;;US 0333065 W,2002-10-18,ANALYTE SENSORS AND METHODS FOR MAKING THEM,"Embodiments of the invention provide analyte sensors (100) having stabilized coating compositions and methods for making such sensors. Illustrative embodiments include electrochemical glucose sensors (100) having stabilized glucose oxidase coatings (110) that are generated for example, via spin coating processes.",MEDTRONIC MINIMED INC,HOSS UDO;;BRANCH KEVIN D;;SHAH RAJIV;;NORONHA GLENN;;ZHANG YANAN;;HOLKER JAMES D;;MASTROTOTARO JOHN J,,https://lens.org/017-459-617-660-137,Patent Application,no,0,0,10,10,0,A61B5/1486;;A61B5/1486;;C12Q1/006;;C12Q1/006;;G01N27/307;;G01N27/307,A61B5/00;;C12Q1/00;;G01N27/30,,0,0,,,,DISCONTINUED
228,US,A1,US 2008/0019269 A1,064-921-262-795-842,2008-01-24,2008,US 48893906 A,2006-07-18,US 48893906 A,2006-07-18,Proactive mechanism for supporting the global management of vehicle traffic flow,"The invention addresses the disadvantage of automated vehicle traffic management systems by providing a solution for predicting and avoiding traffic congestion before the congestion is experienced. The invention includes a decentralized mechanism for predicting congestion. An exemplary embodiment of the invention uses a system of sensors to determine current traffic flow; the sensors communicate their state to a network of servers and then an algorithm is applied to the collected data to predict traffic congestion; upon detection of congestion, signals are communicated to the system controllers to prevent the traffic congestion.",BISDIKIAN CHATSCHIK;;BRANCH JOEL W;;COHEN NORMAN H;;DAVIS JOHN S;;EBLING MARIA R;;SOW DABY M,BISDIKIAN CHATSCHIK;;BRANCH JOEL W;;COHEN NORMAN H;;DAVIS JOHN S;;EBLING MARIA R;;SOW DABY M,INTERNATIONAL BUSINESS MACHINES CORPORATION (2006-06-19),https://lens.org/064-921-262-795-842,Patent Application,yes,12,16,3,3,0,G08G1/0112;;G08G1/0112;;G08G1/0116;;G08G1/0116;;G08G1/0133;;G08G1/0133;;G08G1/0145;;G08G1/0145;;G08G1/096811;;G08G1/096811;;G08G1/096844;;G08G1/096844;;H04L67/12;;H04L67/12,H04L12/26,370/230;;370/238;;370/252,0,0,,,,INACTIVE
229,US,A1,US 2014/0037917 A1,025-042-955-270-701,2014-02-06,2014,US 201313954199 A,2013-07-30,US 201313954199 A;;US 201261677737 P,2012-07-31,PRINTED LAMINATE WITH DIGITAL PRINTING AND METHOD FOR MANUFACTURE,"A printed laminate includes a substrate and a priming layer positioned over the substrate, wherein digital printing is applied to the priming layer. A top coat layer is applied over the digital printing and the priming layer, the top coat layer being composed of a clear hot melt polyurethane first top coat layer and a clear UV cured acrylic second top coat layer.",WILSONART LLC,BRANCH JOE E;;KENDALL ERIC W;;KREBS ROBERT R;;MCSPEDON JOHN P;;STEPAN JANET;;WILLIAMS JOEL L,,https://lens.org/025-042-955-270-701,Patent Application,yes,6,7,2,2,0,B41M7/0045;;B41M7/0045;;B05D7/57;;B32B7/12;;B32B7/12;;B32B21/02;;B32B21/02;;B32B21/08;;B32B21/08;;B32B27/08;;B32B27/08;;B32B27/42;;B32B27/42;;B32B38/145;;B32B38/145;;B32B2037/243;;B32B2037/243;;B32B2255/10;;B32B2255/10;;B32B2255/26;;B32B2255/26;;B32B2307/558;;B32B2307/558;;B32B2307/718;;B32B2307/718;;B32B2307/75;;B32B2307/75;;B32B2317/16;;B32B2317/16;;B41M5/0017;;B41M5/0017;;B41M5/0047;;B41M5/0047;;B41M7/0027;;B41M7/0027;;Y10T428/24884;;Y10T428/24884,B41M7/00;;B05D7/00,428/205;;427/258,0,0,,,,DISCONTINUED
230,EP,A2,EP 1554567 A2,017-213-492-243-662,2005-07-20,2005,EP 03777673 A,2003-10-17,US 0333065 W;;US 27376702 A,2002-10-18,ANALYTE SENSORS AND METHODS FOR MAKING THEM,,MEDTRONIC MINIMED INC,HOLKER JAMES D;;MASTROTOTARO JOHN J;;NORONHA GLENN;;SHAH RAJIV;;ZHANG YANAN;;HOSS UDO;;BRANCH KEVIN D,,https://lens.org/017-213-492-243-662,Patent Application,yes,0,0,10,10,0,A61B5/1486;;A61B5/1486;;C12Q1/006;;C12Q1/006;;G01N27/307;;G01N27/307,G06F19/00;;A61B5/00;;B05D1/40;;C12Q1/00;;G01N27/30;;G01N27/403,,0,0,,,,DISCONTINUED
231,US,A1,US 2008/0167795 A1,035-803-342-273-367,2008-07-10,2008,US 5453008 A,2008-03-25,US 5453008 A;;US 48893906 A,2006-07-18,Proactive Mechanism for Supporting the Global Managment of Vehicle Traffic Flow,"The invention addresses the disadvantage of automated vehicle traffic management systems by providing a solution for predicting and avoiding traffic congestion before the congestion is experienced. The invention includes a decentralized mechanism for predicting congestion. An exemplary embodiment of the invention uses a system of sensors to determine current traffic flow; the sensors communicate their state to a network of servers and then an algorithm is applied to the collected data to predict traffic congestion; upon detection of congestion, signals are communicated to the system controllers to prevent the traffic congestion.",IBM,BISDIKIAN CHATSCHIK;;BRANCH JOEL W;;COHEN NORMAN H;;DAVIS JOHN S;;EBLING MARIA R;;SOW DABY M,,https://lens.org/035-803-342-273-367,Patent Application,yes,18,9,3,3,0,G08G1/0112;;G08G1/0112;;G08G1/0116;;G08G1/0116;;G08G1/0133;;G08G1/0133;;G08G1/0145;;G08G1/0145;;G08G1/096811;;G08G1/096811;;G08G1/096844;;G08G1/096844;;H04L67/12;;H04L67/12,G08G1/127,701/118,0,0,,,,DISCONTINUED
232,US,A1,US 2012/0004273 A1,154-121-392-552-15X,2012-01-05,2012,US 52458008 A,2008-01-30,GB 0701986 A;;GB 0701977 A;;EP 2008051084 W,2007-02-01,GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS,"Disclosed herein are compounds of formula (I) and: wherein: X is Ar—C(O)CH(R 20 )— or Ar 1 —NHC(O)CH 2 —; and Ar is:naphthyl optionally substituted with one or more groups Y;pyridyl optionally substituted with one or more groups Z; orthe group Ar 1 etc, these compounds being useful for treating neurological diseases such as schizophrenia, dementia or attention deficit disorder.",AHMAD NADIA MAMOONA;;BRANCH CLIVE LESLIE;;JAXA-CHAMIEC ALBERT ANDRZEJ;;QUAI LAI JUSTINE YEUN;;NASH DAVID JOHN,AHMAD NADIA MAMOONA;;BRANCH CLIVE LESLIE;;JAXA-CHAMIEC ALBERT ANDRZEJ;;QUAI LAI JUSTINE YEUN;;NASH DAVID JOHN,,https://lens.org/154-121-392-552-15X,Patent Application,yes,0,0,4,6,0,C07D235/02;;A61P15/10;;A61P21/02;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P29/00;;A61P43/00;;C07D235/02,A61K31/4184;;A61P25/00;;A61P25/18;;C07D235/02,514/387;;548/300.7,0,0,,,,DISCONTINUED
233,US,A1,US 2004/0074785 A1,132-821-828-230-231,2004-04-22,2004,US 27376702 A,2002-10-18,US 27376702 A,2002-10-18,Analyte sensors and methods for making them,"
   Embodiments of the invention provide analyte sensors having stabilized coating compositions and methods for making such sensors. Illustrative embodiments include electrochemical glucose sensors having stabilized glucose oxidase coatings that are generated for example, via spin coating processes. 
",HOLKER JAMES D.;;MASTROTOTARO JOHN J.;;NORONHA GLENN;;SHAH RAJIV;;ZHANG YANAN;;HOSS UDO;;BRANCH KEVIN D.,HOLKER JAMES D;;MASTROTOTARO JOHN J;;NORONHA GLENN;;SHAH RAJIV;;ZHANG YANAN;;HOSS UDO;;BRANCH KEVIN D,MEDTRONIC MINIMED INC (2003-01-02),https://lens.org/132-821-828-230-231,Patent Application,yes,74,467,10,10,0,A61B5/1486;;A61B5/1486;;C12Q1/006;;C12Q1/006;;G01N27/307;;G01N27/307,A61B5/00;;C12Q1/00;;G01N27/30,205/777.5;;204/403.01,0,0,,,,DISCONTINUED
234,DE,T2,DE 69822711 T2,150-139-674-789-446,2005-02-10,2005,DE 69822711 T,1998-06-30,US 88705297 A,1997-07-02,Verfarhen zur Herstellung von Dialkylnaphthalin,,KOBE STEEL LTD;;EXXONMOBIL OIL CORP,MOTOYUKI OSAKA BRANCH KOBE STE;;YAMAMOTO KOBE CORP RES LAB KOB;;SAPRE AJIT VISHWANATH;;MCWILLIAMS JOHN PAUL,,https://lens.org/150-139-674-789-446,Granted Patent,no,0,0,12,12,0,C07C2/66;;C07C6/126;;C07C15/24;;C07C2529/70;;C07C15/24;;C07C15/24;;C07C2529/70;;C07C2/66;;C07C6/126,B01J29/04;;C07B61/00;;C07C2/66;;C07C6/12;;C07C15/24,,0,0,,,,EXPIRED
235,AU,A8,AU 2003/286473 A8,172-202-178-339-849,2004-05-04,2004,AU 2003/286473 A,2003-10-17,US 27376702 A;;US 0333065 W,2002-10-18,Analyte sensors and methods for making them,,MEDTRONIC MINIMED INC,NORONHA GLENN;;ZHANG YANAN;;HOLKER JAMES D;;SHAH RAJIV;;BRANCH KEVIN D;;HOSS UDO;;MASTROTOTARO JOHN J,,https://lens.org/172-202-178-339-849,Patent Application,no,0,0,10,10,0,A61B5/1486;;A61B5/1486;;C12Q1/006;;C12Q1/006;;G01N27/307;;G01N27/307,A61B5/00;;C12Q1/00;;G01N27/30,,0,0,,,,DISCONTINUED
236,DE,D1,DE 69822711 D1,131-693-163-380-752,2004-05-06,2004,DE 69822711 T,1998-06-30,US 88705297 A,1997-07-02,Verfarhen zur Herstellung von Dialkylnaphthalinen,,KOBE STEEL LTD;;EXXONMOBIL OIL CORP,MOTOYUKI OSAKA BRANCH KOBE STE;;YAMAMOTO KOBE CORP RES LAB KOB;;SAPRE AJIT VISHWANATH;;MCWILLIAMS JOHN PAUL,,https://lens.org/131-693-163-380-752,Granted Patent,no,0,0,12,12,0,C07C2/66;;C07C6/126;;C07C15/24;;C07C2529/70;;C07C15/24;;C07C15/24;;C07C2529/70;;C07C2/66;;C07C6/126,B01J29/04;;C07B61/00;;C07C2/66;;C07C6/12;;C07C15/24,,0,0,,,,EXPIRED
237,US,B2,US 8576066 B2,190-532-521-051-530,2013-11-05,2013,US 201113036612 A,2011-02-28,US 201113036612 A,2011-02-28,Managing emergency response services using mobile communication devices,One or more embodiments manage emergency response services. An emergency event is determined to have occurred. A set of civilian responders currently available to respond to the emergency event is selected from a plurality of civilian responders in response to determining that the emergency event has occurred. Each civilian responder in the set of civilian responders is associated with at least one wireless communication device. The set of civilian responders is notified that the emergency event has occurred. A set of emergency event information associated with the emergency event is transmitted to at least one wireless communication device associated with each civilian responder in the set of civilian responders.,BIVENS JOHN ALAN;;BRANCH JOEL W;;IDAS RAJARSH;;FARRELL ROBERT G;;HOBSON STACY F;;SOW DABY M;;IBM,BIVENS JOHN ALAN;;BRANCH JOEL W;;IDAS RAJARSH;;FARRELL ROBERT G;;HOBSON STACY F;;SOW DABY M,GENERAC HOLDINGS INC (2022-01-01);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2011-03-01);;GENERAC POWER SYSTEMS INC (2022-01-01);;ECOBEE TECHNOLOGIES ULC (2021-12-31);;ECOBEE TECHNOLOGIES INC (2021-12-22),https://lens.org/190-532-521-051-530,Granted Patent,yes,22,16,2,2,0,G08B25/003;;G08B25/003;;G08B25/005;;G08B25/005;;G08B25/009;;G08B25/009,G08B1/08,340/539.13;;455/404.1;;455/404.2,0,0,,,,ACTIVE
238,WO,A2,WO 2004/036183 A2,055-142-121-682-546,2004-04-29,2004,US 0333065 W,2003-10-17,US 27376702 A,2002-10-18,ANALYTE SENSORS AND METHODS FOR MAKING THEM,"Embodiments of the invention provide analyte sensors (100) having stabilized coating compositions and methods for making such sensors. Illustrative embodiments include electrochemical glucose sensors (100) having stabilized glucose oxidase coatings (110) that are generated for example, via spin coating processes.",MEDTRONIC MINIMED INC,HOLKER JAMES D;;MASTROTOTARO JOHN J;;NORONHA GLENN;;SHAH RAJIV;;ZHANG YANAN;;HOSS UDO;;BRANCH KEVIN D,,https://lens.org/055-142-121-682-546,Patent Application,yes,0,43,10,10,0,A61B5/1486;;A61B5/1486;;C12Q1/006;;C12Q1/006;;G01N27/307;;G01N27/307,A61B5/00;;C12Q1/00;;G01N27/30,,0,0,,,,PENDING
239,WO,A1,WO 2014/022361 A1,123-452-559-221-304,2014-02-06,2014,US 2013/0052675 W,2013-07-30,US 201261677737 P,2012-07-31,PRINTED LAMINATE WITH DIGITAL PRINTING AND METHOD FOR MANUFACTURE,"A printed laminate includes a substrate and a priming layer positioned over the substrate, wherein digital printing is applied to the priming layer, A top coat layer is applied over the digital printing and the priming layer, the top coat layer being composed of a clear hot melt poiyureihane first top coat layer and a clear UV cured acrylic second top coat layer.",WILSONART LLC,BRANCH JOE E;;KENDALL ERIC W;;KREBS ROBERT R;;MCSPEDON JOHN P;;STEPAN JANET;;WILLIAMS JOEL L,,https://lens.org/123-452-559-221-304,Patent Application,yes,5,1,2,2,0,B41M7/0045;;B41M7/0045;;B05D7/57;;B32B7/12;;B32B7/12;;B32B21/02;;B32B21/02;;B32B21/08;;B32B21/08;;B32B27/08;;B32B27/08;;B32B27/42;;B32B27/42;;B32B38/145;;B32B38/145;;B32B2037/243;;B32B2037/243;;B32B2255/10;;B32B2255/10;;B32B2255/26;;B32B2255/26;;B32B2307/558;;B32B2307/558;;B32B2307/718;;B32B2307/718;;B32B2307/75;;B32B2307/75;;B32B2317/16;;B32B2317/16;;B41M5/0017;;B41M5/0017;;B41M5/0047;;B41M5/0047;;B41M7/0027;;B41M7/0027;;Y10T428/24884;;Y10T428/24884,B29C45/14,,0,0,,,,PENDING
240,US,A1,US 2023/0191115 A1,105-956-256-587-313,2023-06-22,2023,US 202118017770 A,2021-07-14,US 202118017770 A;;US 202063072571 P;;US 202063058776 P;;US 2021/0041506 W,2020-07-30,STRETCHABLE FABRIC SLEEVE FOR FUNCTIONAL ELECTRICAL STIMULATION AND/OR ELECTROMYOGRAPHY,"A device for functional electrical stimulation (FES), neuromuscular electrical stimulation (NMES), and/or in receiving electromyography (EMG) signals includes a sleeve and electrodes. The sleeve is sized and shaped to be worn on a human arm, and comprises a stretchable fabric The sleeve has a distal end disposed on or adjacent a wrist of the human arm when the sleeve is worn on the human arm and a proximal end opposite from the distal end. The electrodes are secured with the sleeve and positioned to contact skin of the human arm when the sleeve is worn on the human arm. The sleeve may include an inner sleeve contact with the skin and an outer sleeve disposed over the inner sleeve. The inner sleeve has openings in which the electrodes are disposed.",BATTELLE MEMORIAL INSTITUTE,BLUM TIMOTHY M;;BRANCH JOSHUA R;;COLACHIS SAMUEL;;NOONAN AMANDA I;;BARTHOLOMEW JOHN E;;ANNETTA NICHOLAS;;DAVIS YELENA,,https://lens.org/105-956-256-587-313,Patent Application,yes,0,2,8,8,0,A61B5/4836;;A61B5/389;;A61B5/296;;A61B5/256;;A61B5/304;;A61B5/313;;A61N1/36003;;A61N1/36031;;A61N1/0452;;A61N1/0484;;A61B5/4836;;A61B5/296;;A61B5/389;;A61B5/304;;A61N1/36003;;A61B5/313;;A61N1/36031;;A61B5/256;;A61N1/0452;;A61N1/0484;;A61N1/0452;;A61N1/0456;;A61N1/0476;;A61N1/0484;;A61N1/36031;;A61B5/296;;A61B5/397;;A61B5/301;;A61B5/256;;A61B5/313;;A61B5/4836;;A61B5/6824;;A61B5/725;;A61B2562/0209;;A61B2562/046;;A61B2562/182;;A61N1/36003,A61N1/04,,0,0,,,,PENDING
241,US,B2,US 7725250 B2,164-293-712-224-061,2010-05-25,2010,US 48893906 A,2006-07-18,US 48893906 A,2006-07-18,Proactive mechanism for supporting the global management of vehicle traffic flow,"The invention addresses the disadvantage of automated vehicle traffic management systems by providing a solution for predicting and avoiding traffic congestion before the congestion is experienced. The invention includes a decentralized mechanism for predicting congestion. An exemplary embodiment of the invention uses a system of sensors to determine current traffic flow; the sensors communicate their state to a network of servers and then an algorithm is applied to the collected data to predict traffic congestion; upon detection of congestion, signals are communicated to the system controllers to prevent the traffic congestion.",IBM,BISDIKIAN CHATSCHIK;;BRANCH JOEL W;;COHEN NORMAN H;;DAVIS II JOHN S;;EBLING MARIA R;;SOW DABY M,INTERNATIONAL BUSINESS MACHINES CORPORATION (2006-06-19),https://lens.org/164-293-712-224-061,Granted Patent,yes,19,11,3,3,0,G08G1/0112;;G08G1/0112;;G08G1/0116;;G08G1/0116;;G08G1/0133;;G08G1/0133;;G08G1/0145;;G08G1/0145;;G08G1/096811;;G08G1/096811;;G08G1/096844;;G08G1/096844;;H04L67/12;;H04L67/12,G06G7/76,701/117,0,0,,,,INACTIVE
242,US,A1,US 2023/0277109 A1,144-534-520-386-831,2023-09-07,2023,US 202118017899 A,2021-07-30,US 202118017899 A;;US 202063072571 P;;US 202063058776 P;;US 2021/0043892 W,2020-07-30,"ELECTRONIC DRIVING CIRCUIT FOR SLEEVE FOR FES, NMES, AND/OR EMG READOUT, AND SLEEVE INCLUDING SAME","A device for functional electrical stimulation (FES), neuromuscular electrical stimulation (NMES), and/or in receiving electromyography (EMG) signals includes a sleeve and electrodes. The sleeve is sized and shaped to be worn on a human arm, and comprises a stretchable fabric The electrodes are secured with the sleeve and positioned to contact skin of the human arm when the sleeve is worn on the human arm. An electronic circuit is configured to operate the electrodes. The electronic circuit includes relays connecting the electrodes with a stimulator for performing FES or NMES, and EMG readout circuitry connecting the electrodes with an EMG amplifier. The relays are closed during FES or NMES to connect the stimulator with the electrodes. The relays are open during EMG readout to isolate the stimulator from the EMG amplifier.",BATTELLE MEMORIAL INSTITUTE,BLUM TIMOTHY M;;BRANCH JOSHUA R;;COLACHIS SAMUEL;;NOONAN AMANDA I;;BARTHOLOMEW JOHN E;;ANNETTA NICHOLAS;;DAVIS YELENA,,https://lens.org/144-534-520-386-831,Patent Application,yes,0,0,8,8,0,A61B5/4836;;A61B5/389;;A61B5/296;;A61B5/256;;A61B5/304;;A61B5/313;;A61N1/36003;;A61N1/36031;;A61N1/0452;;A61N1/0484;;A61B5/4836;;A61B5/296;;A61B5/389;;A61B5/304;;A61N1/36003;;A61B5/313;;A61N1/36031;;A61B5/256;;A61N1/0452;;A61N1/0484;;A61N1/0452;;A61N1/0456;;A61N1/0476;;A61N1/0484;;A61N1/36031;;A61B5/296;;A61B5/397;;A61B5/301;;A61B5/256;;A61B5/313;;A61B5/4836;;A61B5/6824;;A61B5/725;;A61B2562/0209;;A61B2562/046;;A61B2562/182;;A61N1/36003,A61B5/00;;A61B5/256;;A61B5/296;;A61B5/301;;A61B5/313;;A61B5/397;;A61N1/04;;A61N1/36,,0,0,,,,PENDING
243,DE,D1,DE 60130536 D1,019-257-487-719-184,2007-10-31,2007,DE 60130536 T,2001-02-09,US 50220400 A;;US 50244400 A;;US 77928201 A;;US 0104270 W,2000-02-10,ANALYTENSENSOR,"A sensor (400) and method of making the same for implantation in a body that includes a substrate (402) with notches (406) cut in the substrate to form a necked down region (412) in the substrate; and at least one sensor electrode (404) formed from one or more conductive layers. Preferably, the thickness of the substrate (402) ranges from approximately 25 mu to 350 mu , but the thickness of the substrate can range from 5 mu to 750 mu . The sensor may be incorporated into a sensor assembly including a slotted needle (408) having a slot (410). The notches (406) creating the necked down region (412) allow the substrate (402) to slide into the slotted needle, which has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region (414) of the substrate is prevented from pulling out of the slotted needle (408) through the slot (410). The slot (410) of the slotted needle (408) may also permit the necked down region (412) of the substrate (402) to slide down the slot.",MEDTRONIC MINIMED INC,HOLKER JAMES D;;CALLE GUILLERMO A;;BRANCH KEVIN D;;MASTROTORARO JOHN J;;VAN ANTWERP WILLIAM P;;VAN ANTWERP NANNETTE,,https://lens.org/019-257-487-719-184,Granted Patent,no,0,0,14,18,0,A61B5/14532;;A61B5/14865;;A61B5/6849,A61B5/00;;A61B5/145;;A61B5/1473;;A61B5/1486;;A61B5/15;;A61B5/157;;G01N27/28;;G01N27/327,,0,0,,,,EXPIRED
244,WO,A2,WO 2000/049940 A2,173-528-627-920-660,2000-08-31,2000,US 0003856 W,2000-02-15,US 12165599 P;;US 50184800 A,1999-02-25,GLUCOSE SENSOR PACKAGE SYSTEM,"A glucose sensor package system that includes a glucose sensor (300) and a protective package (310) that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered.",MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,,https://lens.org/173-528-627-920-660,Patent Application,yes,7,332,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,A61B5/00;;G01N27/28;;A61B5/145;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,,0,0,,,,PATENTED
245,EP,A2,EP 1154717 A2,052-669-480-296-614,2001-11-21,2001,EP 00908653 A,2000-02-15,US 0003856 W;;US 12165599 P;;US 50184800 A,1999-02-25,GLUCOSE SENSOR PACKAGE SYSTEM,"A glucose sensor package system that includes a glucose sensor and a protective package that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered.",MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,"MEDTRONIC MINIMED, INC. (2002-08-28);;MEDTRONIC MINIMED, INC., US (2013-12-13)",https://lens.org/052-669-480-296-614,Patent Application,yes,0,0,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,G01N27/28;;A61B5/00;;A61B5/145;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,,0,0,,,,EXPIRED
246,EP,A2,EP 1253852 A2,054-781-024-784-836,2002-11-06,2002,EP 01909055 A,2001-02-09,US 0104270 W;;US 50220400 A;;US 50244400 A;;US 77928201 A,2000-02-10,ANALYTE SENSOR,"A sensor (400) and method of making the same for implantation in a body that includes a substrate (402) with notches (406) cut in the substrate to form a necked down region (412) in the substrate; and at least one sensor electrode (404) formed from one or more conductive layers. Preferably, the thickness of the substrate (402) ranges from approximately 25 mu to 350 mu , but the thickness of the substrate can range from 5 mu to 750 mu . The sensor may be incorporated into a sensor assembly including a slotted needle (408) having a slot (410). The notches (406) creating the necked down region (412) allow the substrate (402) to slide into the slotted needle, which has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region (414) of the substrate is prevented from pulling out of the slotted needle (408) through the slot (410). The slot (410) of the slotted needle (408) may also permit the necked down region (412) of the substrate (402) to slide down the slot.",MINIMED INC,HOLKER JAMES D;;CALLE GUILLERMO A;;BRANCH KEVIN D;;MASTROTORARO JOHN J;;VAN ANTWERP WILLIAM P;;VAN ANTWERP NANNETTE,"MEDTRONIC MINIMED, INC. (2003-01-08)",https://lens.org/054-781-024-784-836,Patent Application,yes,0,0,14,18,0,A61B5/14532;;A61B5/14865;;A61B5/6849,A61B5/145;;A61B5/00;;A61B5/1473;;A61B5/1486;;A61B5/15;;A61B5/157;;G01N27/28;;G01N27/327,,0,0,,,,EXPIRED
247,DK,T3,DK 1154717 T3,096-756-377-953-382,2006-01-23,2006,DK 00908653 T,2000-02-15,US 12165599 P;;US 50184800 A,1999-02-25,Pakningssystem til glukosesensor,"A glucose sensor package system that includes a glucose sensor and a protective package that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered.",MEDTRONIC MINIMED INC,BRANCH KEVIN D;;MCIVOR K COLLIN;;CABERNOCH JAMES L;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,,https://lens.org/096-756-377-953-382,Granted Patent,no,0,0,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,A61B5/00;;G01N27/28;;A61B5/145;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,,0,0,,,,EXPIRED
248,EP,B1,EP 1253852 B1,132-770-096-300-814,2007-09-19,2007,EP 01909055 A,2001-02-09,US 0104270 W;;US 50220400 A;;US 50244400 A;;US 77928201 A,2000-02-10,ANALYTE SENSOR,"A sensor (400) and method of making the same for implantation in a body that includes a substrate (402) with notches (406) cut in the substrate to form a necked down region (412) in the substrate; and at least one sensor electrode (404) formed from one or more conductive layers. Preferably, the thickness of the substrate (402) ranges from approximately 25 mu to 350 mu , but the thickness of the substrate can range from 5 mu to 750 mu . The sensor may be incorporated into a sensor assembly including a slotted needle (408) having a slot (410). The notches (406) creating the necked down region (412) allow the substrate (402) to slide into the slotted needle, which has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region (414) of the substrate is prevented from pulling out of the slotted needle (408) through the slot (410). The slot (410) of the slotted needle (408) may also permit the necked down region (412) of the substrate (402) to slide down the slot.",MEDTRONIC MINIMED INC,HOLKER JAMES D;;CALLE GUILLERMO A;;BRANCH KEVIN D;;MASTROTORARO JOHN J;;VAN ANTWERP WILLIAM P;;VAN ANTWERP NANNETTE,"MEDTRONIC MINIMED, INC. (2003-01-08)",https://lens.org/132-770-096-300-814,Granted Patent,yes,3,4,14,18,0,A61B5/14532;;A61B5/14865;;A61B5/6849,A61B5/00;;A61B5/145;;A61B5/1473;;A61B5/1486;;A61B5/15;;A61B5/157;;G01N27/28;;G01N27/327,,3,0,,,"STIEGLITZ T ET AL: ""Flexible, polyimide-based neural interfaces"" PROCEEDINGS OF THE SEVENTH INTERNATIONAL CONFERENCE ON MICROELECTRONICS FOR NEURAL, FUZZY AND BIO-INSPIRED SYSTEMS, PROCEEDINGS OF THE SEVENTH INTERNATIONAL CONFERENCE ON MICROELECTRONICS FOR NEURAL, FUZZY AND BIO-INSPIRED SYSTEMS. MICRONEURO'99, GRA, pages 112-119, XP002169360 1999, Los Alamitos, CA, USA, IEEE Comput. Soc, USA ISBN: 0-7695-0043-9;;BLUM N A ET AL: ""MULTISITE MICROPROBES FOR NEURAL RECORDINGS"" IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING,US,IEEE INC. NEW YORK, vol. 38, no. 1, 1991, pages 68-74, XP000225249 ISSN: 0018-9294;;""DESIGN AND FABRICATION OF AN INTEGRATED PH, OXYGEN CONTENT AND TEMPERATURE SENSOR"" IBM TECHNICAL DISCLOSURE BULLETIN, IBM CORP. NEW YORK, US, vol. 34, no. 2, 1 July 1991 (1991-07-01), pages 462-464, XP000211172 ISSN: 0018-8689",EXPIRED
249,EP,B1,EP 1154717 B1,169-319-314-845-211,2005-09-07,2005,EP 00908653 A,2000-02-15,US 0003856 W;;US 12165599 P;;US 50184800 A,1999-02-25,GLUCOSE SENSOR PACKAGE SYSTEM,"A glucose sensor package system that includes a glucose sensor and a protective package that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered.",MEDTRONIC MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,"MEDTRONIC MINIMED, INC. (2002-08-28);;MEDTRONIC MINIMED, INC., US (2013-12-13)",https://lens.org/169-319-314-845-211,Granted Patent,yes,10,0,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,G01N27/28;;A61B5/00;;A61B5/145;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,,0,0,,,,EXPIRED
250,AU,A,AU 2000/029958 A,193-230-044-337-143,2000-09-14,2000,AU 2000/029958 A,2000-02-15,US 12165599 P;;US 50184800 A;;US 0003856 W,1999-02-25,Glucose sensor package system,"A glucose sensor package system that includes a glucose sensor and a protective package that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered.",MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;ANTWERP NANNETTE M VAN;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,,https://lens.org/193-230-044-337-143,Patent Application,no,0,0,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,G01N27/28;;A61B5/00;;A61B5/145;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,,0,0,,,,DISCONTINUED
251,CA,C,CA 2395868 C,014-567-759-945-153,2009-07-14,2009,CA 2395868 A,2001-02-09,US 50220400 A;;US 50244400 A;;US 77928201 A;;US 0104270 W,2000-02-10,IMPROVED ANALYTE SENSOR AND METHOD OF MAKING THE SAME,"A sensor (400) and method of making the same for implantation in a body that includes a substrate (402) with notches (406) cut in the substrate to form a necked down region (412) in the substrate; and at least one sensor electrode (404) formed from one or more conductive layers. Preferably, the thickness of the substrate (402) ranges from approximately 25 .mu. to 350 .mu., but the thickness of the substrate can range from 5 .mu. to 750 .mu.. The sensor may be incorporated into a sensor assembly including a slotted needle (408) having a slot (410). The notches (406) creating the necked down region (412) allow the substrate (402) to slide into the slotted needle, which has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region (414) of the substrate is prevented from pulling out of the slotted needle (408) through the slot (410). The slot (410) of the slotted needle (408) may also permit the necked down region (412) of the substrate (402) to slide down the slot.",MEDTRONIC MINIMED INC,BRANCH KEVIN D;;VAN ANTWERP NANNETTE;;VAN ANTWERP WILLIAM P;;MASTROTORARO JOHN J;;HOLKER JAMES D;;CALLE GUILLERMO A,,https://lens.org/014-567-759-945-153,Granted Patent,no,0,0,14,18,0,A61B5/14532;;A61B5/14865;;A61B5/6849,A61B5/00;;A61B5/145;;A61B5/1473;;A61B5/1486;;A61B5/15;;A61B5/157;;G01N27/28;;G01N27/327,,0,0,,,,EXPIRED
252,DE,T2,DE 60130536 T2,041-625-899-640-820,2008-06-26,2008,DE 60130536 T,2001-02-09,US 50220400 A;;US 50244400 A;;US 77928201 A;;US 0104270 W,2000-02-10,ANALYTENSENSOR,"A sensor (400) and method of making the same for implantation in a body that includes a substrate (402) with notches (406) cut in the substrate to form a necked down region (412) in the substrate; and at least one sensor electrode (404) formed from one or more conductive layers. Preferably, the thickness of the substrate (402) ranges from approximately 25 mu to 350 mu , but the thickness of the substrate can range from 5 mu to 750 mu . The sensor may be incorporated into a sensor assembly including a slotted needle (408) having a slot (410). The notches (406) creating the necked down region (412) allow the substrate (402) to slide into the slotted needle, which has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region (414) of the substrate is prevented from pulling out of the slotted needle (408) through the slot (410). The slot (410) of the slotted needle (408) may also permit the necked down region (412) of the substrate (402) to slide down the slot.",MEDTRONIC MINIMED INC,HOLKER JAMES D;;CALLE GUILLERMO A;;BRANCH KEVIN D;;MASTROTORARO JOHN J;;VAN ANTWERP WILLIAM P;;VAN ANTWERP NANNETTE,,https://lens.org/041-625-899-640-820,Granted Patent,no,0,1,14,18,0,A61B5/14532;;A61B5/14865;;A61B5/6849,A61B5/00;;A61B5/145;;A61B5/1473;;A61B5/1486;;A61B5/15;;A61B5/157;;G01N27/28;;G01N27/327,,0,0,,,,EXPIRED
253,CA,C,CA 2568226 C,172-203-640-541-33X,2007-06-12,2007,CA 2568226 A,2000-02-15,US 12165599 P;;US 50184800 A;;CA 2354145 A,1999-02-25,GLUCOSE SENSOR PACKAGE SYSTEM,"A glucose sensor package system that includes a glucose sensor and a protective package that indicates exposure to temperature changes to indicat e proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered.",MEDTRONIC MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;MASTROTOTARO JOHN J;;HALILI EDGARDO C;;VAN ANTWERP NANNETTE M,,https://lens.org/172-203-640-541-33X,Granted Patent,no,0,0,2,22,0,,A61L2/08;;A61B5/1477;;A61L2/28,,0,0,,,,EXPIRED
254,US,A1,US 2002/0032374 A1,141-399-412-092-053,2002-03-14,2002,US 77928201 A,2001-02-08,US 77928201 A;;US 50244400 A;;US 50220400 A,2000-02-10,Analyte sensor and method of making the same,"
   A sensor and method of making the same for implantation in a body that includes a substrate with notches cut in the substrate to form a necked down region in the substrate; and at least one sensor electrode formed from one or more conductive layers. Preferably, the thickness of the substrate ranges from approximately 25 to 350 , but the thickness of the substrate can range from 5 to 750 . The sensor may be incorporated in to a sensor assembly includes a slotted needle having a slot. The notches creating the necked down region allow the substrate to slide into the slotted needle, which that has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region of the substrate is prevented from pulling out of the slotted needle through the slot. The slot of the slotted needle may also permit the necked down region of the substrate to slide down the slot. 
",HOLKER JAMES D.;;CALLE GUILLERMO A.;;BRANCH KEVIN D.;;MASTROTOTARO JOHN J.;;VAN ANTWERP WILLIAM P.;;VAN ANTWERP NANNETTE,HOLKER JAMES D;;CALLE GUILLERMO A;;BRANCH KEVIN D;;MASTROTOTARO JOHN J;;VAN ANTWERP WILLIAM P;;VAN ANTWERP NANNETTE,MEDTRONIC MINIMED INC (2001-02-02),https://lens.org/141-399-412-092-053,Patent Application,yes,7,68,3,18,0,A61B5/14865;;A61M2005/1726;;A61B5/6849;;A61B5/14865;;A61M2005/1726;;A61B5/6849,A61B5/00,600/373;;604/272,0,0,,,,EXPIRED
255,US,B2,US 6520326 B2,109-946-257-664-583,2003-02-18,2003,US 97385201 A,2001-10-09,US 97385201 A;;US 50184800 A;;US 12165599 P,1999-02-25,Glucose sensor package system,"
    A glucose sensor package system that includes a glucose sensor and a protective package that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered. 
",MEDTRONIC MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,,https://lens.org/109-946-257-664-583,Granted Patent,yes,3,593,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,A61B5/00;;G01N27/28;;A61B5/145;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,206/305;;600/345;;600/365;;600/347;;422/1;;422/22;;206/438;;206/363;;206/459.1,0,0,,,,EXPIRED
256,CA,A1,CA 2580887 A1,185-686-818-276-539,2000-08-31,2000,CA 2580887 A,2000-02-15,US 12165599 P;;US 50184800 A;;CA 2568226 A,1999-02-25,GLUCOSE SENSOR PACKAGE SYSTEM,,MEDTRONIC MINIMED INC,BRANCH KEVIN D;;HALILI EDGARDO C;;MASTROTOTARO JOHN J;;CABERNOCH JAMES L;;VAN ANTWERP NANNETTE M;;MCIVOR K COLLIN,,https://lens.org/185-686-818-276-539,Patent Application,no,0,0,1,22,0,,A61B5/1486;;G01K11/12;;G01N27/327,,0,0,,,,DISCONTINUED
257,US,B2,US 9705972 B2,053-180-470-113-688,2017-07-11,2017,US 201414529653 A,2014-10-31,US 201414529653 A,2014-10-31,Managing a set of data,"Aspects of the disclosure include managing a set of data associated with a corpus. By analyzing the corpus, a domain is established to characterize the subject matter of the set of data. A user identifier is generated for a portion of the set of data. Based upon a credibility computation, a quality factor for a portion of the set of data is determined. The credibility computation includes using both the domain and the user identifier to determine the quality factor for the portion of the set of data. The quality factor for the portion of the set of data is compared with a threshold. In response to a quality factor for a portion of the set of data exceeding the threshold, the portion of the set of data is selected.",IBM,AARON ANDREW S;;BRANCH JOEL W;;GUO SHANG Q;;LENCHNER JONATHAN;;MAZZELLA DANIEL A;;MUKHERJEE MAHARAJ;;NELSON JOHN C,INTERNATIONAL BUSINESS MACHINES CORPORATION (2014-10-14),https://lens.org/053-180-470-113-688,Granted Patent,yes,10,3,2,2,0,G06F16/951;;G06F16/951;;H04L67/10;;H04L67/10,G06F17/30;;H04L29/08,,4,2,017-068-540-018-091;;024-925-878-840-127,10.1109/cicybs.2009.4925088;;10.1109/mic.2007.125,"Anonymous, “Method to extract simple and compound terms from text corpuses (without performing full semantic analysis)”, IP.com Prior Art Database Technical Disclosure. IP.com Electronic Publication Jul. 25, 2012. IP.com No. IPCOM000220204D. 6 pages.;;Anonymous, “Method of visualizing social comment interactions in a large web-document corpus”, IP.com Prior Art Database Technical Disclosure. IP.com Electronic Publication Aug. 12, 2013. IP.com No. IPCOM000229976D. 3 pages.;;Bhattarai, A., et al., “Characterizing Comment Spam in the Blogosphere through Content Analysis”, IEEE Symposium on Computational Intelligence in Cyber Security, 2009. pp. 37-44. DOI: 10.1109/CICYBS.2009.4925088.;;Heymann, P., et al., “Fighting Spam on Social Websites a Survey of Approaches and Future Challenges”, IEEE Internet Computing, 2007. Issue: 6, vol. 11, pp. 36-45. DOI: 10.1109/MIC.2007.125.",ACTIVE
258,CA,C,CA 2354145 C,074-315-173-562-070,2007-02-13,2007,CA 2354145 A,2000-02-15,US 12165599 P;;US 50184800 A;;US 0003856 W,1999-02-25,GLUCOSE SENSOR PACKAGE SYSTEM,"A glucose sensor package system that includes a glucose sensor (300) and a protective package (310) that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered.",MINIMED INC,CABERNOCH JAMES L;;MCIVOR COLLIN K;;MASTROTOTARO JOHN J;;VAN ANTWERP NANNETTE M;;BRANCH KEVIN D;;HALILI EDGARDO C,,https://lens.org/074-315-173-562-070,Granted Patent,no,0,0,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,G01N27/28;;A61B5/00;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,,0,0,,,,EXPIRED
259,WO,A9,WO 2001/058348 A9,065-345-682-580-980,2002-10-17,2002,US 0104270 W,2001-02-09,US 50220400 A;;US 50244400 A;;US 77928201 A,2000-02-10,IMPROVED ANALYTE SENSOR AND METHOD OF MAKING THE SAME,"A sensor (400) and method of making the same for implantation in a body that includes a substrate (402) with notches (406) cut in the substrate to form a necked down region (412) in the substrate; and at least one sensor electrode (404) formed from one or more conductive layers. Preferably, the thickness of the substrate (402) ranges from approximately 25 mu to 350 mu , but the thickness of the substrate can range from 5 mu to 750 mu . The sensor may be incorporated into a sensor assembly including a slotted needle (408) having a slot (410). The notches (406) creating the necked down region (412) allow the substrate (402) to slide into the slotted needle, which has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region (414) of the substrate is prevented from pulling out of the slotted needle (408) through the slot (410). The slot (410) of the slotted needle (408) may also permit the necked down region (412) of the substrate (402) to slide down the slot.",MINIMED INC,HOLKER JAMES D;;CALLE GUILLERMO A;;BRANCH KEVIN D;;MASTROTORARO JOHN J;;VAN ANTWERP WILLIAM P;;VAN ANTWERP NANNETTE,,https://lens.org/065-345-682-580-980,Patent Application,no,0,0,14,18,0,A61B5/14532;;A61B5/14865;;A61B5/6849,A61B5/145;;A61B5/00;;A61B5/1473;;A61B5/1486;;A61B5/15;;A61B5/157;;G01N27/28;;G01N27/327,,0,0,,,,PATENTED
260,JP,A,JP 2005128025 A,174-798-444-588-796,2005-05-19,2005,JP 2004343019 A,2004-11-26,US 12165599 P;;US 50184800 A,1999-02-25,GLUCOSE SENSOR PACKAGE SYSTEM,"<P>PROBLEM TO BE SOLVED: To embody a glucose monitor system which is associated with a subcutaneous glucose sensor set and provides continuous data records being read by the sensor set for a prescribed period of time. <P>SOLUTION: A glucose sensor package system includes a glucose sensor 300 and a protective package 310 indicating exposure to temperature changes in order to indicate proper temperature control. The invention also covers methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of electrodes on the glucose sensor are also covered. <P>COPYRIGHT: (C)2005,JPO&NCIPI",MEDTRONIC MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;ANTWERP NANNETTE M VAN;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,,https://lens.org/174-798-444-588-796,Patent Application,no,0,6,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,G01N27/28;;A61B5/00;;A61B5/145;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,,0,0,,,,PENDING
261,WO,A3,WO 2000/049940 A3,161-019-567-902-91X,2001-01-04,2001,US 0003856 W,2000-02-15,US 12165599 P;;US 50184800 A,1999-02-25,GLUCOSE SENSOR PACKAGE SYSTEM,"A glucose sensor package system that includes a glucose sensor (300) and a protective package (310) that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered.",MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,,https://lens.org/161-019-567-902-91X,Search Report,yes,10,0,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,A61B5/00;;G01N27/28;;A61B5/145;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,,0,0,,,,PATENTED
262,WO,A2,WO 2001/058348 A2,177-413-560-454-903,2001-08-16,2001,US 0104270 W,2001-02-09,US 50220400 A;;US 50244400 A;;US 77928201 A,2000-02-10,IMPROVED ANALYTE SENSOR AND METHOD OF MAKING THE SAME,"A sensor (400) and method of making the same for implantation in a body that includes a substrate (402) with notches (406) cut in the substrate to form a necked down region (412) in the substrate; and at least one sensor electrode (404) formed from one or more conductive layers. Preferably, the thickness of the substrate (402) ranges from approximately 25 ν to 350 ν, but the thickness of the substrate can range from 5 ν to 750 ν. The sensor may be incorporated into a sensor assembly including a slotted needle (408) having a slot (410). The notches (406) creating the necked down region (412) allow the substrate (402) to slide into the slotted needle, which has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region (414) of the substrate is prevented from pulling out of the slotted needle (408) through the slot (410). The slot (410) of the slotted needle (408) may also permit the necked down region (412) of the substrate (402) to slide down the slot.",MINIMED INC,HOLKER JAMES D;;CALLE GUILLERMO A;;BRANCH KEVIN D;;MASTROTORARO JOHN J;;VAN ANTWERP WILLIAM P;;VAN ANTWERP NANNETTE,,https://lens.org/177-413-560-454-903,Patent Application,yes,8,190,14,18,0,A61B5/14532;;A61B5/14865;;A61B5/6849,A61B5/145;;A61B5/00;;A61B5/1473;;A61B5/1486;;A61B5/15;;A61B5/157;;G01N27/28;;G01N27/327,,0,0,,,,PATENTED
263,AU,A,AU 2001/036848 A,005-311-273-965-79X,2001-08-20,2001,AU 2001/036848 A,2001-02-09,US 50220400 A;;US 50244400 A;;US 77928201 A;;US 0104270 W,2000-02-10,Improved analyte sensor and method of making the same,"A sensor (400) and method of making the same for implantation in a body that includes a substrate (402) with notches (406) cut in the substrate to form a necked down region (412) in the substrate; and at least one sensor electrode (404) formed from one or more conductive layers. Preferably, the thickness of the substrate (402) ranges from approximately 25 mu to 350 mu , but the thickness of the substrate can range from 5 mu to 750 mu . The sensor may be incorporated into a sensor assembly including a slotted needle (408) having a slot (410). The notches (406) creating the necked down region (412) allow the substrate (402) to slide into the slotted needle, which has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region (414) of the substrate is prevented from pulling out of the slotted needle (408) through the slot (410). The slot (410) of the slotted needle (408) may also permit the necked down region (412) of the substrate (402) to slide down the slot.",MINIMED INC,HOLKER JAMES D;;CALLE GUILLERMO A;;BRANCH KEVIN D;;MASTROTORARO JOHN J;;ANTWERP WILLIAM P VAN;;ANTWERP NANNETTE VAN,,https://lens.org/005-311-273-965-79X,Patent Application,no,0,0,14,18,0,A61B5/14532;;A61B5/14865;;A61B5/6849,A61B5/145;;A61B5/00;;A61B5/1473;;A61B5/1486;;A61B5/15;;A61B5/157;;G01N27/28;;G01N27/327,,0,0,,,,PENDING
264,US,B2,US 6892085 B2,016-104-522-322-590,2005-05-10,2005,US 30451802 A,2002-11-26,US 30451802 A;;US 97385201 A;;US 50184800 A;;US 12165599 P,1999-02-25,Glucose sensor package system,"A glucose sensor package system that includes a glucose sensor and a protective package that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered.",MEDTRONIC MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,,https://lens.org/016-104-522-322-590,Granted Patent,yes,22,686,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,A61B5/00;;A61B5/145;;A61B5/1473;;G01N27/28;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,600/347;;600/345;;600/365;;600/372,0,0,,,,EXPIRED
265,JP,A,JP 2005279285 A,084-016-076-947-756,2005-10-13,2005,JP 2005127159 A,2005-04-25,US 50220400 A;;US 50244400 A;;US 77928201 A,2000-02-10,IMPROVED ANALYTE SENSOR,"<P>PROBLEM TO BE SOLVED: To provide an improved analyte sensor assembly including a sensor and a slotted needle with a slot. <P>SOLUTION: A sensor (400) and method of making the same for implantation in a body that includes a substrate (402) with notches cut in the substrate to form a necked down region (412) in the substrate; and at least one sensor electrode (404) formed from one or more conductive layers. The sensor (400) may be incorporated in to a sensor assembly includes a slotted needle (408) having a slot (410). The notches (406) creating the necked down region (412) allow the substrate (402) to slide into the slotted needle (408), which has the slot narrow enough to permit passage of the necked down region (412). <P>COPYRIGHT: (C)2006,JPO&NCIPI",MEDTRONIC MINIMED INC,HOLKER JAMES D;;CALLE GUILLERMO A;;BRANCH KEVIN D;;MASTROTOTARO JOHN J;;VAN ANTWERP WILLIAM P;;VAN ANTWERP NANNETTE,,https://lens.org/084-016-076-947-756,Patent Application,no,0,2,14,18,0,A61B5/14532;;A61B5/14865;;A61B5/6849,A61B5/145;;A61B5/00;;A61B5/1473;;A61B5/1486;;A61B5/15;;A61B5/157;;G01N27/28;;G01N27/327,,0,0,,,,INACTIVE
266,US,B1,US 6360888 B1,152-169-443-827-88X,2002-03-26,2002,US 50184800 A,2000-02-10,US 50184800 A;;US 12165599 P,1999-02-25,Glucose sensor package system,"
    A glucose sensor package system that includes a glucose sensor and a protective package that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered. 
",MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,MEDTRONIC MINIMED INC (2000-02-03),https://lens.org/152-169-443-827-88X,Granted Patent,yes,18,701,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,A61B5/00;;A61B5/145;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/28;;G01N27/327;;G01N27/416,206/305;;206/306;;206/438;;206/363;;206/459.1;;600/347;;600/345;;600/365,0,0,,,,EXPIRED
267,CA,A1,CA 2568226 A1,198-139-630-092-825,2000-08-31,2000,CA 2568226 A,2000-02-15,US 12165599 P;;US 50184800 A;;CA 2354145 A,1999-02-25,GLUCOSE SENSOR PACKAGE SYSTEM,,MEDTRONIC MINIMED INC,MASTROTOTARO JOHN J;;CABERNOCH JAMES L;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MCIVOR K COLLIN;;BRANCH KEVIN D,,https://lens.org/198-139-630-092-825,Patent Application,no,0,0,2,22,0,,A61L2/08;;A61B5/1477;;A61L2/28,,0,0,,,,EXPIRED
268,US,A1,US 2016/0124946 A1,092-312-084-787-920,2016-05-05,2016,US 201414529653 A,2014-10-31,US 201414529653 A,2014-10-31,MANAGING A SET OF DATA,"Aspects of the disclosure include managing a set of data associated with a corpus. By analyzing the corpus, a domain is established to characterize the subject matter of the set of data. A user identifier is generated for a portion of the set of data. Based upon a credibility computation, a quality factor for a portion of the set of data is determined. The credibility computation includes using both the domain and the user identifier to determine the quality factor for the portion of the set of data. The quality factor for the portion of the set of data is compared with a threshold. In response to a quality factor for a portion of the set of data exceeding the threshold, the portion of the set of data is selected.",IBM,AARON ANDREW S;;BRANCH JOEL W;;GUO SHANG Q;;LENCHNER JONATHAN;;MAZZELLA DANIEL A;;MUKHERJEE MAHARAJ;;NELSON JOHN C,INTERNATIONAL BUSINESS MACHINES CORPORATION (2014-10-14),https://lens.org/092-312-084-787-920,Patent Application,yes,6,1,2,2,0,G06F16/951;;G06F16/951;;H04L67/10;;H04L67/10,G06F17/30;;H04L29/08,,0,0,,,,ACTIVE
269,AT,T1,AT E303750 T1,179-159-050-590-587,2005-09-15,2005,AT 00908653 T,2000-02-15,US 12165599 P;;US 50184800 A;;US 0003856 W,1999-02-25,HALTERUNGSSYSTEM FÜR GLUCOSESENSOR,"A glucose sensor package system that includes a glucose sensor and a protective package that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered.",MEDTRONIC MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,,https://lens.org/179-159-050-590-587,Granted Patent,no,0,0,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,G01N27/28;;A61B5/00;;A61B5/145;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,,0,0,,,,EXPIRED
270,US,A1,US 2003/0078481 A1,101-688-192-632-045,2003-04-24,2003,US 30451802 A,2002-11-26,US 30451802 A;;US 97385201 A;;US 50184800 A;;US 12165599 P,1999-02-25,Glucose sensor package system,"
   A glucose sensor package system that includes a glucose sensor and a protective package that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered. 
",MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,,https://lens.org/101-688-192-632-045,Patent Application,yes,10,265,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,A61B5/00;;G01N27/28;;A61B5/145;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,600/347,0,0,,,,EXPIRED
271,US,A1,US 2002/0023852 A1,102-134-267-737-370,2002-02-28,2002,US 97385201 A,2001-10-09,US 97385201 A;;US 50184800 A;;US 12165599 P,1999-02-25,Glucose sensor package system,"
   A glucose sensor package system that includes a glucose sensor and a protective package that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transporting and sterilizing the package. In addition, glucose sensors directed to various sizing and positioning of the electrodes on the glucose sensor are covered. 
",MINIMED INC,MCIVOR K COLLIN;;CABERNOCH JAMES L;;BRANCH KEVIN D;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MASTROTOTARO JOHN J,,https://lens.org/102-134-267-737-370,Patent Application,yes,0,413,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,A61B5/00;;A61B5/145;;G01N27/28;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,206/305;;600/347,0,0,,,,EXPIRED
272,CA,A1,CA 2395868 A1,110-771-142-288-497,2001-08-16,2001,CA 2395868 A,2001-02-09,US 50220400 A;;US 50244400 A;;US 77928201 A;;US 0104270 W,2000-02-10,IMPROVED ANALYTE SENSOR AND METHOD OF MAKING THE SAME,"A sensor (400) and method of making the same for implantation in a body that includes a substrate (402) with notches (406) cut in the substrate to form a necked down region (412) in the substrate; and at least one sensor electrode (404) formed from one or more conductive layers. Preferably, the thickness o f the substrate (402) ranges from approximately 25 .mu. to 350 .mu., but the thickness of the substrate can range from 5 .mu. to 750 .mu.. The sensor may be incorporated into a sensor assembly including a slotted needle (408) havi ng a slot (410). The notches (406) creating the necked down region (412) allow the substrate (402) to slide into the slotted needle, which has the slot narrow enough to permit passage of the necked down region. However, a non- necked down region (414) of the substrate is prevented from pulling out of t he slotted needle (408) through the slot (410). The slot (410) of the slotted needle (408) may also permit the necked down region (412) of the substrate (402) to slide down the slot.",MEDTRONIC MINIMED INC,VAN ANTWERP NANNETTE;;HOLKER JAMES D;;CALLE GUILLERMO A;;MASTROTORARO JOHN J;;VAN ANTWERP WILLIAM P;;BRANCH KEVIN D,,https://lens.org/110-771-142-288-497,Patent Application,no,0,0,14,18,0,A61B5/14532;;A61B5/14865;;A61B5/6849,A61B5/145;;A61B5/00;;A61B5/1473;;A61B5/1486;;A61B5/15;;A61B5/157;;G01N27/28;;G01N27/327,,0,0,,,,EXPIRED
273,CA,A1,CA 2354145 A1,153-403-792-772-484,2000-08-31,2000,CA 2354145 A,2000-02-15,US 12165599 P;;US 50184800 A;;US 0003856 W,1999-02-25,GLUCOSE SENSOR PACKAGE SYSTEM,"A glucose sensor package system that includes a glucose sensor (300) and a protective package (310) that indicates exposure to temperature changes to indicate proper temperature control. Also covered are methods of transportin g and sterilizing the package. In addition, glucose sensors directed to variou s sizing and positioning of the electrodes on the glucose sensor are covered.< /SDOAB>",MINIMED INC,BRANCH KEVIN D;;VAN ANTWERP NANNETTE M;;HALILI EDGARDO C;;MASTROTOTARO JOHN J;;MCIVOR COLLIN K;;CABERNOCH JAMES L,,https://lens.org/153-403-792-772-484,Patent Application,no,0,0,19,22,0,A61B5/14532;;A61B5/14865;;A61B5/6849;;A61B5/14865;;A61B5/6849;;A61B5/14532,G01N27/28;;A61B5/00;;A61B5/145;;A61B5/1473;;A61B5/1486;;B65B55/02;;C12M1/40;;G01N27/327;;G01N27/416,,0,0,,,,EXPIRED
274,WO,A3,WO 2001/058348 A3,172-324-700-152-872,2002-02-14,2002,US 0104270 W,2001-02-09,US 50220400 A;;US 50244400 A;;US 77928201 A,2000-02-10,IMPROVED ANALYTE SENSOR AND METHOD OF MAKING THE SAME,"A sensor (400) and method of making the same for implantation in a body that includes a substrate (402) with notches (406) cut in the substrate to form a necked down region (412) in the substrate; and at least one sensor electrode (404) formed from one or more conductive layers. Preferably, the thickness of the substrate (402) ranges from approximately 25 ν to 350 ν, but the thickness of the substrate can range from 5 ν to 750 ν. The sensor may be incorporated into a sensor assembly including a slotted needle (408) having a slot (410). The notches (406) creating the necked down region (412) allow the substrate (402) to slide into the slotted needle, which has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region (414) of the substrate is prevented from pulling out of the slotted needle (408) through the slot (410). The slot (410) of the slotted needle (408) may also permit the necked down region (412) of the substrate (402) to slide down the slot.",MINIMED INC,HOLKER JAMES D;;CALLE GUILLERMO A;;BRANCH KEVIN D;;MASTROTORARO JOHN J;;VAN ANTWERP WILLIAM P;;VAN ANTWERP NANNETTE,,https://lens.org/172-324-700-152-872,Search Report,yes,3,0,14,18,0,A61B5/14532;;A61B5/14865;;A61B5/6849,A61B5/145;;A61B5/00;;A61B5/1473;;A61B5/1486;;A61B5/15;;A61B5/157;;G01N27/28;;G01N27/327,,3,2,001-738-426-066-312;;063-482-685-927-052,10.1109/mn.1999.758853;;10.1109/10.68211;;2026434,"STIEGLITZ T ET AL: ""Flexible, polyimide-based neural interfaces"", PROCEEDINGS OF THE SEVENTH INTERNATIONAL CONFERENCE ON MICROELECTRONICS FOR NEURAL, FUZZY AND BIO-INSPIRED SYSTEMS, PROCEEDINGS OF THE SEVENTH INTERNATIONAL CONFERENCE ON MICROELECTRONICS FOR NEURAL, FUZZY AND BIO-INSPIRED SYSTEMS. MICRONEURO'99, GRA, 1999, Los Alamitos, CA, USA, IEEE Comput. Soc, USA, pages 112 - 119, XP002169360, ISBN: 0-7695-0043-9;;BLUM N A ET AL: ""MULTISITE MICROPROBES FOR NEURAL RECORDINGS"", IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING,US,IEEE INC. NEW YORK, vol. 38, no. 1, 1991, pages 68 - 74, XP000225249, ISSN: 0018-9294;;""DESIGN AND FABRICATION OF AN INTEGRATED PH, OXYGEN CONTENT AND TEMPERATURE SENSOR"", IBM TECHNICAL DISCLOSURE BULLETIN, IBM CORP. NEW YORK, US, vol. 34, no. 2, 1 July 1991 (1991-07-01), pages 462 - 464, XP000211172, ISSN: 0018-8689",PATENTED
275,US,B2,US 7003336 B2,196-746-273-639-539,2006-02-21,2006,US 77928201 A,2001-02-08,US 77928201 A;;US 50244400 A;;US 50220400 A,2000-02-10,Analyte sensor method of making the same,"A sensor and method of making the same for implantation in a body that includes a substrate with notches cut in the substrate to form a necked down region in the substrate; and at least one sensor electrode formed from one or more conductive layers. Preferably, the thickness of the substrate ranges from approximately 25μ to 350μ, but the thickness of the substrate can range from 5μ to 750μ. The sensor may be incorporated in to a sensor assembly includes a slotted needle having a slot. The notches creating the necked down region allow the substrate to slide into the slotted needle, which that has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region of the substrate is prevented from pulling out of the slotted needle through the slot. The slot of the slotted needle may also permit the necked down region of the substrate to slide down the slot.",MEDTRONIC MINIMED INC,HOLKER JAMES D;;CALLE GUILLERMO A;;BRANCH KEVIN D;;MASTROTOTARO JOHN J;;VAN ANTWERP WILLIAM P;;VAN ANTWERP NANNETTE,MEDTRONIC MINIMED INC (2001-02-02),https://lens.org/196-746-273-639-539,Granted Patent,yes,27,842,3,18,0,A61B5/14865;;A61M2005/1726;;A61B5/6849;;A61B5/14865;;A61M2005/1726;;A61B5/6849,A61B5/00;;B65D85/38;;A61B5/04;;A61B5/05,600/316;;600/347;;600/391;;206/305,10,3,124-660-118-050-67X;;068-386-284-377-434;;006-551-352-957-447,10.1016/0250-6874(89)87015-5;;10.1016/0956-5663(91)85005-h;;2049169;;10.1016/0956-5663(92)85056-g,"Koudelka, M. et al., ""Planar Amperometric Enzyme-Based Glucose Microelectrode"", Sensors and Actuators, 18 (Elsevier Sequoia, The Netherlands-1989), pp. 157-165.;;Koudelka, M. et al., ""In-vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors"", Biosensors & Bioelectronics 6 (Elsevier Science Publishers Ltd., England-1991), pp. 31-36.;;Mastrototaro, John M. et al., ""An electroenzymatic glucose sensor fabricated on a flexible substrate"", Sensors and Actuators B. 5 (Elsevier Sequoia-1991), pp. 139-144.;;Urban, G. et al., ""Miniaturized multi-enzyme biosensors integrated with pH sensors on flexible polymer carriers for in vivo applications"", Biosensors & Bioelectronics 7 (Elsevier Science Publishers Ltd.-1992), pp. 733-739.;;""3M Specifications and Design Guidelines, Microflex circuits for IC Interconnect Solutions,"" pp. 1-32 (the entire document), 1997 (3M Electronic Products Division, Austin TX).;;""3M Offers More Solutions for the Semiconductor Industry"" the entire document, 1997 (3M Electronic Products Division, Austin TX).;;""Microflex Solutions from 3M"", the entire document, 1996 (3M Electronic Products Division, Austin TX).;;""Micron Wide Conductors and Space on . . . PZT, Alumina, Glass and Flexible Material"" 1 page, no date (Metrigraphics, Wilmington, MA).;;""Flexible circuits at Extreme Density"", 8 unnumbered pages of various dates (Metrigraphics, Wilmington, MA).;;""Metrigraphics Ion Beam Etching Capability"", 1 page, no date (Metrigraphics Wilmington, MA).",EXPIRED
276,CA,A1,CA 2663140 A1,167-548-372-681-872,2001-08-16,2001,CA 2663140 A,2001-02-09,US 50220400 A;;US 50244400 A;;US 77928201 A;;CA 2395868 A,2000-02-10,IMPROVED ANALYTE SENSOR AND METHOD OF MAKING THE SAME,"A sensor and method of making the same for implantation in a body that includes a substrate with notches cut in the substrate to form a necked down region in the substrate; and at least one sensor electrode formed from one o r more conductive layers. Preferably, the thickness of the substrate ranges from approximately 25.mu. to 350.mu., but the thickness of the substrate can range from 5.mu. to 750.mu.. The sensor may be incorporated in to a sensor assembl y includes a slotted needle having a slot. The notches creating the necked dow n region allow the substrate to slide into the slotted needle, which has the slot narrow enough to permit passage of the necked down region. However, a non-necked down region of the substrate is prevented from pulling out of the slotted needle through the slot. The slot of the slotted needle may also permit the necked down region of the substrate to slide down the slot.",MEDTRONIC MINIMED INC,HOLKER JAMES D;;VAN ANTWERP NANNETTE M;;VAN ANTWERP WILLIAM PETER;;MASTROTOTARO JOHN JOSEPH;;BRANCH KEVIN D;;CALLE GUILLERMO A,,https://lens.org/167-548-372-681-872,Patent Application,no,0,0,3,18,0,A61B5/14865;;A61M2005/1726;;A61B5/6849;;A61B5/14865;;A61M2005/1726;;A61B5/6849,G01N33/66;;A61B5/00;;G01N33/53,,0,0,,,,DISCONTINUED
277,DE,T2,DE 60212968 T2,080-832-248-377-033,2007-02-01,2007,DE 60212968 T,2002-06-25,GB 0115863 A;;GB 0130342 A;;EP 0207009 W,2001-06-28,N-AROYL-(CYCLISCHES AMIN)-DERIVATE ALS OREXINREZEPTOR ANTAGONISTEN,,SMITHKLINE BEECHAM PLC,BRANCH LESLIE;;CHAN NGOR;;JOHNS AMANDA;;JOHNSON NORBERT;;NASH JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER ALAN;;STEAD ELIZABETH;;STEMP GEOFFREY,,https://lens.org/080-832-248-377-033,Granted Patent,no,0,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,C07D417/14;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/445;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D407/06;;C07D407/14;;C07D409/14;;C07D411/14;;C07D413/14;;C07D417/04;;C07D471/04;;C07D491/04,,0,0,,,,EXPIRED
278,WO,A1,WO 2019/169269 A1,117-569-529-261-614,2019-09-06,2019,US 2019/0020295 W,2019-03-01,US 201862637311 P,2018-03-01,SYSTEMS AND METHODS FOR AUTOMATED ASSESSMENT AND MONITORING OF BODILY FLUIDS,"Systems and methods for automated assessment and monitoring of bodily fluids are disclosed. In one embodiment, a system for provisioning a treatment composition to a bladder of a patient includes: an irrigation bag that carries the treatment composition; a catheter configured for connecting the irrigation bag to the bladder; a flow regulator configured for controlling a flow of the treatment composition from the irrigation bag to the bladder; and a drainage bag in fluid communication with the bladder through a drainage tubing of the catheter. The drainage tubing is configured for draining urine from the bladder. The system also includes: a first sensor for detecting a first amount of the treatment composition in the irrigation bag; a second sensor for detecting a second amount of urine in the drainage bag; a third sensor for detecting a concentration of particles in the urine carried by the drainage bag; and a controller.",UNIV WASHINGTON,CHEN TONY;;SUN JIALU;;SWEET ROBERT;;GORE JOHN;;LIU JONATHAN;;POSNER JONATHAN;;RANDAD AKSHAY;;BRANCH ALLEGRA;;KAMPIANAKIS ELEFTHERIOS;;COVELLI VELEZ CLAUDIA,,https://lens.org/117-569-529-261-614,Patent Application,yes,8,0,2,2,0,A61M3/022;;A61M3/0208;;A61M2210/1085;;A61M3/0212;;A61M3/0204;;A61M2205/3393;;A61M2205/3313;;A61M2205/3375;;A61M2205/50;;A61M3/0241;;A61M2205/3389;;A61M2202/0496;;A61M3/0283;;A61M3/0295;;A61M3/0287;;A61M1/73;;A61M1/777;;A61M1/77;;A61M3/0287;;A61M25/0041;;A61M39/22;;A61M2202/0496;;A61M2205/18;;A61M2205/3313;;A61M2205/3334;;A61M2205/3375;;A61M2205/3393;;A61M3/022;;A61M1/73;;A61M1/77;;A61M1/777;;A61M3/0241;;A61M3/0283,A61M3/02,,1,1,004-180-731-766-023,pmc1864807;;16859225;;10.1080/10790268.2006.11753877,"WAITES ET AL., EVALUATION OF 3 METHODS OF BLADDER IRRIGATION TO TREAT BACTERIURIA IN PERSONS WITH NEUROGENIC BLADDER, 3 November 2006 (2006-11-03)",PENDING
279,DE,D1,DE 60212968 D1,052-425-108-677-76X,2006-08-17,2006,DE 60212968 T,2002-06-25,GB 0115863 A;;GB 0130342 A;;EP 0207009 W,2001-06-28,N-AROYL-(CYCLISCHES AMIN)-DERIVATE ALS OREXINREZEPTOR ANTAGONISTEN,,SMITHKLINE BEECHAM PLC,BRANCH LESLIE;;CHAN NGOR;;JOHNS AMANDA;;JOHNSON NORBERT;;NASH JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER ALAN;;STEAD ELIZABETH;;STEMP GEOFFREY,,https://lens.org/052-425-108-677-76X,Granted Patent,no,0,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/4184;;C07D417/14;;A61K31/426;;C07D491/048;;A61K31/445;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D407/06;;C07D407/14;;C07D409/14;;C07D411/14;;C07D413/14;;C07D417/04;;C07D471/04;;C07D491/04,,0,0,,,,EXPIRED
280,US,A1,US 2004/0180887 A1,030-791-275-730-216,2004-09-16,2004,US 48113304 A,2004-04-26,EP 0207009 W;;GB 0115863 A;;GB 0130342 A,2001-06-28,N-aroyl cyclic amine derivatives as orexin receptor antagonists,"
    This invention relates to N-aroyl cyclic amine derivatives of formula (1), wherein X represents a bond, oxygen, NR ³ or a group (CH ₂ ), wherein n represents 1, 2 or 3; Y represents CH ₂ , CO, CH(OH), or CH ₂ CH(OH); Het is an optionally substituted bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; Ar ² represents an optionally substituted phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S and their use as pharmaceuticals, specifically as orexin receptor antagonists. 
",BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,SMITHKLINE BEECHAM LIMITED (2003-12-03),https://lens.org/030-791-275-730-216,Patent Application,yes,8,29,33,36,1,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/4184;;A61K31/426;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;C07D491/048;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,514/232.5;;514/252.02;;514/252.13;;514/254.09;;514/254.02;;514/254.05;;514/326;;544/124;;544/114;;544/132;;544/238;;544/359;;544/369;;X54437;;544/371;;546/207;;546/209;;X54621,0,0,,,,EXPIRED
281,US,A1,US 2008/0318944 A1,013-907-198-416-682,2008-12-25,2008,US 92640907 A,2007-10-29,US 92640907 A;;GB 0115863 A;;GB 0130342 A;;US 48113304 A;;EP 0207009 W,2001-06-28,N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,"Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.",SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,SMITHKLINE BEECHAM LIMITED (2009-10-27),https://lens.org/013-907-198-416-682,Patent Application,yes,8,0,33,36,1,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/454;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/4525;;A61K31/453;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,514/233.5;;546/196;;546/175;;546/194;;544/130;;544/333;;546/146;;546/199;;514/256;;514/318;;514/320;;514/322,0,0,,,,EXPIRED
282,AT,T1,AT E332300 T1,015-403-015-588-603,2006-07-15,2006,AT 02754750 T,2002-06-25,GB 0115863 A;;GB 0130342 A,2001-06-28,N-AROYL-(CYCLISCHES AMIN)-DERIVATE ALS OREXINREZEPTOR ANTAGONISTEN,,SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,,https://lens.org/015-403-015-588-603,Granted Patent,no,0,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,C07D491/048;;A61K31/4184;;A61K31/426;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,,0,0,,,,EXPIRED
283,EP,B1,EP 1399441 B1,148-642-877-145-890,2006-07-05,2006,EP 02754750 A,2002-06-25,EP 0207009 W;;GB 0115863 A;;GB 0130342 A,2001-06-28,N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,,SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,,https://lens.org/148-642-877-145-890,Granted Patent,yes,4,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,C07D417/14;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/445;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D407/06;;C07D407/14;;C07D409/14;;C07D411/14;;C07D413/14;;C07D417/04;;C07D471/04;;C07D491/04,,0,0,,,,EXPIRED
284,WO,A1,WO 2003/002561 A1,007-014-522-964-942,2003-01-09,2003,EP 0207009 W,2002-06-25,GB 0115863 A;;GB 0130342 A,2001-06-28,N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,"This invention relates to N-aroyl cyclic amine derivatives of formula (I), wherein X represents a bond, oxygen , NR3 or a group (CH¿2?), wherein n represents 1, 2 or 3; Y represents CH2, CO, CH(OH), or CH2CH(OH); Het is an optionally substituted bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; Ar?2¿ represents an optionally substituted phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S and their use as pharmaceuticals, specifically as orexin receptor antagonists.",SMITHKLINE BEECHAM PLC;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,,https://lens.org/007-014-522-964-942,Patent Application,yes,4,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/4184;;A61K31/426;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;C07D491/048;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,,0,0,,,,PATENTED
285,US,B2,US 7893090 B2,090-996-247-591-912,2011-02-22,2011,US 92807207 A,2007-10-30,US 92807207 A;;GB 0115863 A;;GB 0130342 A;;US 48113304 A;;EP 0207009 W,2001-06-28,N-aroyl cyclic amine derivatives as orexin receptor antagonists,"Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.",SMITHKLINE BEECHAM LTD,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,SMITHKLINE BEECHAM LIMITED (2009-10-27),https://lens.org/090-996-247-591-912,Granted Patent,yes,12,0,33,36,1,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/4525;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,514/320;;546/196,30,28,138-203-456-051-370;;007-923-861-080-314;;012-694-121-059-071;;035-230-547-171-641;;099-184-466-878-140;;037-469-660-808-218;;009-754-100-164-028;;011-298-048-949-13X;;000-221-724-823-643;;002-534-268-092-196;;002-849-210-009-421;;012-351-604-758-470;;015-451-806-293-402;;029-836-899-292-569;;045-228-127-987-257;;034-882-327-596-637;;057-803-665-807-229;;083-018-851-541-531;;046-641-365-452-325;;082-858-121-007-885;;088-688-006-859-838;;008-837-569-840-780;;036-128-714-171-303;;029-287-258-575-906;;012-469-368-317-65X;;051-058-212-425-724;;022-621-934-382-031;;134-806-580-190-885,10.1038/nm1544;;17259994;;10.1073/pnas.96.19.10911;;10485925;;pmc17982;;10712652;;10.1046/j.1460-9568.2000.00919.x;;10.1021/cr950066q;;11848856;;16357203;;10.1073/pnas.0507480102;;pmc1323172;;16476667;;10.1016/j.neuron.2006.01.016;;16100511;;10.1038/nature04071;;10.1248/cpb.32.3840;;6529791;;10.1002/hlca.19920750108;;10.1021/jm030982t;;14971895;;10.1016/s0014-2999(02)01429-2;;12007536;;pmc1574197;;14691055;;10.1038/sj.bjp.0705610;;11459658;;10.1016/s0960-894x(01)00343-2;;11205420;;10.1007/s002130000550;;15893404;;10.1016/j.peptides.2005.03.042;;10.1016/j.bbr.2004.11.011;;15836896;;15639184;;10.1016/j.bbr.2004.07.012;;15059692;;10.1016/j.physbeh.2004.01.009;;10.1016/s0304-3940(03)00066-1;;12697296;;10.1016/s0167-0115(01)00358-5;;11830290;;10.1016/s0304-3959(00)00470-x;;11323129;;11298806;;10.1046/j.0953-816x.2001.01518.x;;10.1038/sj.bjp.0703953;;11250867;;pmc1572677;;10.1007/s002130000551;;11205421;;11102651;;10.1016/s0167-0115(00)00199-3;;12450737;;10.1016/s0143-4179(02)00085-9;;10906799;;10.1016/s0166-2236(00)01594-0;;10.1146/annurev.neuro.25.112701.142826;;12052911,"Brisbare-Roch et al. Nature Medicine, 13(2): 150-155 (2007).;;Hagan et al. Proc. Natl. Acad. Sci. USA., 96: 10911-10916 (1999).;;Piper et al. Eur. J. Neurosci., 12: 726-730 (2000).;;Patani et al. Chem. Rev., 96: 3147-3176 (1996).;;Boutrel et al. PNAS, 102(52): 19168-19173 (2005).;;Borglund et al. Neuron, 49: 589-601 (2006).;;Harris et al. Nature, 437: 556-559 (2005).;;Mori et al. Chem. Pharm. Bull., 32(10): 3840-3847 (1984).;;Defoin et al. Helv. Chim. Acta, 75(1): 109-123 (1992).;;Lang et al. J. Med. Chem., 47: 1153-1160 (2004).;;Smart et al. Euro. J. Pharm., 440: 199-212 (2002).;;Langmead et al. Br. J. Pharmacol., 141: 340-346 (2004).;;Porter et al. Bioorg. & Med. Chem. Lett., 11: 1907-1910 (2001).;;Duxon et al. Psychopharmacology, 153: 203-209 (2001).;;White et al. Peptides, 26: 2331-2338 (2005).;;Ishii et al. Behav. Brain Res., 160: 11-24 (2005).;;Ishii et al. Behav. Brain Res., 157: 331-341 (2005).;;Ishii et al. Physiol. & Behav., 81: 129-140 (2004).;;Smith et al. Neurosci. Lett., 341: 256-258 (2003).;;Haynes et al. Regulatory Peptides, 104: 153-159 (2002).;;Bingham et al. Pain, 92: 81-90 (2001).;;Rodgers et al. Eur. J. Neurosci., 13: 1444-1452 (2001).;;Smart et al. Br. J. Pharmacol., 132: 1179-1182 (2001).;;Jones et al. Psychopharmacology, 153: 210-218 (2001).;;Haynes et al. Regulatory Peptides, 96: 45-51 (2000).;;Rodgers et al. Neuropeptides, 36(5): 303-325 (2002).;;Patini et al., Chem. Rev., 96: 3147-3148 (1996).;;Kilduff et al. Trends Neurosci., 23: 359-365 (2000).;;Taheri et al. Annu. Rev. Neurosci., 25: 283-313 (2002).;;Cai et al. Expert Opin. Ther. Patents, 16(5): 631-646 (2006).",EXPIRED
286,US,A1,US 2009/0036442 A1,165-268-119-132-475,2009-02-05,2009,US 92637507 A,2007-10-29,US 92637507 A;;GB 0115863 A;;GB 0130342 A;;US 48113304 A;;EP 0207009 W,2001-06-28,N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,"Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.",SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,SMITHKLINE BEECHAM LIMITED (2009-10-27),https://lens.org/165-268-119-132-475,Patent Application,yes,8,0,33,36,1,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/454;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/4525;;A61K31/453;;A61K31/4545;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;A61P43/00;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,514/233.5;;514/314;;514/307;;546/195;;546/168;;546/194;;544/130;;544/333;;546/146;;514/256;;514/318;;514/320;;514/322;;546/199,0,0,,,,EXPIRED
287,HU,A2,HU P0400326 A2,083-442-099-104-837,2004-09-28,2004,HU P0400326 A,2002-06-25,EP 0207009 W;;GB 0115863 A;;GB 0130342 A,2001-06-28,N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,"A találmány (I) általános képletű vegyületekre - amelyek képletében Xjelentése kémiai kötés, oxigénatom, NR3 vagy -(CH2)n- általánosképletű csoport; n értéke 1, 2 vagy 3; Y jelentése CH2, CO, CH(OH)vagy -CH2CH(OH)- képletű csoport; Het jelentése a nitrogén-, oxigén-és kénatom közül kiválasztott legfeljebb 4 heteroatomot tartalmazó,adott esetben szubsztituált biciklusos heteroarilcsoport; Ar2jelentése fenilcsoport vagy a nitrogén-, oxigén- és kénatom közülkiválasztott legfeljebb 3 heteroatomot tartalmazó öt- vagy hattagúheterociklusos csoport, ahol a fenilcsoport vagy a heterociklusoscsoport R1 csoporttal és adott esetben további szubsztituensekkelszubsztituált; vagy Ar2 jelentése adott esetben szubsztituáltbiciklusos aromás vagy adott esetben szubsztituált, a nitrogén-,oxigén- és kénatom közül kiválasztott legfeljebb 3 heteroatomottartalmazó biciklusos heteroaromás csoport; Rl jelentése hidrogénatom,adott esetben szubsztituált 1-4 szénatomos alkoxicsoport, halogénatom,cianocsoport, adott esetben szubsztituált 1-6 szénatomos alkilcsoport,adott esetben szubsztituált fenilcsoport vagy adott esetbenszubsztituált, a nitrogén-, oxigén- és kénatom közül kiválasztottlegfeljebb 4 heteroatomot tartalmazó, öt- vagy hattagú heterociklusoscsoport; R3 jelentése hidrogénatom vagy adott esetben szubsztituált 1-4 szénatomos alkilcsoport, ami más, mint ha Het jelentéseindolilcsoport, ahol R3 jelentése hidrogénatom vagy 1-4 szénatomosalkilcsoport; és gyógyászatilag elfogadható sóik, valamint avegyületek gyógyszerészeti alkalmazására, közelebbről orexin receptorantagonistákként történő felhasználására vonatkozik. Ó",SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,,https://lens.org/083-442-099-104-837,Patent Application,no,0,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/4184;;A61K31/426;;C07D491/048;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,,0,0,,,,DISCONTINUED
288,PL,A1,PL 367677 A1,141-808-040-274-466,2005-03-07,2005,PL 36767702 A,2002-06-25,GB 0115863 A;;GB 0130342 A,2001-06-28,N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,,SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,,https://lens.org/141-808-040-274-466,Patent Application,no,0,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/4184;;A61K31/426;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;C07D491/048;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,,0,0,,,,DISCONTINUED
289,US,B2,US 7897618 B2,147-949-076-685-416,2011-03-01,2011,US 92637507 A,2007-10-29,US 92637507 A;;GB 0115863 A;;GB 0130342 A;;US 48113304 A;;EP 0207009 W,2001-06-28,N-aroyl cyclic amine derivatives as orexin receptor antagonists,"Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.",SMITHKLINE BEECHAM LTD,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,SMITHKLINE BEECHAM LIMITED (2009-10-27),https://lens.org/147-949-076-685-416,Granted Patent,yes,12,0,33,36,1,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/4545;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/453;;A61K31/454;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,514/307;;514/309;;514/310;;546/141;;546/143;;546/145;;546/146,30,28,138-203-456-051-370;;007-923-861-080-314;;012-694-121-059-071;;035-230-547-171-641;;099-184-466-878-140;;037-469-660-808-218;;009-754-100-164-028;;011-298-048-949-13X;;000-221-724-823-643;;002-534-268-092-196;;002-849-210-009-421;;012-351-604-758-470;;015-451-806-293-402;;029-836-899-292-569;;045-228-127-987-257;;034-882-327-596-637;;057-803-665-807-229;;083-018-851-541-531;;046-641-365-452-325;;082-858-121-007-885;;088-688-006-859-838;;008-837-569-840-780;;036-128-714-171-303;;029-287-258-575-906;;012-469-368-317-65X;;051-058-212-425-724;;022-621-934-382-031;;134-806-580-190-885,10.1038/nm1544;;17259994;;10.1073/pnas.96.19.10911;;10485925;;pmc17982;;10712652;;10.1046/j.1460-9568.2000.00919.x;;10.1021/cr950066q;;11848856;;16357203;;10.1073/pnas.0507480102;;pmc1323172;;16476667;;10.1016/j.neuron.2006.01.016;;16100511;;10.1038/nature04071;;10.1248/cpb.32.3840;;6529791;;10.1002/hlca.19920750108;;10.1021/jm030982t;;14971895;;10.1016/s0014-2999(02)01429-2;;12007536;;pmc1574197;;14691055;;10.1038/sj.bjp.0705610;;11459658;;10.1016/s0960-894x(01)00343-2;;11205420;;10.1007/s002130000550;;15893404;;10.1016/j.peptides.2005.03.042;;10.1016/j.bbr.2004.11.011;;15836896;;15639184;;10.1016/j.bbr.2004.07.012;;15059692;;10.1016/j.physbeh.2004.01.009;;10.1016/s0304-3940(03)00066-1;;12697296;;10.1016/s0167-0115(01)00358-5;;11830290;;10.1016/s0304-3959(00)00470-x;;11323129;;11298806;;10.1046/j.0953-816x.2001.01518.x;;10.1038/sj.bjp.0703953;;11250867;;pmc1572677;;10.1007/s002130000551;;11205421;;11102651;;10.1016/s0167-0115(00)00199-3;;12450737;;10.1016/s0143-4179(02)00085-9;;10906799;;10.1016/s0166-2236(00)01594-0;;10.1146/annurev.neuro.25.112701.142826;;12052911,"Brisbare-Roch et al. Nature Medicine, 13(2): 150-155 (2007).;;Hagan et al. Proc. Natl. Acad. Sci. USA., 96: 10911-10916 (1999).;;Piper et al. Eur. J. Neurosci., 12: 726-730 (2000).;;Patani et al. Chem. Rev., 96: 3147-3176 (1996).;;Boutrel et al. PNAS, 102(52): 19168-19173 (2005).;;Borglund et al. Neuron, 49: 589-601 (2006).;;Harris et al. Nature, 437: 556-559 (2005).;;Mori et al. Chem. Pharm. Bull., 32(10): 3840-3847 (1984).;;Defoin et al. Helv. Chim. Acta, 75(1): 109-123 (1992).;;Lang et al. J. Med. Chem., 47: 1153-1160 (2004).;;Smart et al. Euro. J. Pharm., 440: 199-212 (2002).;;Langmead et al. Br. J. Pharmacol., 141: 340-346 (2004).;;Porter et al. Bioorg. & Med. Chem. Lett., 11: 1907-1910 (2001).;;Duxon et al. Psychopharmacology, 153: 203-209 (2001).;;White et al. Peptides, 26: 2331-2338 (2005).;;Ishii et al. Behav. Brain Res., 160: 11-24 (2005).;;Ishii et al. Behav. Brain Res., 157: 331-341 (2005).;;Ishii et al. Physiol. & Behav., 81: 129-140 (2004).;;Smith et al. Neurosci. Lett., 341: 256-258 (2003).;;Haynes et al. Regulatory Peptides, 104: 153-159 (2002).;;Bingham et al. Pain, 92: 81-90 (2001).;;Rodgers et al. Eur. J. Neurosci., 13: 1444-1452 (2001).;;Smart et al. Br. J. Pharmacol., 132: 1179-1182 (2001).;;Jones et al. Psychopharmacology, 153: 210-218 (2001).;;Haynes et al. Regulatory Peptides, 96: 45-51 (2000).;;Rodgers et al. Neuropeptides, 36(5): 303-325 (2002).;;Patini et al., Chem. Rev., 96: 3147-3148 (1996).;;Kilduff et al. Trends Neurosci., 23: 359-365 (2000).;;Taheri et al. Annu. Rev. Neurosci., 25: 283-313 (2002).;;Cai et al. Expert Opin. Ther. Patents, 16(5): 631-646 (2006).",EXPIRED
290,US,B2,US 7928125 B2,055-279-661-414-208,2011-04-19,2011,US 92640907 A,2007-10-29,US 92640907 A;;GB 0115863 A;;GB 0130342 A;;US 48113304 A;;EP 0207009 W,2001-06-28,N-aroyl cyclic amine derivatives as orexin receptor antagonists,"Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.",SMITHKLINE BEECHAM LTD,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,SMITHKLINE BEECHAM LIMITED (2009-10-27),https://lens.org/055-279-661-414-208,Granted Patent,yes,12,0,33,36,1,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/454;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/4525;;A61K31/453;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,514/320;;546/196,30,28,138-203-456-051-370;;007-923-861-080-314;;012-694-121-059-071;;035-230-547-171-641;;099-184-466-878-140;;037-469-660-808-218;;009-754-100-164-028;;011-298-048-949-13X;;000-221-724-823-643;;002-534-268-092-196;;002-849-210-009-421;;012-351-604-758-470;;015-451-806-293-402;;029-836-899-292-569;;045-228-127-987-257;;034-882-327-596-637;;057-803-665-807-229;;083-018-851-541-531;;046-641-365-452-325;;082-858-121-007-885;;088-688-006-859-838;;008-837-569-840-780;;036-128-714-171-303;;029-287-258-575-906;;012-469-368-317-65X;;051-058-212-425-724;;022-621-934-382-031;;134-806-580-190-885,10.1038/nm1544;;17259994;;10.1073/pnas.96.19.10911;;10485925;;pmc17982;;10712652;;10.1046/j.1460-9568.2000.00919.x;;10.1021/cr950066q;;11848856;;16357203;;10.1073/pnas.0507480102;;pmc1323172;;16476667;;10.1016/j.neuron.2006.01.016;;16100511;;10.1038/nature04071;;10.1248/cpb.32.3840;;6529791;;10.1002/hlca.19920750108;;10.1021/jm030982t;;14971895;;10.1016/s0014-2999(02)01429-2;;12007536;;pmc1574197;;14691055;;10.1038/sj.bjp.0705610;;11459658;;10.1016/s0960-894x(01)00343-2;;11205420;;10.1007/s002130000550;;15893404;;10.1016/j.peptides.2005.03.042;;10.1016/j.bbr.2004.11.011;;15836896;;15639184;;10.1016/j.bbr.2004.07.012;;15059692;;10.1016/j.physbeh.2004.01.009;;10.1016/s0304-3940(03)00066-1;;12697296;;10.1016/s0167-0115(01)00358-5;;11830290;;10.1016/s0304-3959(00)00470-x;;11323129;;11298806;;10.1046/j.0953-816x.2001.01518.x;;10.1038/sj.bjp.0703953;;11250867;;pmc1572677;;10.1007/s002130000551;;11205421;;11102651;;10.1016/s0167-0115(00)00199-3;;12450737;;10.1016/s0143-4179(02)00085-9;;10906799;;10.1016/s0166-2236(00)01594-0;;10.1146/annurev.neuro.25.112701.142826;;12052911,"Brisbare-Roch et al. Nature Medicine, 13(2): 150-155 (2007).;;Hagan et al. Proc. Natl. Acad. Sci. USA., 96: 10911-10916 (1999).;;Piper et al. Eur. J. Neurosci., 12: 726-730 (2000).;;Patani et al. Chem. Rev., 96: 3147-3176 (1996).;;Boutrel et al. PNAS, 102(52): 19168-19173 (2005).;;Borglund et al. Neuron, 49: 589-601 (2006).;;Harris et al. Nature, 437: 556-559 (2005).;;Mori et al. Chem. Pharm. Bull., 32(10): 3840-3847 (1984).;;Defoin et al. Helv. Chim. Acta, 75(1): 109-123 (1992).;;Lang et al. J. Med. Chem., 47: 1153-1160 (2004).;;Smart et al. Euro. J. Pharm., 440: 199-212 (2002).;;Langmead et al. Br. J. Pharmacol., 141: 340-346 (2004).;;Porter et al. Bioorg. & Med. Chem. Lett., 11: 1907-1910 (2001).;;Duxon et al. Psychopharmacology, 153: 203-209 (2001).;;White et al. Peptides, 26: 2331-2338 (2005).;;Ishii et al. Behav. Brain Res., 160: 11-24 (2005).;;Ishii et al. Behav. Brain Res., 157: 331-341 (2005).;;Ishii et al. Physiol. & Behay., 81: 129-140 (2004).;;Smith et al. Neurosci. Lett., 341: 256-258 (2003).;;Haynes et al. Regulatory Peptides, 104: 153-159 (2002).;;Bingham et al. Pain, 92: 81-90 (2001).;;Rodgers et al. Eur. J. Neurosci., 13: 1444-1452 (2001).;;Smart et al. Br. J. Pharmacol., 132: 1179-1182 (2001).;;Jones et al. Psychopharmacology, 153: 210-218 (2001).;;Haynes et al. Regulatory Peptides, 96: 45-51 (2000).;;Rodgers et al. Neuropeptides, 36(5): 303-325 (2002).;;Patini et al., Chem. Rev., 96: 3147-3148 (1996).;;Kilduff et al. Trends Neurosci., 23: 359-365 (2000).;;Taheri et al. Annu. Rev. Neurosci., 25: 283-313 (2002).;;Cai et al. Expert Opin. Ther. Patents, 16(5): 631-646 (2006).",EXPIRED
291,NO,L,NO 20035739 L,031-281-508-570-177,2004-02-24,2004,NO 20035739 A,2003-12-19,EP 0207009 W;;GB 0115863 A;;GB 0130342 A,2001-06-28,N-aroyl syklisk aminderivater som orexin reseptorantagonister,,SMITHKLINE BEECHAM PLC,STEMP GEOFFREY;;CHAN WAI NGOR;;JOHNS AMANDA;;BRANCH CLIVE LESLIE;;JOHNSON CHRISTOPHER NORBERT;;PORTER RODERICK ALAN;;NOVELLI RICCARDO;;NASH DAVID JOHN;;PILLEUX JEAN-PIERRE;;STEAD RACHEL ELIZABETH ANNE,,https://lens.org/031-281-508-570-177,Abstract,no,0,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,C07D417/14;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/445;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D471/04;;C07D491/04,,0,0,,,,DISCONTINUED
292,NO,D0,NO 20035739 D0,116-345-133-227-47X,2003-12-19,2003,NO 20035739 A,2003-12-19,EP 0207009 W;;GB 0115863 A;;GB 0130342 A,2001-06-28,N-aroyl syklisk aminderivater som orexin reseptorantagonister,,SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,,https://lens.org/116-345-133-227-47X,Patent Application,no,0,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,,0,0,,,,DISCONTINUED
293,EP,A1,EP 1399441 A1,156-805-934-053-030,2004-03-24,2004,EP 02754750 A,2002-06-25,EP 0207009 W;;GB 0115863 A;;GB 0130342 A,2001-06-28,N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,,SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,,https://lens.org/156-805-934-053-030,Patent Application,yes,0,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/4184;;A61K31/426;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;C07D491/048;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,,0,0,,,,EXPIRED
294,ZA,B,ZA 200309293 B,025-513-376-019-203,2004-07-22,2004,ZA 200309293 A,2003-11-28,GB 0115863 A,2001-06-28,N-aroyl cyclic amine derivatives as orexin receptor antagonists.,,SMITHKLINE BEECHAM PLC,LESLIE BRANCH CLIVE;;JOHNS AMANDA;;JOHN NASH DAVID;;PILLEUX JEAN-PIERRE;;ANNE STEAD RACHEL ELIZABETH;;NGOR CHAN WAI;;NORBERT JOHNSON CHRISTOPHER;;NOVELLI RICCARDO;;ALAN PORTER RODERICK;;STEMP GEOFFREY,,https://lens.org/025-513-376-019-203,Granted Patent,no,0,0,2,36,0,,A61K/;;A61P/;;C07D/,,0,0,,,,EXPIRED
295,US,A1,US 2009/0012083 A1,057-970-092-200-945,2009-01-08,2009,US 92639807 A,2007-10-29,US 92639807 A;;GB 0115863 A;;GB 0130342 A;;US 48113304 A;;EP 0207009 W,2001-06-28,N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,"Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.",SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,SMITHKLINE BEECHAM LIMITED (2009-10-27),https://lens.org/057-970-092-200-945,Patent Application,yes,7,1,33,36,1,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/454;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/4525;;A61K31/453;;A61K31/4545;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,514/234.5;;546/196;;546/194;;546/168;;544/130;;544/333;;546/146;;546/199;;514/320;;514/318;;514/314;;514/307;;514/233.5;;514/256;;514/322,0,0,,,,EXPIRED
296,EP,A1,EP 1705179 A1,153-061-657-763-406,2006-09-27,2006,EP 06013820 A,2002-06-25,EP 02754750 A;;GB 0115863 A;;GB 0130342 A,2001-06-28,N-aroyl cyclic amine derivatives as orexin receptor antagonists,"This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals, specifically as orexin receptor antagonists.
 ",SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAL NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,SMITHKLINE BEECHAM LIMITED (2010-04-21),https://lens.org/153-061-657-763-406,Patent Application,yes,4,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,C07D417/14;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/445;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D211/00;;C07D213/00;;C07D231/00;;C07D263/00;;C07D271/00;;C07D277/00;;C07D307/00;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D407/06;;C07D407/14;;C07D409/14;;C07D411/14;;C07D413/14;;C07D417/04;;C07D471/04;;C07D491/04,,0,0,,,,DISCONTINUED
297,CA,A1,CA 2451464 A1,155-246-464-524-162,2003-01-09,2003,CA 2451464 A,2002-06-25,EP 0207009 W;;GB 0115863 A;;GB 0130342 A,2001-06-28,N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,"This invention relates to N-aroyl cyclic amine derivatives of formula (I), wherein X represents a bond, oxygen , NR3 or a group (CH2), wherein n represents 1, 2 or 3; Y represents CH2, CO, CH(OH), or CH2CH(OH); Het is an optionally substituted bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; Ar2 represents an optionally substitut ed phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroato ms selected from N, O and S and their use as pharmaceuticals, specifically as orexin receptor antagonists.",SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;JOHNS AMANDA;;PILLEUX JEAN-PIERRE;;NOVELLI RICCARDO;;STEMP GEOFFREY;;JOHNSON CHRISTOPHER NORBERT;;STEAD RACHEL ELIZABETH ANNE,,https://lens.org/155-246-464-524-162,Patent Application,no,0,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,C07D491/048;;A61K31/4184;;A61K31/426;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,,0,0,,,,DISCONTINUED
298,US,B2,US 7470710 B2,078-211-420-832-189,2008-12-30,2008,US 48113304 A,2004-04-26,EP 0207009 W;;GB 0115863 A;;GB 0130342 A,2001-06-28,N-aroyl cyclic amine derivatives as orexin receptor antagonists,"This invention relates to N-aroyl cyclic amine derivatives of formula (I), wherein X represents a bond, oxygen, NR 3 or a group (CH 2 ), wherein n represents 1, 2 or 3; Y represents CH 2 , CO, CH(OH), or CH 2 CH(OH); Het is an optionally substituted bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; Ar 2 represents an optionally substituted phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S and their use as pharmaceuticals, specifically as orexin receptor antagonists.",SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,SMITHKLINE BEECHAM LIMITED (2003-12-03),https://lens.org/078-211-420-832-189,Granted Patent,yes,12,4,33,36,1,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/4525;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/453;;A61K31/4535;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D407/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,514/320;;514/321;;514/322;;514/323;;514/324;;546/196;;546/198;;546/199;;546/202,30,30,002-534-268-092-196;;002-849-210-009-421;;035-230-547-171-641;;022-621-934-382-031;;134-806-580-190-885;;010-282-085-965-89X;;011-298-048-949-13X;;000-221-724-823-643;;012-351-604-758-470;;015-451-806-293-402;;029-836-899-292-569;;045-228-127-987-257;;034-882-327-596-637;;057-803-665-807-229;;083-018-851-541-531;;046-641-365-452-325;;082-858-121-007-885;;088-688-006-859-838;;008-837-569-840-780;;036-128-714-171-303;;029-287-258-575-906;;012-469-368-317-65X;;051-058-212-425-724;;099-184-466-878-140;;037-469-660-808-218;;009-754-100-164-028;;138-203-456-051-370;;007-923-861-080-314;;012-694-121-059-071;;035-230-547-171-641,10.1021/jm030982t;;14971895;;10.1016/s0014-2999(02)01429-2;;12007536;;10.1021/cr950066q;;11848856;;10906799;;10.1016/s0166-2236(00)01594-0;;10.1146/annurev.neuro.25.112701.142826;;12052911;;10.1517/13543776.16.5.631;;10.1248/cpb.32.3840;;6529791;;10.1002/hlca.19920750108;;pmc1574197;;14691055;;10.1038/sj.bjp.0705610;;11459658;;10.1016/s0960-894x(01)00343-2;;11205420;;10.1007/s002130000550;;15893404;;10.1016/j.peptides.2005.03.042;;10.1016/j.bbr.2004.11.011;;15836896;;15639184;;10.1016/j.bbr.2004.07.012;;15059692;;10.1016/j.physbeh.2004.01.009;;10.1016/s0304-3940(03)00066-1;;12697296;;10.1016/s0167-0115(01)00358-5;;11830290;;10.1016/s0304-3959(00)00470-x;;11323129;;11298806;;10.1046/j.0953-816x.2001.01518.x;;10.1038/sj.bjp.0703953;;11250867;;pmc1572677;;10.1007/s002130000551;;11205421;;11102651;;10.1016/s0167-0115(00)00199-3;;12450737;;10.1016/s0143-4179(02)00085-9;;16357203;;10.1073/pnas.0507480102;;pmc1323172;;16476667;;10.1016/j.neuron.2006.01.016;;16100511;;10.1038/nature04071;;10.1038/nm1544;;17259994;;10.1073/pnas.96.19.10911;;10485925;;pmc17982;;10712652;;10.1046/j.1460-9568.2000.00919.x;;10.1021/cr950066q;;11848856,"Lang et al., J. Med. Chem., 2004, 47, p. 1153-1160.;;Smart et al., Euro. J. Pharm., 2002, 440, p. 199-212.;;Patini et al., ""Bioisosterism: A Rational, etc.,"" Chem. Rev. 1996, 96, 3147-3418, 3170.;;Kildufff et atl., ""The hypocretin/orexin, etc.,"" Trends Neurosci., 2000, 23, 359-365.;;Taheri et al., ""The Role of Hypocretins, etc.,"" Annu. Rev. Neurosci., 2002, 25: 283-313.;;Cai et al., ""Antagonists of the orexin rexeptors"", Expert Opin. Ther. Patents (2006) 16(5), 631-646.;;Mori et al. Chem. Pharm. Bull., 32(10): 3840-3847 (1984).;;Defoin et al. Helv. Chim. Acta, 75(1): 109-123 (1992).;;Langmead et al. Br. J. Pharmacol., 141: 340-346 (2004).;;Porter et al. Bioorg. & Med. Chem. Lett., 11: 1907-1910 (2001).;;Duxon et al. Psychopharmacology, 153: 203-209 (2001).;;White et al. Peptides, 26: 2331-2338 (2005).;;Ishii et al. Behav. Brain Res., 160: 11-24 (2005).;;Ishii et al. Behav. Brain Res., 157:331-341 (2005).;;Ishii et al. Physiol. & Behav., 81: 129-140 (2004).;;Smith et al. Neurosci. Lett., 341: 256-258 (2003).;;Haynes et al. Regulatory Peptides, 104: 153-159 (2002).;;Bingham et al. Pain, 92: 81-90 (2001).;;Rodgers et al. Eur. J. Neurosci., 13: 1444-1452 (2001).;;Smart et al. Br. J. Pharmacol., 132: 1179-1182 (2001).;;Jones et al. Psychopharmacology, 153: 210-218 (2001).;;Haynes et al. Regulatory Peptides, 96:45-51 (2000).;;Rodgers et al. Neuropeptides, 36(5): 303-325 (2002).;;Boutrel et al. PNAS, 102(52): 19168-19173 (2005).;;Borglund et al. Neuron, 49: 589-601 (2006).;;Harris et al. Nature, 437: 556-559 (2005).;;Brisbare-Roch et al. Nature Medicine, 13(2): 150-155 (2007).;;Hagan et al. Proc. Natl. Acad. Sci. USA., 96: 10911-10916 (1999).;;Piper et al. Eur. J. Neurosci., 12: 726-730 (2000).;;Patani et al. Chem. Rev., 96: 3147-3176 (1996).",EXPIRED
299,BR,A,BR 0210609 A,116-283-960-514-404,2004-07-20,2004,BR 0210609 A,2002-06-25,EP 0207009 W;;GB 0115863 A;;GB 0130342 A,2001-06-28,Derivados de amina cìclica n-aroila como antagonistas do receptor da orexina,"""DERIVADOS DE AMINA CìCLICA N-AROILA COMO ANTAGONISTAS DO RECEPTOR DA OREXINA"". Esta invenção diz respeito a derivados de amina cíclica N-aroila de fórmula (1), em que X representa uma ligação, oxigênio, NR^ 3^ ou um grupo (CH~ 2~), em que n representa 1, 2 ou 3; Y representa CH~ 2~, CO, CH (OH), ou CH~ 2~CH (OH); Het é um grupo heteroarila bicíclica opcionalmente substituído que contém até 4 heteroátomos selecionados de N, 0 e S; Ar^ 2^ N representa um grupo fenila ou heterociclila 5 ou 6 membrado opcionalmente substituído que contém até 3 heteroátomos selecionados de N, 0 e S e o uso dos mesmo como produtos farmacêuticos, especificamente como antagonistas do receptor da orexina.",SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,,https://lens.org/116-283-960-514-404,Patent Application,no,0,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,C07D491/048;;A61K31/4184;;A61K31/426;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,,0,0,,,,DISCONTINUED
300,CZ,A3,CZ 20033437 A3,173-796-878-661-625,2004-09-15,2004,CZ 20033437 A,2002-06-25,GB 0115863 A;;GB 0130342 A,2001-06-28,N-aroyl cyclic amine derivatives functioning as orexin receptor antagonists,,SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,,https://lens.org/173-796-878-661-625,Patent Application,no,0,0,33,36,0,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/4184;;A61K31/426;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;C07D491/048;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,,0,0,,,,PENDING
301,US,B2,US 7928124 B2,034-049-858-440-13X,2011-04-19,2011,US 92639807 A,2007-10-29,US 92639807 A;;GB 0115863 A;;GB 0130342 A;;US 48113304 A;;EP 0207009 W,2001-06-28,N-aroyl cyclic amine derivatives as orexin receptor antagonists,"Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.",SMITHKLINE BEECHAM LTD,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,SMITHKLINE BEECHAM LIMITED (2009-10-27),https://lens.org/034-049-858-440-13X,Granted Patent,yes,12,0,33,36,1,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/4433;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/444;;A61K31/453;;A61K31/454;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,514/318;;546/193,30,28,099-184-466-878-140;;037-469-660-808-218;;009-754-100-164-028;;011-298-048-949-13X;;000-221-724-823-643;;002-534-268-092-196;;002-849-210-009-421;;012-351-604-758-470;;015-451-806-293-402;;029-836-899-292-569;;045-228-127-987-257;;034-882-327-596-637;;057-803-665-807-229;;083-018-851-541-531;;046-641-365-452-325;;082-858-121-007-885;;088-688-006-859-838;;008-837-569-840-780;;036-128-714-171-303;;029-287-258-575-906;;012-469-368-317-65X;;051-058-212-425-724;;022-621-934-382-031;;134-806-580-190-885;;138-203-456-051-370;;007-923-861-080-314;;012-694-121-059-071;;035-230-547-171-641,16357203;;10.1073/pnas.0507480102;;pmc1323172;;16476667;;10.1016/j.neuron.2006.01.016;;16100511;;10.1038/nature04071;;10.1248/cpb.32.3840;;6529791;;10.1002/hlca.19920750108;;10.1021/jm030982t;;14971895;;10.1016/s0014-2999(02)01429-2;;12007536;;pmc1574197;;14691055;;10.1038/sj.bjp.0705610;;11459658;;10.1016/s0960-894x(01)00343-2;;11205420;;10.1007/s002130000550;;15893404;;10.1016/j.peptides.2005.03.042;;10.1016/j.bbr.2004.11.011;;15836896;;15639184;;10.1016/j.bbr.2004.07.012;;15059692;;10.1016/j.physbeh.2004.01.009;;10.1016/s0304-3940(03)00066-1;;12697296;;10.1016/s0167-0115(01)00358-5;;11830290;;10.1016/s0304-3959(00)00470-x;;11323129;;11298806;;10.1046/j.0953-816x.2001.01518.x;;10.1038/sj.bjp.0703953;;11250867;;pmc1572677;;10.1007/s002130000551;;11205421;;11102651;;10.1016/s0167-0115(00)00199-3;;12450737;;10.1016/s0143-4179(02)00085-9;;10906799;;10.1016/s0166-2236(00)01594-0;;10.1146/annurev.neuro.25.112701.142826;;12052911;;10.1038/nm1544;;17259994;;10.1073/pnas.96.19.10911;;10485925;;pmc17982;;10712652;;10.1046/j.1460-9568.2000.00919.x;;10.1021/cr950066q;;11848856,"Boutrel et al. PNAS, 102(52): 19168-19173 (2005).;;Borglund et al. Neuron, 49: 589-601 (2006).;;Harris et al. Nature, 437: 556-559 (2005).;;Mori et al. Chem. Pharm. Bull., 32(10): 3840-3847 (1984).;;Defoin et al. Helv. Chim. Acta, 75(1): 109-123 (1992).;;Lang et al. J. Med. Chem., 47: 1153-1160 (2004).;;Smart et al. Euro. J. Pharm., 440: 199-212 (2002).;;Langmead et al. Br. J. Pharmacol., 141: 340-346 (2004).;;Porter et al. Bioorg. & Med. Chem. Lett., 11: 1907-1910 (2001).;;Duxon et al. Psychopharmacology, 153: 203-209 (2001).;;White et al. Peptides, 26: 2331-2338 (2005).;;Ishii et al. Behav. Brain Res., 160: 11-24 (2005).;;Ishii et al. Behav. Brain Res., 157: 331-341 (2005).;;Ishii et al. Physiol. & Behav., 81: 129-140 (2004).;;Smith et al. Neurosci. Lett., 341: 256-258 (2003).;;Haynes et al. Regulatory Peptides, 104: 153-159 (2002).;;Bingham et al. Pain, 92: 81-90 (2001).;;Rodgers et al. Eur. J. Neurosci., 13: 1444-1452 (2001).;;Smart et al. Br. J. Pharmacol., 132: 1179-1182 (2001).;;Jones et al. Psychopharmacology, 153: 210-218 (2001).;;Haynes et al. Regulatory Peptides, 96: 45-51 (2000).;;Rodgers et al. Neuropeptides, 36(5): 303-325 (2002).;;Patini et al., Chem. Rev., 96: 3147-3148 (1996).;;Kilduff et al. Trends Neurosci., 23: 359-365 (2000).;;Taheri et al. Annu. Rev. Neurosci., 25: 283-313 (2002).;;Cai et al. Expert Opin. Ther. Patents, 16(5): 631-646 (2006).;;Brisbare-Roch et al. Nature Medicine, 13(2): 150-155 (2007).;;Hagan et al. Proc. Natl. Acad. Sci. USA., 96: 10911-10916 (1999).;;Piper et al. Eur. J. Neurosci., 12: 726-730 (2000).;;Patani et al. Chem. Rev., 96: 3147-3176 (1996).",EXPIRED
302,US,A1,US 2009/0012122 A1,028-658-706-733-415,2009-01-08,2009,US 92807207 A,2007-10-30,US 92807207 A;;GB 0115863 A;;GB 0130342 A;;US 48113304 A;;EP 0207009 W,2001-06-28,N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS,"Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.",SMITHKLINE BEECHAM PLC,BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;JOHNS AMANDA;;JOHNSON CHRISTOPHER NORBERT;;NASH DAVID JOHN;;NOVELLI RICCARDO;;PILLEUX JEAN-PIERRE;;PORTER RODERICK ALAN;;STEAD RACHEL ELIZABETH ANNE;;STEMP GEOFFREY,SMITHKLINE BEECHAM LIMITED (2009-10-27),https://lens.org/028-658-706-733-415,Patent Application,yes,8,7,33,36,1,C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04;;A61P1/04;;A61P1/08;;A61P1/14;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P3/00;;A61P3/10;;A61P35/00;;A61P3/04;;A61P37/08;;A61P43/00;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;C07D417/14;;C07D417/14;;C07D405/06;;C07D413/14;;C07D401/06;;C07D403/14;;C07D417/04;;C07D409/14;;C07D405/14;;C07D491/04;;C07D471/04;;C07D401/14,A61K31/454;;A61K31/4184;;C07D491/048;;A61K31/426;;A61K31/453;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P1/04;;A61P1/08;;A61P1/14;;A61P3/04;;A61P3/10;;A61P5/02;;A61P5/10;;A61P5/38;;A61P7/00;;A61P9/02;;A61P9/04;;A61P9/12;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P19/10;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P35/00;;A61P37/08;;C07D401/06;;C07D401/14;;C07D403/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/04;;C07D417/14;;C07D471/04;;C07D491/04,514/318;;546/196;;546/194;;546/199;;514/322;;514/320,0,0,,,,EXPIRED
303,US,A1,US 2021/0085853 A1,079-828-148-478-294,2021-03-25,2021,US 201916976397 A,2019-03-01,US 201916976397 A;;US 201862637311 P;;US 2019/0020295 W,2018-03-01,SYSTEMS AND METHODS FOR AUTOMATED ASSESSMENT AND MONITORING OF BODILY FLUIDS,"Systems and methods for automated assessment and monitoring of bodily fluids are disclosed. In one embodiment, a system for provisioning a treatment composition to a bladder of a patient includes: an irrigation bag that carries the treatment composition; a catheter configured for connecting the irrigation bag to the bladder; a flow regulator configured for controlling a flow of the treatment composition from the irrigation bag to the bladder; and a drainage bag in fluid communication with the bladder through a drainage tubing of the catheter. The drainage tubing is configured for draining urine from the bladder. The system also includes: a first sensor for detecting a first amount of the treatment composition in the irrigation bag; a second sensor for detecting a second amount of urine in the drainage bag; a third sensor for detecting a concentration of particles in the urine carried by the drainage bag; and a controller.",UNIV WASHINGTON,CHEN TONY;;SUN JIALU;;SWEET ROBERT MARTEN;;GORE JOHN LAWRENCE;;LIU JONATHAN TENG-CHIEH;;POSNER JONATHAN DOV;;RANDAD AKSHAY PURUSHOTTAMJI;;BRANCH ALLEGRA JOYCE;;KAMPIANAKIS ELEFTHERIOS;;COVELLI VELEZ CLAUDIA JIMENA,UNIVERSITY OF WASHINGTON (2020-09-02),https://lens.org/079-828-148-478-294,Patent Application,yes,1,6,2,2,0,A61M3/022;;A61M3/0208;;A61M2210/1085;;A61M3/0212;;A61M3/0204;;A61M2205/3393;;A61M2205/3313;;A61M2205/3375;;A61M2205/50;;A61M3/0241;;A61M2205/3389;;A61M2202/0496;;A61M3/0283;;A61M3/0295;;A61M3/0287;;A61M1/73;;A61M1/777;;A61M1/77;;A61M3/0287;;A61M25/0041;;A61M39/22;;A61M2202/0496;;A61M2205/18;;A61M2205/3313;;A61M2205/3334;;A61M2205/3375;;A61M2205/3393;;A61M3/022;;A61M1/73;;A61M1/77;;A61M1/777;;A61M3/0241;;A61M3/0283,A61M3/02;;A61M25/00;;A61M39/22,,0,0,,,,PENDING
304,AT,T1,AT E421499 T1,154-193-945-970-70X,2009-02-15,2009,AT 05820721 T,2005-12-21,GB 0428231 A;;GB 0509204 A;;GB 0524322 A,2004-12-23,INHIBITOREN DES GLYCINTRANSPORTS,,GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE A;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/154-193-945-970-70X,Granted Patent,no,0,0,11,40,0,C07C211/27;;C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;A61P1/08;;A61P1/14;;A61P15/10;;A61P15/12;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/04;;A61P43/00;;C07C235/60;;C07C211/27;;C07C233/78;;C07C323/62;;C07C235/50,,,0,0,,,,INACTIVE
305,TW,A,TW 200633956 A,143-782-617-225-838,2006-10-01,2006,TW 94145552 A,2005-12-21,GB 0428231 A;;GB 0509204 A;;GB 0524322 A,2004-12-23,Compounds,"The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.",GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;LAI JUSTINE YEUN QUAI;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/143-782-617-225-838,Patent of Addition,no,0,0,11,40,0,C07C211/27;;C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;A61P1/08;;A61P1/14;;A61P15/10;;A61P15/12;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/04;;A61P43/00;;C07C235/60;;C07C211/27;;C07C233/78;;C07C323/62;;C07C235/50,,,0,0,,,,PENDING
306,EP,A1,EP 1858869 A1,053-414-500-069-921,2007-11-28,2007,EP 06723520 A,2006-03-09,EP 2006002484 W;;GB 0505084 A,2005-03-11,ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS,,GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;DEAN ANTHONY WILLIAM;;DOYLE PAUL MARTIN;;EVANS BRIAN;;GILPIN MARTIN LEONARD;;GOUGH SHARON LISA;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;WARD SIMON EDWARD,,https://lens.org/053-414-500-069-921,Patent Application,yes,0,0,5,5,0,A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;C07D231/12;;C07D231/12;;C07D209/08;;C07D209/08;;C07D213/56;;C07D213/56;;C07D213/74;;C07D213/74;;C07D295/192;;C07D295/192;;C07D307/54;;C07D307/54;;C07D333/24;;C07D333/24;;C07D405/12;;C07D405/12;;C07D471/04;;C07D471/04,C07D295/18;;A61K31/445;;A61K31/4523;;A61K31/4525;;A61K31/4545;;A61P25/00;;C07D209/08;;C07D213/56;;C07D213/74;;C07D231/12;;C07D295/192;;C07D307/38;;C07D307/54;;C07D307/64;;C07D333/24;;C07D405/12;;C07D471/04,,1,0,,,See references of WO 2006094842A1,DISCONTINUED
307,WO,A1,WO 2006/094842 A1,164-735-079-680-453,2006-09-14,2006,EP 2006002484 W,2006-03-09,GB 0505084 A,2005-03-11,ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS,"The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, n, X, Y and Z are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",GLAXO GROUP LTD;;BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;DEAN ANTHONY WILLIAM;;DOYLE PAUL MARTIN;;EVANS BRIAN;;GILPIN MARTIN LEONARD;;GOUGH SHARON LISA;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;WARD SIMON EDWARD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;DEAN ANTHONY WILLIAM;;DOYLE PAUL MARTIN;;EVANS BRIAN;;GILPIN MARTIN LEONARD;;GOUGH SHARON LISA;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;WARD SIMON EDWARD,,https://lens.org/164-735-079-680-453,Patent Application,yes,3,14,5,5,0,A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;C07D231/12;;C07D231/12;;C07D209/08;;C07D209/08;;C07D213/56;;C07D213/56;;C07D213/74;;C07D213/74;;C07D295/192;;C07D295/192;;C07D307/54;;C07D307/54;;C07D333/24;;C07D333/24;;C07D405/12;;C07D405/12;;C07D471/04;;C07D471/04,C07D295/18;;A61K31/445;;A61K31/4523;;A61K31/4525;;A61K31/4545;;A61P25/00;;C07D209/08;;C07D213/56;;C07D213/74;;C07D231/12;;C07D295/192;;C07D307/38;;C07D307/54;;C07D307/64;;C07D333/24;;C07D405/12;;C07D471/04,,0,0,,,,PENDING
308,US,A1,US 2008/0255144 A1,070-443-832-344-159,2008-10-16,2008,US 90815106 A,2006-03-09,GB 0505084 A;;EP 2006002484 W,2005-03-11,Acylated Piperidines as Glycine Transporter Inhibitors,"The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R 1 , n, X, Y and Z are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;DEAN ANTHONY WILLIAM;;DOYLE PAUL MARTIN;;EVANS BRIAN;;GILPIN MARTIN LEONARD;;GOUGH SHARON LISA;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;WARD SIMON EDWARD,GLAXO GROUP LIMITED (2006-05-05),https://lens.org/070-443-832-344-159,Patent Application,yes,2,0,5,5,0,A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;C07D231/12;;C07D231/12;;C07D209/08;;C07D209/08;;C07D213/56;;C07D213/56;;C07D213/74;;C07D213/74;;C07D295/192;;C07D295/192;;C07D307/54;;C07D307/54;;C07D333/24;;C07D333/24;;C07D405/12;;C07D405/12;;C07D471/04;;C07D471/04,A61K31/496;;A61K31/495;;A61P25/18;;C07D209/08;;C07D213/56;;C07D213/74;;C07D231/12;;C07D241/04;;C07D295/192;;C07D307/54;;C07D333/24;;C07D401/04;;C07D401/10;;C07D405/10;;C07D405/12;;C07D471/04,514/253.04;;544/391;;544/379;;544/360;;544/362;;514/255.01;;514/254.1;;514/253.01,0,0,,,,DISCONTINUED
309,EP,A1,EP 1838663 A1,019-482-806-621-143,2007-10-03,2007,EP 05820721 A,2005-12-21,GB 2005004943 W;;GB 0428231 A;;GB 0509204 A;;GB 0524322 A,2004-12-23,GLYCINE TRANSPORT INHIBITORS,,GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE A;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/019-482-806-621-143,Patent Application,yes,0,0,11,40,0,C07C211/27;;C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;A61P1/08;;A61P1/14;;A61P15/10;;A61P15/12;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/04;;A61P43/00;;C07C235/60;;C07C211/27;;C07C233/78;;C07C323/62;;C07C235/50,C07C233/78;;A61K31/166;;C07C211/27,,0,0,,,,ACTIVE
310,DE,D1,DE 602005012550 D1,197-190-279-862-286,2009-03-12,2009,DE 602005012550 T,2005-12-21,GB 0428231 A;;GB 0509204 A;;GB 0524322 A;;GB 2005004943 W,2004-12-23,INHIBITOREN DES GLYCINTRANSPORTS,,GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE A;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/197-190-279-862-286,Granted Patent,no,0,0,11,40,0,C07C211/27;;C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;A61P1/08;;A61P1/14;;A61P15/10;;A61P15/12;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/04;;A61P43/00;;C07C235/60;;C07C211/27;;C07C233/78;;C07C323/62;;C07C235/50,C07C233/78;;A61K31/166;;C07C211/27,,0,0,,,,ACTIVE
311,WO,A1,WO 2006/067417 A1,009-398-132-165-713,2006-06-29,2006,GB 2005004943 W,2005-12-21,GB 0428231 A;;GB 0509204 A;;GB 0524322 A,2004-12-23,GLYCINE TRANSPORT INHIBITORS,"The present invention relates to compounds of Formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.",GLAXO GROUP LTD;;BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE ANNE;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE ANNE;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/009-398-132-165-713,Patent Application,yes,2,6,11,40,0,C07C211/27;;C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;A61P1/08;;A61P1/14;;A61P15/10;;A61P15/12;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/04;;A61P43/00;;C07C235/60;;C07C211/27;;C07C233/78;;C07C323/62;;C07C235/50,C07C233/78;;A61K31/166;;C07C211/27,,0,0,,,,PENDING
312,EP,B1,EP 1838663 B1,188-422-864-749-94X,2009-01-21,2009,EP 05820721 A,2005-12-21,GB 2005004943 W;;GB 0428231 A;;GB 0509204 A;;GB 0524322 A,2004-12-23,GLYCINE TRANSPORT INHIBITORS,,GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE A;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/188-422-864-749-94X,Granted Patent,yes,2,0,11,40,0,C07C211/27;;C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;A61P1/08;;A61P1/14;;A61P15/10;;A61P15/12;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/04;;A61P43/00;;C07C235/60;;C07C211/27;;C07C233/78;;C07C323/62;;C07C235/50,C07C233/78;;A61K31/166;;C07C211/27,,0,0,,,,ACTIVE
313,PE,A1,PE 20061330 A1,185-616-524-648-84X,2006-12-27,2006,PE 2005001500 A,2005-12-16,GB 0428231 A;;GB 0509204 A;;GB 0524322 A,2004-12-23,COMPUESTOS DERIVADOS DE BENZAMIDA COMO INHIBIDORES DEL TRANSPORTADOR DE GLICINA,"REFERIDA A UN COMPUESTO DERIVADO DE BENZAMIDA DE FORMULA I, DONDE Z1 ES ALQUILO C1-C4, CICLOALQUILO C3-C6, ALQUILTIO C1-C4, FENILO, ENTRE OTROS; Z2 ES H, HALOGENO, ALQUILO C1-C4, ENTRE OTROS; Z3 ES H, HALOGENO, ALQUILO C1-C4, ENTE OTROS; Z4 ES H, HALOGENO, ALQUILOC1-C4, ENTRE OTROS; Z5 ES H, CLORO, YODO, HIDROXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (±)-N-[2-(DIMETILAMINO)-2-METIL-1-FENILPROPIL]-2,3-DIMETILBENZAMIDA, (±)-N-[2-(DIMETILAMINO)-2-METIL-1-FENILPROPIL]-2,6-DIMETILBENZAMIDA, (±)-N-[2-(DIMETILAMINO)-2-METIL-1-FENILPROPIL]-2-METIL-5-(TRIFLUOROMETIL)BENZAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DEL TRANSPORTADOR DE GLICINA Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS Y NEUROPSIQUIATRICOS, PARTICULARMENTE, PSICOSIS, DEMENCIA O TRASTORNO DE DEFICIT DE ATENCION",GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;COULTON STEVEN;;HARRIS ANDREW JONATHAN;;MACRITCHIE JACQUELINE ANNE;;NASH DAVID JOHN;;SPADA SIMONE;;WARD SIMON EDWARD;;THEWLIS KEVIN MICHAEL;;PORTER RODERICK ALAN;;MARSHALL HOWARD ROBERT;;LAI JUSTINE YEUN QUAI;;GILPIN MARTIN LEONARD;;CHAN WAI NGOR,,https://lens.org/185-616-524-648-84X,Patent Application,no,0,0,11,40,0,C07C211/27;;C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;A61P1/08;;A61P1/14;;A61P15/10;;A61P15/12;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/04;;A61P43/00;;C07C235/60;;C07C211/27;;C07C233/78;;C07C323/62;;C07C235/50,A61K31/166;;C07C211/00;;C07C211/27;;C07C233/00;;C07C233/78,,0,0,,,,ACTIVE
314,US,A1,US 2009/0270510 A1,178-995-272-874-451,2009-10-29,2009,US 72221305 A,2005-12-21,GB 0428231 A;;GB 0509204 A;;GB 0524322 A;;GB 2005004943 W,2004-12-23,GLYCINE TRANSPORT INHIBITORS,"The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.",GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;LAI JUSTINE YEUN QUAI;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,GLAXO GROUP LIMITED (2005-11-22),https://lens.org/178-995-272-874-451,Patent Application,yes,0,0,11,40,0,C07C211/27;;C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;A61P1/08;;A61P1/14;;A61P15/10;;A61P15/12;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/04;;A61P43/00;;C07C235/60;;C07C211/27;;C07C233/78;;C07C323/62;;C07C235/50,A61K31/166;;C07C211/27;;C07C233/78;;C07C321/10,514/618;;564/162;;514/617;;564/185;;564/372,0,0,,,,DISCONTINUED
315,WO,A1,WO 2006/094843 A1,067-740-383-379-892,2006-09-14,2006,EP 2006002485 W,2006-03-09,GB 0505086 A,2005-03-11,PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS,"The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, n, X, Y and Z are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",GLAXO GROUP LTD;;BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;BROWN BETHANY JOY;;CHAN WAI NGOR;;COULTON STEVEN;;DEAN ANTHONY WILLIAM;;DOYLE PAUL MARTIN;;EVANS BRIAN;;GILPIN MARTIN LEONARD;;GOUGH SHARON LISA;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STASI LUIGI PIERO,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;BROWN BETHANY JOY;;CHAN WAI NGOR;;COULTON STEVEN;;DEAN ANTHONY WILLIAM;;DOYLE PAUL MARTIN;;EVANS BRIAN;;GILPIN MARTIN LEONARD;;GOUGH SHARON LISA;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STASI LUIGI PIERO,,https://lens.org/067-740-383-379-892,Patent Application,yes,2,9,5,5,0,A61P1/14;;A61P3/04;;A61P15/10;;A61P15/12;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P25/36;;A61P43/00;;C07D213/73;;C07D213/73;;C07D213/75;;C07D213/75;;C07D213/85;;C07D213/85;;C07D215/38;;C07D215/38;;C07D239/42;;C07D239/42;;C07D241/44;;C07D241/44;;C07D295/192;;C07D295/192;;C07D487/04;;C07D487/04,C07D295/18;;A61K31/437;;A61K31/444;;A61K31/4709;;A61K31/495;;A61K31/498;;A61K31/5377;;A61P25/00;;C07D213/73;;C07D213/75;;C07D213/85;;C07D215/38;;C07D239/42;;C07D241/44;;C07D295/192;;C07D487/04,,0,0,,,,PENDING
316,EP,A1,EP 1858868 A1,057-702-021-418-399,2007-11-28,2007,EP 06723516 A,2006-03-09,EP 2006002480 W;;GB 0505085 A,2005-03-11,COMPOUNDS,,GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;BROWN BETHANY JOY;;CHAN WAI NGOR;;COULTON STEVEN;;DEAN ANTHONY WILLIAM;;DOYLE PAUL MARTIN;;EVANS BRIAN;;GILPIN MARTIN LEONARD;;GOUGH SHARON LISA;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STASI LUIGI PIERO,,https://lens.org/057-702-021-418-399,Patent Application,yes,0,0,4,4,0,A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D295/192,C07D295/18;;A61K31/495;;A61P25/00,,1,0,,,See references of WO 2006094840A1,DISCONTINUED
317,EP,A1,EP 1856077 A1,066-749-906-302-718,2007-11-21,2007,EP 06723521 A,2006-03-09,EP 2006002485 W;;GB 0505086 A,2005-03-11,PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS,,GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;BROWN BETHANY JOY;;CHAN WAI NGOR;;COULTON STEVEN;;DEAN ANTHONY WILLIAM;;DOYLE PAUL MARTIN;;EVANS BRIAN;;GILPIN MARTIN LEONARD;;GOUGH SHARON LISA;;MACRITCHIE JACQUELINE A;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STASI LUIGI PIERO,,https://lens.org/066-749-906-302-718,Patent Application,yes,0,0,5,5,0,A61P1/14;;A61P3/04;;A61P15/10;;A61P15/12;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P25/36;;A61P43/00;;C07D213/73;;C07D213/73;;C07D213/75;;C07D213/75;;C07D213/85;;C07D213/85;;C07D215/38;;C07D215/38;;C07D239/42;;C07D239/42;;C07D241/44;;C07D241/44;;C07D295/192;;C07D295/192;;C07D487/04;;C07D487/04,C07D295/18;;A61K31/437;;A61K31/444;;A61K31/4709;;A61K31/495;;A61K31/498;;A61K31/5377;;A61P25/00;;C07D213/73;;C07D213/75;;C07D213/85;;C07D215/38;;C07D239/42;;C07D241/44;;C07D295/192;;C07D487/04,,1,0,,,See references of WO 2006094843A1,DISCONTINUED
318,WO,A1,WO 2006/094840 A1,142-005-587-665-468,2006-09-14,2006,EP 2006002480 W,2006-03-09,GB 0505085 A,2005-03-11,COMPOUNDS,"The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, n, X, Y and Z are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.",GLAXO GROUP LTD;;BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;BROWN BETHANY JOY;;CHAN WAI NGOR;;COULTON STEVEN;;DEAN ANTHONY WILLIAM;;DOYLE PAUL MARTIN;;EVANS BRIAN;;GILPIN MARTIN LEONARD;;GOUGH SHARON LISA;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STASI LUIGI PIERO,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;BROWN BETHANY JOY;;CHAN WAI NGOR;;COULTON STEVEN;;DEAN ANTHONY WILLIAM;;DOYLE PAUL MARTIN;;EVANS BRIAN;;GILPIN MARTIN LEONARD;;GOUGH SHARON LISA;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;STASI LUIGI PIERO,,https://lens.org/142-005-587-665-468,Patent Application,yes,3,6,4,4,0,A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D295/192,C07D295/18;;A61K31/495;;A61P25/00,,0,0,,,,PENDING
319,CA,A1,CA 2592467 A1,093-004-869-080-695,2006-06-29,2006,CA 2592467 A,2005-12-21,GB 0428231 A;;GB 0509204 A;;GB 0524320 A;;GB 2005004951 W,2004-12-23,GLYCINE TRANSPORT INHIBITORS,,GLAXO GROUP LTD,LAI JUSTINE YEUN QUAI;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;PORTER RODERICK ALAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD;;MACRITCHIE JACQUELINE ANNE;;BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;NASH DAVID JOHN;;COULTON STEVEN;;CHAN WAI NGOR;;SPADA SIMONE;;MARSHALL HOWARD ROBERT,,https://lens.org/093-004-869-080-695,Patent Application,no,0,0,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,A61K31/166;;C07C233/78;;C07C211/36,,0,0,,,,DISCONTINUED
320,PE,A1,PE 20061156 A1,031-611-415-689-354,2006-12-16,2006,PE 2005001492 A,2005-12-16,GB 0428231 A;;GB 0509204 A;;GB 0524320 A,2004-12-23,DERIVADOS DE BENZAMIDA COMO AGENTES INHIBIDORES DEL TRANSPORTADOR DE GLICINA,"REFERIDA A UN COMPUESTO DE FORMULA (I), DONDE Z1 ES ALQUILO C1-C4, CICLOALQUILO C3-C6, ALCOXI C1-C4, ENTRE OTROS; Z2 ES H, HALOGENO, CN, FENILO, ENTRE OTROS; Z3 ES H, HALOGENO, ALQUILO C1-C4, HALOALCOXI C1-C4, ENTRE OTROS; Z4 ES H, HALOGENO, ALQUILO C1-C3, HALOALQUILO C1-C4, ENTRE OTROS; Z5 ES H, OH, FENILO, ALCOXI C1-C4, ENTRE OTROS; R3 Y R4 SON H, ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO CON UNO O MAS Y; Y ES OH, ALCOXI C1-C4, HALOALCOXI C1-C4 O CICLOALQUILO C3-C5, O R3 Y R4 JUNTO CON EL ATOMO DE N AL QUE ESTAN UNIDOS FORMAN UN ANILLO CARBOCICLICO SATURADO O PARCIALMENTE INSATURADO DE 4 A 7 MIEMBROS OPCIONALMENTE SUSTITUIDO; R5 Y R6 SON ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO CON UNO O MAS X; X ES HALOGENO, OH, ALCOXI C1-C4, ENTRE OTROS, O R5 Y R6 JUNTO CON EL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN UN ANILLO CARBOCICLICO SATURADO DE 5 O 6 MIEMBROS OPCIONALMENTE SUSTITUIDO. SON COMPUESTOS PREFERIDOS: (±)-2,6-DICLORO-N-[[1-(DIMETILAMINO)CICLOPENTIL](FENIL)METIL]-BENZAMIDA, (±)-2,4-DICLORO-N-[[1-(DIMETILAMINO)CICLOPENTIL](FENIL)METIL]-BENZAMIDA, (±)-N-[[1-(DIMETILAMINO)CICLOPENTIL](FENIL)METIL]-2,3-DIMETILBENZAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DEL TRANSPORTADOR DE GLICINA GlyT1 Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS Y NEUROPSIQUIATRICOS, INCLUYENDO ESQUIZOFRENIA",GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;COULTON STEVEN;;HARRIS ANDREW JONATHAN;;LAI JUSTINE YEUN QUAI;;MACRITCHIE JACQUELINE ANNE;;PORTER RODERICK ALAN;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD;;SPADA SIMONE;;NASH DAVID JOHN;;MARSHALL HOWARD ROBERT;;JAXA-CHAMIEC ALBERT ANDRZEJ;;GILPIN MARTIN LEONARD;;CHAN WAI NGOR,,https://lens.org/031-611-415-689-354,Patent Application,no,0,0,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,A61K31/166;;C07C211/00;;C07C211/36;;C07C233/00;;C07C233/78,,0,0,,,,ACTIVE
321,WO,A1,WO 2006/067423 A1,183-581-841-199-451,2006-06-29,2006,GB 2005004951 W,2005-12-21,GB 0428231 A;;GB 0509204 A;;GB 0524320 A,2004-12-23,GLYCINE TRANSPORT INHIBITORS,"The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.",GLAXO GROUP LTD;;BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE ANNE;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE ANNE;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/183-581-841-199-451,Patent Application,yes,2,17,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,C07C233/78;;A61K31/166;;C07C211/36,,2,2,040-442-819-212-204;;033-484-976-765-859,10.1021/ja00537a046;;10.1002/chem.200204674;;12866563,"P.N. BECKER ET AL.: ""A New Method for 1,2-Diamination of Alkenes Using Cyclopentadienylnitrosylcobalt Dimer/NO/LiAlH4"", J. AM. CHEM. SOC., vol. 102, 1980, pages 5676 - 5677, XP002374266;;A. VISO ET AL.: ""Highly Diatereoselective [3+2]Cycloadditions between Nonracemic p-Tolylsulfinimines and Iminoesters: An Efficient Entry to Enantiopure Imidazolidines and Vicinal Diaminoalcohols"", CHEM. EUR. J., vol. 9, 2003, pages 2867 - 2876, XP002374267",PENDING
322,TW,A,TW 200633957 A,004-527-608-000-516,2006-10-01,2006,TW 94145554 A,2005-12-21,GB 0428231 A;;GB 0509204 A;;GB 0524320 A,2004-12-23,Compounds,"The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.",GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE ANNE;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/004-527-608-000-516,Patent of Addition,no,0,0,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,,,0,0,,,,PENDING
323,MA,B1,MA 29099 B1,127-805-230-153-488,2007-12-03,2007,MA 30002 A,2007-06-18,GB 0428231 A;;GB 0509204 A;;GB 0524320 A,2004-12-23,INHIBITEURS DE TRANSPORT DE LA GLYCINE,,GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE ANNE;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/127-805-230-153-488,Granted Patent,no,0,0,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,,,0,0,,,,ACTIVE
324,NO,L,NO 20073300 L,171-023-252-695-412,2007-08-28,2007,NO 20073300 A,2007-06-27,GB 0428231 A;;GB 0509204 A;;GB 0524320 A;;GB 2005004951 W,2004-12-23,Glycintransportinhibitorer,"Foreliggende oppfinnelse angår forbindelser med formel (I), eller salter eller solvater derav, deres anvendelse ved fremstilling av medikamenter for behandling av neurologiske og neuropsykiatriske forstyrrelser, særlig psykoser, demens eller oppmerksomhetssviktforstyrrelse.Oppfinnelsen innbefatter ytterligere fremgangsmåter for fremstilling av disse forbindelsene og farmasøytiske formuleringer derav. (I)",GLAXO GROUP LTD,CHAN WAI NGOR;;BRANCH CLIVE LESLIE;;COULTON STEVEN;;PORTER RODERICK ALAN;;MARSHALL HOWARD ROBERT;;THEWLIS KEVIN MICHAEL;;NASH DAVID JOHN;;SPADA SIMONE;;WARD SIMON EDWARD;;BRADLEY DANIEL MARCUS;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;LAI JUSTINE YEUN QUAI;;MACRITCHIE JACQUELINE ANNE,,https://lens.org/171-023-252-695-412,Abstract,no,0,0,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,C07C233/78;;A61K31/166;;A61P25/18,,0,0,,,,DISCONTINUED
325,ZA,B,ZA 200704726 B,018-925-790-772-644,2009-02-25,2009,ZA 200704726 A,2007-06-14,GB 0428231 A,2004-12-23,Glycine transport inhibitors,,GLAXO GROUP LTD,MARCUS BRADLEY DANIEL;;STEVEN COULTON;;ANDRZEJ JAXA-CHAMIEC ALBERT;;ANNE MACRITCHIE JACQUELINE;;SIMONE SPADA;;LESLIE BRANCH CLIVE;;LEONARD GILPEN MARTIN;;QUAI LAI JUSTINE YEUN;;JOHN NASH DAVID;;MICHAEL THEWLIS KEVIN;;NGOR CHAN WAI;;JONATHAN HARRIS ANDREW;;ROBERT MARSHALL HOWARD;;ALAN PORTER RODERICK;;EDWARD WARD SIMON,,https://lens.org/018-925-790-772-644,Granted Patent,no,0,0,3,40,0,,A61K/;;C07C/,,0,0,,,,ACTIVE
326,US,A1,US 2008/0287547 A1,114-656-318-130-24X,2008-11-20,2008,US 71833305 A,2005-12-21,GB 0428231 A;;GB 0509204 A;;GB 0524320 A;;GB 2005004951 W,2004-12-23,Glycine Transport Inhibitors,"The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.",BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;LAI JUSTINE YEUN QUAI;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;LAI JUSTINE YEUN QUAI;;MACRITCHIE JACQUELINE ANNE;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,GLAXO GROUP LIMITED (2005-11-22),https://lens.org/114-656-318-130-24X,Patent Application,yes,4,1,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,A61K31/166;;A61P25/00;;A61P25/18;;C07C233/65,514/617;;564/168,0,0,,,,INACTIVE
327,AU,A1,AU 2005/317950 A1,072-724-844-550-324,2006-06-29,2006,AU 2005/317950 A,2005-12-21,GB 0428231 A;;GB 0524320 A;;GB 0509204 A;;GB 2005004951 W,2004-12-23,Glycine transport inhibitors,,GLAXO GROUP LTD,SPADA SIMONE;;HARRIS ANDREW JONATHAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;THEWLIS KEVIN MICHAEL;;GILPIN MARTIN LEONARD;;MACRITCHIE JACQUELINE ANNE;;LAI JUSTINE YEUN QUAI;;BRADLEY DANIEL MARCUS;;COULTON STEVEN;;MARSHALL HOWARD ROBERT;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;WARD SIMON EDWARD,,https://lens.org/072-724-844-550-324,Patent Application,no,0,0,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,C07C233/78;;A61K31/166;;C07C211/36,,0,0,,,,DISCONTINUED
328,BR,A2,BR PI0519366 A2,167-948-411-706-060,2009-01-20,2009,BR PI0519366 A,2005-12-21,GB 0428231 A;;GB 0509204 A;;GB 0524320 A;;GB 2005004951 W,2004-12-23,inibidores do transporte de glicina,"INIBIDORES DO TRANSPORTE DE GLICINA. A presente invenção se refere a compostos de fórmula (I) ou a seus sais ou solvatos, a seu uso na fabricação de medicamentos para o tratamento de transtornos neurológicos e neuropsiquiátricos, em particular psicoses, demência ou transtorno de déficit de atenção. A invenção também compreende processos para a preparação desses compostos e suas formulações farmacêuticas.",GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHE JAQUELINE ANNE;;NASH DAVID JOHN;;PORTER ALAN RODERICK;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/167-948-411-706-060,Patent Application,no,0,0,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,C07C233/78;;A61K31/166;;C07C211/36,,0,0,,,,DISCONTINUED
329,KR,A,KR 20070091210 A,037-677-393-498-177,2007-09-07,2007,KR 20077016780 A,2007-07-20,GB 0428231 A;;GB 0509204 A;;GB 0524320 A,2004-12-23,GLYCINE TRANSPORT INHIBITORS,"The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.",GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;JAXA CHAMIEC ALBERT ANDRZEJ;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE ANNE;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/037-677-393-498-177,Patent Application,no,0,0,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,C07C233/80;;A61K31/166;;C07C211/36;;C07C233/77,,0,0,,,,DISCONTINUED
330,EA,B1,EA 011638 B1,088-706-806-927-268,2009-04-28,2009,EA 200701356 A,2005-12-21,GB 0428231 A;;GB 0509204 A;;GB 0524320 A;;GB 2005004951 W,2004-12-23,GLYCINE TRANSPORT INHIBITORS,"The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.",GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;JILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;LAI JUSTINE YEUN QUAI;;MACRITCHIE HOWARD ROBERT;;MACRITCHIE QACQUELINE ANNE;;NASH DAVID JOHN;;POETER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/088-706-806-927-268,Granted Patent,no,2,2,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,C07C233/78;;A61K31/166;;C07C211/36,,2,2,040-442-819-212-204;;033-484-976-765-859,10.1021/ja00537a046;;10.1002/chem.200204674;;12866563,"P.N. BECKER ET AL.: ""A New Method for 1,2-Diamination of Alkenes Using Cyclopentadienylnitrosylcobalt Dimer/NO/LiAlH4"", J. AM. CHEM. SOC., vol. 102, 1980, pages 5676-5677, XP002374266, Table I, third entry (2-methyl-l-phenylpropane-1,2-diamine);;A. VISO ET AL.: ""Highly Diatereoselective [3+2]Cycloadditions between Nonracemic p-Tolylsulfinimines and Iminoesters: An Efficient Entry to Enantiopure Imidazolidines and Vicinal Diaminoalcohols"", CHEM. EUR. J., vol. 9, 2003, pages 2867-2876, XP002374267, Compound 18a",ACTIVE
331,MX,A,MX 2007007888 A,159-069-048-048-858,2007-07-18,2007,MX 2007007888 A,2005-12-21,GB 0428231 A;;GB 0509204 A;;GB 0524320 A;;GB 2005004951 W,2004-12-23,GLYCINE TRANSPORT INHIBITORS.,"The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.",GLAXO GROUP LTD,COULTON STEVEN;;PORTER RODERICK ALAN;;LAI JUSTINE YEUN QUAI;;WARD SIMON EDWARD;;BRADLEY DANIEL MARCUS;;THEWLIS KEVIN MICHAEL;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE ANNE;;NASH DAVID JOHN;;SPADA SIMONE,,https://lens.org/159-069-048-048-858,Patent Application,no,0,0,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,A61K31/166;;C07C233/78;;C07C211/36,,0,0,,,,ACTIVE
332,EP,A1,EP 1841727 A1,123-928-733-540-695,2007-10-10,2007,EP 05820463 A,2005-12-21,GB 2005004951 W;;GB 0428231 A;;GB 0509204 A;;GB 0524320 A,2004-12-23,GLYCINE TRANSPORT INHIBITORS,,GLAXO GROUP LTD,BRADLEY DANIEL MARCUS;;BRANCH CLIVE LESLIE;;CHAN WAI NGOR;;COULTON STEVEN;;GILPIN MARTIN LEONARD;;HARRIS ANDREW JONATHAN;;JAXA-CHAMIEC ALBERT ANDRZEJ;;LAI JUSTINE YEUN QUAI;;MARSHALL HOWARD ROBERT;;MACRITCHIE JACQUELINE ANNE;;NASH DAVID JOHN;;PORTER RODERICK ALAN;;SPADA SIMONE;;THEWLIS KEVIN MICHAEL;;WARD SIMON EDWARD,,https://lens.org/123-928-733-540-695,Patent Application,yes,0,0,18,40,0,C07C233/78;;C07C235/50;;C07C235/60;;C07C323/62;;C07D205/04;;C07D207/20;;C07D209/02;;C07D295/13;;C07D307/22;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P25/00;;A61P25/18;;A61P25/28;;C07C233/80;;C07C233/77;;A61K31/166;;C07C211/36;;C07C233/78;;C07C323/62;;C07D207/20;;C07D307/22;;C07C235/60;;C07D295/13;;C07C235/50;;C07D205/04;;C07D209/02;;C07C2601/08;;C07C2601/14;;C07C2601/02,C07C233/78;;A61K31/166;;C07C211/36,,0,0,,,,DISCONTINUED
